<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/stylesheet.xsl" type="text/xsl"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://feeds.transistor.fm/medsider-learn-from-medtech-and-healthtech-experts" title="MP3 Audio"/>
    <atom:link rel="hub" href="https://pubsubhubbub.appspot.com/"/>
    <podcast:podping usesPodping="true"/>
    <title>Medsider: Learn from Medtech and Healthtech Founders and CEOs</title>
    <generator>Transistor (https://transistor.fm)</generator>
    <itunes:new-feed-url>https://feeds.transistor.fm/medsider-learn-from-medtech-and-healthtech-experts</itunes:new-feed-url>
    <description>Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.</description>
    <copyright>© 2024 Medsider</copyright>
    <podcast:guid>d30090f8-bd89-5db0-baa8-76e97e2ed63f</podcast:guid>
    <podcast:locked owner="hello@medsider.com">no</podcast:locked>
    <language>en-us</language>
    <pubDate>Mon, 04 May 2026 16:54:12 +0000</pubDate>
    <lastBuildDate>Mon, 04 May 2026 16:54:22 +0000</lastBuildDate>
    <link>https://medsider.com</link>
    <image>
      <url>https://img.transistorcdn.com/ApMnzUivjFo0J-Usk2XujQT6jW2OHni-3IrWsC8D73k/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzM2MTYwLzE2OTUx/MzY5NjUtYXJ0d29y/ay5qcGc.jpg</url>
      <title>Medsider: Learn from Medtech and Healthtech Founders and CEOs</title>
      <link>https://medsider.com</link>
    </image>
    <itunes:category text="Business">
      <itunes:category text="Entrepreneurship"/>
    </itunes:category>
    <itunes:category text="Business">
      <itunes:category text="Management"/>
    </itunes:category>
    <itunes:type>episodic</itunes:type>
    <itunes:author>Scott Nelson</itunes:author>
    <itunes:image href="https://img.transistorcdn.com/ApMnzUivjFo0J-Usk2XujQT6jW2OHni-3IrWsC8D73k/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzM2MTYwLzE2OTUx/MzY5NjUtYXJ0d29y/ay5qcGc.jpg"/>
    <itunes:summary>Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.</itunes:summary>
    <itunes:subtitle>Learn from the brightest CEOs in medtech and healthtech.</itunes:subtitle>
    <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
    <itunes:owner>
      <itunes:name>Scott Nelson</itunes:name>
    </itunes:owner>
    <itunes:complete>No</itunes:complete>
    <itunes:explicit>No</itunes:explicit>
    <item>
      <title>Finding the Clinical Need Hiding in Plain Sight: Interview with LightForce CEO Alfred Griffin</title>
      <itunes:title>Finding the Clinical Need Hiding in Plain Sight: Interview with LightForce CEO Alfred Griffin</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">09521c33-4fe4-4bdc-a4b5-e4ceeec74a20</guid>
      <link>https://www.medsider.com/interviews/alfred-griffin-lightforce</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we sat down with <a href="https://www.linkedin.com/in/alfred-griffin-343b8153/">Alfred Griffin</a>, co-founder and CEO of <a href="https://lf.co/">LightForce</a>.</p><p>LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.</p><p>Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.</p><p>In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/alfred-griffin-lightforce">here's a link to the full interview with Alfred Griffin.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:43) - How growing up in a family of dentists shaped Alfred’s path into orthodontics</li>
<li>(07:41) - How LightForce uses digital planning and 3D printing to create fully customized braces</li>
<li>(08:48) - Why LightForce isn’t a brilliant idea, but an obvious fix for the teen braces market that aligners missed</li>
<li>(12:19) - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies</li>
<li>(17:30) - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps</li>
<li>(30:56) - The 3-part secret to LightForce adoption by physicians</li>
<li>(36:42) - How Alfred approaches fundraising, matching investors to the company’s stage and needs</li>
<li>(41:51) - About LightForce’s digital factories and why they’re the company’s core moat</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we sat down with <a href="https://www.linkedin.com/in/alfred-griffin-343b8153/">Alfred Griffin</a>, co-founder and CEO of <a href="https://lf.co/">LightForce</a>.</p><p>LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.</p><p>Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.</p><p>In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/alfred-griffin-lightforce">here's a link to the full interview with Alfred Griffin.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:43) - How growing up in a family of dentists shaped Alfred’s path into orthodontics</li>
<li>(07:41) - How LightForce uses digital planning and 3D printing to create fully customized braces</li>
<li>(08:48) - Why LightForce isn’t a brilliant idea, but an obvious fix for the teen braces market that aligners missed</li>
<li>(12:19) - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies</li>
<li>(17:30) - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps</li>
<li>(30:56) - The 3-part secret to LightForce adoption by physicians</li>
<li>(36:42) - How Alfred approaches fundraising, matching investors to the company’s stage and needs</li>
<li>(41:51) - About LightForce’s digital factories and why they’re the company’s core moat</li>
</ul>]]>
      </content:encoded>
      <pubDate>Mon, 04 May 2026 16:54:12 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a20f9f5e/3990be1b.mp3" length="121238588" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3hybhTc0nk0AiGiS3zIaiDHDu2A1dVZApqXrtiFrO4A/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wNWQw/Y2EzYzY1YTMwZWM5/OGRkY2Y4YmI1ODFm/ZDI0MC5qcGc.jpg"/>
      <itunes:duration>3030</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of Medsider Radio, we sat down with <a href="https://www.linkedin.com/in/alfred-griffin-343b8153/">Alfred Griffin</a>, co-founder and CEO of <a href="https://lf.co/">LightForce</a>.</p><p>LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.</p><p>Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.</p><p>In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/alfred-griffin-lightforce">here's a link to the full interview with Alfred Griffin.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:43) - How growing up in a family of dentists shaped Alfred’s path into orthodontics</li>
<li>(07:41) - How LightForce uses digital planning and 3D printing to create fully customized braces</li>
<li>(08:48) - Why LightForce isn’t a brilliant idea, but an obvious fix for the teen braces market that aligners missed</li>
<li>(12:19) - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies</li>
<li>(17:30) - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps</li>
<li>(30:56) - The 3-part secret to LightForce adoption by physicians</li>
<li>(36:42) - How Alfred approaches fundraising, matching investors to the company’s stage and needs</li>
<li>(41:51) - About LightForce’s digital factories and why they’re the company’s core moat</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/a20f9f5e/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/a20f9f5e/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/a20f9f5e/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/a20f9f5e/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/a20f9f5e/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/a20f9f5e/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies</title>
      <itunes:title>Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ed1b3550-7996-4ed4-99bf-7c5dd78ac93d</guid>
      <link>https://www.medsider.com/interviews/laura-yecies-osteoboost</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/laurayecies/">Laura Yecies</a>, CEO of <a href="https://www.osteoboost.com/">Osteoboost</a>.</p><p>Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.</p><p>Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. </p><p><br>In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/laura-yecies-osteoboost">here's a link to the full interview with Laura Yecies.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:49) - An overview of Laura’s background and her transition from consumer tech to medtech</li>
<li>(04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need</li>
<li>(08:31) - How Osteoboost designed its device with the consumer experience in mind</li>
<li>(15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path</li>
<li>(19:50) - How to design clinical trials that reflect real-world use and drive patient compliance</li>
<li>(25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization</li>
<li>(28:48) - Why Laura believed the problem wasn’t demand — it was lack of options</li>
<li>(33:57) - How patients can become a powerful “sales force” in healthcare</li>
<li>(38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/laurayecies/">Laura Yecies</a>, CEO of <a href="https://www.osteoboost.com/">Osteoboost</a>.</p><p>Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.</p><p>Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. </p><p><br>In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/laura-yecies-osteoboost">here's a link to the full interview with Laura Yecies.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:49) - An overview of Laura’s background and her transition from consumer tech to medtech</li>
<li>(04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need</li>
<li>(08:31) - How Osteoboost designed its device with the consumer experience in mind</li>
<li>(15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path</li>
<li>(19:50) - How to design clinical trials that reflect real-world use and drive patient compliance</li>
<li>(25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization</li>
<li>(28:48) - Why Laura believed the problem wasn’t demand — it was lack of options</li>
<li>(33:57) - How patients can become a powerful “sales force” in healthcare</li>
<li>(38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later</li>
</ul>]]>
      </content:encoded>
      <pubDate>Mon, 06 Apr 2026 20:01:44 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ae4089ee/65509b34.mp3" length="130568312" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/siOn3w7VRAL825oLT5L1_mQsJa2HnM2xXCm_giU-7C8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS84OGI1/OGRkMjY1NWU4Yjhl/NDE3NGIzMDVlYjIz/NjIyZC5qcGc.jpg"/>
      <itunes:duration>3263</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/laurayecies/">Laura Yecies</a>, CEO of <a href="https://www.osteoboost.com/">Osteoboost</a>.</p><p>Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.</p><p>Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. </p><p><br>In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/laura-yecies-osteoboost">here's a link to the full interview with Laura Yecies.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:49) - An overview of Laura’s background and her transition from consumer tech to medtech</li>
<li>(04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need</li>
<li>(08:31) - How Osteoboost designed its device with the consumer experience in mind</li>
<li>(15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path</li>
<li>(19:50) - How to design clinical trials that reflect real-world use and drive patient compliance</li>
<li>(25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization</li>
<li>(28:48) - Why Laura believed the problem wasn’t demand — it was lack of options</li>
<li>(33:57) - How patients can become a powerful “sales force” in healthcare</li>
<li>(38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/ae4089ee/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/ae4089ee/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/ae4089ee/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/ae4089ee/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/ae4089ee/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/ae4089ee/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>What It Takes to Win Physician Confidence: Interview with Secure Closure CEO Stephen Belcher</title>
      <itunes:title>What It Takes to Win Physician Confidence: Interview with Secure Closure CEO Stephen Belcher</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e8709894-862a-4e82-9973-1b46750bddb4</guid>
      <link>https://www.medsider.com/interviews/stephen-belcher-secure-closure</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marketingmedicaldevices/">Stephen Belcher</a>, co-founder and CEO of <a href="https://www.secure-closure.com/">Secure Closure</a>.</p><p>Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.</p><p>Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.</p><p>In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/stephen-belcher-secure-closure">here's a link to the full interview with Stephen Belcher.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Stephen Belcher’s background and the journey that led him to founding Secure Closure</li>
<li>(08:04) - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation</li>
<li>(13:53) - Stephen's lessons learned from large strategics and how he simplifies them for a startup</li>
<li>(19:22) - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress</li>
<li>(23:36) - Why physician adoption depends on consistent outcomes, not early excitement or new features</li>
<li>(28:10) - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures</li>
<li>(34:14) - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny</li>
<li>(40:31) - How Stephen navigates early fundraising</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marketingmedicaldevices/">Stephen Belcher</a>, co-founder and CEO of <a href="https://www.secure-closure.com/">Secure Closure</a>.</p><p>Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.</p><p>Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.</p><p>In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/stephen-belcher-secure-closure">here's a link to the full interview with Stephen Belcher.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Stephen Belcher’s background and the journey that led him to founding Secure Closure</li>
<li>(08:04) - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation</li>
<li>(13:53) - Stephen's lessons learned from large strategics and how he simplifies them for a startup</li>
<li>(19:22) - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress</li>
<li>(23:36) - Why physician adoption depends on consistent outcomes, not early excitement or new features</li>
<li>(28:10) - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures</li>
<li>(34:14) - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny</li>
<li>(40:31) - How Stephen navigates early fundraising</li>
</ul>]]>
      </content:encoded>
      <pubDate>Mon, 30 Mar 2026 13:56:05 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/049c6883/963246c7.mp3" length="122051469" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/elltk3NHI-L8LAuddx-gyj6zUEchF7WeCCDp3vqOVAo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jOWM2/NWNmZjIzNGYxMDU4/MmM5Mzc4YWY4NWI4/NDcwZS5qcGc.jpg"/>
      <itunes:duration>3050</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marketingmedicaldevices/">Stephen Belcher</a>, co-founder and CEO of <a href="https://www.secure-closure.com/">Secure Closure</a>.</p><p>Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.</p><p>Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.</p><p>In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/stephen-belcher-secure-closure">here's a link to the full interview with Stephen Belcher.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Stephen Belcher’s background and the journey that led him to founding Secure Closure</li>
<li>(08:04) - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation</li>
<li>(13:53) - Stephen's lessons learned from large strategics and how he simplifies them for a startup</li>
<li>(19:22) - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress</li>
<li>(23:36) - Why physician adoption depends on consistent outcomes, not early excitement or new features</li>
<li>(28:10) - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures</li>
<li>(34:14) - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny</li>
<li>(40:31) - How Stephen navigates early fundraising</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/049c6883/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/049c6883/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/049c6883/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/049c6883/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/049c6883/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/049c6883/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay</title>
      <itunes:title>The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">1e1fa5fb-2661-4000-b0dd-ad71bf1686c5</guid>
      <link>https://www.medsider.com/interviews/daniel-estay-sonovascular</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/daniel-estay-22a07271/">Daniel Estay</a>, founder and CEO of <a href="https://www.sonovascular.com/">SonoVascular</a>.</p><p>SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.</p><p>Dan has over 35 years of global medtech experience, including business development roles at Johnson &amp; Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.</p><p>In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/daniel-estay-sonovascular">here's a link to the full interview with Daniel Estay.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Dan Estay’s background and the journey that led him to SonoVascular</li>
<li>(08:04) - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis</li>
<li>(13:33) - Why differentiation alone isn’t enough, and how Dan evaluates market size and viability before building</li>
<li>(18:38) - The four risks every medtech founder should assess: technical, clinical, regulatory, and market</li>
<li>(21:55) - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site</li>
<li>(29:05) - Why Dan would rethink his use of convertible notes and approach the cap table more strategically</li>
<li>(38:28) - Why grants should supplement your funding strategy, not lead it</li>
<li>(42:46) - What Dan looks for when hiring for startups</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/daniel-estay-22a07271/">Daniel Estay</a>, founder and CEO of <a href="https://www.sonovascular.com/">SonoVascular</a>.</p><p>SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.</p><p>Dan has over 35 years of global medtech experience, including business development roles at Johnson &amp; Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.</p><p>In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/daniel-estay-sonovascular">here's a link to the full interview with Daniel Estay.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Dan Estay’s background and the journey that led him to SonoVascular</li>
<li>(08:04) - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis</li>
<li>(13:33) - Why differentiation alone isn’t enough, and how Dan evaluates market size and viability before building</li>
<li>(18:38) - The four risks every medtech founder should assess: technical, clinical, regulatory, and market</li>
<li>(21:55) - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site</li>
<li>(29:05) - Why Dan would rethink his use of convertible notes and approach the cap table more strategically</li>
<li>(38:28) - Why grants should supplement your funding strategy, not lead it</li>
<li>(42:46) - What Dan looks for when hiring for startups</li>
</ul>]]>
      </content:encoded>
      <pubDate>Mon, 23 Mar 2026 20:13:17 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e0d9cb47/9bb26b2f.mp3" length="123680971" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/by63tmvuCRK6oRW-AlwXaewAIrwVToZGVCo4ObYUx98/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82NGY5/MWFhZGM3MWM3OTQx/ZDBiN2E5M2NiZTJj/MjRjMC5qcGc.jpg"/>
      <itunes:duration>3091</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/daniel-estay-22a07271/">Daniel Estay</a>, founder and CEO of <a href="https://www.sonovascular.com/">SonoVascular</a>.</p><p>SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.</p><p>Dan has over 35 years of global medtech experience, including business development roles at Johnson &amp; Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.</p><p>In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/daniel-estay-sonovascular">here's a link to the full interview with Daniel Estay.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:52) - An overview of Dan Estay’s background and the journey that led him to SonoVascular</li>
<li>(08:04) - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis</li>
<li>(13:33) - Why differentiation alone isn’t enough, and how Dan evaluates market size and viability before building</li>
<li>(18:38) - The four risks every medtech founder should assess: technical, clinical, regulatory, and market</li>
<li>(21:55) - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site</li>
<li>(29:05) - Why Dan would rethink his use of convertible notes and approach the cap table more strategically</li>
<li>(38:28) - Why grants should supplement your funding strategy, not lead it</li>
<li>(42:46) - What Dan looks for when hiring for startups</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/e0d9cb47/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/e0d9cb47/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/e0d9cb47/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/e0d9cb47/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/e0d9cb47/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/e0d9cb47/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>Testing Demand Before Perfecting Technology: Interview with Eyebot CEO Matthias Hofmann</title>
      <itunes:title>Testing Demand Before Perfecting Technology: Interview with Eyebot CEO Matthias Hofmann</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">eb3302af-6fb3-4787-a38a-3684c9bb53eb</guid>
      <link>https://www.medsider.com/interviews/matthias-hofmann-eyebot</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mchofmann/">Matthias Hofmann</a>, CEO of <a href="https://www.eyebot.co/">Eyebot</a>.</p><p>Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.</p><p>Before Eyebot, Matthias led product development at Formlabs and served as an R&amp;D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. </p><p>In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/matthias-hofmann-eyebot">here's a link to the full interview with Matthias Hofmann.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:53) - Overview of Matthias’s background and the journey that led him into vision care startups</li>
<li>(05:58) - Lessons from solving the right problem the wrong way at EyeNetra</li>
<li>(08:44) - Why Eyebot chose a kiosk interface instead of smartphone vision testing</li>
<li>(11:08) - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds</li>
<li>(18:17) - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall</li>
<li>(29:01) - How clinical studies and iteration built the evidence retailers needed to trust the technology</li>
<li>(33:17) - What commercialization revealed about consumer behavior in eyewear retail</li>
<li>(37:07) - Matthias’s fundraising advice: run your raise over Zoom and don’t lead with your pitch deck</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mchofmann/">Matthias Hofmann</a>, CEO of <a href="https://www.eyebot.co/">Eyebot</a>.</p><p>Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.</p><p>Before Eyebot, Matthias led product development at Formlabs and served as an R&amp;D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. </p><p>In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/matthias-hofmann-eyebot">here's a link to the full interview with Matthias Hofmann.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:53) - Overview of Matthias’s background and the journey that led him into vision care startups</li>
<li>(05:58) - Lessons from solving the right problem the wrong way at EyeNetra</li>
<li>(08:44) - Why Eyebot chose a kiosk interface instead of smartphone vision testing</li>
<li>(11:08) - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds</li>
<li>(18:17) - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall</li>
<li>(29:01) - How clinical studies and iteration built the evidence retailers needed to trust the technology</li>
<li>(33:17) - What commercialization revealed about consumer behavior in eyewear retail</li>
<li>(37:07) - Matthias’s fundraising advice: run your raise over Zoom and don’t lead with your pitch deck</li>
</ul>]]>
      </content:encoded>
      <pubDate>Mon, 16 Mar 2026 23:56:27 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/187fe16f/45bbede2.mp3" length="120653645" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/oo3ap5Egv-6Wq9v_lST4sHK1oMOor4dv3tWYARuDI54/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS84MWRk/NmUzY2VjNzUyYjYz/ZmQ0YmYxZDY4MjRl/NjZiYy5qcGc.jpg"/>
      <itunes:duration>3016</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mchofmann/">Matthias Hofmann</a>, CEO of <a href="https://www.eyebot.co/">Eyebot</a>.</p><p>Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.</p><p>Before Eyebot, Matthias led product development at Formlabs and served as an R&amp;D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. </p><p>In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/matthias-hofmann-eyebot">here's a link to the full interview with Matthias Hofmann.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(02:53) - Overview of Matthias’s background and the journey that led him into vision care startups</li>
<li>(05:58) - Lessons from solving the right problem the wrong way at EyeNetra</li>
<li>(08:44) - Why Eyebot chose a kiosk interface instead of smartphone vision testing</li>
<li>(11:08) - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds</li>
<li>(18:17) - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall</li>
<li>(29:01) - How clinical studies and iteration built the evidence retailers needed to trust the technology</li>
<li>(33:17) - What commercialization revealed about consumer behavior in eyewear retail</li>
<li>(37:07) - Matthias’s fundraising advice: run your raise over Zoom and don’t lead with your pitch deck</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/187fe16f/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/187fe16f/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/187fe16f/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/187fe16f/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/187fe16f/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/187fe16f/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>How to Decide Where to Deploy Capital in Growth-Stage Medtech: Interview with CMR Surgical CEO Massimiliano (Max) Colella</title>
      <itunes:title>How to Decide Where to Deploy Capital in Growth-Stage Medtech: Interview with CMR Surgical CEO Massimiliano (Max) Colella</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e2be74e6-3c7d-4843-bf66-e28db2ae62ba</guid>
      <link>https://www.medsider.com/interviews/max-colella-cmr-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/massimilianocolellajnj/"> Massimiliano (Max) Colella</a>, CEO of<a href="https://cmrsurgical.com/"> CMR Surgical</a>.</p><p>CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.</p><p>Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson &amp; Johnson and Smith &amp; Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.</p><p>In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/max-colella-cmr-surgical">here's a link to the full interview with Max Colella.</a> </p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:08) - An overview of Max's background and the journey that led him to CMR Surgical</li>
<li>(06:53) - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems</li>
<li>(16:18) - How Max restructured internal processes at CMR to eliminate large-company bureaucracy</li>
<li>(21:09) - How market research reshaped CMR’s U.S. strategy beyond ambulatory surgery centers</li>
<li>(28:48) - Max’s capital allocation philosophy: prioritize system performance and stability before expanding capabilities</li>
<li>(32:19) - Max's take on Techmed and the future of robotics</li>
<li>(36:36) - Why clearly defined roles between board and management are critical for governance</li>
<li>(41:10) - Max’s philosophy around hiring for mindset over skill</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/massimilianocolellajnj/"> Massimiliano (Max) Colella</a>, CEO of<a href="https://cmrsurgical.com/"> CMR Surgical</a>.</p><p>CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.</p><p>Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson &amp; Johnson and Smith &amp; Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.</p><p>In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/max-colella-cmr-surgical">here's a link to the full interview with Max Colella.</a> </p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:08) - An overview of Max's background and the journey that led him to CMR Surgical</li>
<li>(06:53) - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems</li>
<li>(16:18) - How Max restructured internal processes at CMR to eliminate large-company bureaucracy</li>
<li>(21:09) - How market research reshaped CMR’s U.S. strategy beyond ambulatory surgery centers</li>
<li>(28:48) - Max’s capital allocation philosophy: prioritize system performance and stability before expanding capabilities</li>
<li>(32:19) - Max's take on Techmed and the future of robotics</li>
<li>(36:36) - Why clearly defined roles between board and management are critical for governance</li>
<li>(41:10) - Max’s philosophy around hiring for mindset over skill</li>
</ul>]]>
      </content:encoded>
      <pubDate>Tue, 10 Mar 2026 17:42:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/fe537d08/1c89b126.mp3" length="118472376" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/6dWp1rZcXlLIXHXOVDHJCYpLZ7neEUh_cB_LtMuE3B8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lNDIw/YjE0NTEyYzY3NWMz/NWNhMDljYTQyZTVi/MDg0MS5qcGc.jpg"/>
      <itunes:duration>2961</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/massimilianocolellajnj/"> Massimiliano (Max) Colella</a>, CEO of<a href="https://cmrsurgical.com/"> CMR Surgical</a>.</p><p>CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.</p><p>Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson &amp; Johnson and Smith &amp; Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.</p><p>In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/max-colella-cmr-surgical">here's a link to the full interview with Max Colella.</a> </p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:08) - An overview of Max's background and the journey that led him to CMR Surgical</li>
<li>(06:53) - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems</li>
<li>(16:18) - How Max restructured internal processes at CMR to eliminate large-company bureaucracy</li>
<li>(21:09) - How market research reshaped CMR’s U.S. strategy beyond ambulatory surgery centers</li>
<li>(28:48) - Max’s capital allocation philosophy: prioritize system performance and stability before expanding capabilities</li>
<li>(32:19) - Max's take on Techmed and the future of robotics</li>
<li>(36:36) - Why clearly defined roles between board and management are critical for governance</li>
<li>(41:10) - Max’s philosophy around hiring for mindset over skill</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/fe537d08/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/fe537d08/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/fe537d08/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/fe537d08/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/fe537d08/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/fe537d08/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>Designing Consumer-Facing Medical Technology: Interview with Indomo CEO Rick Bente</title>
      <itunes:title>Designing Consumer-Facing Medical Technology: Interview with Indomo CEO Rick Bente</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">f506f38b-1723-4c8e-88ac-407541a3e56b</guid>
      <link>https://www.medsider.com/interviews/rick-bente-indomo</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rick-bente/">Rick Bente</a>, co-founder and CEO of <a href="https://www.indomotx.com/">Indomo</a>.</p><p>Indomo’s flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.</p><p>Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.</p><p>In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/rick-bente-indomo">here's a link to the full interview with Rick Bente.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:39) - An overview of Rick’s background and the mission behind Indomo</li>
<li>(08:24) - The core idea behind Indomo’s ClearPen — bringing dermatologist treatments into patients’ homes</li>
<li>(13:32) - Why early-stage startups should fail fast on the hardest technical problems</li>
<li>(16:41) - How to design medical devices that are easy to use and difficult to misuse</li>
<li>(21:17) - How usability studies with patients and physicians shape better device design</li>
<li>(23:59) - When should a startup stay in stealth — and when is it time to tell the story?</li>
<li>(28:52) - Rick's fundraising playbook: mapping capital to milestones and real value creation</li>
<li>(37:22) - Rick's hiring lesson: why curiosity matters more than pedigree when building an early-stage startup team</li>
</ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rick-bente/">Rick Bente</a>, co-founder and CEO of <a href="https://www.indomotx.com/">Indomo</a>.</p><p>Indomo’s flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.</p><p>Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.</p><p>In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/rick-bente-indomo">here's a link to the full interview with Rick Bente.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:39) - An overview of Rick’s background and the mission behind Indomo</li>
<li>(08:24) - The core idea behind Indomo’s ClearPen — bringing dermatologist treatments into patients’ homes</li>
<li>(13:32) - Why early-stage startups should fail fast on the hardest technical problems</li>
<li>(16:41) - How to design medical devices that are easy to use and difficult to misuse</li>
<li>(21:17) - How usability studies with patients and physicians shape better device design</li>
<li>(23:59) - When should a startup stay in stealth — and when is it time to tell the story?</li>
<li>(28:52) - Rick's fundraising playbook: mapping capital to milestones and real value creation</li>
<li>(37:22) - Rick's hiring lesson: why curiosity matters more than pedigree when building an early-stage startup team</li>
</ul>]]>
      </content:encoded>
      <pubDate>Tue, 24 Feb 2026 17:54:02 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3f476c1d/7c198840.mp3" length="119856335" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/GtxDGXxcOBw1T7DenDTGViNkQaOYIOuk2QzobBJ9XpQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81MDQ4/MmNmZTQ3MGFjMDA1/NjRlZWYyOTYxYWI0/ZjM2MS5qcGc.jpg"/>
      <itunes:duration>2996</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rick-bente/">Rick Bente</a>, co-founder and CEO of <a href="https://www.indomotx.com/">Indomo</a>.</p><p>Indomo’s flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.</p><p>Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.</p><p>In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/rick-bente-indomo">here's a link to the full interview with Rick Bente.</a></p><p><strong>KEY MOMENTS FROM THE INTERVIEW</strong><br></p><ul><li>(03:39) - An overview of Rick’s background and the mission behind Indomo</li>
<li>(08:24) - The core idea behind Indomo’s ClearPen — bringing dermatologist treatments into patients’ homes</li>
<li>(13:32) - Why early-stage startups should fail fast on the hardest technical problems</li>
<li>(16:41) - How to design medical devices that are easy to use and difficult to misuse</li>
<li>(21:17) - How usability studies with patients and physicians shape better device design</li>
<li>(23:59) - When should a startup stay in stealth — and when is it time to tell the story?</li>
<li>(28:52) - Rick's fundraising playbook: mapping capital to milestones and real value creation</li>
<li>(37:22) - Rick's hiring lesson: why curiosity matters more than pedigree when building an early-stage startup team</li>
</ul>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/3f476c1d/transcription.vtt" type="text/vtt" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/3f476c1d/transcription.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/3f476c1d/transcription.json" type="application/json" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/3f476c1d/transcription.txt" type="text/plain"/>
      <podcast:transcript url="https://share.transistor.fm/s/3f476c1d/transcription" type="text/html"/>
      <podcast:chapters url="https://share.transistor.fm/s/3f476c1d/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>Why Commercial Discipline Starts Long Before Launch: Interview with RenovoRx CEO Shaun Bagai</title>
      <itunes:title>Why Commercial Discipline Starts Long Before Launch: Interview with RenovoRx CEO Shaun Bagai</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b61841fc-77d9-47d2-8c50-5f6dd2102638</guid>
      <link>https://www.medsider.com/interviews/shaun-bagai-renovoRx</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shaun-r-bagai/">Shaun Bagai</a>, CEO of <a href="https://www.linkedin.com/company/renovorx/">RenovoRx</a>. </p><p><br>The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer. </p><p>Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic. </p><p>In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/shaun-bagai-renovoRx">here's a link to the full interview with Shaun Bagai.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shaun-r-bagai/">Shaun Bagai</a>, CEO of <a href="https://www.linkedin.com/company/renovorx/">RenovoRx</a>. </p><p><br>The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer. </p><p>Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic. </p><p>In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/shaun-bagai-renovoRx">here's a link to the full interview with Shaun Bagai.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 17 Feb 2026 20:55:32 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d767aef6/2d577aa8.mp3" length="135535415" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/kRubqdPJ2YyzW-VpKMmFxCKLTqKbL-LDsfpmPTTcndg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iZTEz/NjY4MzMxMWVkYTFj/ZmIwNTlmYjkzODIx/M2Y1Yi5qcGc.jpg"/>
      <itunes:duration>3388</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shaun-r-bagai/">Shaun Bagai</a>, CEO of <a href="https://www.linkedin.com/company/renovorx/">RenovoRx</a>. </p><p><br>The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer. </p><p>Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic. </p><p>In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/shaun-bagai-renovoRx">here's a link to the full interview with Shaun Bagai.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Using Private Capital to Preserve Control: Interview with SynerFuse CEO Justin Zenanko</title>
      <itunes:title>Using Private Capital to Preserve Control: Interview with SynerFuse CEO Justin Zenanko</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a908eaf1-f650-4d21-bf49-1cfa1f10e03a</guid>
      <link>https://www.medsider.com/interviews/justin-zenanko-synerfuse</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/justin-zenanko-83641864">Justin Zenanko</a>, co-founder &amp; CEO of <a href="https://www.synerfuse.com/">SynerFuse</a>.</p><p>SynerFuse is developing the e-TLIF procedure, which combines spinal fusion with neuromodulation by placing leads directly at exposed nerves during surgery.</p><p>A certified public accountant and serial entrepreneur, Justin previously served as CFO and senior vice president of corporate development at Recombinetics, where he led fundraising efforts totaling $68 million.</p><p>In this interview, Justin discusses approaching FDA interactions as negotiations, validating procedures with off-the-shelf components before investing in custom devices, and structuring private raises through investment banks to preserve control while delaying institutional venture capital.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/justin-zenanko-synerfuse">here's a link to the full interview with Justin Zenanko.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/justin-zenanko-83641864">Justin Zenanko</a>, co-founder &amp; CEO of <a href="https://www.synerfuse.com/">SynerFuse</a>.</p><p>SynerFuse is developing the e-TLIF procedure, which combines spinal fusion with neuromodulation by placing leads directly at exposed nerves during surgery.</p><p>A certified public accountant and serial entrepreneur, Justin previously served as CFO and senior vice president of corporate development at Recombinetics, where he led fundraising efforts totaling $68 million.</p><p>In this interview, Justin discusses approaching FDA interactions as negotiations, validating procedures with off-the-shelf components before investing in custom devices, and structuring private raises through investment banks to preserve control while delaying institutional venture capital.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/justin-zenanko-synerfuse">here's a link to the full interview with Justin Zenanko.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 10 Feb 2026 21:21:09 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/442e0ef5/ebbb9b16.mp3" length="137304439" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/kN-IFNc2KHmiGLSsEpOWIsn1JzRhIvvMw5sS82ht-2c/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xYWNj/NmJhMDQ1YjhkNzJi/ZTA2MDRkNTRmZGEx/M2YxOS5qcGc.jpg"/>
      <itunes:duration>3432</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/justin-zenanko-83641864">Justin Zenanko</a>, co-founder &amp; CEO of <a href="https://www.synerfuse.com/">SynerFuse</a>.</p><p>SynerFuse is developing the e-TLIF procedure, which combines spinal fusion with neuromodulation by placing leads directly at exposed nerves during surgery.</p><p>A certified public accountant and serial entrepreneur, Justin previously served as CFO and senior vice president of corporate development at Recombinetics, where he led fundraising efforts totaling $68 million.</p><p>In this interview, Justin discusses approaching FDA interactions as negotiations, validating procedures with off-the-shelf components before investing in custom devices, and structuring private raises through investment banks to preserve control while delaying institutional venture capital.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/justin-zenanko-synerfuse">here's a link to the full interview with Justin Zenanko.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Small UX Details Can Matter More Than Years of R&amp;D: Interview with Eli Health CEO Marina Pavlovic Rivas</title>
      <itunes:title>Why Small UX Details Can Matter More Than Years of R&amp;D: Interview with Eli Health CEO Marina Pavlovic Rivas</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7e807aa2-3f3f-402b-892e-e53cedbe1410</guid>
      <link>https://www.medsider.com/interviews/marina-pavlovic-rivas-eli-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marinapavlovicrivas/">Marina Pavlovic Rivas</a>, co-founder &amp; CEO of <a href="https://eli.health/">Eli Health</a>.</p><p>The company is focused on making hormone data accessible in real time through its saliva-based testing system that delivers results through a mobile app. </p><p>A data scientist by training, Marina previously founded Gradiant AI, a machine learning company that was acquired in 2019. </p><p>In this interview, Marina discusses how to evaluate form factor options without locking into a design too early, what beta testing reveals that years of lab work can't, and how existing consumer spending patterns influence positioning and pricing strategies. She also shares how regulatory considerations shaped product decisions from the outset and why building in-house proved more efficient than outsourcing when external partners said the company’s goals were impossible.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/marina-pavlovic-rivas-eli-health">here's a link to the full interview with Marina Pavlovic Rivas.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marinapavlovicrivas/">Marina Pavlovic Rivas</a>, co-founder &amp; CEO of <a href="https://eli.health/">Eli Health</a>.</p><p>The company is focused on making hormone data accessible in real time through its saliva-based testing system that delivers results through a mobile app. </p><p>A data scientist by training, Marina previously founded Gradiant AI, a machine learning company that was acquired in 2019. </p><p>In this interview, Marina discusses how to evaluate form factor options without locking into a design too early, what beta testing reveals that years of lab work can't, and how existing consumer spending patterns influence positioning and pricing strategies. She also shares how regulatory considerations shaped product decisions from the outset and why building in-house proved more efficient than outsourcing when external partners said the company’s goals were impossible.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/marina-pavlovic-rivas-eli-health">here's a link to the full interview with Marina Pavlovic Rivas.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 27 Jan 2026 18:07:05 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0830440c/c82dd07c.mp3" length="120727834" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/H4TLKfV9NQ9Q4OVNmhNLX7I9VqlZ04wzQxiuWQT2lVg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NTIz/YWQ1OGI0NWNiNzA1/MGEyNjU3YjRhZDZi/ZWI1Ny5qcGc.jpg"/>
      <itunes:duration>3017</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marinapavlovicrivas/">Marina Pavlovic Rivas</a>, co-founder &amp; CEO of <a href="https://eli.health/">Eli Health</a>.</p><p>The company is focused on making hormone data accessible in real time through its saliva-based testing system that delivers results through a mobile app. </p><p>A data scientist by training, Marina previously founded Gradiant AI, a machine learning company that was acquired in 2019. </p><p>In this interview, Marina discusses how to evaluate form factor options without locking into a design too early, what beta testing reveals that years of lab work can't, and how existing consumer spending patterns influence positioning and pricing strategies. She also shares how regulatory considerations shaped product decisions from the outset and why building in-house proved more efficient than outsourcing when external partners said the company’s goals were impossible.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/marina-pavlovic-rivas-eli-health">here's a link to the full interview with Marina Pavlovic Rivas.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building Fast Without Cutting Corners: Interview with Excision Medical CEO Greg Walters</title>
      <itunes:title>Building Fast Without Cutting Corners: Interview with Excision Medical CEO Greg Walters</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a688f46f-a07e-4002-bca0-6c6ad947e4cf</guid>
      <link>https://www.medsider.com/interviews/greg-walters-excision-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-walters-7b5a2917/">Greg Walters</a>, co-founder &amp; CEO of <a href="https://www.excisionmed.com/">Excision Medical</a>. Excision is developing a leaflet modification system to enable lifetime management of aortic stenosis.</p><p>Greg has almost 40 years of experience in cardiovascular devices, holding leadership roles at Kensey Nash Corporation where he led the development of Angio-Seal and several endovascular programs. He later co-founded Essential Medical, which was acquired by Teleflex in 2018, and is an inventor on more than 75 U.S. and European patents.</p><p>In this interview, Greg discusses why early-stage teams should build to learn rather than to impress, using functional prototypes to generate real feedback and fundraising momentum. He outlines how disciplined safety work — not perfection — defines first-in-human readiness, and what makes a pre-revenue company attractive to strategic acquirers. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-walters-excision-medical">here's a link to the full interview with Greg Walters.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-walters-7b5a2917/">Greg Walters</a>, co-founder &amp; CEO of <a href="https://www.excisionmed.com/">Excision Medical</a>. Excision is developing a leaflet modification system to enable lifetime management of aortic stenosis.</p><p>Greg has almost 40 years of experience in cardiovascular devices, holding leadership roles at Kensey Nash Corporation where he led the development of Angio-Seal and several endovascular programs. He later co-founded Essential Medical, which was acquired by Teleflex in 2018, and is an inventor on more than 75 U.S. and European patents.</p><p>In this interview, Greg discusses why early-stage teams should build to learn rather than to impress, using functional prototypes to generate real feedback and fundraising momentum. He outlines how disciplined safety work — not perfection — defines first-in-human readiness, and what makes a pre-revenue company attractive to strategic acquirers. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-walters-excision-medical">here's a link to the full interview with Greg Walters.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 21 Jan 2026 02:37:26 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e787b2be/3aa6294c.mp3" length="128208030" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3neHm1qdk2Vu8VyBZ22Se6D2AYYhcRnalgxZKR9utbE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xODZj/NjNmYzQ2NWY1YWE0/MDdkMGM1ZjZhNjRk/ZjIzMy5qcGc.jpg"/>
      <itunes:duration>3204</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-walters-7b5a2917/">Greg Walters</a>, co-founder &amp; CEO of <a href="https://www.excisionmed.com/">Excision Medical</a>. Excision is developing a leaflet modification system to enable lifetime management of aortic stenosis.</p><p>Greg has almost 40 years of experience in cardiovascular devices, holding leadership roles at Kensey Nash Corporation where he led the development of Angio-Seal and several endovascular programs. He later co-founded Essential Medical, which was acquired by Teleflex in 2018, and is an inventor on more than 75 U.S. and European patents.</p><p>In this interview, Greg discusses why early-stage teams should build to learn rather than to impress, using functional prototypes to generate real feedback and fundraising momentum. He outlines how disciplined safety work — not perfection — defines first-in-human readiness, and what makes a pre-revenue company attractive to strategic acquirers. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p><br></p><p>First, if you’re into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/subscribe">Medsider.com</a> and sign up for our free newsletter.</p><p><br></p><p>And if you’re ready to level up your medtech game, you should check out <a href="https://medsider.com/courses">Medsider Courses</a> — 8-week masterclasses covering topics like fundraising, M&amp;A and exit planning, design and development, clinical and regulatory strategy, and commercialization.</p><p><br>These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our <a href="https://medsider.com/subscribe">All-Access Pass</a>.</p><p><br></p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-walters-excision-medical">here's a link to the full interview with Greg Walters.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building Faster by Questioning Dogma: Interview with Future Cardia CEO Jaeson Bang</title>
      <itunes:title>Building Faster by Questioning Dogma: Interview with Future Cardia CEO Jaeson Bang</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">92f2bafc-773f-47d9-b48a-b928047d6d61</guid>
      <link>https://www.medsider.com/interviews/jaeson-bang-future-cardia</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jaeson-bang-1a29aa1a">Jaeson Bang</a>, Founder &amp; CEO of <a href="https://www.futurecardia.com/">Future Cardia</a>. Future Cardia is developing a subcutaneous heart-failure monitoring platform designed to capture both electrical and mechanical cardiac signals through a simple office-based procedure.</p><p><br>Jaeson brings more than two decades of experience building implantable cardiac technologies across Medtronic, CVRx, EBR Systems, and Abiomed. Drawing on that background, he questioned industry assumptions around miniaturization and invasive workflows — and built a device that prioritizes performance, durability, and clinical practicality instead.</p><p><br>In this interview, Jaeson shares how challenging a core constraint unlocked a faster development path, why deep domain expertise matters more than thrift in regulated markets, and how raising capital outside traditional VC can preserve leverage and buy time.</p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/jaeson-bang-future-cardia">here's a link to the full interview with Jaeson Bang.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jaeson-bang-1a29aa1a">Jaeson Bang</a>, Founder &amp; CEO of <a href="https://www.futurecardia.com/">Future Cardia</a>. Future Cardia is developing a subcutaneous heart-failure monitoring platform designed to capture both electrical and mechanical cardiac signals through a simple office-based procedure.</p><p><br>Jaeson brings more than two decades of experience building implantable cardiac technologies across Medtronic, CVRx, EBR Systems, and Abiomed. Drawing on that background, he questioned industry assumptions around miniaturization and invasive workflows — and built a device that prioritizes performance, durability, and clinical practicality instead.</p><p><br>In this interview, Jaeson shares how challenging a core constraint unlocked a faster development path, why deep domain expertise matters more than thrift in regulated markets, and how raising capital outside traditional VC can preserve leverage and buy time.</p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/jaeson-bang-future-cardia">here's a link to the full interview with Jaeson Bang.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 13 Jan 2026 21:48:27 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/19dfc6ff/62fc3d54.mp3" length="132381195" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ITrDaRnnnsbSmL3_OfURew_mldPBqUTIw0Efb77OlIc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYzZi/MGNjYjI5MWE1ZDNi/YWI3OWIwNjQ4MTE2/ZWUwNy5qcGc.jpg"/>
      <itunes:duration>3309</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jaeson-bang-1a29aa1a">Jaeson Bang</a>, Founder &amp; CEO of <a href="https://www.futurecardia.com/">Future Cardia</a>. Future Cardia is developing a subcutaneous heart-failure monitoring platform designed to capture both electrical and mechanical cardiac signals through a simple office-based procedure.</p><p><br>Jaeson brings more than two decades of experience building implantable cardiac technologies across Medtronic, CVRx, EBR Systems, and Abiomed. Drawing on that background, he questioned industry assumptions around miniaturization and invasive workflows — and built a device that prioritizes performance, durability, and clinical practicality instead.</p><p><br>In this interview, Jaeson shares how challenging a core constraint unlocked a faster development path, why deep domain expertise matters more than thrift in regulated markets, and how raising capital outside traditional VC can preserve leverage and buy time.</p><p>If you'd rather read than listen, <a href="https://www.medsider.com/interviews/jaeson-bang-future-cardia">here's a link to the full interview with Jaeson Bang.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec</title>
      <itunes:title>The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a9097ba2-7a18-49ac-80ec-1feba9893a7d</guid>
      <link>https://www.medsider.com/interviews/adam-kadlec-rivermark-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down <a href="https://www.linkedin.com/in/adam-kadlec-195a67b2/">Dr. Adam Kadlec</a>, practicing urologist and co-founder of <a href="https://www.rivermarkmedical.com/">Rivermark Medical</a>.</p><p>Rivermark is a clinical-stage company developing FloStent, a first-line, reversible device therapy for benign prostatic hyperplasia (BPH).</p><p>Before launching Rivermark, Adam built a thriving urological practice in Milwaukee and consulted for several device companies — experiences that ultimately revealed how early true device development begins and why physicians rarely get the chance to influence innovation upstream. Partnering with medtech operator Andy Doraiswamy, Adam transitioned from clinician to CEO and is now leading Rivermark through its pivotal trial.</p><p>In this interview, Adam shares why workflow integration is one of the most overlooked drivers of adoption, how physician-innovators can build the right decision-making infrastructure, and why understanding who <em>actually</em> enrolls patients at clinical sites can make or break a trial. He also touches on the mindset required to stay resilient through the ups and downs of building a medtech startup.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/adam-kadlec-rivermark-medical">here's a link to the full interview with Adam Kadlec.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down <a href="https://www.linkedin.com/in/adam-kadlec-195a67b2/">Dr. Adam Kadlec</a>, practicing urologist and co-founder of <a href="https://www.rivermarkmedical.com/">Rivermark Medical</a>.</p><p>Rivermark is a clinical-stage company developing FloStent, a first-line, reversible device therapy for benign prostatic hyperplasia (BPH).</p><p>Before launching Rivermark, Adam built a thriving urological practice in Milwaukee and consulted for several device companies — experiences that ultimately revealed how early true device development begins and why physicians rarely get the chance to influence innovation upstream. Partnering with medtech operator Andy Doraiswamy, Adam transitioned from clinician to CEO and is now leading Rivermark through its pivotal trial.</p><p>In this interview, Adam shares why workflow integration is one of the most overlooked drivers of adoption, how physician-innovators can build the right decision-making infrastructure, and why understanding who <em>actually</em> enrolls patients at clinical sites can make or break a trial. He also touches on the mindset required to stay resilient through the ups and downs of building a medtech startup.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/adam-kadlec-rivermark-medical">here's a link to the full interview with Adam Kadlec.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 16 Dec 2025 15:46:20 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/17081e54/59e90e85.mp3" length="76635128" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/RCH1rmWwzx8G4a2fbHw-NQuM7NyGLSn0M2K9u8msYIg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yOWVj/OTdiMzkxYmZmNDE2/OTQ1MDQ2NjFlY2M4/OGE3NC5qcGc.jpg"/>
      <itunes:duration>3454</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down <a href="https://www.linkedin.com/in/adam-kadlec-195a67b2/">Dr. Adam Kadlec</a>, practicing urologist and co-founder of <a href="https://www.rivermarkmedical.com/">Rivermark Medical</a>.</p><p>Rivermark is a clinical-stage company developing FloStent, a first-line, reversible device therapy for benign prostatic hyperplasia (BPH).</p><p>Before launching Rivermark, Adam built a thriving urological practice in Milwaukee and consulted for several device companies — experiences that ultimately revealed how early true device development begins and why physicians rarely get the chance to influence innovation upstream. Partnering with medtech operator Andy Doraiswamy, Adam transitioned from clinician to CEO and is now leading Rivermark through its pivotal trial.</p><p>In this interview, Adam shares why workflow integration is one of the most overlooked drivers of adoption, how physician-innovators can build the right decision-making infrastructure, and why understanding who <em>actually</em> enrolls patients at clinical sites can make or break a trial. He also touches on the mindset required to stay resilient through the ups and downs of building a medtech startup.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/adam-kadlec-rivermark-medical">here's a link to the full interview with Adam Kadlec.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD</title>
      <itunes:title>Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ca0a689b-c0df-4715-9876-4cb3038aa18f</guid>
      <link>https://www.medsider.com/interviews/andrew-holman-inmedix</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/andrewjholman/">Andrew Holman</a>, MD, CEO of <a href="https://inmedix.com/">Inmedix</a>. </p><p>Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.</p><p>Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.</p><p>In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/andrew-holman-inmedix">here's a link to the full interview with Andrew Holman.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/andrewjholman/">Andrew Holman</a>, MD, CEO of <a href="https://inmedix.com/">Inmedix</a>. </p><p>Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.</p><p>Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.</p><p>In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/andrew-holman-inmedix">here's a link to the full interview with Andrew Holman.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 10 Dec 2025 00:34:11 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f7fff545/09b2e1c9.mp3" length="126006456" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Kms-8BKGFizMW-ZAv1uca9zNKEMhWiyuxnyju8NcINA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hOWE5/MWVjYTAxMjI5YWY0/MGY3OGVhZWM5M2Nl/MTk0Yy5qcGc.jpg"/>
      <itunes:duration>3150</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/andrewjholman/">Andrew Holman</a>, MD, CEO of <a href="https://inmedix.com/">Inmedix</a>. </p><p>Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.</p><p>Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.</p><p>In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/andrew-holman-inmedix">here's a link to the full interview with Andrew Holman.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Build Evidence in Layers, Not Leaps: Interview with May Health CEO Colby Holtshouse</title>
      <itunes:title>Build Evidence in Layers, Not Leaps: Interview with May Health CEO Colby Holtshouse</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7af6aff0-2584-4277-9d9a-f6cf08d78967</guid>
      <link>https://www.medsider.com/interviews/colby-holtshouse-may-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/colbymcg/">Colby Holtshouse</a>, President and CEO of <a href="https://mayhealth.com/">May Health.<br></a><br></p><p>May Health is developing a minimally invasive ovarian ablation therapy designed to restore ovulation in women with polycystic ovary syndrome (PCOS) and PCOS-related infertility.</p><p>Before May Health, Colby served as Global Medtech Commercial Lead at Organon, overseeing the worldwide launch of the Jada System following Organon’s acquisition of Alydia Health, where she held roles including COO, Interim CEO, and VP of Marketing. She has also held leadership positions at Pelvalon, AccessClosure, Medtronic, and Guidant.</p><p>In this discussion, Colby shares why early clinical evidence should be built in focused layers rather than oversized, all-at-once trials. She explains how a small, deliberate early launch can reveal the workflow nuances and real-world expectations no study ever captures. And she outlines why founders should define the raise first — and how clarity, preparation, and a deep understanding of strategic partners can dramatically accelerate the fundraising process.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/colby-holtshouse-may-health">here's a link to the full interview with Colby Holtshouse.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/colbymcg/">Colby Holtshouse</a>, President and CEO of <a href="https://mayhealth.com/">May Health.<br></a><br></p><p>May Health is developing a minimally invasive ovarian ablation therapy designed to restore ovulation in women with polycystic ovary syndrome (PCOS) and PCOS-related infertility.</p><p>Before May Health, Colby served as Global Medtech Commercial Lead at Organon, overseeing the worldwide launch of the Jada System following Organon’s acquisition of Alydia Health, where she held roles including COO, Interim CEO, and VP of Marketing. She has also held leadership positions at Pelvalon, AccessClosure, Medtronic, and Guidant.</p><p>In this discussion, Colby shares why early clinical evidence should be built in focused layers rather than oversized, all-at-once trials. She explains how a small, deliberate early launch can reveal the workflow nuances and real-world expectations no study ever captures. And she outlines why founders should define the raise first — and how clarity, preparation, and a deep understanding of strategic partners can dramatically accelerate the fundraising process.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/colby-holtshouse-may-health">here's a link to the full interview with Colby Holtshouse.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 03 Dec 2025 02:35:12 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/48df6f36/062bfa50.mp3" length="132709475" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/otjqEN0RkkR2wL5K7XYx3QyKnECgo04azL0M4spDK_U/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85ZWE2/MGY0NjQ5NWRmNDdj/NjFhOTJjNGY1ZThl/NTZjMC5qcGc.jpg"/>
      <itunes:duration>3318</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/colbymcg/">Colby Holtshouse</a>, President and CEO of <a href="https://mayhealth.com/">May Health.<br></a><br></p><p>May Health is developing a minimally invasive ovarian ablation therapy designed to restore ovulation in women with polycystic ovary syndrome (PCOS) and PCOS-related infertility.</p><p>Before May Health, Colby served as Global Medtech Commercial Lead at Organon, overseeing the worldwide launch of the Jada System following Organon’s acquisition of Alydia Health, where she held roles including COO, Interim CEO, and VP of Marketing. She has also held leadership positions at Pelvalon, AccessClosure, Medtronic, and Guidant.</p><p>In this discussion, Colby shares why early clinical evidence should be built in focused layers rather than oversized, all-at-once trials. She explains how a small, deliberate early launch can reveal the workflow nuances and real-world expectations no study ever captures. And she outlines why founders should define the raise first — and how clarity, preparation, and a deep understanding of strategic partners can dramatically accelerate the fundraising process.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/colby-holtshouse-may-health">here's a link to the full interview with Colby Holtshouse.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Resource Constraints Can Enhance Your Development Process: Interview with Reia CEO Kaitlin Maier</title>
      <itunes:title>How Resource Constraints Can Enhance Your Development Process: Interview with Reia CEO Kaitlin Maier</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">dc84e5a9-b6d7-4999-8106-3cca55f58265</guid>
      <link>https://www.medsider.com/interviews/kaitlin-maier-reia</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kaitlin-maier/">Kaitlin Maier</a>, co-founder and CEO of <a href="https://www.reiahealth.com/">Reia</a>. Reia has developed a self-managed pessary — a collapsible device that empowers women to treat pelvic organ prolapse comfortably and independently.</p><p> A mechanical engineering graduate of Dartmouth, Kaitlin previously worked at Sherpa Technology Group, developing patent strategies for leading life science and technology firms. </p><p>In this conversation, Kaitlin shares how she and her co-founders turned a student project into an FDA-cleared product using resource constraints as a design advantage. She explains how to turn FDA feedback into forward momentum, why running an NIH-funded randomized controlled trial (RCT) strengthened both credibility and confidence, and how non-dilutive funding can buy the time and control founders need to build on their own terms.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kaitlin-maier-reia">here's a link to the full interview with Kaitlin Maier.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kaitlin-maier/">Kaitlin Maier</a>, co-founder and CEO of <a href="https://www.reiahealth.com/">Reia</a>. Reia has developed a self-managed pessary — a collapsible device that empowers women to treat pelvic organ prolapse comfortably and independently.</p><p> A mechanical engineering graduate of Dartmouth, Kaitlin previously worked at Sherpa Technology Group, developing patent strategies for leading life science and technology firms. </p><p>In this conversation, Kaitlin shares how she and her co-founders turned a student project into an FDA-cleared product using resource constraints as a design advantage. She explains how to turn FDA feedback into forward momentum, why running an NIH-funded randomized controlled trial (RCT) strengthened both credibility and confidence, and how non-dilutive funding can buy the time and control founders need to build on their own terms.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kaitlin-maier-reia">here's a link to the full interview with Kaitlin Maier.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 18 Nov 2025 21:32:16 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/65df47ff/749df5c5.mp3" length="134202652" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/SUmElxdkOGMCZ_aMrhMk3y9w9Q5exribFhBoZY_H2c8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yNWJj/ZDNmMWEwYjgyYzVl/ZTM2ZDVhZWI3OWIy/YWU0Yy5qcGc.jpg"/>
      <itunes:duration>3355</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kaitlin-maier/">Kaitlin Maier</a>, co-founder and CEO of <a href="https://www.reiahealth.com/">Reia</a>. Reia has developed a self-managed pessary — a collapsible device that empowers women to treat pelvic organ prolapse comfortably and independently.</p><p> A mechanical engineering graduate of Dartmouth, Kaitlin previously worked at Sherpa Technology Group, developing patent strategies for leading life science and technology firms. </p><p>In this conversation, Kaitlin shares how she and her co-founders turned a student project into an FDA-cleared product using resource constraints as a design advantage. She explains how to turn FDA feedback into forward momentum, why running an NIH-funded randomized controlled trial (RCT) strengthened both credibility and confidence, and how non-dilutive funding can buy the time and control founders need to build on their own terms.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kaitlin-maier-reia">here's a link to the full interview with Kaitlin Maier.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>You’re Never Too Small to be an Acquirer: Interview with Hera Biotech CEO Somer Baburek</title>
      <itunes:title>You’re Never Too Small to be an Acquirer: Interview with Hera Biotech CEO Somer Baburek</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">2314b7ec-7ed5-4280-a676-2a9b0c99fd70</guid>
      <link>https://www.medsider.com/interviews/somer-baburek-hera-biotech</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/somerbaburek/">Somer Baburek</a>, CEO and co-founder of <a href="https://herabiotech.com/">Hera Biotech</a>. Hera is developing AI-driven tissue diagnostics for conditions that disproportionately affect women, including endometriosis and cervical cancer.</p><p>Before launching Hera, Somer spent nearly a decade in venture capital, where she evaluated early-stage medtech startups and learned what separates the survivors from the rest.</p><p>In this conversation, Somer explains how Hera designed global clinical pathways that balance cost and credibility, why boutique CROs can outperform big names, and how a pre-commercial startup completed three strategic acquisitions using equity and brand trust rather than cash.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/somer-baburek-hera-biotech">here's a link to the full interview with Somer Baburek.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/somerbaburek/">Somer Baburek</a>, CEO and co-founder of <a href="https://herabiotech.com/">Hera Biotech</a>. Hera is developing AI-driven tissue diagnostics for conditions that disproportionately affect women, including endometriosis and cervical cancer.</p><p>Before launching Hera, Somer spent nearly a decade in venture capital, where she evaluated early-stage medtech startups and learned what separates the survivors from the rest.</p><p>In this conversation, Somer explains how Hera designed global clinical pathways that balance cost and credibility, why boutique CROs can outperform big names, and how a pre-commercial startup completed three strategic acquisitions using equity and brand trust rather than cash.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/somer-baburek-hera-biotech">here's a link to the full interview with Somer Baburek.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 12 Nov 2025 04:20:29 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ece861b4/b1102e33.mp3" length="133362630" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ndUSUHJkK6wZl4lqT3k5Gpz3L3F-xioOaM6WAqZ3dgg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wN2I2/Y2ZjYTJjNzZiYzM0/NjE3MGY4ZTRkOWE5/YWQ1ZS5qcGc.jpg"/>
      <itunes:duration>3334</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/somerbaburek/">Somer Baburek</a>, CEO and co-founder of <a href="https://herabiotech.com/">Hera Biotech</a>. Hera is developing AI-driven tissue diagnostics for conditions that disproportionately affect women, including endometriosis and cervical cancer.</p><p>Before launching Hera, Somer spent nearly a decade in venture capital, where she evaluated early-stage medtech startups and learned what separates the survivors from the rest.</p><p>In this conversation, Somer explains how Hera designed global clinical pathways that balance cost and credibility, why boutique CROs can outperform big names, and how a pre-commercial startup completed three strategic acquisitions using equity and brand trust rather than cash.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/somer-baburek-hera-biotech">here's a link to the full interview with Somer Baburek.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Some of the Best Medtech Opportunities Hide in Plain Sight: Interview with BRIJ Medical CEO Tim Gleeson</title>
      <itunes:title>Why Some of the Best Medtech Opportunities Hide in Plain Sight: Interview with BRIJ Medical CEO Tim Gleeson</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a9f283bf-b2e3-4e11-a9b1-c8ef48ac3614</guid>
      <link>https://www.medsider.com/interviews/tim-gleeson-brij-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timjgleeson/">Tim Gleeson</a>, CEO of <a href="https://brijmedical.com/">BRIJ Medical</a>, a company rethinking one of the oldest procedures in medicine — surgical wound closure.</p><p>BRIJ’s Brijjit Force Modulating Tissue Bridge is a small, non-invasive clip designed to redistribute tension across incisions, helping wounds heal with fewer complications and smaller scars.</p><p>An accomplished entrepreneur and investor, Tim also founded and led Novasyte Health through its acquisition by IQVIA and later launched VIDANT Capital. A former Medtronic executive, Tim brings global experience and a lifelong passion for building impactful medtech ventures.</p><p>In this interview, Tim shares why the biggest opportunities often hide in “boring” markets, how focusing on physician champions and patient psychology drives commercial traction, and why the best fundraisers plan for twice the time and four times the cost.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tim-gleeson-brij-medical">here's a link to the full interview with Tim Gleeson.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timjgleeson/">Tim Gleeson</a>, CEO of <a href="https://brijmedical.com/">BRIJ Medical</a>, a company rethinking one of the oldest procedures in medicine — surgical wound closure.</p><p>BRIJ’s Brijjit Force Modulating Tissue Bridge is a small, non-invasive clip designed to redistribute tension across incisions, helping wounds heal with fewer complications and smaller scars.</p><p>An accomplished entrepreneur and investor, Tim also founded and led Novasyte Health through its acquisition by IQVIA and later launched VIDANT Capital. A former Medtronic executive, Tim brings global experience and a lifelong passion for building impactful medtech ventures.</p><p>In this interview, Tim shares why the biggest opportunities often hide in “boring” markets, how focusing on physician champions and patient psychology drives commercial traction, and why the best fundraisers plan for twice the time and four times the cost.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tim-gleeson-brij-medical">here's a link to the full interview with Tim Gleeson.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 28 Oct 2025 22:20:42 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/5e32c755/da2b604e.mp3" length="125778691" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/qGeYb-tgBnmuHY4lGFVLwLT9xHEAFeaHLilJLDndYYA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xZTYx/ZTYyODU5NTcxYmZh/MTg0ZWQ2OWJiODVm/MGNjYy5qcGc.jpg"/>
      <itunes:duration>3144</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timjgleeson/">Tim Gleeson</a>, CEO of <a href="https://brijmedical.com/">BRIJ Medical</a>, a company rethinking one of the oldest procedures in medicine — surgical wound closure.</p><p>BRIJ’s Brijjit Force Modulating Tissue Bridge is a small, non-invasive clip designed to redistribute tension across incisions, helping wounds heal with fewer complications and smaller scars.</p><p>An accomplished entrepreneur and investor, Tim also founded and led Novasyte Health through its acquisition by IQVIA and later launched VIDANT Capital. A former Medtronic executive, Tim brings global experience and a lifelong passion for building impactful medtech ventures.</p><p>In this interview, Tim shares why the biggest opportunities often hide in “boring” markets, how focusing on physician champions and patient psychology drives commercial traction, and why the best fundraisers plan for twice the time and four times the cost.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tim-gleeson-brij-medical">here's a link to the full interview with Tim Gleeson.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Solve the Workflow, Unlock the Market: Interview with Cooler Heads CEO Kate Dilligan</title>
      <itunes:title>Solve the Workflow, Unlock the Market: Interview with Cooler Heads CEO Kate Dilligan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5a32d446-26b4-4445-802d-4c442b703355</guid>
      <link>https://www.medsider.com/interviews/kate-dilligan-cooler-heads</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kate-dilligan/">Kate Dilligan,</a> CEO of <a href="https://coolerheads.com/">Cooler Heads</a>.</p><p>Cooler Heads is a commercial-stage company addressing a problem affecting many chemotherapy patients undergoing treatment for solid tumors: hair loss and the loss of privacy that comes with it. The company's FDA-cleared medical device, Amma, makes scalp cooling accessible by fitting into infusion center workflows rather than disrupting them.</p><p>Kate brings an unconventional background to medtech — from political fundraising to developing classified software for the U.S. government. As a solo female founder who had never worked in hardware, she started Cooler Heads in 2018 after her own experience with breast cancer. By mid-2025, the company had raised $11 million in Series A funding and placed devices across 27 states, with most accounts having never offered scalp cooling before.</p><p>In this interview, Kate shares how to design for health system adoption by solving workflow problems first, why saying “no” to scope creep protects your first-generation product, and how political fundraising tactics translate directly to building investor relationships in medtech.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kate-dilligan-cooler-heads">here's a link to the full interview with Kate Dilligan.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kate-dilligan/">Kate Dilligan,</a> CEO of <a href="https://coolerheads.com/">Cooler Heads</a>.</p><p>Cooler Heads is a commercial-stage company addressing a problem affecting many chemotherapy patients undergoing treatment for solid tumors: hair loss and the loss of privacy that comes with it. The company's FDA-cleared medical device, Amma, makes scalp cooling accessible by fitting into infusion center workflows rather than disrupting them.</p><p>Kate brings an unconventional background to medtech — from political fundraising to developing classified software for the U.S. government. As a solo female founder who had never worked in hardware, she started Cooler Heads in 2018 after her own experience with breast cancer. By mid-2025, the company had raised $11 million in Series A funding and placed devices across 27 states, with most accounts having never offered scalp cooling before.</p><p>In this interview, Kate shares how to design for health system adoption by solving workflow problems first, why saying “no” to scope creep protects your first-generation product, and how political fundraising tactics translate directly to building investor relationships in medtech.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kate-dilligan-cooler-heads">here's a link to the full interview with Kate Dilligan.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 22 Oct 2025 15:22:16 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d60bff0e/b62a4228.mp3" length="147562701" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/hUO5NUOGyp9UeayEa1lUZErTKIzZFwfGR4rbiUvCovI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85Nzg4/MTg2ZDhiZThkNDc3/YTkxYzU2MGI3ZjFj/NGI2ZS5qcGc.jpg"/>
      <itunes:duration>3689</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kate-dilligan/">Kate Dilligan,</a> CEO of <a href="https://coolerheads.com/">Cooler Heads</a>.</p><p>Cooler Heads is a commercial-stage company addressing a problem affecting many chemotherapy patients undergoing treatment for solid tumors: hair loss and the loss of privacy that comes with it. The company's FDA-cleared medical device, Amma, makes scalp cooling accessible by fitting into infusion center workflows rather than disrupting them.</p><p>Kate brings an unconventional background to medtech — from political fundraising to developing classified software for the U.S. government. As a solo female founder who had never worked in hardware, she started Cooler Heads in 2018 after her own experience with breast cancer. By mid-2025, the company had raised $11 million in Series A funding and placed devices across 27 states, with most accounts having never offered scalp cooling before.</p><p>In this interview, Kate shares how to design for health system adoption by solving workflow problems first, why saying “no” to scope creep protects your first-generation product, and how political fundraising tactics translate directly to building investor relationships in medtech.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kate-dilligan-cooler-heads">here's a link to the full interview with Kate Dilligan.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Build the Medical Case Before Chasing the Consumer Market: Interview with Wellysis CEO Young Juhn</title>
      <itunes:title>Build the Medical Case Before Chasing the Consumer Market: Interview with Wellysis CEO Young Juhn</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">0aa7f92d-d608-4fc7-b8a8-c92c9f47a7f5</guid>
      <link>https://www.medsider.com/interviews/young-juhn-wellysis</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/yjuhn/">Young Juhn</a>, CEO of <a href="https://www.wellysis.com/">Wellysis</a>.</p><p>Wellysis is the Samsung spinout behind S-Patch, a lightweight wearable that enables long-term ECG monitoring without the discomfort of established cardiac monitoring devices.</p><p>Young has spent more than two decades bridging hospital and home-based care — from his early career at Johnson &amp; Johnson, to more than a decade at Kaiser Permanente, to leading healthcare innovation at Samsung before spinning out Wellysis in 2019.</p><p>In this interview, Young shares why patient interviews should shape product design, how regulatory clearance is just the starting point for global commercialization, and why building a medical foundation before branching into consumer markets is critical for lasting adoption.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/young-juhn-wellysis">here's a link to the full interview with Young Juhn.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/yjuhn/">Young Juhn</a>, CEO of <a href="https://www.wellysis.com/">Wellysis</a>.</p><p>Wellysis is the Samsung spinout behind S-Patch, a lightweight wearable that enables long-term ECG monitoring without the discomfort of established cardiac monitoring devices.</p><p>Young has spent more than two decades bridging hospital and home-based care — from his early career at Johnson &amp; Johnson, to more than a decade at Kaiser Permanente, to leading healthcare innovation at Samsung before spinning out Wellysis in 2019.</p><p>In this interview, Young shares why patient interviews should shape product design, how regulatory clearance is just the starting point for global commercialization, and why building a medical foundation before branching into consumer markets is critical for lasting adoption.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/young-juhn-wellysis">here's a link to the full interview with Young Juhn.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 14 Oct 2025 22:47:26 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/05294b29/f7466ab7.mp3" length="138216769" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-vr0gXgQrLa54pO1U_CeGXu4Czqpv8orsGg8uRKIWDI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS84MzQ0/NDYzOWU1ZjkyYjM0/YjBiYzQ0NzMxOTAw/ZjI5OS5qcGc.jpg"/>
      <itunes:duration>3455</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/yjuhn/">Young Juhn</a>, CEO of <a href="https://www.wellysis.com/">Wellysis</a>.</p><p>Wellysis is the Samsung spinout behind S-Patch, a lightweight wearable that enables long-term ECG monitoring without the discomfort of established cardiac monitoring devices.</p><p>Young has spent more than two decades bridging hospital and home-based care — from his early career at Johnson &amp; Johnson, to more than a decade at Kaiser Permanente, to leading healthcare innovation at Samsung before spinning out Wellysis in 2019.</p><p>In this interview, Young shares why patient interviews should shape product design, how regulatory clearance is just the starting point for global commercialization, and why building a medical foundation before branching into consumer markets is critical for lasting adoption.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/young-juhn-wellysis">here's a link to the full interview with Young Juhn.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>3 Filters That Separate Breakthrough Devices from Failed Ventures: Interview with Tulavi CEO Josh Vose</title>
      <itunes:title>3 Filters That Separate Breakthrough Devices from Failed Ventures: Interview with Tulavi CEO Josh Vose</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7613760d-1470-47ee-b632-4fbd28eddb97</guid>
      <link>https://www.medsider.com/interviews/josh-vose-tulavi-therapeutics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/josh-vose-7306661/">Josh Vose</a>, CEO of <a href="https://tulavi.com/">Tulavi Therapeutics</a>.</p><p><br>Tulavi is advancing hydrogel-based implants like the allay Hydrogel Cap, which is designed to optimize nerve injury recovery and reduce the risk of neuroma formation.</p><p>Josh is a physician, engineer, and entrepreneur with more than 20 years of experience in medical devices. He has held leadership roles at Medtronic following its acquisition of PEAK Surgical and drove growth at startups including SIA Health, which he led through commercialization and acquisition by Integra LifeSciences.</p><p>In this interview, Josh shares why defining the clinical problem with absolute clarity is the foundation of medtech success, and how leaning into the harder regulatory path can create lasting moats.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/josh-vose-tulavi-therapeutics">here's a link to the full interview with Josh Vose.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/josh-vose-7306661/">Josh Vose</a>, CEO of <a href="https://tulavi.com/">Tulavi Therapeutics</a>.</p><p><br>Tulavi is advancing hydrogel-based implants like the allay Hydrogel Cap, which is designed to optimize nerve injury recovery and reduce the risk of neuroma formation.</p><p>Josh is a physician, engineer, and entrepreneur with more than 20 years of experience in medical devices. He has held leadership roles at Medtronic following its acquisition of PEAK Surgical and drove growth at startups including SIA Health, which he led through commercialization and acquisition by Integra LifeSciences.</p><p>In this interview, Josh shares why defining the clinical problem with absolute clarity is the foundation of medtech success, and how leaning into the harder regulatory path can create lasting moats.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/josh-vose-tulavi-therapeutics">here's a link to the full interview with Josh Vose.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 30 Sep 2025 17:18:46 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8aa791fc/af76240e.mp3" length="132859627" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/HCOt90X5bOSi3mKFTAUpkhQF5U4LWnXXI7yNPjon944/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zZGU4/ODYzMjA2MjJmNzRm/Mzg3OTNmMjVmYTk5/MjlhYy5qcGc.jpg"/>
      <itunes:duration>3321</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/josh-vose-7306661/">Josh Vose</a>, CEO of <a href="https://tulavi.com/">Tulavi Therapeutics</a>.</p><p><br>Tulavi is advancing hydrogel-based implants like the allay Hydrogel Cap, which is designed to optimize nerve injury recovery and reduce the risk of neuroma formation.</p><p>Josh is a physician, engineer, and entrepreneur with more than 20 years of experience in medical devices. He has held leadership roles at Medtronic following its acquisition of PEAK Surgical and drove growth at startups including SIA Health, which he led through commercialization and acquisition by Integra LifeSciences.</p><p>In this interview, Josh shares why defining the clinical problem with absolute clarity is the foundation of medtech success, and how leaning into the harder regulatory path can create lasting moats.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/josh-vose-tulavi-therapeutics">here's a link to the full interview with Josh Vose.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building Adoption Into the Design of Your Device: Interview with TRiCares CEO Ahmed Elmouelhi</title>
      <itunes:title>Building Adoption Into the Design of Your Device: Interview with TRiCares CEO Ahmed Elmouelhi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9bf6f295-ba2d-4e94-b1a6-eb1ddc80f025</guid>
      <link>https://www.medsider.com/interviews/ahmed-elmouelhi-tricares</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ahmed-elmouelhi-2271193/">Ahmed Elmouelhi</a>, CEO of <a href="https://www.tricares.com/">TRiCares</a>.  </p><p>TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.</p><p>Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men’s health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.</p><p>In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ahmed-elmouelhi-tricares">here's a link to the full interview with Ahmed Elmouelhi.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ahmed-elmouelhi-2271193/">Ahmed Elmouelhi</a>, CEO of <a href="https://www.tricares.com/">TRiCares</a>.  </p><p>TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.</p><p>Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men’s health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.</p><p>In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ahmed-elmouelhi-tricares">here's a link to the full interview with Ahmed Elmouelhi.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 23 Sep 2025 21:31:39 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3693dffb/2dd24b45.mp3" length="123865091" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/MLG9bf5iHx0d6A8QMNTW2NYNZN2MmdRti5SXsLHgOmU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hYTdh/MzFkNzBjYzQ0OWI1/ZTYwNmNlMGI0MTRj/ZDU3MC5qcGc.jpg"/>
      <itunes:duration>3096</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ahmed-elmouelhi-2271193/">Ahmed Elmouelhi</a>, CEO of <a href="https://www.tricares.com/">TRiCares</a>.  </p><p>TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.</p><p>Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men’s health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.</p><p>In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ahmed-elmouelhi-tricares">here's a link to the full interview with Ahmed Elmouelhi.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Use the ‘Arm Hair Test’ as Your Medtech Compass: Interview with Voyager Biomedical CEO Marc Penna</title>
      <itunes:title>Use the ‘Arm Hair Test’ as Your Medtech Compass: Interview with Voyager Biomedical CEO Marc Penna</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">35f8e4ee-a895-464f-8775-91a64a323f1d</guid>
      <link>https://www.medsider.com/interviews/marc-penna-voyager-biomedical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marcpenna/">Marc Penna</a>, CEO of <a href="https://www.voyagerbiomedical.com/">Voyager Biomedical</a>. </p><p>Voyager is a clinical-stage company tackling one of the most persistent challenges in dialysis care: reliable vascular access. </p><p>Marc has more than 20 years of experience leading clinical research and regulatory programs across cardiology, vascular disease, and oncology. Since 2014, he has focused on early-stage ventures, with leadership roles at Intact Vascular and Vesper Medical — both acquired by Philips — as well as senior positions at Edwards Lifesciences, Boston Scientific, and AngioDynamics.</p><p>In this interview, Marc shares how to pressure-test new medtech ideas, why collaboration with regulators and trial sites builds lasting credibility, and how disciplined fundraising and smart exit planning can set startups apart.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/marc-penna-voyager-biomedical">here's a link to the full interview with Marc Penna.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marcpenna/">Marc Penna</a>, CEO of <a href="https://www.voyagerbiomedical.com/">Voyager Biomedical</a>. </p><p>Voyager is a clinical-stage company tackling one of the most persistent challenges in dialysis care: reliable vascular access. </p><p>Marc has more than 20 years of experience leading clinical research and regulatory programs across cardiology, vascular disease, and oncology. Since 2014, he has focused on early-stage ventures, with leadership roles at Intact Vascular and Vesper Medical — both acquired by Philips — as well as senior positions at Edwards Lifesciences, Boston Scientific, and AngioDynamics.</p><p>In this interview, Marc shares how to pressure-test new medtech ideas, why collaboration with regulators and trial sites builds lasting credibility, and how disciplined fundraising and smart exit planning can set startups apart.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/marc-penna-voyager-biomedical">here's a link to the full interview with Marc Penna.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 17 Sep 2025 02:46:50 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/dff43f7f/eec456da.mp3" length="116095333" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/OJb-4xkN0H9e1sZs7mkcjA5i-3qkMR7bAXUE1MORZE4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMjZl/OTg4NTk1YTg3OWIz/NzIyZDE5MDU2OTI4/Y2I0MC5qcGc.jpg"/>
      <itunes:duration>2902</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marcpenna/">Marc Penna</a>, CEO of <a href="https://www.voyagerbiomedical.com/">Voyager Biomedical</a>. </p><p>Voyager is a clinical-stage company tackling one of the most persistent challenges in dialysis care: reliable vascular access. </p><p>Marc has more than 20 years of experience leading clinical research and regulatory programs across cardiology, vascular disease, and oncology. Since 2014, he has focused on early-stage ventures, with leadership roles at Intact Vascular and Vesper Medical — both acquired by Philips — as well as senior positions at Edwards Lifesciences, Boston Scientific, and AngioDynamics.</p><p>In this interview, Marc shares how to pressure-test new medtech ideas, why collaboration with regulators and trial sites builds lasting credibility, and how disciplined fundraising and smart exit planning can set startups apart.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/marc-penna-voyager-biomedical">here's a link to the full interview with Marc Penna.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Evolving Your Capital Strategy as You Grow: Interview with Efemoral Medical CEO Christopher Haig</title>
      <itunes:title>Evolving Your Capital Strategy as You Grow: Interview with Efemoral Medical CEO Christopher Haig</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a75eea4c-65d6-4f6f-9aea-8422f7a224b1</guid>
      <link>https://www.medsider.com/interviews/christopher-haig-efemoral-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/christopher-haig-7b899512/">Christopher Haig</a>, co-founder and CEO of <a href="https://efemoralmedical.com/">Efemoral Medical</a>. </p><p>Efemoral is developing bioresorbable scaffold technology for peripheral arterial disease.<br> <br>Chris has over 25 years of experience in cardiovascular devices, holding leadership roles at strategics including Guidant Corporation and Abbott Vascular, and driving growth at startups such as Calypso Medical and QT Vascular, where he built commercial infrastructure and launched multiple products ahead of its $55 million IPO.</p><p>In this interview, Chris shares how bioresorbable scaffold technology found new life for peripheral arterial disease — and the lessons on matching tech to significant needs and choosing trial sites for lasting data.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/christopher-haig-efemoral-medical">here's a link to the full interview with Christopher Haig.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/christopher-haig-7b899512/">Christopher Haig</a>, co-founder and CEO of <a href="https://efemoralmedical.com/">Efemoral Medical</a>. </p><p>Efemoral is developing bioresorbable scaffold technology for peripheral arterial disease.<br> <br>Chris has over 25 years of experience in cardiovascular devices, holding leadership roles at strategics including Guidant Corporation and Abbott Vascular, and driving growth at startups such as Calypso Medical and QT Vascular, where he built commercial infrastructure and launched multiple products ahead of its $55 million IPO.</p><p>In this interview, Chris shares how bioresorbable scaffold technology found new life for peripheral arterial disease — and the lessons on matching tech to significant needs and choosing trial sites for lasting data.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/christopher-haig-efemoral-medical">here's a link to the full interview with Christopher Haig.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 03 Sep 2025 18:18:25 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f90200f4/c67b48fc.mp3" length="127987217" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/bAmupCi18DGARqxBPqodrdzFLKxXqaKncwPdCX1Utfo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yY2Ni/MmQyZDk3NTE5ZDJl/MzUzODA2YjYwZDg0/ZmVkOC5qcGc.jpg"/>
      <itunes:duration>3200</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/christopher-haig-7b899512/">Christopher Haig</a>, co-founder and CEO of <a href="https://efemoralmedical.com/">Efemoral Medical</a>. </p><p>Efemoral is developing bioresorbable scaffold technology for peripheral arterial disease.<br> <br>Chris has over 25 years of experience in cardiovascular devices, holding leadership roles at strategics including Guidant Corporation and Abbott Vascular, and driving growth at startups such as Calypso Medical and QT Vascular, where he built commercial infrastructure and launched multiple products ahead of its $55 million IPO.</p><p>In this interview, Chris shares how bioresorbable scaffold technology found new life for peripheral arterial disease — and the lessons on matching tech to significant needs and choosing trial sites for lasting data.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/christopher-haig-efemoral-medical">here's a link to the full interview with Christopher Haig.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Company Building Starts with Discipline: Interview with Evident Vascular CEO Howard Rosen</title>
      <itunes:title>Company Building Starts with Discipline: Interview with Evident Vascular CEO Howard Rosen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8d174e09-3d6d-454e-81a4-79e19ce1b5c9</guid>
      <link>https://www.medsider.com/interviews/howard-rosen-evident-vascular</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/howardmrosen/">Howard Rosen</a>, co-Founder and CEO of<a href="https://evidentvascular.com/"> Evident Vascular</a>, a company developing an AI-powered intravascular ultrasound (IVUS) platform to improve vascular imaging and intervention.</p><p> Before co-founding Evident, Howard held senior leadership roles at Intact Vascular and Vesper Medical, guiding both companies through successful acquisitions by Philips. He also served in executive roles at Haemonetics and BG Medicine, and spent over two decades at Boston Scientific, where he held a range of leadership positions across the peripheral and cardiovascular franchises.</p><p>In this interview, Howard shares why launching right — not fast — is the key to success in medtech. He breaks down how Evident built early momentum by investing in deep market validation, engaging KOLs as true collaborators, and resisting scope creep at every turn. Howard also unpacks the company’s deliberate regulatory strategy, using early FDA engagement as a tool to de-risk development. On the fundraising front, he explains why board composition matters more than valuation, and why strategic acquirers respond best to credibility, not cold outreach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/howard-rosen-evident-vascular">here's a link to the full interview with Howard Rosen.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/howardmrosen/">Howard Rosen</a>, co-Founder and CEO of<a href="https://evidentvascular.com/"> Evident Vascular</a>, a company developing an AI-powered intravascular ultrasound (IVUS) platform to improve vascular imaging and intervention.</p><p> Before co-founding Evident, Howard held senior leadership roles at Intact Vascular and Vesper Medical, guiding both companies through successful acquisitions by Philips. He also served in executive roles at Haemonetics and BG Medicine, and spent over two decades at Boston Scientific, where he held a range of leadership positions across the peripheral and cardiovascular franchises.</p><p>In this interview, Howard shares why launching right — not fast — is the key to success in medtech. He breaks down how Evident built early momentum by investing in deep market validation, engaging KOLs as true collaborators, and resisting scope creep at every turn. Howard also unpacks the company’s deliberate regulatory strategy, using early FDA engagement as a tool to de-risk development. On the fundraising front, he explains why board composition matters more than valuation, and why strategic acquirers respond best to credibility, not cold outreach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/howard-rosen-evident-vascular">here's a link to the full interview with Howard Rosen.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 26 Aug 2025 17:36:27 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/5ed6010e/843f9c05.mp3" length="125624696" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Y4WO8K4Z8dMG7cauzxhZv4AH5n8r1YTP6wgiy3O7sPs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80MDAz/NzQ0NDc5NmY1ZDk5/NTE2ZDU0ZDA2Zjdm/YTRjYS5qcGc.jpg"/>
      <itunes:duration>3140</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/howardmrosen/">Howard Rosen</a>, co-Founder and CEO of<a href="https://evidentvascular.com/"> Evident Vascular</a>, a company developing an AI-powered intravascular ultrasound (IVUS) platform to improve vascular imaging and intervention.</p><p> Before co-founding Evident, Howard held senior leadership roles at Intact Vascular and Vesper Medical, guiding both companies through successful acquisitions by Philips. He also served in executive roles at Haemonetics and BG Medicine, and spent over two decades at Boston Scientific, where he held a range of leadership positions across the peripheral and cardiovascular franchises.</p><p>In this interview, Howard shares why launching right — not fast — is the key to success in medtech. He breaks down how Evident built early momentum by investing in deep market validation, engaging KOLs as true collaborators, and resisting scope creep at every turn. Howard also unpacks the company’s deliberate regulatory strategy, using early FDA engagement as a tool to de-risk development. On the fundraising front, he explains why board composition matters more than valuation, and why strategic acquirers respond best to credibility, not cold outreach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/howard-rosen-evident-vascular">here's a link to the full interview with Howard Rosen.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Navigate Undefined Markets in Medtech: Interview with Materna Medical CEO Tracy MacNeal</title>
      <itunes:title>How to Navigate Undefined Markets in Medtech: Interview with Materna Medical CEO Tracy MacNeal</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">51851e7f-7722-4cbe-a8ed-928a92dd7194</guid>
      <link>https://www.medsider.com/interviews/tracy-macneal-materna-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/tracymacneal/">Tracy MacNeal</a>, President and CEO of<a href="https://www.maternamedical.com/"> Materna Medical</a>. <br> <br>Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and<a href="https://www.hellomilli.com/"> Milli</a>, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.</p><p>Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women’s health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women’s Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.</p><p>In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tracy-macneal-materna-medical">here's a link to the full interview with Tracy MacNeal.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/tracymacneal/">Tracy MacNeal</a>, President and CEO of<a href="https://www.maternamedical.com/"> Materna Medical</a>. <br> <br>Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and<a href="https://www.hellomilli.com/"> Milli</a>, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.</p><p>Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women’s health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women’s Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.</p><p>In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tracy-macneal-materna-medical">here's a link to the full interview with Tracy MacNeal.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 19 Aug 2025 20:51:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/dc01a93d/fb208d20.mp3" length="117226856" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/_KV8_rG-6REuGeH4n0lxHiAkhBYM-_RavMTM2Ta6o1I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85ODY2/ODBlMmY3ODcyMmM1/ZmRjMWIwNmQ4NzI2/NTdhYy5qcGc.jpg"/>
      <itunes:duration>2931</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/tracymacneal/">Tracy MacNeal</a>, President and CEO of<a href="https://www.maternamedical.com/"> Materna Medical</a>. <br> <br>Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and<a href="https://www.hellomilli.com/"> Milli</a>, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.</p><p>Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women’s health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women’s Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.</p><p>In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/tracy-macneal-materna-medical">here's a link to the full interview with Tracy MacNeal.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>3 Signs Your Medtech Idea Could be a Viable Business: Interview with Prana Surgical CEO Joanna Nathan</title>
      <itunes:title>3 Signs Your Medtech Idea Could be a Viable Business: Interview with Prana Surgical CEO Joanna Nathan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c1f2b2d9-b069-4b1c-a7fb-2f12483bcaee</guid>
      <link>https://www.medsider.com/interviews/joanna-nathan-prana-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joannacnathan/">Joanna Nathan</a>, CEO and co-founder of <a href="https://www.pranasurgical.com/">Prana Surgical</a> — a startup developing image-guided surgical platforms for precision oncology. </p><p> Joanna's career spans translational research at Texas Heart Institute, product development at Saranas, and portfolio management at Mercury Fund and Johnson &amp; Johnson's Center for Device Innovation. She mentors founders through her not-for-profit organization Enventure and teaches entrepreneurship at Rice University's Jones School of Business.</p><p>In this interview, Joanna shares her framework for evaluating which medtech ideas merit pursuit, revealing three critical signals every founder should look for: clinical urgency that requires no convincing, favorable asymmetry between value and technical risk, and optimal market timing. Joanna also demonstrates how systematic grant applications and strategic resource allocation can extend runway while building investor credibility, and addresses the unique psychological challenges of building life-critical devices.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/joanna-nathan-prana-surgical">here's a link to the full interview with Joanna Nathan.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joannacnathan/">Joanna Nathan</a>, CEO and co-founder of <a href="https://www.pranasurgical.com/">Prana Surgical</a> — a startup developing image-guided surgical platforms for precision oncology. </p><p> Joanna's career spans translational research at Texas Heart Institute, product development at Saranas, and portfolio management at Mercury Fund and Johnson &amp; Johnson's Center for Device Innovation. She mentors founders through her not-for-profit organization Enventure and teaches entrepreneurship at Rice University's Jones School of Business.</p><p>In this interview, Joanna shares her framework for evaluating which medtech ideas merit pursuit, revealing three critical signals every founder should look for: clinical urgency that requires no convincing, favorable asymmetry between value and technical risk, and optimal market timing. Joanna also demonstrates how systematic grant applications and strategic resource allocation can extend runway while building investor credibility, and addresses the unique psychological challenges of building life-critical devices.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/joanna-nathan-prana-surgical">here's a link to the full interview with Joanna Nathan.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 06 Aug 2025 15:07:57 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/180d8a66/322c2432.mp3" length="105970177" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DYrYpBn3bMiTnkwH7CqxWxl1-u8MXe7bRJ-4JNZbRLg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jYTdk/N2M1MzRkYzkyNzk4/OTAwYTQyMGYyOTM3/YWVlNi5qcGc.jpg"/>
      <itunes:duration>2649</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joannacnathan/">Joanna Nathan</a>, CEO and co-founder of <a href="https://www.pranasurgical.com/">Prana Surgical</a> — a startup developing image-guided surgical platforms for precision oncology. </p><p> Joanna's career spans translational research at Texas Heart Institute, product development at Saranas, and portfolio management at Mercury Fund and Johnson &amp; Johnson's Center for Device Innovation. She mentors founders through her not-for-profit organization Enventure and teaches entrepreneurship at Rice University's Jones School of Business.</p><p>In this interview, Joanna shares her framework for evaluating which medtech ideas merit pursuit, revealing three critical signals every founder should look for: clinical urgency that requires no convincing, favorable asymmetry between value and technical risk, and optimal market timing. Joanna also demonstrates how systematic grant applications and strategic resource allocation can extend runway while building investor credibility, and addresses the unique psychological challenges of building life-critical devices.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/joanna-nathan-prana-surgical">here's a link to the full interview with Joanna Nathan.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Who You Raise From Matters Most: Interview with Firefly Neuroscience CEO Greg Lipschitz</title>
      <itunes:title>Who You Raise From Matters Most: Interview with Firefly Neuroscience CEO Greg Lipschitz</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">25e37761-a315-450d-b877-83984c82222b</guid>
      <link>https://www.medsider.com/interviews/greg-lipschitz-firefly-neuroscience</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-lipschitz-cfa-8a12b020/">Greg Lipschitz</a>, CEO of <a href="https://fireflyneuro.com/">Firefly Neuroscience</a>.<br> <br>Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology objectively measures brain function through EEG analysis. With a proprietary database spanning twelve cognitive disorders, the company serves both clinical practitioners and pharmaceutical partners.</p><p>Greg brings extensive experience in private equity, investment banking, capital markets, and finance to his leadership role. As Managing Director of Old Stone Advisors and former Vice President of Lazer Capital, Greg has advised on over $1 billion in transactions. He is a Chartered Financial Analyst.</p><p>In this interview, Greg shares insights on strategic fundraising approaches, platform prioritization decisions, and building commercial momentum in healthcare through direct sales and customer feedback loops.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-lipschitz-firefly-neuroscience">here's a link to the full interview with Greg Lipschitz.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-lipschitz-cfa-8a12b020/">Greg Lipschitz</a>, CEO of <a href="https://fireflyneuro.com/">Firefly Neuroscience</a>.<br> <br>Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology objectively measures brain function through EEG analysis. With a proprietary database spanning twelve cognitive disorders, the company serves both clinical practitioners and pharmaceutical partners.</p><p>Greg brings extensive experience in private equity, investment banking, capital markets, and finance to his leadership role. As Managing Director of Old Stone Advisors and former Vice President of Lazer Capital, Greg has advised on over $1 billion in transactions. He is a Chartered Financial Analyst.</p><p>In this interview, Greg shares insights on strategic fundraising approaches, platform prioritization decisions, and building commercial momentum in healthcare through direct sales and customer feedback loops.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-lipschitz-firefly-neuroscience">here's a link to the full interview with Greg Lipschitz.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 29 Jul 2025 20:12:10 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d1c6ff1d/0d4f90f6.mp3" length="104372514" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/kOaAFwthLaQSuyrnur7Rt4jmgYqlidsFMAPZgcEYONQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jMjE0/ZWE0NzZjZGQ2YjQ5/YTczZjhkNDQ1MDAz/ZWQyNC5qcGc.jpg"/>
      <itunes:duration>2609</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/greg-lipschitz-cfa-8a12b020/">Greg Lipschitz</a>, CEO of <a href="https://fireflyneuro.com/">Firefly Neuroscience</a>.<br> <br>Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology objectively measures brain function through EEG analysis. With a proprietary database spanning twelve cognitive disorders, the company serves both clinical practitioners and pharmaceutical partners.</p><p>Greg brings extensive experience in private equity, investment banking, capital markets, and finance to his leadership role. As Managing Director of Old Stone Advisors and former Vice President of Lazer Capital, Greg has advised on over $1 billion in transactions. He is a Chartered Financial Analyst.</p><p>In this interview, Greg shares insights on strategic fundraising approaches, platform prioritization decisions, and building commercial momentum in healthcare through direct sales and customer feedback loops.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/greg-lipschitz-firefly-neuroscience">here's a link to the full interview with Greg Lipschitz.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty</title>
      <itunes:title>AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">63e2b82a-e972-405a-a27d-c671e9e37c67</guid>
      <link>https://www.medsider.com/interviews/maulik-nanavaty-anumana</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mauliknanavaty/">Maulik Nanavaty</a>, CEO of<a href="https://anumana.ai/"> Anumana</a>.<br> <br>Anumana, an AI-driven health technology company focused on cardiovascular care, is taking a pragmatic approach to scaling AI in medicine.</p><p>Maulik is a seasoned healthcare executive with over 30 years of global experience in the medical device industry. He spent 18 years at Boston Scientific, where he led its $1B+ Neuromodulation division and served as President of Boston Scientific Japan. Prior to that, he held leadership positions at Baxter. Known for driving innovation in implantable and artificial intelligence (AI)-powered technologies, Maulik also serves on the board of Rani Therapeutics.</p><p>In this interview, Maulik shares why building a strong risk-benefit case and designing around real-world clinician needs are key to adoption. With data from over 20 million patients and a focus on transparency, Anumana is reshaping how AI reaches the point of care.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/maulik-nanavaty-anumana">here's a link to the full interview with Maulik Nanavaty.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mauliknanavaty/">Maulik Nanavaty</a>, CEO of<a href="https://anumana.ai/"> Anumana</a>.<br> <br>Anumana, an AI-driven health technology company focused on cardiovascular care, is taking a pragmatic approach to scaling AI in medicine.</p><p>Maulik is a seasoned healthcare executive with over 30 years of global experience in the medical device industry. He spent 18 years at Boston Scientific, where he led its $1B+ Neuromodulation division and served as President of Boston Scientific Japan. Prior to that, he held leadership positions at Baxter. Known for driving innovation in implantable and artificial intelligence (AI)-powered technologies, Maulik also serves on the board of Rani Therapeutics.</p><p>In this interview, Maulik shares why building a strong risk-benefit case and designing around real-world clinician needs are key to adoption. With data from over 20 million patients and a focus on transparency, Anumana is reshaping how AI reaches the point of care.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/maulik-nanavaty-anumana">here's a link to the full interview with Maulik Nanavaty.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 22 Jul 2025 17:34:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a493d6a5/236a59e1.mp3" length="116005354" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/MccP9V47W4B59VT2XxSGTG0MacOpnd7Jhgz86oCEPW8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yOWQz/NDVlYTcwNTM1YzI3/MzRhOGYzOTA2N2Qz/ZThlYi5qcGc.jpg"/>
      <itunes:duration>2900</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mauliknanavaty/">Maulik Nanavaty</a>, CEO of<a href="https://anumana.ai/"> Anumana</a>.<br> <br>Anumana, an AI-driven health technology company focused on cardiovascular care, is taking a pragmatic approach to scaling AI in medicine.</p><p>Maulik is a seasoned healthcare executive with over 30 years of global experience in the medical device industry. He spent 18 years at Boston Scientific, where he led its $1B+ Neuromodulation division and served as President of Boston Scientific Japan. Prior to that, he held leadership positions at Baxter. Known for driving innovation in implantable and artificial intelligence (AI)-powered technologies, Maulik also serves on the board of Rani Therapeutics.</p><p>In this interview, Maulik shares why building a strong risk-benefit case and designing around real-world clinician needs are key to adoption. With data from over 20 million patients and a focus on transparency, Anumana is reshaping how AI reaches the point of care.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/maulik-nanavaty-anumana">here's a link to the full interview with Maulik Nanavaty.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Case for Open-Source Medtech: Interview with Openwater Founder Mary Lou Jepsen</title>
      <itunes:title>A Case for Open-Source Medtech: Interview with Openwater Founder Mary Lou Jepsen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d6661344-81fa-4dd1-8ae8-9748b2ac4a04</guid>
      <link>https://www.medsider.com/interviews/mary-lou-jepsen-openwater</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/majepsen/">Mary Lou Jepsen</a>, founder and Chairman of <a href="https://www.openwater.health/">Openwater</a>, a medtech company developing breakthrough diagnostic and therapeutic wearables for cancer, stroke, mental illness, and beyond. <br> <br>Openwater is rethinking how medical devices are built — not as single-purpose machines, but as flexible platforms that function more like smartphones. </p><p>A physicist and prolific inventor, Mary Lou holds nearly 300 patents and has launched over 50 products across VR, AR, holography, and consumer electronics. Previously, she led engineering at Intel, Facebook, and Google, taught at MIT, and now serves on the boards of Lear Corporation and Luminar Technologies. She has been named to <em>Time</em> magazine’s list of the 100 most influential people. </p><p>In this interview, Mary Lou explains why the traditional “one disease, one device” model falls short, and how her team is applying consumer electronics and open-source principles to develop scalable, software-driven tools. Backed by renowned investors including Khosla Ventures, Vitalik Buterin, and Esther Dyson, Openwater is aiming to make advanced care more accessible worldwide.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/mary-lou-jepsen-openwater">here's a link to the full interview with Mary Lou Jepsen.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/majepsen/">Mary Lou Jepsen</a>, founder and Chairman of <a href="https://www.openwater.health/">Openwater</a>, a medtech company developing breakthrough diagnostic and therapeutic wearables for cancer, stroke, mental illness, and beyond. <br> <br>Openwater is rethinking how medical devices are built — not as single-purpose machines, but as flexible platforms that function more like smartphones. </p><p>A physicist and prolific inventor, Mary Lou holds nearly 300 patents and has launched over 50 products across VR, AR, holography, and consumer electronics. Previously, she led engineering at Intel, Facebook, and Google, taught at MIT, and now serves on the boards of Lear Corporation and Luminar Technologies. She has been named to <em>Time</em> magazine’s list of the 100 most influential people. </p><p>In this interview, Mary Lou explains why the traditional “one disease, one device” model falls short, and how her team is applying consumer electronics and open-source principles to develop scalable, software-driven tools. Backed by renowned investors including Khosla Ventures, Vitalik Buterin, and Esther Dyson, Openwater is aiming to make advanced care more accessible worldwide.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/mary-lou-jepsen-openwater">here's a link to the full interview with Mary Lou Jepsen.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 08 Jul 2025 23:21:11 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/48e09c3c/3b7653b5.mp3" length="170610678" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/rfxN6ylohZzJjCJjgkS-X6oS63hpjyKHeoWWWpU3ot0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lMGQ1/ZDA4NTUzN2RiNjky/MzJlNzYyODBlNzY0/Y2Q2Zi5qcGc.jpg"/>
      <itunes:duration>4265</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/majepsen/">Mary Lou Jepsen</a>, founder and Chairman of <a href="https://www.openwater.health/">Openwater</a>, a medtech company developing breakthrough diagnostic and therapeutic wearables for cancer, stroke, mental illness, and beyond. <br> <br>Openwater is rethinking how medical devices are built — not as single-purpose machines, but as flexible platforms that function more like smartphones. </p><p>A physicist and prolific inventor, Mary Lou holds nearly 300 patents and has launched over 50 products across VR, AR, holography, and consumer electronics. Previously, she led engineering at Intel, Facebook, and Google, taught at MIT, and now serves on the boards of Lear Corporation and Luminar Technologies. She has been named to <em>Time</em> magazine’s list of the 100 most influential people. </p><p>In this interview, Mary Lou explains why the traditional “one disease, one device” model falls short, and how her team is applying consumer electronics and open-source principles to develop scalable, software-driven tools. Backed by renowned investors including Khosla Ventures, Vitalik Buterin, and Esther Dyson, Openwater is aiming to make advanced care more accessible worldwide.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/mary-lou-jepsen-openwater">here's a link to the full interview with Mary Lou Jepsen.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Talk About a Technology No One’s Seen Before: Interview with Asensus Surgical CEO Anthony Fernando</title>
      <itunes:title>How to Talk About a Technology No One’s Seen Before: Interview with Asensus Surgical CEO Anthony Fernando</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d3bb206a-2677-4705-b38f-c50edb0bc5b0</guid>
      <link>https://www.medsider.com/interviews/anthony-fernando-asensus-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/anthony-fernando/">Anthony Fernando</a>, President and CEO of <a href="https://www.asensus.com/">Asensus Surgical</a>.</p><p>Asensus is expanding the role of robotics in the OR with its performance-guided surgery platform — a digital-first, AI-enabled system designed to enhance precision and real-time decision-making. </p><p>A mechanical engineer by training, Anthony has more than two decades of experience spanning medtech, robotics, and global operations. He joined Asensus in 2015 and previously served as Chief Operating Officer and Chief Technology Officer. Earlier in his career, Anthony held leadership roles at Stryker, Becton Dickinson, PerkinElmer, and Varian, where he focused on advancing automation and medical device innovation across international markets.</p><p>In this interview, Anthony shares how the Durham, NC–based Asensus navigated uncharted regulatory territory for a first-of-its-kind technology and proactively made the case for acquisition — well before KARL STORZ came to the table.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/anthony-fernando-asensus-surgical">here's a link to the full interview with Anthony Fernando.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/anthony-fernando/">Anthony Fernando</a>, President and CEO of <a href="https://www.asensus.com/">Asensus Surgical</a>.</p><p>Asensus is expanding the role of robotics in the OR with its performance-guided surgery platform — a digital-first, AI-enabled system designed to enhance precision and real-time decision-making. </p><p>A mechanical engineer by training, Anthony has more than two decades of experience spanning medtech, robotics, and global operations. He joined Asensus in 2015 and previously served as Chief Operating Officer and Chief Technology Officer. Earlier in his career, Anthony held leadership roles at Stryker, Becton Dickinson, PerkinElmer, and Varian, where he focused on advancing automation and medical device innovation across international markets.</p><p>In this interview, Anthony shares how the Durham, NC–based Asensus navigated uncharted regulatory territory for a first-of-its-kind technology and proactively made the case for acquisition — well before KARL STORZ came to the table.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/anthony-fernando-asensus-surgical">here's a link to the full interview with Anthony Fernando.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 01 Jul 2025 22:27:28 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/613c1e58/e487507b.mp3" length="123580998" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/FaLgK1RBgZL9N7rPbAEiQO92KpomuOTXgyU384fj3-Q/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hZmI4/MDRjZDRiOWNjNTQ0/NTQxOWZjNmE2MDFi/ZjY3OS5qcGc.jpg"/>
      <itunes:duration>3089</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/anthony-fernando/">Anthony Fernando</a>, President and CEO of <a href="https://www.asensus.com/">Asensus Surgical</a>.</p><p>Asensus is expanding the role of robotics in the OR with its performance-guided surgery platform — a digital-first, AI-enabled system designed to enhance precision and real-time decision-making. </p><p>A mechanical engineer by training, Anthony has more than two decades of experience spanning medtech, robotics, and global operations. He joined Asensus in 2015 and previously served as Chief Operating Officer and Chief Technology Officer. Earlier in his career, Anthony held leadership roles at Stryker, Becton Dickinson, PerkinElmer, and Varian, where he focused on advancing automation and medical device innovation across international markets.</p><p>In this interview, Anthony shares how the Durham, NC–based Asensus navigated uncharted regulatory territory for a first-of-its-kind technology and proactively made the case for acquisition — well before KARL STORZ came to the table.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/anthony-fernando-asensus-surgical">here's a link to the full interview with Anthony Fernando.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Evolving the Sales Model with Product Maturity: Interview with AVITA Medical CEO James Corbett</title>
      <itunes:title>Evolving the Sales Model with Product Maturity: Interview with AVITA Medical CEO James Corbett</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c7a81956-4fb2-43f5-bfa6-cf32d43a7737</guid>
      <link>https://www.medsider.com/interviews/jim-corbett-avita-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a really engaging conversation with <a href="https://www.linkedin.com/in/james-corbett-6917338/">James (Jim) Corbett</a>, CEO of <a href="https://avitamedical.com/">AVITA Medical</a>.</p><p>AVITA Medical’s RECELL system uses Spray-On Skin Cell technology to accelerate healing for patients with severe burns and wounds. </p><p> Jim brings nearly 40 years of medical device leadership experience to AVITA Medical. His career spans global commercial and operational roles, including President of Boston Scientific and General Manager of Scimed Life Systems. Jim has served as CEO of six companies, including three publicly traded entities — Microtherapeutics, ev3, and Alphatec Spine — as well as CathWorks, Home Diagnostics, and Vertos Medical.</p><p>In this interview, Jim shares lessons from a career spanning global medtech leadership positions — including the importance of hands-on fundraising, adapting sales strategies as products mature, and how generating clinical evidence beyond FDA requirements serves commercial adoption.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/jim-corbett-avita-medical">here's a link to the full interview with Jim Corbett.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a really engaging conversation with <a href="https://www.linkedin.com/in/james-corbett-6917338/">James (Jim) Corbett</a>, CEO of <a href="https://avitamedical.com/">AVITA Medical</a>.</p><p>AVITA Medical’s RECELL system uses Spray-On Skin Cell technology to accelerate healing for patients with severe burns and wounds. </p><p> Jim brings nearly 40 years of medical device leadership experience to AVITA Medical. His career spans global commercial and operational roles, including President of Boston Scientific and General Manager of Scimed Life Systems. Jim has served as CEO of six companies, including three publicly traded entities — Microtherapeutics, ev3, and Alphatec Spine — as well as CathWorks, Home Diagnostics, and Vertos Medical.</p><p>In this interview, Jim shares lessons from a career spanning global medtech leadership positions — including the importance of hands-on fundraising, adapting sales strategies as products mature, and how generating clinical evidence beyond FDA requirements serves commercial adoption.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/jim-corbett-avita-medical">here's a link to the full interview with Jim Corbett.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 25 Jun 2025 15:52:24 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/06a2c610/fb2fa14d.mp3" length="131578529" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/JH1f-otyD9vOLydmVVxMurRTAlCRL6SDGos1tLYRcBw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wNjZh/MjIxNGE5MzRjYmQ3/ZjQ4NzZlODQzYzYz/OWM4Mi5qcGc.jpg"/>
      <itunes:duration>3289</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a really engaging conversation with <a href="https://www.linkedin.com/in/james-corbett-6917338/">James (Jim) Corbett</a>, CEO of <a href="https://avitamedical.com/">AVITA Medical</a>.</p><p>AVITA Medical’s RECELL system uses Spray-On Skin Cell technology to accelerate healing for patients with severe burns and wounds. </p><p> Jim brings nearly 40 years of medical device leadership experience to AVITA Medical. His career spans global commercial and operational roles, including President of Boston Scientific and General Manager of Scimed Life Systems. Jim has served as CEO of six companies, including three publicly traded entities — Microtherapeutics, ev3, and Alphatec Spine — as well as CathWorks, Home Diagnostics, and Vertos Medical.</p><p>In this interview, Jim shares lessons from a career spanning global medtech leadership positions — including the importance of hands-on fundraising, adapting sales strategies as products mature, and how generating clinical evidence beyond FDA requirements serves commercial adoption.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/jim-corbett-avita-medical">here's a link to the full interview with Jim Corbett.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Great Data Isn’t Enough to Drive Adoption: Interview with Adagio Medical CEO Todd Usen</title>
      <itunes:title>Why Great Data Isn’t Enough to Drive Adoption: Interview with Adagio Medical CEO Todd Usen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ff56c8a9-d813-4855-9108-0374d379ec33</guid>
      <link>https://www.medsider.com/interviews/todd-usen-adagio-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/toddusen/">Todd Usen</a>, CEO of<a href="https://adagiomedical.com/"> Adagio Medical</a>.</p><p>Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  </p><p>Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.</p><p>In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/todd-usen-adagio-medical">here's a link to the full interview with Todd Usen.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/toddusen/">Todd Usen</a>, CEO of<a href="https://adagiomedical.com/"> Adagio Medical</a>.</p><p>Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  </p><p>Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.</p><p>In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/todd-usen-adagio-medical">here's a link to the full interview with Todd Usen.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 12 Jun 2025 00:48:43 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/dbf3de72/2e4466d9.mp3" length="123466029" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/4bcTXgyQoI_HT3O_T-ihDsX4_CmDL6tKXPuq5CuaLzs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xZTM4/MWJlMTNjNzFjNzdh/NGNjZjFiY2Y0ODc1/MjhmNC5qcGc.jpg"/>
      <itunes:duration>3086</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/toddusen/">Todd Usen</a>, CEO of<a href="https://adagiomedical.com/"> Adagio Medical</a>.</p><p>Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  </p><p>Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.</p><p>In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/todd-usen-adagio-medical">here's a link to the full interview with Todd Usen.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Designing Your Device for Adoption: Interview with InfoBionic CEO Stuart Long</title>
      <itunes:title>Designing Your Device for Adoption: Interview with InfoBionic CEO Stuart Long</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">853c1bed-c72d-4b8c-a114-53b89330d951</guid>
      <link>https://www.medsider.com/interviews/stuart-long-infobionic</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/stuartelong/">Stuart Long</a>, CEO of <a href="https://infobionic.ai/">InfoBionic</a>. </p><p>InfoBionic's virtual cardiac telemetry platform, MoMe ARC®, brings together a tiered hospital-grade monitoring capability powered by advanced AI-enabled analysis for cardiac interventions.</p><p>Stuart has over two decades of experience in the medical device and healthcare technology sectors, with a focus on driving rapid commercial growth. His leadership spans roles including CEO of Monarch Medical Systems, global chief marketing and sales officer at CapsuleTech, and executive positions at Philips Healthcare, Agfa HealthCare, AMICAS, and FUJIFILM USA. At CapsuleTech, he developed strategic initiatives that led to the company’s acquisition by Qualcomm Life. </p><p>In this interview, Stuart shares insights on combining debt and equity financing, hybrid commercial approaches, and positioning startups for acquisitions through adjacent market development — all while maintaining the persistence needed to survive the long game.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/stuart-long-infobionic">here's a link to the full interview with Stuart Long.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/stuartelong/">Stuart Long</a>, CEO of <a href="https://infobionic.ai/">InfoBionic</a>. </p><p>InfoBionic's virtual cardiac telemetry platform, MoMe ARC®, brings together a tiered hospital-grade monitoring capability powered by advanced AI-enabled analysis for cardiac interventions.</p><p>Stuart has over two decades of experience in the medical device and healthcare technology sectors, with a focus on driving rapid commercial growth. His leadership spans roles including CEO of Monarch Medical Systems, global chief marketing and sales officer at CapsuleTech, and executive positions at Philips Healthcare, Agfa HealthCare, AMICAS, and FUJIFILM USA. At CapsuleTech, he developed strategic initiatives that led to the company’s acquisition by Qualcomm Life. </p><p>In this interview, Stuart shares insights on combining debt and equity financing, hybrid commercial approaches, and positioning startups for acquisitions through adjacent market development — all while maintaining the persistence needed to survive the long game.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/stuart-long-infobionic">here's a link to the full interview with Stuart Long.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Jun 2025 15:22:51 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/69b95d49/52b590a6.mp3" length="132420700" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/2svxfis09YA1L6fVKDKaz204Qf7JDFTZ5ooCxKTb28w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NzM4/OTViZmZlOGM4Yjk1/ZTgzMWE1ZDk0Y2Zl/YmNiMC5qcGc.jpg"/>
      <itunes:duration>3310</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/stuartelong/">Stuart Long</a>, CEO of <a href="https://infobionic.ai/">InfoBionic</a>. </p><p>InfoBionic's virtual cardiac telemetry platform, MoMe ARC®, brings together a tiered hospital-grade monitoring capability powered by advanced AI-enabled analysis for cardiac interventions.</p><p>Stuart has over two decades of experience in the medical device and healthcare technology sectors, with a focus on driving rapid commercial growth. His leadership spans roles including CEO of Monarch Medical Systems, global chief marketing and sales officer at CapsuleTech, and executive positions at Philips Healthcare, Agfa HealthCare, AMICAS, and FUJIFILM USA. At CapsuleTech, he developed strategic initiatives that led to the company’s acquisition by Qualcomm Life. </p><p>In this interview, Stuart shares insights on combining debt and equity financing, hybrid commercial approaches, and positioning startups for acquisitions through adjacent market development — all while maintaining the persistence needed to survive the long game.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/stuart-long-infobionic">here's a link to the full interview with Stuart Long.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From FDA Reviewer to Medtech CEO: Interview with Zenflow CEO Shreya Mehta</title>
      <itunes:title>From FDA Reviewer to Medtech CEO: Interview with Zenflow CEO Shreya Mehta</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">14e42567-f5e9-4c0c-b86d-281fae854728</guid>
      <link>https://www.medsider.com/interviews/shreya-mehta-zenflow</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shreya-mehta-49a0575/">Shreya Mehta</a>, co-founder and CEO of<a href="https://www.zenflow.com/"> Zenflow</a>.</p><p>Zenflow is a medical device company focused on treating benign prostatic hyperplasia (BPH).</p><p> A biomedical engineer, Shreya brings over 15 years of experience in medtech, including serving as a lead reviewer at the FDA, where she specialized in cardiovascular devices. Shreya co-founded Zenflow in 2014 out of the Stanford Biodesign Innovation Fellowship. The company was one of the first medical device startups backed by Y Combinator and also received early support from StartX and the UCSF Rosenman Institute at QB3.</p><p>Shreya's experience at Zenflow reveals strategies for grounding innovation in patient needs, building productive FDA relationships, and leveraging accelerator programs to transform academic concepts into viable businesses.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/shreya-mehta-zenflow">here's a link to the full interview with Shreya Mehta.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shreya-mehta-49a0575/">Shreya Mehta</a>, co-founder and CEO of<a href="https://www.zenflow.com/"> Zenflow</a>.</p><p>Zenflow is a medical device company focused on treating benign prostatic hyperplasia (BPH).</p><p> A biomedical engineer, Shreya brings over 15 years of experience in medtech, including serving as a lead reviewer at the FDA, where she specialized in cardiovascular devices. Shreya co-founded Zenflow in 2014 out of the Stanford Biodesign Innovation Fellowship. The company was one of the first medical device startups backed by Y Combinator and also received early support from StartX and the UCSF Rosenman Institute at QB3.</p><p>Shreya's experience at Zenflow reveals strategies for grounding innovation in patient needs, building productive FDA relationships, and leveraging accelerator programs to transform academic concepts into viable businesses.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/shreya-mehta-zenflow">here's a link to the full interview with Shreya Mehta.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 29 May 2025 15:58:57 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e0db427e/ba9678da.mp3" length="101583667" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/KCH73Dfgc2cLiZmys30S4L8Pu5pG09nIc8WgDE3SXL0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iYmZl/ODdlZGJlYTZmNTM0/YTQ1NTg1YjIwM2Ey/MDdiOC5qcGc.jpg"/>
      <itunes:duration>2539</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shreya-mehta-49a0575/">Shreya Mehta</a>, co-founder and CEO of<a href="https://www.zenflow.com/"> Zenflow</a>.</p><p>Zenflow is a medical device company focused on treating benign prostatic hyperplasia (BPH).</p><p> A biomedical engineer, Shreya brings over 15 years of experience in medtech, including serving as a lead reviewer at the FDA, where she specialized in cardiovascular devices. Shreya co-founded Zenflow in 2014 out of the Stanford Biodesign Innovation Fellowship. The company was one of the first medical device startups backed by Y Combinator and also received early support from StartX and the UCSF Rosenman Institute at QB3.</p><p>Shreya's experience at Zenflow reveals strategies for grounding innovation in patient needs, building productive FDA relationships, and leveraging accelerator programs to transform academic concepts into viable businesses.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/shreya-mehta-zenflow">here's a link to the full interview with Shreya Mehta.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Challenging the Gold Standard: Interview with Profound Medical CEO Arun Menawat</title>
      <itunes:title>Challenging the Gold Standard: Interview with Profound Medical CEO Arun Menawat</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">0073823c-041d-4446-87ce-f557f13a832e</guid>
      <link>https://www.medsider.com/interviews/arun-menawat-profound-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with Dr. <a href="http://linkedin.com/in/arun-menawat-1b13185">Arun Menawat</a>, Chairman and CEO of<a href="https://profoundmedical.com/"> Profound Medical</a>. </p><p>Profound is commercializing the TULSA-PRO system, an alternative approach to prostate cancer treatment that uses MRI-guided thermal ultrasound to target and eliminate cancerous tissue without surgical incisions. </p><p>Before joining Profound in 2016, Arun served as the Chairman and CEO of Novadaq Technologies for 13 years, guiding the company from a startup to one of the fastest-growing, NASDAQ-listed medical technology businesses with a market cap exceeding one billion USD. Earlier in his career, Arun served as President of Cedara Software, a company that developed the industry’s first medical imaging software platform. Today, it’s part of IBM’s Watson Health.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Arun shares insights on building credibility with physicians, the strategic approach to clinical trials that led to their recent Medicare reimbursement coverage, and his vision for transforming the future of surgery beyond prostate cancer.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/arun-menawat-profound-medical">here's a link to the full interview with Arun Menawat.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with Dr. <a href="http://linkedin.com/in/arun-menawat-1b13185">Arun Menawat</a>, Chairman and CEO of<a href="https://profoundmedical.com/"> Profound Medical</a>. </p><p>Profound is commercializing the TULSA-PRO system, an alternative approach to prostate cancer treatment that uses MRI-guided thermal ultrasound to target and eliminate cancerous tissue without surgical incisions. </p><p>Before joining Profound in 2016, Arun served as the Chairman and CEO of Novadaq Technologies for 13 years, guiding the company from a startup to one of the fastest-growing, NASDAQ-listed medical technology businesses with a market cap exceeding one billion USD. Earlier in his career, Arun served as President of Cedara Software, a company that developed the industry’s first medical imaging software platform. Today, it’s part of IBM’s Watson Health.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Arun shares insights on building credibility with physicians, the strategic approach to clinical trials that led to their recent Medicare reimbursement coverage, and his vision for transforming the future of surgery beyond prostate cancer.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/arun-menawat-profound-medical">here's a link to the full interview with Arun Menawat.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 14 May 2025 17:25:31 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/813ea8c4/e11428ea.mp3" length="122274743" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DZpAmkWz-OpCi6onRIzpwbmAFlutNBD2Zi801WDhP6c/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wMzI3/YWE4MmRkM2ZlNjA1/NDg2YjZjMTExZmI2/MDNjMy5qcGc.jpg"/>
      <itunes:duration>3057</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with Dr. <a href="http://linkedin.com/in/arun-menawat-1b13185">Arun Menawat</a>, Chairman and CEO of<a href="https://profoundmedical.com/"> Profound Medical</a>. </p><p>Profound is commercializing the TULSA-PRO system, an alternative approach to prostate cancer treatment that uses MRI-guided thermal ultrasound to target and eliminate cancerous tissue without surgical incisions. </p><p>Before joining Profound in 2016, Arun served as the Chairman and CEO of Novadaq Technologies for 13 years, guiding the company from a startup to one of the fastest-growing, NASDAQ-listed medical technology businesses with a market cap exceeding one billion USD. Earlier in his career, Arun served as President of Cedara Software, a company that developed the industry’s first medical imaging software platform. Today, it’s part of IBM’s Watson Health.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Arun shares insights on building credibility with physicians, the strategic approach to clinical trials that led to their recent Medicare reimbursement coverage, and his vision for transforming the future of surgery beyond prostate cancer.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/arun-menawat-profound-medical">here's a link to the full interview with Arun Menawat.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Breaking Down Barriers in Women's Health: Interview with Neuraura CEO Claire Dixon</title>
      <itunes:title>Breaking Down Barriers in Women's Health: Interview with Neuraura CEO Claire Dixon</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">1049c5fe-0550-4c6d-b047-119cc2866984</guid>
      <link>https://www.medsider.com/interviews/claire-dixon-neuraura</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/claire-e-dixon/">Claire Dixon</a>, CEO of<a href="https://www.neuraura.com/"> Neuraura</a>.</p><p>Neuraura is developing <a href="https://www.getlooop.com/">LoOop</a>, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.</p><p>Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the “Top 200 Trailblazing Leaders in Women's Health and femtech” by Women of Wearables.</p><p>In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/claire-dixon-neuraura">here's a link to the full interview with Claire Dixon</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/claire-e-dixon/">Claire Dixon</a>, CEO of<a href="https://www.neuraura.com/"> Neuraura</a>.</p><p>Neuraura is developing <a href="https://www.getlooop.com/">LoOop</a>, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.</p><p>Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the “Top 200 Trailblazing Leaders in Women's Health and femtech” by Women of Wearables.</p><p>In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/claire-dixon-neuraura">here's a link to the full interview with Claire Dixon</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 07 May 2025 15:58:29 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f0c9b722/790ec9ef.mp3" length="128486664" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Xac6w_7_VenuOTkwr7taa8jCqpopAKXSv90cx5vN44o/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lNzM1/YmU3MWY5Yzc1MGM2/YWExNTBlNzdhMWU5/YjA2Ni5qcGc.jpg"/>
      <itunes:duration>3212</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/claire-e-dixon/">Claire Dixon</a>, CEO of<a href="https://www.neuraura.com/"> Neuraura</a>.</p><p>Neuraura is developing <a href="https://www.getlooop.com/">LoOop</a>, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.</p><p>Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the “Top 200 Trailblazing Leaders in Women's Health and femtech” by Women of Wearables.</p><p>In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/claire-dixon-neuraura">here's a link to the full interview with Claire Dixon</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Taking Retinal Imaging Beyond Ophthalmology: Interview with identifeye HEALTH CEO Vicky Demas</title>
      <itunes:title>Taking Retinal Imaging Beyond Ophthalmology: Interview with identifeye HEALTH CEO Vicky Demas</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">731dd2b2-442c-4951-bf68-92cae693df88</guid>
      <link>https://www.medsider.com/interviews/vicky-demas-identifeye-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/vasiliki-vicky-demas-79a23510/">Vicky Demas</a>, CEO of <a href="https://www.identifeye.health/">identifeye HEALTH</a> (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.</p><p>Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.</p><p>In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/vicky-demas-identifeye-health">here's a link to the full interview with Vicky Demas.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/vasiliki-vicky-demas-79a23510/">Vicky Demas</a>, CEO of <a href="https://www.identifeye.health/">identifeye HEALTH</a> (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.</p><p>Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.</p><p>In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/vicky-demas-identifeye-health">here's a link to the full interview with Vicky Demas.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 30 Apr 2025 01:37:33 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/54f2f2fd/57a61d79.mp3" length="51629106" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/L_V1ONyRuXoRCCMHhw1QxuVO6d5AC7-isiRhUx2X2fA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xN2Fh/YjllNTdmNzZiMDQ4/ZmU0ZjVmMGZkNGMy/ZDg0Yy5qcGc.jpg"/>
      <itunes:duration>3226</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/vasiliki-vicky-demas-79a23510/">Vicky Demas</a>, CEO of <a href="https://www.identifeye.health/">identifeye HEALTH</a> (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.</p><p>Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.</p><p>In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/vicky-demas-identifeye-health">here's a link to the full interview with Vicky Demas.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building the Beachhead Strategy: Interview with Axena Health Leaders Randy Pritchard and Erica Rogers</title>
      <itunes:title>Building the Beachhead Strategy: Interview with Axena Health Leaders Randy Pritchard and Erica Rogers</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d05b5f22-1b61-487c-a3df-e03497a6ff92</guid>
      <link>https://www.medsider.com/interviews/randy-pritchard-erica-rogers-axena-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/randy-pritchard/">Randy Pritchard</a> and <a href="https://www.linkedin.com/in/erica-rogers-bb93a97/">Erica Rogers</a>, leaders of <a href="https://axenahealth.com/">Axena Health</a>. Axena is transforming pelvic floor therapy with <a href="https://levacares.com/">Leva</a>, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes. </p><p>Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.</p><p>In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/randy-pritchard-erica-rogers-axena-health">here's a link to the full interview with Randy Pritchard and Erica Rogers.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/randy-pritchard/">Randy Pritchard</a> and <a href="https://www.linkedin.com/in/erica-rogers-bb93a97/">Erica Rogers</a>, leaders of <a href="https://axenahealth.com/">Axena Health</a>. Axena is transforming pelvic floor therapy with <a href="https://levacares.com/">Leva</a>, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes. </p><p>Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.</p><p>In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/randy-pritchard-erica-rogers-axena-health">here's a link to the full interview with Randy Pritchard and Erica Rogers.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 16 Apr 2025 15:32:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a34e0f74/333da079.mp3" length="52838688" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/kbtR2TbvMnGw9T2Sx60EbJAw6aZ18OvS3VRZ9JxPfU4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZjkw/MWUyN2YzOTRhODJl/NjMxYWQ2NGM5MmYy/Yzc3Mi5qcGc.jpg"/>
      <itunes:duration>3301</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/randy-pritchard/">Randy Pritchard</a> and <a href="https://www.linkedin.com/in/erica-rogers-bb93a97/">Erica Rogers</a>, leaders of <a href="https://axenahealth.com/">Axena Health</a>. Axena is transforming pelvic floor therapy with <a href="https://levacares.com/">Leva</a>, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes. </p><p>Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.</p><p>In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/randy-pritchard-erica-rogers-axena-health">here's a link to the full interview with Randy Pritchard and Erica Rogers.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Great Product vs. a Great Business: Interview with EDAP TMS CEO Ryan Rhodes</title>
      <itunes:title>A Great Product vs. a Great Business: Interview with EDAP TMS CEO Ryan Rhodes</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e2db24c2-ea71-4d79-adba-8680b0aec29b</guid>
      <link>https://www.medsider.com/interviews/ryan-rhodes-edap-tms</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/">Ryan Rhodes</a>, CEO of<a href="https://focalone.com/"> EDAP TMS</a>. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation. </p><p>Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&amp;J) in sales, marketing, and market development.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ryan-rhodes-edap-tms">here's a link to the full interview with Ryan Rhodes.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/">Ryan Rhodes</a>, CEO of<a href="https://focalone.com/"> EDAP TMS</a>. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation. </p><p>Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&amp;J) in sales, marketing, and market development.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ryan-rhodes-edap-tms">here's a link to the full interview with Ryan Rhodes.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 08 Apr 2025 21:03:28 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4e97ed9f/b389cfd0.mp3" length="87581817" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/EPfdRNOjtypbQ78AOVQvVozNDR9RKvU_lalCelidY5M/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yYWE0/ZTEzYTkxOGU1ZTVh/YTc5OTdhMGU5Y2Fi/NGFjOS5qcGc.jpg"/>
      <itunes:duration>3647</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/">Ryan Rhodes</a>, CEO of<a href="https://focalone.com/"> EDAP TMS</a>. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation. </p><p>Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&amp;J) in sales, marketing, and market development.</p><p>In this interview,<a href="https://www.linkedin.com/in/ryan-rhodes-992503b0/"> </a>Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/ryan-rhodes-edap-tms">here's a link to the full interview with Ryan Rhodes.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Hard Truth About Partnerships: Interview with Vivos CEO Kirk Huntsman</title>
      <itunes:title>The Hard Truth About Partnerships: Interview with Vivos CEO Kirk Huntsman</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">6803cffc-8312-44de-81e4-068c53ea75e5</guid>
      <link>https://www.medsider.com/interviews/kirk-huntsman-vivos</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirkhuntsman/">Kirk Huntsman</a>, CEO of <a href="https://vivos.com/patients/">Vivos</a>, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).</p><p> Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.</p><p>In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kirk-huntsman-vivos">here's a link to the full interview with Kirk Huntsman.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirkhuntsman/">Kirk Huntsman</a>, CEO of <a href="https://vivos.com/patients/">Vivos</a>, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).</p><p> Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.</p><p>In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kirk-huntsman-vivos">here's a link to the full interview with Kirk Huntsman.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 02 Apr 2025 15:30:01 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ca6e5bff/9d9c15fb.mp3" length="91626722" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/hSM1-Y3Aku7i222a3yurC5ma8pI-3vWQc_6tqwODv5o/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iZmM0/ZGMyMDcyN2Q0MWQ4/MmQxODIyYjhkZjQ0/NzU1NS5qcGc.jpg"/>
      <itunes:duration>3816</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirkhuntsman/">Kirk Huntsman</a>, CEO of <a href="https://vivos.com/patients/">Vivos</a>, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).</p><p> Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.</p><p>In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/kirk-huntsman-vivos">here's a link to the full interview with Kirk Huntsman.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Is Your Medtech Idea Worth Pursuing?: Interview with BrainSpace CEO Caitlin Morse</title>
      <itunes:title>Is Your Medtech Idea Worth Pursuing?: Interview with BrainSpace CEO Caitlin Morse</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9b609344-0121-4e73-a412-b0d39eaa9c0d</guid>
      <link>https://www.medsider.com/interviews/caitlin-morse-brainspace</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/caitlinmorse/">Caitlin Morse</a>, CEO and co-founder of<a href="https://www.brainspacemed.com/"> BrainSpace</a>, who has a decade of experience spanning medtech consulting, product development, and strategic advising. </p><p>BrainSpace is developing an innovative precision drainage system with continuous ICP monitoring designed to automate cerebrospinal fluid management for patients recovering from strokes, traumatic brain injuries, and neurosurgery. </p><p>In this interview, Caitlin shares her advice on assessing the viability of a medtech idea, tells the story of how her prototype won over stakeholders, and discusses navigating the development phase while balancing clinical and regulatory demands.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/caitlin-morse-brainspace">here's a link to the full interview with Caitlin Morse.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/caitlinmorse/">Caitlin Morse</a>, CEO and co-founder of<a href="https://www.brainspacemed.com/"> BrainSpace</a>, who has a decade of experience spanning medtech consulting, product development, and strategic advising. </p><p>BrainSpace is developing an innovative precision drainage system with continuous ICP monitoring designed to automate cerebrospinal fluid management for patients recovering from strokes, traumatic brain injuries, and neurosurgery. </p><p>In this interview, Caitlin shares her advice on assessing the viability of a medtech idea, tells the story of how her prototype won over stakeholders, and discusses navigating the development phase while balancing clinical and regulatory demands.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/caitlin-morse-brainspace">here's a link to the full interview with Caitlin Morse.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 19 Mar 2025 17:32:35 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9d37f470/41ab6024.mp3" length="88567078" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/4z6v_fJKIXEKwl2V4LvBq40seSG191e-AyUBvPx9JmU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zYjlm/ZWM4ZGNmZmVjNjgw/MzI2MTQ3ZmI5OTdm/NWQ5ZS5qcGc.jpg"/>
      <itunes:duration>3688</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/caitlinmorse/">Caitlin Morse</a>, CEO and co-founder of<a href="https://www.brainspacemed.com/"> BrainSpace</a>, who has a decade of experience spanning medtech consulting, product development, and strategic advising. </p><p>BrainSpace is developing an innovative precision drainage system with continuous ICP monitoring designed to automate cerebrospinal fluid management for patients recovering from strokes, traumatic brain injuries, and neurosurgery. </p><p>In this interview, Caitlin shares her advice on assessing the viability of a medtech idea, tells the story of how her prototype won over stakeholders, and discusses navigating the development phase while balancing clinical and regulatory demands.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/caitlin-morse-brainspace">here's a link to the full interview with Caitlin Morse.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Succeed Without Venture Capital: Interview with Front Line Medical Co-Founders Drs. Asha Parekh and Adam Power</title>
      <itunes:title>How to Succeed Without Venture Capital: Interview with Front Line Medical Co-Founders Drs. Asha Parekh and Adam Power</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5d8b8eff-867b-425f-acfa-3878941da763</guid>
      <link>https://www.medsider.com/interviews/asha-parekh-adam-power-front-line-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with Drs. <a href="https://www.linkedin.com/in/ashaparekh/">Asha Parekh</a> and <a href="https://www.linkedin.com/in/adam-power-861b34b/">Adam Power</a>, co-founders of <a href="https://frontlinemedtech.com/">Front Line Medical Technologies</a>. The company's COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System) is a compact, minimally invasive device, designed for temporary aortic occlusion in trauma situations. </p><p>Asha has a PhD in Biomedical Engineering from Western University, and combines technical expertise with entrepreneurial leadership. Adam is an academic and practicing vascular surgeon at Western University, with extensive training from institutions including Dalhousie, McMaster, and Mayo Clinic.</p><p>In this interview, they discuss how their clinical-engineer partnership accelerated development, their approach to clinical studies for regulatory clearance across multiple geographies, and their strategic decision to avoid VC funding during early development—and how that decision paid off.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/asha-parekh-adam-power-front-line-medical">here's a link to the full interview with Asha Parekh and Adam Power.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with Drs. <a href="https://www.linkedin.com/in/ashaparekh/">Asha Parekh</a> and <a href="https://www.linkedin.com/in/adam-power-861b34b/">Adam Power</a>, co-founders of <a href="https://frontlinemedtech.com/">Front Line Medical Technologies</a>. The company's COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System) is a compact, minimally invasive device, designed for temporary aortic occlusion in trauma situations. </p><p>Asha has a PhD in Biomedical Engineering from Western University, and combines technical expertise with entrepreneurial leadership. Adam is an academic and practicing vascular surgeon at Western University, with extensive training from institutions including Dalhousie, McMaster, and Mayo Clinic.</p><p>In this interview, they discuss how their clinical-engineer partnership accelerated development, their approach to clinical studies for regulatory clearance across multiple geographies, and their strategic decision to avoid VC funding during early development—and how that decision paid off.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/asha-parekh-adam-power-front-line-medical">here's a link to the full interview with Asha Parekh and Adam Power.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 12 Mar 2025 14:38:25 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7b064b07/9ead45c7.mp3" length="93575608" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/MgJoMGmV-zh2NOcpucchCoq1jPOoCN6LWtOyAF88jbc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iNzEw/MDQ2YzRlMjhmODMz/YWUwMDFiNWIxNjhl/ZDFiOS5qcGc.jpg"/>
      <itunes:duration>3891</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with Drs. <a href="https://www.linkedin.com/in/ashaparekh/">Asha Parekh</a> and <a href="https://www.linkedin.com/in/adam-power-861b34b/">Adam Power</a>, co-founders of <a href="https://frontlinemedtech.com/">Front Line Medical Technologies</a>. The company's COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System) is a compact, minimally invasive device, designed for temporary aortic occlusion in trauma situations. </p><p>Asha has a PhD in Biomedical Engineering from Western University, and combines technical expertise with entrepreneurial leadership. Adam is an academic and practicing vascular surgeon at Western University, with extensive training from institutions including Dalhousie, McMaster, and Mayo Clinic.</p><p>In this interview, they discuss how their clinical-engineer partnership accelerated development, their approach to clinical studies for regulatory clearance across multiple geographies, and their strategic decision to avoid VC funding during early development—and how that decision paid off.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://www.medsider.com/interviews/asha-parekh-adam-power-front-line-medical">here's a link to the full interview with Asha Parekh and Adam Power.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Your 'Kitty Hawk Moment' Matters: Interview with Elucid CEO Kelly Huang</title>
      <itunes:title>Why Your 'Kitty Hawk Moment' Matters: Interview with Elucid CEO Kelly Huang</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">1843484d-4eb8-487a-a164-bfc779227e61</guid>
      <link>https://medsider.com/interviews/kelly-huang-elucid</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kelly-huang-phd/">Kelly Huang</a>, President and CEO of <a href="https://elucid.com/">Elucid</a>. Elucid has developed a platform that uses AI to analyze cardiac CT scans to provide a detailed, non-invasive assessment of a patient’s arterial plaque.<br> <br>Kelly's journey spans nearly 30 years of leadership in healthcare, with expertise in driving innovation and growth across medical devices, diagnostics, health IT, and consumer health. Before Elucid, he served as COO at Cardea Bio, leading its successful acquisition by Paragraf, and as CEO of Obalon Therapeutics, where he introduced noninvasive medical devices to expand treatment options for physicians. Kelly's career also includes senior roles at L-Nutra, Nestlé/Galderma, Endo Pharmaceuticals, and Johnson &amp; Johnson.</p><p>In this interview, Kelly shares advice on how to successfully bring novel devices to market, secure reimbursement, and drive adoption by focusing on the essentials—collaboration, trust, robust data, and transparency.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-huang-elucid">here's a link to the full interview with Kelly Huang.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kelly-huang-phd/">Kelly Huang</a>, President and CEO of <a href="https://elucid.com/">Elucid</a>. Elucid has developed a platform that uses AI to analyze cardiac CT scans to provide a detailed, non-invasive assessment of a patient’s arterial plaque.<br> <br>Kelly's journey spans nearly 30 years of leadership in healthcare, with expertise in driving innovation and growth across medical devices, diagnostics, health IT, and consumer health. Before Elucid, he served as COO at Cardea Bio, leading its successful acquisition by Paragraf, and as CEO of Obalon Therapeutics, where he introduced noninvasive medical devices to expand treatment options for physicians. Kelly's career also includes senior roles at L-Nutra, Nestlé/Galderma, Endo Pharmaceuticals, and Johnson &amp; Johnson.</p><p>In this interview, Kelly shares advice on how to successfully bring novel devices to market, secure reimbursement, and drive adoption by focusing on the essentials—collaboration, trust, robust data, and transparency.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-huang-elucid">here's a link to the full interview with Kelly Huang.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 05 Mar 2025 17:30:21 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/50f35062/59473c24.mp3" length="46126021" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/FytWdzO_a3z7cYvTtA99vacWAXTTqx6NxCr7_8lT8zw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82MTVi/YTcyMmMwOTE2NTFh/MGQzZmY3M2VjZDIw/N2I2OS5qcGc.jpg"/>
      <itunes:duration>2889</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kelly-huang-phd/">Kelly Huang</a>, President and CEO of <a href="https://elucid.com/">Elucid</a>. Elucid has developed a platform that uses AI to analyze cardiac CT scans to provide a detailed, non-invasive assessment of a patient’s arterial plaque.<br> <br>Kelly's journey spans nearly 30 years of leadership in healthcare, with expertise in driving innovation and growth across medical devices, diagnostics, health IT, and consumer health. Before Elucid, he served as COO at Cardea Bio, leading its successful acquisition by Paragraf, and as CEO of Obalon Therapeutics, where he introduced noninvasive medical devices to expand treatment options for physicians. Kelly's career also includes senior roles at L-Nutra, Nestlé/Galderma, Endo Pharmaceuticals, and Johnson &amp; Johnson.</p><p>In this interview, Kelly shares advice on how to successfully bring novel devices to market, secure reimbursement, and drive adoption by focusing on the essentials—collaboration, trust, robust data, and transparency.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-huang-elucid">here's a link to the full interview with Kelly Huang.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>De-Risk and Execute to Create Value: Interview with Supira Medical CEO Nitin Salunke, PhD </title>
      <itunes:title>De-Risk and Execute to Create Value: Interview with Supira Medical CEO Nitin Salunke, PhD </itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">1970df7b-2777-4037-bf57-b5901a393692</guid>
      <link>https://medsider.com/interviews/nitin-salunke-supira-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/drnitinsalunke/">Nitin Salunke</a>, President and CEO of <a href="https://supiramedical.com/">Supira Medical</a>, a <a href="https://www.shifamed.com/company-portfolio/">Shifamed</a> portfolio company. Supira is developing a catheter-based heart pump that provides hemodynamic support for patients undergoing high-risk heart procedures. <br> <br>Before Supira, Nitin was Vice President of R&amp;D at Medtronic Neurovascular, overseeing global product development. He has also held leadership roles at Altura Medical, Cordis Corp (then a Johnson &amp; Johnson company), and W.L. Gore &amp; Associates. Nitin holds a PhD in Mechanical Engineering and is an inventor and co-author on many patents and publications.</p><p>In this interview, Nitin shares the philosophy that guided his journey as CEO of Supira, his strategy to evaluate and address major risk factors in medtech, how to generate value for all stakeholders—patients, physicians, and investors, and his formula for creating a next-gen medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/nitin-salunke-supira-medical">here's a link to the full interview with Nitin Salunke.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/drnitinsalunke/">Nitin Salunke</a>, President and CEO of <a href="https://supiramedical.com/">Supira Medical</a>, a <a href="https://www.shifamed.com/company-portfolio/">Shifamed</a> portfolio company. Supira is developing a catheter-based heart pump that provides hemodynamic support for patients undergoing high-risk heart procedures. <br> <br>Before Supira, Nitin was Vice President of R&amp;D at Medtronic Neurovascular, overseeing global product development. He has also held leadership roles at Altura Medical, Cordis Corp (then a Johnson &amp; Johnson company), and W.L. Gore &amp; Associates. Nitin holds a PhD in Mechanical Engineering and is an inventor and co-author on many patents and publications.</p><p>In this interview, Nitin shares the philosophy that guided his journey as CEO of Supira, his strategy to evaluate and address major risk factors in medtech, how to generate value for all stakeholders—patients, physicians, and investors, and his formula for creating a next-gen medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/nitin-salunke-supira-medical">here's a link to the full interview with Nitin Salunke.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Feb 2025 17:59:48 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/6f7647b7/9a074ec9.mp3" length="33175456" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-csx_SOtmz8_9EnDCG9Br1Pv8oEGj20pKwb7Vejylf0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81MTAy/MjMwNTZkNDE4ZTQw/NWFiYjA2NTcwODdl/OTI1Yi5qcGc.jpg"/>
      <itunes:duration>2172</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/drnitinsalunke/">Nitin Salunke</a>, President and CEO of <a href="https://supiramedical.com/">Supira Medical</a>, a <a href="https://www.shifamed.com/company-portfolio/">Shifamed</a> portfolio company. Supira is developing a catheter-based heart pump that provides hemodynamic support for patients undergoing high-risk heart procedures. <br> <br>Before Supira, Nitin was Vice President of R&amp;D at Medtronic Neurovascular, overseeing global product development. He has also held leadership roles at Altura Medical, Cordis Corp (then a Johnson &amp; Johnson company), and W.L. Gore &amp; Associates. Nitin holds a PhD in Mechanical Engineering and is an inventor and co-author on many patents and publications.</p><p>In this interview, Nitin shares the philosophy that guided his journey as CEO of Supira, his strategy to evaluate and address major risk factors in medtech, how to generate value for all stakeholders—patients, physicians, and investors, and his formula for creating a next-gen medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/nitin-salunke-supira-medical">here's a link to the full interview with Nitin Salunke.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Two Stakeholders You Can’t Ignore: Interview with Tioga CEO Mike Dineen</title>
      <itunes:title>Two Stakeholders You Can’t Ignore: Interview with Tioga CEO Mike Dineen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5f0611e2-f6e4-42aa-aaae-de1ca15ceb2c</guid>
      <link>https://medsider.com/interviews/mike-dineen-tioga-cardiovascular</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mike-dineen-6222a/">Mike Dineen</a>, co-founder and CEO of <a href="https://tiogacardiovascular.com/">Tioga Cardiovascular</a>, a<a href="https://www.shifamed.com/company-portfolio/"> Shifamed</a> portfolio company. Tioga is developing a minimally invasive transcatheter mitral valve replacement (TMVR) device to address mitral regurgitation (MR) - a condition where blood flows backward into the heart, often causing heart failure.</p><p>Mike has 30 years of experience in leading and scaling innovative medical device startups, and is co-inventor on more than 65 patents. His track record encompasses leadership roles at Kalila Medical (acquired by Abbott and later divested to Terumo), Maya Medical (acquired by Covidien), and Aspire Medical (acquired by Philips/Respironics). </p><p>In this interview, Mike discusses why engaging with physicians early is essential and what he prioritizes in those conversations, the importance of pushing for early pre-clinical testing and how to best approach it, and his strategy for raising capital by targeting early-stage investors with a clear, exit-focused plan.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/mike-dineen-tioga-cardiovascular">here's a link to the full interview with Mike Dineen.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mike-dineen-6222a/">Mike Dineen</a>, co-founder and CEO of <a href="https://tiogacardiovascular.com/">Tioga Cardiovascular</a>, a<a href="https://www.shifamed.com/company-portfolio/"> Shifamed</a> portfolio company. Tioga is developing a minimally invasive transcatheter mitral valve replacement (TMVR) device to address mitral regurgitation (MR) - a condition where blood flows backward into the heart, often causing heart failure.</p><p>Mike has 30 years of experience in leading and scaling innovative medical device startups, and is co-inventor on more than 65 patents. His track record encompasses leadership roles at Kalila Medical (acquired by Abbott and later divested to Terumo), Maya Medical (acquired by Covidien), and Aspire Medical (acquired by Philips/Respironics). </p><p>In this interview, Mike discusses why engaging with physicians early is essential and what he prioritizes in those conversations, the importance of pushing for early pre-clinical testing and how to best approach it, and his strategy for raising capital by targeting early-stage investors with a clear, exit-focused plan.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/mike-dineen-tioga-cardiovascular">here's a link to the full interview with Mike Dineen.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 19 Feb 2025 16:37:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/071ac9df/cf86ea33.mp3" length="42773066" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/6c8ZaWnSm0MPWHngLkYBcF4eGdwgAqqhin1Fm4nbHZ8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83ODFh/MTFiOTU1N2U4ZWFl/YzQ5NjBhNzIwMzE0/MzNkMy5qcGc.jpg"/>
      <itunes:duration>2978</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mike-dineen-6222a/">Mike Dineen</a>, co-founder and CEO of <a href="https://tiogacardiovascular.com/">Tioga Cardiovascular</a>, a<a href="https://www.shifamed.com/company-portfolio/"> Shifamed</a> portfolio company. Tioga is developing a minimally invasive transcatheter mitral valve replacement (TMVR) device to address mitral regurgitation (MR) - a condition where blood flows backward into the heart, often causing heart failure.</p><p>Mike has 30 years of experience in leading and scaling innovative medical device startups, and is co-inventor on more than 65 patents. His track record encompasses leadership roles at Kalila Medical (acquired by Abbott and later divested to Terumo), Maya Medical (acquired by Covidien), and Aspire Medical (acquired by Philips/Respironics). </p><p>In this interview, Mike discusses why engaging with physicians early is essential and what he prioritizes in those conversations, the importance of pushing for early pre-clinical testing and how to best approach it, and his strategy for raising capital by targeting early-stage investors with a clear, exit-focused plan.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/mike-dineen-tioga-cardiovascular">here's a link to the full interview with Mike Dineen.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Validate Your Idea Rigorously: Interview with Flow Medical CEO Jennifer Fried</title>
      <itunes:title>How to Validate Your Idea Rigorously: Interview with Flow Medical CEO Jennifer Fried</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">bfc7598a-30ab-45e2-bd79-1a6aeda55bd0</guid>
      <link>https://medsider.com/interviews/jennifer-fried-flow-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/friedjennifer/">Jennifer Fried</a>, co-founder and CEO of <a href="https://www.flowmedical.co/">Flow Medical</a>. Her startup is developing an advanced catheter designed to treat pulmonary embolisms.</p><p>Jennifer started<strong> </strong>her career<strong> </strong>as a healthcare venture capitalist and consultant at Bain &amp; Company. Before co-founding Flow Medical, Jennifer was the CEO and co-founder of ExplORer Surgical, a surgical software platform spun out of research at The University of Chicago. Under her leadership, ExplORer grew from an idea to a global product, earning accolades, like being named one of the Top 50 Healthcare Technology CEOs, and partnerships with major medical device companies. Jennifer successfully exited the business in 2021, when it was acquired by GHX.</p><p><br>In this interview, Jennifer shares insights on navigating M&amp;As, raising capital, and tips for validating ideas. She explains why engaging early with potential acquirers is key, how challenging your assumptions can save years of effort, and the importance of tailoring your pitch and building lasting investor relationships.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jennifer-fried-flow-medical">here's a link to the full interview with Jennifer Fried.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/friedjennifer/">Jennifer Fried</a>, co-founder and CEO of <a href="https://www.flowmedical.co/">Flow Medical</a>. Her startup is developing an advanced catheter designed to treat pulmonary embolisms.</p><p>Jennifer started<strong> </strong>her career<strong> </strong>as a healthcare venture capitalist and consultant at Bain &amp; Company. Before co-founding Flow Medical, Jennifer was the CEO and co-founder of ExplORer Surgical, a surgical software platform spun out of research at The University of Chicago. Under her leadership, ExplORer grew from an idea to a global product, earning accolades, like being named one of the Top 50 Healthcare Technology CEOs, and partnerships with major medical device companies. Jennifer successfully exited the business in 2021, when it was acquired by GHX.</p><p><br>In this interview, Jennifer shares insights on navigating M&amp;As, raising capital, and tips for validating ideas. She explains why engaging early with potential acquirers is key, how challenging your assumptions can save years of effort, and the importance of tailoring your pitch and building lasting investor relationships.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jennifer-fried-flow-medical">here's a link to the full interview with Jennifer Fried.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 18 Feb 2025 10:22:34 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8a1396fd/ac6e15d4.mp3" length="51072914" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/f8umXAWYCFv-Ov-da0uOdyEqBl3xplQO15aRKL0pqCU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zZmJh/NzM1NGQyMDZmOTg4/YjBhNTk3YThmYzU3/ZTIzOS5qcGc.jpg"/>
      <itunes:duration>3218</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/friedjennifer/">Jennifer Fried</a>, co-founder and CEO of <a href="https://www.flowmedical.co/">Flow Medical</a>. Her startup is developing an advanced catheter designed to treat pulmonary embolisms.</p><p>Jennifer started<strong> </strong>her career<strong> </strong>as a healthcare venture capitalist and consultant at Bain &amp; Company. Before co-founding Flow Medical, Jennifer was the CEO and co-founder of ExplORer Surgical, a surgical software platform spun out of research at The University of Chicago. Under her leadership, ExplORer grew from an idea to a global product, earning accolades, like being named one of the Top 50 Healthcare Technology CEOs, and partnerships with major medical device companies. Jennifer successfully exited the business in 2021, when it was acquired by GHX.</p><p><br>In this interview, Jennifer shares insights on navigating M&amp;As, raising capital, and tips for validating ideas. She explains why engaging early with potential acquirers is key, how challenging your assumptions can save years of effort, and the importance of tailoring your pitch and building lasting investor relationships.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jennifer-fried-flow-medical">here's a link to the full interview with Jennifer Fried.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Who’s Paying for It?: Interview with Aclarion CEO Brent Ness</title>
      <itunes:title>Who’s Paying for It?: Interview with Aclarion CEO Brent Ness</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">de78fb42-48db-4656-9194-b06edecff0a4</guid>
      <link>https://medsider.com/interviews/brent-ness-aclarion</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/brentrness/">Brent Ness</a>, President and CEO of<a href="https://conformalmedical.com/"> </a><a href="https://aclarion.com/">Aclarion</a>, a startup developing a decision-support tool designed to improve the diagnosis and treatment of chronic low back pain. </p><p>Brent has over 28 years of experience in medtech. Before Aclarion, he led Cleerly as President &amp; CCO, driving the adoption of their AI cardiology solution through strategic partnerships. As COO of Mighty Oak Medical, he guided their FIREFLY spine navigation platform from FDA clearance to international launch. At HeartFlow, Brent spearheaded the global expansion of their image-based SaaS solution, and at Medtronic, he led the acquisition and rollout of the O-Arm technology. His career also includes leadership roles at GE Healthcare, Philips North America, and ProNerve.</p><p>In this interview, Brent shares his approach to reimbursement, why continuing to prove your technology is crucial (even after regulatory approval), and how to effectively engage with KOLs for optimal support.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brent-ness-aclarion">here's a link to the full interview with Brent Ness.</a> </p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/brentrness/">Brent Ness</a>, President and CEO of<a href="https://conformalmedical.com/"> </a><a href="https://aclarion.com/">Aclarion</a>, a startup developing a decision-support tool designed to improve the diagnosis and treatment of chronic low back pain. </p><p>Brent has over 28 years of experience in medtech. Before Aclarion, he led Cleerly as President &amp; CCO, driving the adoption of their AI cardiology solution through strategic partnerships. As COO of Mighty Oak Medical, he guided their FIREFLY spine navigation platform from FDA clearance to international launch. At HeartFlow, Brent spearheaded the global expansion of their image-based SaaS solution, and at Medtronic, he led the acquisition and rollout of the O-Arm technology. His career also includes leadership roles at GE Healthcare, Philips North America, and ProNerve.</p><p>In this interview, Brent shares his approach to reimbursement, why continuing to prove your technology is crucial (even after regulatory approval), and how to effectively engage with KOLs for optimal support.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brent-ness-aclarion">here's a link to the full interview with Brent Ness.</a> </p>]]>
      </content:encoded>
      <pubDate>Wed, 22 Jan 2025 18:14:59 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/52548e35/a57d5507.mp3" length="50986595" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/fYAztxUL-08mjb-BrmqkPyNyT80ERkQbzx-R9r9XEa8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lNDJl/MmU2M2RmYWI1Yzg2/NGVmMzhmOTM3ZmQ4/YTY1OS5qcGc.jpg"/>
      <itunes:duration>3161</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/brentrness/">Brent Ness</a>, President and CEO of<a href="https://conformalmedical.com/"> </a><a href="https://aclarion.com/">Aclarion</a>, a startup developing a decision-support tool designed to improve the diagnosis and treatment of chronic low back pain. </p><p>Brent has over 28 years of experience in medtech. Before Aclarion, he led Cleerly as President &amp; CCO, driving the adoption of their AI cardiology solution through strategic partnerships. As COO of Mighty Oak Medical, he guided their FIREFLY spine navigation platform from FDA clearance to international launch. At HeartFlow, Brent spearheaded the global expansion of their image-based SaaS solution, and at Medtronic, he led the acquisition and rollout of the O-Arm technology. His career also includes leadership roles at GE Healthcare, Philips North America, and ProNerve.</p><p>In this interview, Brent shares his approach to reimbursement, why continuing to prove your technology is crucial (even after regulatory approval), and how to effectively engage with KOLs for optimal support.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brent-ness-aclarion">here's a link to the full interview with Brent Ness.</a> </p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Think Commercially from Day One: Interview with Conformal Medical CEO James Reinstein</title>
      <itunes:title>Think Commercially from Day One: Interview with Conformal Medical CEO James Reinstein</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">622498ed-b7b2-4edd-b4f2-6e3fd75bbc42</guid>
      <link>https://medsider.com/interviews/james-reinstein-conformal-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/james-reinstein-7755a634/">James Reinstein</a>, President and CEO of<a href="https://conformalmedical.com/"> Conformal Medical</a>, a company developing a foam device that seals the left atrial appendage (LAA) to reduce the risk of stroke without anticoagulants. </p><p>James has over 30 years of experience in the medical device industry. He’s held executive roles across multiple companies, including Saranas, Cutera, Drawbridge Health, and Aptus Endosystems (acquired by Medtronic). Earlier in his career, he served as Senior VP and Chief Commercial Officer at Cyberonics (now LivaNova) and as Vice President of Boston Scientific’s Asia region.</p><p><br>In this interview, James discusses choosing the right market, simplifying workflows to drive adoption, and balancing clinical focus with early commercialization planning. He also offers fundraising insights, including planning for long-term events like IPOs.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/james-reinstein-conformal-medical">here's a link to the full interview with James Reinstein.</a> </p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/james-reinstein-7755a634/">James Reinstein</a>, President and CEO of<a href="https://conformalmedical.com/"> Conformal Medical</a>, a company developing a foam device that seals the left atrial appendage (LAA) to reduce the risk of stroke without anticoagulants. </p><p>James has over 30 years of experience in the medical device industry. He’s held executive roles across multiple companies, including Saranas, Cutera, Drawbridge Health, and Aptus Endosystems (acquired by Medtronic). Earlier in his career, he served as Senior VP and Chief Commercial Officer at Cyberonics (now LivaNova) and as Vice President of Boston Scientific’s Asia region.</p><p><br>In this interview, James discusses choosing the right market, simplifying workflows to drive adoption, and balancing clinical focus with early commercialization planning. He also offers fundraising insights, including planning for long-term events like IPOs.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/james-reinstein-conformal-medical">here's a link to the full interview with James Reinstein.</a> </p>]]>
      </content:encoded>
      <pubDate>Wed, 15 Jan 2025 16:57:21 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0744b588/788548e3.mp3" length="56106823" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/U5p5hGesSpPshySQLvCCRoJIS2i_hCnTpm7qEPCjhGA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iOGE0/MDk4OWQyYTNlYzVi/ZDQ4NDc2NzY5MmFi/YTI5MC5qcGc.jpg"/>
      <itunes:duration>2959</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/james-reinstein-7755a634/">James Reinstein</a>, President and CEO of<a href="https://conformalmedical.com/"> Conformal Medical</a>, a company developing a foam device that seals the left atrial appendage (LAA) to reduce the risk of stroke without anticoagulants. </p><p>James has over 30 years of experience in the medical device industry. He’s held executive roles across multiple companies, including Saranas, Cutera, Drawbridge Health, and Aptus Endosystems (acquired by Medtronic). Earlier in his career, he served as Senior VP and Chief Commercial Officer at Cyberonics (now LivaNova) and as Vice President of Boston Scientific’s Asia region.</p><p><br>In this interview, James discusses choosing the right market, simplifying workflows to drive adoption, and balancing clinical focus with early commercialization planning. He also offers fundraising insights, including planning for long-term events like IPOs.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/james-reinstein-conformal-medical">here's a link to the full interview with James Reinstein.</a> </p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Maximize Market Opportunity, Minimize Feedback Loops: Interview with SAVA Co-founders Rafaël Michali and Renato Circi</title>
      <itunes:title>Maximize Market Opportunity, Minimize Feedback Loops: Interview with SAVA Co-founders Rafaël Michali and Renato Circi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ea4be01b-7351-4eb5-9b39-eb7e72df6a87</guid>
      <link>https://medsider.com/interviews/rafael-michali-renato-circi-sava</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a great chat with <a href="https://www.linkedin.com/in/rafa%C3%ABl-michali-656136101/">Rafaël Michali</a> and<a href="https://www.linkedin.com/in/circi/"> Renato Circi</a>, co-founders of <a href="https://www.sava.health/">SAVA</a>, a London-based biotechnology startup developing a novel biosensing platform to monitor molecules just below the skin in real time.</p><p>Rafaël and Renato are biomedical engineers from Imperial College London. Both recognized in the Forbes 30 Under 30 list as some of Europe’s most promising young innovators in 2018, the duo raised $13M in funding and built a cross-functional team of now over 40 to develop a next-generation biosensing platform. Together, they built a thesis surrounding preventative health, from which SAVA was formed: redefining healthcare into a system that is accessible, personalized, and preventative.</p><p>In this interview, they talk about the value of identifying a large market with substantial opportunity, how they moved rapidly through development iterations, the right time to exit stealth mode, and the complexities of building a medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/rafael-michali-renato-circi-sava">here's a link to the full interview with Rafaël Michali and Renato Circi.</a> </p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a great chat with <a href="https://www.linkedin.com/in/rafa%C3%ABl-michali-656136101/">Rafaël Michali</a> and<a href="https://www.linkedin.com/in/circi/"> Renato Circi</a>, co-founders of <a href="https://www.sava.health/">SAVA</a>, a London-based biotechnology startup developing a novel biosensing platform to monitor molecules just below the skin in real time.</p><p>Rafaël and Renato are biomedical engineers from Imperial College London. Both recognized in the Forbes 30 Under 30 list as some of Europe’s most promising young innovators in 2018, the duo raised $13M in funding and built a cross-functional team of now over 40 to develop a next-generation biosensing platform. Together, they built a thesis surrounding preventative health, from which SAVA was formed: redefining healthcare into a system that is accessible, personalized, and preventative.</p><p>In this interview, they talk about the value of identifying a large market with substantial opportunity, how they moved rapidly through development iterations, the right time to exit stealth mode, and the complexities of building a medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/rafael-michali-renato-circi-sava">here's a link to the full interview with Rafaël Michali and Renato Circi.</a> </p>]]>
      </content:encoded>
      <pubDate>Wed, 08 Jan 2025 17:56:18 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7335d273/bd22f5d0.mp3" length="43700101" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/hUuU4IwuYt0DZ6kKGvEDPSfXb2q1GPuu1NToJLiAzTw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zOGY1/YzRlZmVjOWFkM2Q3/YThiOWZhZjMzNjU2/ZWIzYy5qcGc.jpg"/>
      <itunes:duration>2730</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a great chat with <a href="https://www.linkedin.com/in/rafa%C3%ABl-michali-656136101/">Rafaël Michali</a> and<a href="https://www.linkedin.com/in/circi/"> Renato Circi</a>, co-founders of <a href="https://www.sava.health/">SAVA</a>, a London-based biotechnology startup developing a novel biosensing platform to monitor molecules just below the skin in real time.</p><p>Rafaël and Renato are biomedical engineers from Imperial College London. Both recognized in the Forbes 30 Under 30 list as some of Europe’s most promising young innovators in 2018, the duo raised $13M in funding and built a cross-functional team of now over 40 to develop a next-generation biosensing platform. Together, they built a thesis surrounding preventative health, from which SAVA was formed: redefining healthcare into a system that is accessible, personalized, and preventative.</p><p>In this interview, they talk about the value of identifying a large market with substantial opportunity, how they moved rapidly through development iterations, the right time to exit stealth mode, and the complexities of building a medical device.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ life science investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/rafael-michali-renato-circi-sava">here's a link to the full interview with Rafaël Michali and Renato Circi.</a> </p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Fixing Healthcare Bottlenecks from First Principles: Interview with Enspectra Health CEO Gabriel Sanchez</title>
      <itunes:title>Fixing Healthcare Bottlenecks from First Principles: Interview with Enspectra Health CEO Gabriel Sanchez</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">200214c0-5948-4aba-891d-59179fc0e1cf</guid>
      <link>https://medsider.com/interviews/gabriel-sanchez-enspectra-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/gabriel-sanchez-a6719837/">Gabriel Sanchez</a>, co-founder and CEO of <a href="https://www.enspectrahealth.com/">Enspectra Health</a>. The company's flagship VIO platform is the first FDA-cleared imaging modality for dermatology in over 25 years. </p><p>Gabriel holds a B.S. in mechanical engineering from MIT and an M.S. and Ph.D. from Stanford University, where he also served as an instructor in bioengineering and launched Enspectra to commercialize his groundbreaking research. VIO enables high-resolution, noninvasive imaging for skin cancer detection and health biometrics.</p><p>In this interview, Gabriel talks about his transition from academia to startups, how he narrowed down his idea to meet a pressing need in healthcare, the importance of speaking FDA’s language—or finding someone who does—and how he balances dilutive and non-dilutive funding. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-sanchez-enspectra-health">here's a link to the full interview with Gabriel Sanchez.</a> </p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/gabriel-sanchez-a6719837/">Gabriel Sanchez</a>, co-founder and CEO of <a href="https://www.enspectrahealth.com/">Enspectra Health</a>. The company's flagship VIO platform is the first FDA-cleared imaging modality for dermatology in over 25 years. </p><p>Gabriel holds a B.S. in mechanical engineering from MIT and an M.S. and Ph.D. from Stanford University, where he also served as an instructor in bioengineering and launched Enspectra to commercialize his groundbreaking research. VIO enables high-resolution, noninvasive imaging for skin cancer detection and health biometrics.</p><p>In this interview, Gabriel talks about his transition from academia to startups, how he narrowed down his idea to meet a pressing need in healthcare, the importance of speaking FDA’s language—or finding someone who does—and how he balances dilutive and non-dilutive funding. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-sanchez-enspectra-health">here's a link to the full interview with Gabriel Sanchez.</a> </p>]]>
      </content:encoded>
      <pubDate>Tue, 17 Dec 2024 14:55:28 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c77879a6/1ae89879.mp3" length="57673696" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/_XMxjDi30Nx5GNyCT-kXNBY4-w0GJaDebcyXPfXCV0w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDUx/MTliZDQ4YTNmNjBl/NGNmMjcwZTI1ZTJl/MTNmYS5qcGc.jpg"/>
      <itunes:duration>3240</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/gabriel-sanchez-a6719837/">Gabriel Sanchez</a>, co-founder and CEO of <a href="https://www.enspectrahealth.com/">Enspectra Health</a>. The company's flagship VIO platform is the first FDA-cleared imaging modality for dermatology in over 25 years. </p><p>Gabriel holds a B.S. in mechanical engineering from MIT and an M.S. and Ph.D. from Stanford University, where he also served as an instructor in bioengineering and launched Enspectra to commercialize his groundbreaking research. VIO enables high-resolution, noninvasive imaging for skin cancer detection and health biometrics.</p><p>In this interview, Gabriel talks about his transition from academia to startups, how he narrowed down his idea to meet a pressing need in healthcare, the importance of speaking FDA’s language—or finding someone who does—and how he balances dilutive and non-dilutive funding. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-sanchez-enspectra-health">here's a link to the full interview with Gabriel Sanchez.</a> </p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Low Drama, High Performance, Big Results: Interview with PhotoniCare CEO Cary Vance</title>
      <itunes:title>Low Drama, High Performance, Big Results: Interview with PhotoniCare CEO Cary Vance</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">f1eba0ec-83c4-46e2-a228-d82bd84ab5f8</guid>
      <link>https://medsider.com/interviews/cary-vance-photonicare</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cary-vance/">Cary Vance</a>, CEO of <a href="https://photoni.care/">PhotoniCare</a>. The company's FDA-cleared OtoSight™ Middle Ear Scope is a clinical diagnostic tool that offers a non-invasive and comprehensive assessment of middle ear fluid.</p><p> Cary is a proven medtech leader with over two decades of experience across large strategics like GE Healthcare and Covidien, and nearly 11 years as CEO of six different startups, including Titan Medical and Hansen Medical where he drove commercialization, fundraising, and M&amp;A opportunities. He's been the Chairman, President, and CEO of PhotoniCare since May 2023.</p><p>In this interview, Cary shares why clinical evidence, workflow efficiency, and financial viability are the three pillars of medtech success and how he prepares for launches and M&amp;As from day one.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cary-vance-photonicare">here's a link to the full interview with Cary Vance.</a> </p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cary-vance/">Cary Vance</a>, CEO of <a href="https://photoni.care/">PhotoniCare</a>. The company's FDA-cleared OtoSight™ Middle Ear Scope is a clinical diagnostic tool that offers a non-invasive and comprehensive assessment of middle ear fluid.</p><p> Cary is a proven medtech leader with over two decades of experience across large strategics like GE Healthcare and Covidien, and nearly 11 years as CEO of six different startups, including Titan Medical and Hansen Medical where he drove commercialization, fundraising, and M&amp;A opportunities. He's been the Chairman, President, and CEO of PhotoniCare since May 2023.</p><p>In this interview, Cary shares why clinical evidence, workflow efficiency, and financial viability are the three pillars of medtech success and how he prepares for launches and M&amp;As from day one.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cary-vance-photonicare">here's a link to the full interview with Cary Vance.</a> </p>]]>
      </content:encoded>
      <pubDate>Wed, 11 Dec 2024 17:31:10 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/76614cf1/f5a0a949.mp3" length="60019913" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DlNQUBg9rkJf-EK-LpgxA3o_zT5cKHaXe90-U4vSOTg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MjZl/MzliYjUyNTFkZjNi/MGQ1OTNlYWM0M2Fh/MThkZC5qcGc.jpg"/>
      <itunes:duration>3220</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cary-vance/">Cary Vance</a>, CEO of <a href="https://photoni.care/">PhotoniCare</a>. The company's FDA-cleared OtoSight™ Middle Ear Scope is a clinical diagnostic tool that offers a non-invasive and comprehensive assessment of middle ear fluid.</p><p> Cary is a proven medtech leader with over two decades of experience across large strategics like GE Healthcare and Covidien, and nearly 11 years as CEO of six different startups, including Titan Medical and Hansen Medical where he drove commercialization, fundraising, and M&amp;A opportunities. He's been the Chairman, President, and CEO of PhotoniCare since May 2023.</p><p>In this interview, Cary shares why clinical evidence, workflow efficiency, and financial viability are the three pillars of medtech success and how he prepares for launches and M&amp;As from day one.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cary-vance-photonicare">here's a link to the full interview with Cary Vance.</a> </p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Execution Beats Flashy Funding: Interview with AccurKardia CEO Juan C. Jimenez</title>
      <itunes:title>Execution Beats Flashy Funding: Interview with AccurKardia CEO Juan C. Jimenez</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">62c3d0bc-f58d-4e44-860e-2bc4c44592d3</guid>
      <link>https://medsider.com/interviews/juan-jimenez-accurkardia</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jcjimenezbosques/">Juan C. Jimenez</a>, co-founder and CEO of <a href="https://www.accurkardia.com/">AccurKardia</a>, a startup developing software that uses ECG data to help doctors detect heart conditions more accurately and efficiently with AI.</p><p> Juan started his career as an investment banker specializing in M&amp;A transactions, then moved on to become President of Puerto Rico’s largest non-emergency medical transportation company, TransCita. Now, he’s making waves in the ECG diagnostics space with AccurKardia. Leveraging his background in finance and healthcare, Juan brings unique expertise on efficiency and scale for medtech startups.</p><p>In this interview, Juan talks about how to scale sustainably with optimal dilution, giving your team space to establish a solid product, forging authentic relationships with potential customers, and leveraging your credibility to move your business forward.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/juan-jimenez-accurkardia">here's a link to the full interview with Juan C. Jimenez.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jcjimenezbosques/">Juan C. Jimenez</a>, co-founder and CEO of <a href="https://www.accurkardia.com/">AccurKardia</a>, a startup developing software that uses ECG data to help doctors detect heart conditions more accurately and efficiently with AI.</p><p> Juan started his career as an investment banker specializing in M&amp;A transactions, then moved on to become President of Puerto Rico’s largest non-emergency medical transportation company, TransCita. Now, he’s making waves in the ECG diagnostics space with AccurKardia. Leveraging his background in finance and healthcare, Juan brings unique expertise on efficiency and scale for medtech startups.</p><p>In this interview, Juan talks about how to scale sustainably with optimal dilution, giving your team space to establish a solid product, forging authentic relationships with potential customers, and leveraging your credibility to move your business forward.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/juan-jimenez-accurkardia">here's a link to the full interview with Juan C. Jimenez.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Dec 2024 18:05:46 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7c2d65d7/9fdab5d2.mp3" length="54572760" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/vxYCyn16Pacxwdhvp7aRF7To3lE3woBtHy-ggMRxSlg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82OGRi/NDNjOTZjYjU3OWUx/MWM4NGVkMzMwZGQ0/YWMxNC5qcGc.jpg"/>
      <itunes:duration>2996</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jcjimenezbosques/">Juan C. Jimenez</a>, co-founder and CEO of <a href="https://www.accurkardia.com/">AccurKardia</a>, a startup developing software that uses ECG data to help doctors detect heart conditions more accurately and efficiently with AI.</p><p> Juan started his career as an investment banker specializing in M&amp;A transactions, then moved on to become President of Puerto Rico’s largest non-emergency medical transportation company, TransCita. Now, he’s making waves in the ECG diagnostics space with AccurKardia. Leveraging his background in finance and healthcare, Juan brings unique expertise on efficiency and scale for medtech startups.</p><p>In this interview, Juan talks about how to scale sustainably with optimal dilution, giving your team space to establish a solid product, forging authentic relationships with potential customers, and leveraging your credibility to move your business forward.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/juan-jimenez-accurkardia">here's a link to the full interview with Juan C. Jimenez.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Thinking Global and Executing Local: Interview with Aether Biomedical CEO Dhruv Agrawal</title>
      <itunes:title>Thinking Global and Executing Local: Interview with Aether Biomedical CEO Dhruv Agrawal</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c7f64889-f0c0-4dc2-947e-2f5d15cb2df5</guid>
      <link>https://medsider.com/interviews/dhruv-agrawal-aether-biomedical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dhruv-agrawal-638b22118/">Dhruv Agrawal</a>, CEO of <a href="https://www.aetherbiomedical.com/">Aether Biomedical</a>. Aether's ZEUS bionic arm is a highly durable, multi-articulating prosthetic designed to handle everyday tasks with improved grip strength and resilience.</p><p>Dhruv found his true calling in building prosthetics while he was studying medicine and proceeded to co-found Aether when he was 18. Since starting Aether, he has helped raise over $15 million in funding and guided the launch of the ZEUS bionic hand, now deployed worldwide, including those impacted by the war in Ukraine.</p><p>In this interview, Dhruv discusses the importance of defining a clear problem statement, his approach to using grants to supplement VC funding, and the lessons he’s learned about evaluating market opportunities while operating globally.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dhruv-agrawal-aether-biomedical">here's a link to the full interview with Dhruv Agrawal.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dhruv-agrawal-638b22118/">Dhruv Agrawal</a>, CEO of <a href="https://www.aetherbiomedical.com/">Aether Biomedical</a>. Aether's ZEUS bionic arm is a highly durable, multi-articulating prosthetic designed to handle everyday tasks with improved grip strength and resilience.</p><p>Dhruv found his true calling in building prosthetics while he was studying medicine and proceeded to co-found Aether when he was 18. Since starting Aether, he has helped raise over $15 million in funding and guided the launch of the ZEUS bionic hand, now deployed worldwide, including those impacted by the war in Ukraine.</p><p>In this interview, Dhruv discusses the importance of defining a clear problem statement, his approach to using grants to supplement VC funding, and the lessons he’s learned about evaluating market opportunities while operating globally.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dhruv-agrawal-aether-biomedical">here's a link to the full interview with Dhruv Agrawal.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 26 Nov 2024 20:04:27 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b08048e8/5fe2fd3f.mp3" length="50922045" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/YZfx2sAviqLbp6i_0DCXymv_nCSop22DMc6Zu3JDLYI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80YWM5/YmY4M2IzYTY5YTIz/NzY3N2ZmNmNlNDk0/YzM2ZC5qcGc.jpg"/>
      <itunes:duration>2849</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dhruv-agrawal-638b22118/">Dhruv Agrawal</a>, CEO of <a href="https://www.aetherbiomedical.com/">Aether Biomedical</a>. Aether's ZEUS bionic arm is a highly durable, multi-articulating prosthetic designed to handle everyday tasks with improved grip strength and resilience.</p><p>Dhruv found his true calling in building prosthetics while he was studying medicine and proceeded to co-found Aether when he was 18. Since starting Aether, he has helped raise over $15 million in funding and guided the launch of the ZEUS bionic hand, now deployed worldwide, including those impacted by the war in Ukraine.</p><p>In this interview, Dhruv discusses the importance of defining a clear problem statement, his approach to using grants to supplement VC funding, and the lessons he’s learned about evaluating market opportunities while operating globally.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">3 packages</a> that will help you make use of our database of <strong>750+ lifescience investors</strong> more efficiently for your fundraise and help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dhruv-agrawal-aether-biomedical">here's a link to the full interview with Dhruv Agrawal.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Move Fast Early, Slow Down When It Counts: Interview with Neuspera CEO Steffen Hovard</title>
      <itunes:title>Move Fast Early, Slow Down When It Counts: Interview with Neuspera CEO Steffen Hovard</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a9f8ff36-3318-466a-9d5c-4e10c0ec486d</guid>
      <link>https://medsider.com/interviews/steffen-hovard-neuspera-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steffen-hovard/">Steffen Hovard</a>, CEO of <a href="https://neuspera.com/">Neuspera Medical</a>, where his team is developing a novel, less invasive device that uses neuromodulation to treat conditions like overactive bladder.</p><p>Previously, Steffen spent two decades at Coloplast, where he held various senior leadership roles that contributed to the company’s growth, including the acquisition of a Minneapolis-based urology business in 2005. With deep expertise in the space, he has consistently driven growth and innovation across multiple functions, positioning himself as a leader of leaders in medtech, with board roles at Medical Alley and AdvaMed.</p><p>In this interview, Steffen talks about confirming market fit before investing, building an early network for key hires and investors, aligning development speed with each phase, engaging with regulators early, and taking a steady, relationship-driven approach to fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steffen-hovard-neuspera-medical">here's a link to the full interview with Steffen Hovard.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steffen-hovard/">Steffen Hovard</a>, CEO of <a href="https://neuspera.com/">Neuspera Medical</a>, where his team is developing a novel, less invasive device that uses neuromodulation to treat conditions like overactive bladder.</p><p>Previously, Steffen spent two decades at Coloplast, where he held various senior leadership roles that contributed to the company’s growth, including the acquisition of a Minneapolis-based urology business in 2005. With deep expertise in the space, he has consistently driven growth and innovation across multiple functions, positioning himself as a leader of leaders in medtech, with board roles at Medical Alley and AdvaMed.</p><p>In this interview, Steffen talks about confirming market fit before investing, building an early network for key hires and investors, aligning development speed with each phase, engaging with regulators early, and taking a steady, relationship-driven approach to fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steffen-hovard-neuspera-medical">here's a link to the full interview with Steffen Hovard.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 13 Nov 2024 17:34:26 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a754efaa/e0759d7d.mp3" length="52132238" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/PZQF2TSyQje4EmP6kIfWN2FiSofJxYcecX7FKbpIGmY/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYjc0/NDNmYjVhOThlOGYy/ZGRiZWU1MmUxZjM1/ZDgzMi5qcGc.jpg"/>
      <itunes:duration>2706</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steffen-hovard/">Steffen Hovard</a>, CEO of <a href="https://neuspera.com/">Neuspera Medical</a>, where his team is developing a novel, less invasive device that uses neuromodulation to treat conditions like overactive bladder.</p><p>Previously, Steffen spent two decades at Coloplast, where he held various senior leadership roles that contributed to the company’s growth, including the acquisition of a Minneapolis-based urology business in 2005. With deep expertise in the space, he has consistently driven growth and innovation across multiple functions, positioning himself as a leader of leaders in medtech, with board roles at Medical Alley and AdvaMed.</p><p>In this interview, Steffen talks about confirming market fit before investing, building an early network for key hires and investors, aligning development speed with each phase, engaging with regulators early, and taking a steady, relationship-driven approach to fundraising.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steffen-hovard-neuspera-medical">here's a link to the full interview with Steffen Hovard.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Power of Quality Data: Interview with CorVista CEO Don Crawford</title>
      <itunes:title>The Power of Quality Data: Interview with CorVista CEO Don Crawford</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">44298ee7-8e7f-4220-9e54-b7f06166a6b5</guid>
      <link>https://medsider.com/interviews/don-crawford-corvista</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with returning guest, <a href="https://www.linkedin.com/in/don-crawford-4809a81a/">Don Crawford</a>, CEO of <a href="https://www.corvista.com/">CorVista Health</a>. CorVista is developing a non-invasive medical device that uses advanced machine-learned algorithms to detect heart conditions, right in a doctor’s office.</p><p>Don's career began at Medtronic, followed by progressively senior sales and marketing roles at Guidant Corporation, Ventritex, and Intermedics, including overseeing a $100 million international cardiovascular business. Before CorVista, he led Sapheon, a venous device company, to a $238 million acquisition by Covidien.</p><p> In this interview, Don talks about the need for focus in startups, the importance of precise data collection, and the value of transparency and respect within teams. He also shares his approach to hiring and building a top-notch group of people.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/don-crawford-corvista">here's a link to the full interview with Don Crawford.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with returning guest, <a href="https://www.linkedin.com/in/don-crawford-4809a81a/">Don Crawford</a>, CEO of <a href="https://www.corvista.com/">CorVista Health</a>. CorVista is developing a non-invasive medical device that uses advanced machine-learned algorithms to detect heart conditions, right in a doctor’s office.</p><p>Don's career began at Medtronic, followed by progressively senior sales and marketing roles at Guidant Corporation, Ventritex, and Intermedics, including overseeing a $100 million international cardiovascular business. Before CorVista, he led Sapheon, a venous device company, to a $238 million acquisition by Covidien.</p><p> In this interview, Don talks about the need for focus in startups, the importance of precise data collection, and the value of transparency and respect within teams. He also shares his approach to hiring and building a top-notch group of people.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/don-crawford-corvista">here's a link to the full interview with Don Crawford.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 07 Nov 2024 05:55:47 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4cf98c46/1afa6eb3.mp3" length="66592905" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/pykmtvDCh6ZWA0D5h6IrGJROZe9MpZHZlu_-qSrnJho/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82Nzdm/MWNmYjJiYWI0OGE3/ZWQzMjVhMzZhOTg1/MTc4OS5qcGc.jpg"/>
      <itunes:duration>3442</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with returning guest, <a href="https://www.linkedin.com/in/don-crawford-4809a81a/">Don Crawford</a>, CEO of <a href="https://www.corvista.com/">CorVista Health</a>. CorVista is developing a non-invasive medical device that uses advanced machine-learned algorithms to detect heart conditions, right in a doctor’s office.</p><p>Don's career began at Medtronic, followed by progressively senior sales and marketing roles at Guidant Corporation, Ventritex, and Intermedics, including overseeing a $100 million international cardiovascular business. Before CorVista, he led Sapheon, a venous device company, to a $238 million acquisition by Covidien.</p><p> In this interview, Don talks about the need for focus in startups, the importance of precise data collection, and the value of transparency and respect within teams. He also shares his approach to hiring and building a top-notch group of people.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/don-crawford-corvista">here's a link to the full interview with Don Crawford.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Build a Delightful Experience for Your Customers: Interview with Somnee CEO Tim Rosa</title>
      <itunes:title>How to Build a Delightful Experience for Your Customers: Interview with Somnee CEO Tim Rosa</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">11402cc7-3e17-409e-b0f1-1a6acf6b1333</guid>
      <link>https://medsider.com/interviews/tim-rosa-somnee</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with, <a href="https://www.linkedin.com/in/timrosa/">Tim Rosa</a>, CEO of <a href="https://somneesleep.com/">Somnee</a>, a company developing wearables based on personalized neuroscience to improve sleep quality. </p><p>Previously, Tim was the CMO at Fitbit, where he played a key role in establishing the health and fitness wearables category. He built the organization’s global marketing function, contributing to the sale of over 140 million devices in 100+ countries. Additionally, he helped drive the company’s IPO and its eventual $2.1 billion sale to Google. Tim has also advised and worked with major brands like Electronic Arts, 2K Sports, ESPN Video Games, and Jasper Health.</p><p>In this interview, Tim shares insights on building and scaling successful brands based on real customer experiences, keeping messaging clear, and using brand strategy as a business foundation. He also shares why solid data and clinical evidence in OTC products are essential and how he generates value out of ongoing research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tim-rosa-somnee">here's a link to the full interview with Tim Rosa.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with, <a href="https://www.linkedin.com/in/timrosa/">Tim Rosa</a>, CEO of <a href="https://somneesleep.com/">Somnee</a>, a company developing wearables based on personalized neuroscience to improve sleep quality. </p><p>Previously, Tim was the CMO at Fitbit, where he played a key role in establishing the health and fitness wearables category. He built the organization’s global marketing function, contributing to the sale of over 140 million devices in 100+ countries. Additionally, he helped drive the company’s IPO and its eventual $2.1 billion sale to Google. Tim has also advised and worked with major brands like Electronic Arts, 2K Sports, ESPN Video Games, and Jasper Health.</p><p>In this interview, Tim shares insights on building and scaling successful brands based on real customer experiences, keeping messaging clear, and using brand strategy as a business foundation. He also shares why solid data and clinical evidence in OTC products are essential and how he generates value out of ongoing research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tim-rosa-somnee">here's a link to the full interview with Tim Rosa.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 30 Oct 2024 16:47:46 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2ae3c725/206ae31a.mp3" length="75896857" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/BJ85XYWX1zWZrEeYRdS_3c9OS_vHLHs-9sYtZM8fKBs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82YTU0/MGY5OGQwMWEyY2Iw/MmM2MWRlZmIxMGQz/MmE5NS5qcGc.jpg"/>
      <itunes:duration>3161</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with, <a href="https://www.linkedin.com/in/timrosa/">Tim Rosa</a>, CEO of <a href="https://somneesleep.com/">Somnee</a>, a company developing wearables based on personalized neuroscience to improve sleep quality. </p><p>Previously, Tim was the CMO at Fitbit, where he played a key role in establishing the health and fitness wearables category. He built the organization’s global marketing function, contributing to the sale of over 140 million devices in 100+ countries. Additionally, he helped drive the company’s IPO and its eventual $2.1 billion sale to Google. Tim has also advised and worked with major brands like Electronic Arts, 2K Sports, ESPN Video Games, and Jasper Health.</p><p>In this interview, Tim shares insights on building and scaling successful brands based on real customer experiences, keeping messaging clear, and using brand strategy as a business foundation. He also shares why solid data and clinical evidence in OTC products are essential and how he generates value out of ongoing research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tim-rosa-somnee">here's a link to the full interview with Tim Rosa.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building Resilience Through Rejection: Interview with Transverse Medical CEO Eric Goslau</title>
      <itunes:title>Building Resilience Through Rejection: Interview with Transverse Medical CEO Eric Goslau</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">82eed106-0542-4520-96e5-a88cb2cb8b1d</guid>
      <link>https://medsider.com/interviews/eric-goslau-transverse-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran, <a href="https://www.linkedin.com/in/eric-goslau-4721261a/">Eric Goslau</a>, the co-founder and CEO of <a href="https://www.transversemedical.com/">Transverse Medical</a>. His startup is developing the Point Guard Cerebral Embolic Protection device that shields the brain from debris during cardiovascular procedures, reducing the risk of strokes.<br> <br>Co-inventor of Point Guard, Eric has 29 years of experience in leadership roles across sales, marketing, and product development. At Transverse, Eric oversees all aspects of the company, including fundraising, clinical planning, and regulatory strategy. He has successfully raised over $14 million through innovative financing strategies.</p><p>In this interview, Eric shares how his background in sales helps him manage various functions of the company, how fundraising cycles have worked for Transverse, and his philosophy when it comes to product development: the enemy of good is perfect.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-goslau-transverse-medical">here's a link to the full interview with Eric Goslau.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran, <a href="https://www.linkedin.com/in/eric-goslau-4721261a/">Eric Goslau</a>, the co-founder and CEO of <a href="https://www.transversemedical.com/">Transverse Medical</a>. His startup is developing the Point Guard Cerebral Embolic Protection device that shields the brain from debris during cardiovascular procedures, reducing the risk of strokes.<br> <br>Co-inventor of Point Guard, Eric has 29 years of experience in leadership roles across sales, marketing, and product development. At Transverse, Eric oversees all aspects of the company, including fundraising, clinical planning, and regulatory strategy. He has successfully raised over $14 million through innovative financing strategies.</p><p>In this interview, Eric shares how his background in sales helps him manage various functions of the company, how fundraising cycles have worked for Transverse, and his philosophy when it comes to product development: the enemy of good is perfect.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-goslau-transverse-medical">here's a link to the full interview with Eric Goslau.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 16 Oct 2024 16:46:30 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2db62857/fc68e446.mp3" length="67408563" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/jL_AJx8AJvWHg8gXCQ0bduxtGSuSkL-VmrSJ9JeuBwc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZWIy/MTBlNjUyMWQ1OTE5/NTc4MzAxZTczMTAy/Yjc5Yi5qcGc.jpg"/>
      <itunes:duration>2808</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran, <a href="https://www.linkedin.com/in/eric-goslau-4721261a/">Eric Goslau</a>, the co-founder and CEO of <a href="https://www.transversemedical.com/">Transverse Medical</a>. His startup is developing the Point Guard Cerebral Embolic Protection device that shields the brain from debris during cardiovascular procedures, reducing the risk of strokes.<br> <br>Co-inventor of Point Guard, Eric has 29 years of experience in leadership roles across sales, marketing, and product development. At Transverse, Eric oversees all aspects of the company, including fundraising, clinical planning, and regulatory strategy. He has successfully raised over $14 million through innovative financing strategies.</p><p>In this interview, Eric shares how his background in sales helps him manage various functions of the company, how fundraising cycles have worked for Transverse, and his philosophy when it comes to product development: the enemy of good is perfect.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-goslau-transverse-medical">here's a link to the full interview with Eric Goslau.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Nothing Matters as Much as Execution and Iteration: Interview with Wyndly CEO Aakash Shah</title>
      <itunes:title>Nothing Matters as Much as Execution and Iteration: Interview with Wyndly CEO Aakash Shah</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c6ca1a0d-b352-4ebf-b222-3761b20db3dd</guid>
      <link>https://medsider.com/interviews/aakash-shah-wyndly</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with the exuberant <a href="https://www.linkedin.com/in/mraakashshah/">Aakash Shah</a>, co-founder and CEO of <a href="https://www.wyndly.com/">Wyndly</a>, a telehealth startup that helps people overcome their allergies with personalized, at-home treatment plans. </p><p>Aakash was part of the Y Combinator W21 batch. As the CEO of Wyndly, he’s led the company from early inception through product development and eventual commercialization. Aakash holds dual degrees in Computer Science and Cognitive Science from the University of Virginia. Outside of Wyndly, he often presents on healthcare, telehealth, and startups, advises entrepreneurs, and hosts the <a href="https://open.spotify.com/show/3H08z4333rhF4QmZJJBPWA">Founders and Builders podcast</a>.</p><p>In this interview, Aakash shares insights on simplifying healthcare access by meeting patients online and emphasizes the importance of learning by doing to accelerate personal and business growth. Aakash also talks about the power of storytelling when engaging customers and investors, and how to leverage video-based social media to reach both consumers and decision-makers effectively.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/aakash-shah-wyndly">here's a link to the full interview with Aakash Shah.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with the exuberant <a href="https://www.linkedin.com/in/mraakashshah/">Aakash Shah</a>, co-founder and CEO of <a href="https://www.wyndly.com/">Wyndly</a>, a telehealth startup that helps people overcome their allergies with personalized, at-home treatment plans. </p><p>Aakash was part of the Y Combinator W21 batch. As the CEO of Wyndly, he’s led the company from early inception through product development and eventual commercialization. Aakash holds dual degrees in Computer Science and Cognitive Science from the University of Virginia. Outside of Wyndly, he often presents on healthcare, telehealth, and startups, advises entrepreneurs, and hosts the <a href="https://open.spotify.com/show/3H08z4333rhF4QmZJJBPWA">Founders and Builders podcast</a>.</p><p>In this interview, Aakash shares insights on simplifying healthcare access by meeting patients online and emphasizes the importance of learning by doing to accelerate personal and business growth. Aakash also talks about the power of storytelling when engaging customers and investors, and how to leverage video-based social media to reach both consumers and decision-makers effectively.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/aakash-shah-wyndly">here's a link to the full interview with Aakash Shah.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 02 Oct 2024 18:18:56 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/55b2e08e/49035033.mp3" length="69000610" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/TjUx4bAk53ByNnbDuDjl4DWce3Jwq8AIBS7hGD2gy2c/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81ZDU0/ZmMzYWYwNTM5YjBm/OTBlM2NjYWU4MjYz/NjAyYS5qcGc.jpg"/>
      <itunes:duration>2874</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with the exuberant <a href="https://www.linkedin.com/in/mraakashshah/">Aakash Shah</a>, co-founder and CEO of <a href="https://www.wyndly.com/">Wyndly</a>, a telehealth startup that helps people overcome their allergies with personalized, at-home treatment plans. </p><p>Aakash was part of the Y Combinator W21 batch. As the CEO of Wyndly, he’s led the company from early inception through product development and eventual commercialization. Aakash holds dual degrees in Computer Science and Cognitive Science from the University of Virginia. Outside of Wyndly, he often presents on healthcare, telehealth, and startups, advises entrepreneurs, and hosts the <a href="https://open.spotify.com/show/3H08z4333rhF4QmZJJBPWA">Founders and Builders podcast</a>.</p><p>In this interview, Aakash shares insights on simplifying healthcare access by meeting patients online and emphasizes the importance of learning by doing to accelerate personal and business growth. Aakash also talks about the power of storytelling when engaging customers and investors, and how to leverage video-based social media to reach both consumers and decision-makers effectively.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/aakash-shah-wyndly">here's a link to the full interview with Aakash Shah.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Finding Opportunities When Curveballs Come Your Way: Interview with Cytovale CEO Ajay Shah</title>
      <itunes:title>Finding Opportunities When Curveballs Come Your Way: Interview with Cytovale CEO Ajay Shah</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ba51f78d-c5a2-4d30-bc8d-a08cc091050f</guid>
      <link>https://medsider.com/interviews/ajay-shah-cytovale</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ajaymukeshshah/">Ajay Shah</a>, co-founder and CEO of <a href="https://cytovale.com/">Cytovale</a>. The company is helping solve the sepsis problem with IntelliSep, a simple, cost-effective, and quick sepsis test. </p><p> Ajay is a serial entrepreneur and engineer with expertise in cell-based diagnostic technologies. Before Cytovale, Ajay co-founded two other life sciences startups, one of which was acquired in 2012. In 2023, Ajay raised a Series C financing round of over $80 million and brought Cytovale’s sepsis test to market. </p><p><br>In this interview, Ajay shares why CEOs should immerse themselves in the problem they’re hoping to tackle, how he nurtures relationships with investors over time, and his opinions on making the transition to entrepreneurship from a non-commercial career path. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ajay-shah-cytovale">here's a link to the full interview with Ajay Shah.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ajaymukeshshah/">Ajay Shah</a>, co-founder and CEO of <a href="https://cytovale.com/">Cytovale</a>. The company is helping solve the sepsis problem with IntelliSep, a simple, cost-effective, and quick sepsis test. </p><p> Ajay is a serial entrepreneur and engineer with expertise in cell-based diagnostic technologies. Before Cytovale, Ajay co-founded two other life sciences startups, one of which was acquired in 2012. In 2023, Ajay raised a Series C financing round of over $80 million and brought Cytovale’s sepsis test to market. </p><p><br>In this interview, Ajay shares why CEOs should immerse themselves in the problem they’re hoping to tackle, how he nurtures relationships with investors over time, and his opinions on making the transition to entrepreneurship from a non-commercial career path. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ajay-shah-cytovale">here's a link to the full interview with Ajay Shah.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 26 Sep 2024 18:07:58 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/af38cf5f/5eba2f42.mp3" length="47598767" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/pTbhPCPgmuPngcu9PsxDoDl3lA82ld8psDvj6UIoKDc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82ODE3/MjRlZWE1ZDc1NmVk/NGU4ZDQyZWI1ZTg2/NzE1Mi5qcGc.jpg"/>
      <itunes:duration>1982</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ajaymukeshshah/">Ajay Shah</a>, co-founder and CEO of <a href="https://cytovale.com/">Cytovale</a>. The company is helping solve the sepsis problem with IntelliSep, a simple, cost-effective, and quick sepsis test. </p><p> Ajay is a serial entrepreneur and engineer with expertise in cell-based diagnostic technologies. Before Cytovale, Ajay co-founded two other life sciences startups, one of which was acquired in 2012. In 2023, Ajay raised a Series C financing round of over $80 million and brought Cytovale’s sepsis test to market. </p><p><br>In this interview, Ajay shares why CEOs should immerse themselves in the problem they’re hoping to tackle, how he nurtures relationships with investors over time, and his opinions on making the transition to entrepreneurship from a non-commercial career path. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ajay-shah-cytovale">here's a link to the full interview with Ajay Shah.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Identifying and Mitigating Key Risk Factors in Medtech Startups: Interview with Adona Medical CEO Brian Fahey</title>
      <itunes:title>Identifying and Mitigating Key Risk Factors in Medtech Startups: Interview with Adona Medical CEO Brian Fahey</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c39ba4d9-a5ab-4299-8944-56c02ac22a86</guid>
      <link>https://medsider.com/interviews/brian-fahey-adona-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with<strong> </strong><a href="https://www.linkedin.com/in/brian-fahey-7251a34/">Brian Fahey</a>, CEO of <a href="https://adonamed.com/">Adona Medical</a>, which is a Shifamed-portfolio company. The Adona Interatrial Shunt is a smart implant designed to enable individualized management of heart failure. </p><p>Before Adona, Brian founded a critical care company, Niveus Medical. He also spent time at J&amp;J Innovation, specializing in drug-device products for oncology, and contributed to the leadership team at Arrinex, a neuromodulation company in the ENT space. An alumnus of the Stanford Biodesign Innovation Program, Brian holds a Ph.D. from Duke University.</p><p>In this interview, Brian talks about the importance of identifying and mitigating medtech’s three major risk factors, how to assess ideas strategically, and how to approach investors and potential M&amp;A transactions. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brian-fahey-adona-medical">here's a link to the full interview with Brian Fahey.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with<strong> </strong><a href="https://www.linkedin.com/in/brian-fahey-7251a34/">Brian Fahey</a>, CEO of <a href="https://adonamed.com/">Adona Medical</a>, which is a Shifamed-portfolio company. The Adona Interatrial Shunt is a smart implant designed to enable individualized management of heart failure. </p><p>Before Adona, Brian founded a critical care company, Niveus Medical. He also spent time at J&amp;J Innovation, specializing in drug-device products for oncology, and contributed to the leadership team at Arrinex, a neuromodulation company in the ENT space. An alumnus of the Stanford Biodesign Innovation Program, Brian holds a Ph.D. from Duke University.</p><p>In this interview, Brian talks about the importance of identifying and mitigating medtech’s three major risk factors, how to assess ideas strategically, and how to approach investors and potential M&amp;A transactions. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brian-fahey-adona-medical">here's a link to the full interview with Brian Fahey.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 11 Sep 2024 15:23:18 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9c4196f4/5d548d71.mp3" length="75047946" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Sbej6Iv-VO0bXPXx-qRreUZfu3Lmd5QoxDBzXdP1fzs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wYTc2/NTI4OTQxMmY2MmZm/Zjc3NjQxNWIxYTIz/MWY3ZS5qcGc.jpg"/>
      <itunes:duration>3126</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with<strong> </strong><a href="https://www.linkedin.com/in/brian-fahey-7251a34/">Brian Fahey</a>, CEO of <a href="https://adonamed.com/">Adona Medical</a>, which is a Shifamed-portfolio company. The Adona Interatrial Shunt is a smart implant designed to enable individualized management of heart failure. </p><p>Before Adona, Brian founded a critical care company, Niveus Medical. He also spent time at J&amp;J Innovation, specializing in drug-device products for oncology, and contributed to the leadership team at Arrinex, a neuromodulation company in the ENT space. An alumnus of the Stanford Biodesign Innovation Program, Brian holds a Ph.D. from Duke University.</p><p>In this interview, Brian talks about the importance of identifying and mitigating medtech’s three major risk factors, how to assess ideas strategically, and how to approach investors and potential M&amp;A transactions. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/brian-fahey-adona-medical">here's a link to the full interview with Brian Fahey.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>De-Risking Your Way to a Successful Fundraise: Interview with WearLinq CEO Konrad Morzkowski</title>
      <itunes:title>De-Risking Your Way to a Successful Fundraise: Interview with WearLinq CEO Konrad Morzkowski</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">221bd70c-87a1-402e-90bf-5aea8b78a793</guid>
      <link>https://medsider.com/interviews/konrad-morzkowski-wearlinq</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/konrad-morzkowski-372883105/">Konrad Morzkowski</a>, co-founder and CEO of<a href="https://wearlinq.com/"> WearLinq</a>. The startup is commercializing eWave, an FDA-cleared EKG monitor for continuous cardiac monitoring. </p><p>Konrad is an engineer from Sweden and a member of Forbes’ 30 under 30 list. After obtaining an MS at Stanford – where he met his co-founders and raised his first round – Konrad dove right into entrepreneurship with WearLinq, a company commercializing consumer-facing digital healthcare solutions with an initial focus on EKG monitoring. </p><p>In this interview, Konrad shares how he optimizes fundraising efforts by aligning them with important milestones, his unconventional methods to gather voice of customer research, and how his startup moved rapidly through product design iterations. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/konrad-morzkowski-wearlinq">here's a link to the full interview with Konrad Morzkowski.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/konrad-morzkowski-372883105/">Konrad Morzkowski</a>, co-founder and CEO of<a href="https://wearlinq.com/"> WearLinq</a>. The startup is commercializing eWave, an FDA-cleared EKG monitor for continuous cardiac monitoring. </p><p>Konrad is an engineer from Sweden and a member of Forbes’ 30 under 30 list. After obtaining an MS at Stanford – where he met his co-founders and raised his first round – Konrad dove right into entrepreneurship with WearLinq, a company commercializing consumer-facing digital healthcare solutions with an initial focus on EKG monitoring. </p><p>In this interview, Konrad shares how he optimizes fundraising efforts by aligning them with important milestones, his unconventional methods to gather voice of customer research, and how his startup moved rapidly through product design iterations. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/konrad-morzkowski-wearlinq">here's a link to the full interview with Konrad Morzkowski.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Sep 2024 16:39:14 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/94937e6b/b8bcb148.mp3" length="58179102" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ZKWlhIyEBt7vgliAnypmrOvLH6nk6SH_6e4lJEnMlPs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kNDQ5/MWU5OTMyODQwZjNh/NjY3NzA5YmIxOTgy/NmQzNi5qcGc.jpg"/>
      <itunes:duration>2423</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/konrad-morzkowski-372883105/">Konrad Morzkowski</a>, co-founder and CEO of<a href="https://wearlinq.com/"> WearLinq</a>. The startup is commercializing eWave, an FDA-cleared EKG monitor for continuous cardiac monitoring. </p><p>Konrad is an engineer from Sweden and a member of Forbes’ 30 under 30 list. After obtaining an MS at Stanford – where he met his co-founders and raised his first round – Konrad dove right into entrepreneurship with WearLinq, a company commercializing consumer-facing digital healthcare solutions with an initial focus on EKG monitoring. </p><p>In this interview, Konrad shares how he optimizes fundraising efforts by aligning them with important milestones, his unconventional methods to gather voice of customer research, and how his startup moved rapidly through product design iterations. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/konrad-morzkowski-wearlinq">here's a link to the full interview with Konrad Morzkowski.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Validating Demand in Medtech: Interview with Pristine Surgical CEO Bryan Lord</title>
      <itunes:title>Validating Demand in Medtech: Interview with Pristine Surgical CEO Bryan Lord</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">bdc629d6-b973-44ad-842f-7c57bd2bd51a</guid>
      <link>https://medsider.com/interviews/bryan-lord-pristine-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/bryanlord/">Bryan Lord</a>, President and CEO of<a href="https://pristinesurgical.com/"> Pristine Surgical</a>. Pristine's flagship product, Summit, is a 4K, single-use digital arthroscope that streamlines arthroscopic procedures.<br> <br>Bryan started his career as a “deal guy” – originally a tech lawyer in Boston, and always involved in startups. He has a wealth of experience across various technology sectors including semiconductors, enterprise software, and medtech, and spanning roles in corporate finance, technology licensing, and M&amp;A. Before Pristine, Bryan also founded three venture organizations: New Venture Advisors, Orthopedic Venture Partners, and Innovation Alliance.</p><p>In this interview, Bryan shares the story of how he evolved his career to become a medtech entrepreneur and the lessons he learned along the way—about how to protect your competitive advantage, how to achieve market pull vs. market push, and the importance of collaborating with experienced mentors.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bryan-lord-pristine-surgical">here's a link to the full interview with Bryan Lord.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/bryanlord/">Bryan Lord</a>, President and CEO of<a href="https://pristinesurgical.com/"> Pristine Surgical</a>. Pristine's flagship product, Summit, is a 4K, single-use digital arthroscope that streamlines arthroscopic procedures.<br> <br>Bryan started his career as a “deal guy” – originally a tech lawyer in Boston, and always involved in startups. He has a wealth of experience across various technology sectors including semiconductors, enterprise software, and medtech, and spanning roles in corporate finance, technology licensing, and M&amp;A. Before Pristine, Bryan also founded three venture organizations: New Venture Advisors, Orthopedic Venture Partners, and Innovation Alliance.</p><p>In this interview, Bryan shares the story of how he evolved his career to become a medtech entrepreneur and the lessons he learned along the way—about how to protect your competitive advantage, how to achieve market pull vs. market push, and the importance of collaborating with experienced mentors.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bryan-lord-pristine-surgical">here's a link to the full interview with Bryan Lord.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 28 Aug 2024 17:18:02 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/11ca38b7/66546c1b.mp3" length="87518769" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/YUACCn7VllZHZLhzTqoFz6D32Z-fScuEIpnuoeukHIQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NGRi/NmQwNTBlMTE5YTI5/MDYyODdjM2E2MWY0/ZjA0MC5qcGc.jpg"/>
      <itunes:duration>3645</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/bryanlord/">Bryan Lord</a>, President and CEO of<a href="https://pristinesurgical.com/"> Pristine Surgical</a>. Pristine's flagship product, Summit, is a 4K, single-use digital arthroscope that streamlines arthroscopic procedures.<br> <br>Bryan started his career as a “deal guy” – originally a tech lawyer in Boston, and always involved in startups. He has a wealth of experience across various technology sectors including semiconductors, enterprise software, and medtech, and spanning roles in corporate finance, technology licensing, and M&amp;A. Before Pristine, Bryan also founded three venture organizations: New Venture Advisors, Orthopedic Venture Partners, and Innovation Alliance.</p><p>In this interview, Bryan shares the story of how he evolved his career to become a medtech entrepreneur and the lessons he learned along the way—about how to protect your competitive advantage, how to achieve market pull vs. market push, and the importance of collaborating with experienced mentors.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bryan-lord-pristine-surgical">here's a link to the full interview with Bryan Lord.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Managing Critical Risks in Early-Stage Medtech: Interview with Instylla CEO Amarpreet Sawhney</title>
      <itunes:title>Managing Critical Risks in Early-Stage Medtech: Interview with Instylla CEO Amarpreet Sawhney</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">47b61ab2-752f-4294-b770-2d6ce81e1192</guid>
      <link>https://medsider.com/interviews/amar-sawhney-instylla</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/amar-sawhney-a4b143/">Amarpreet Sawhney</a>, inventor, serial entrepreneur, and CEO of a few startups, including<a href="https://instylla.com/"> Instylla,</a> which is developing polymerizing liquid embolics that can be used to shut down blood supply to hypervascular tumors and control bleeding.</p><p>Amar is also the CEO of Rejoni, Sealonix, and Pramand. His FDA-approved inventions include ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Together, they have impacted over 8 million patients globally.</p><p>In this episode, Amar shares his frameworks on risk assessment for medtech startups, tips on clinical study design, and how to prioritize indications when working on platform technologies.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/amar-sawhney-instylla">here's a link to the full interview with Amar Sawhney.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/amar-sawhney-a4b143/">Amarpreet Sawhney</a>, inventor, serial entrepreneur, and CEO of a few startups, including<a href="https://instylla.com/"> Instylla,</a> which is developing polymerizing liquid embolics that can be used to shut down blood supply to hypervascular tumors and control bleeding.</p><p>Amar is also the CEO of Rejoni, Sealonix, and Pramand. His FDA-approved inventions include ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Together, they have impacted over 8 million patients globally.</p><p>In this episode, Amar shares his frameworks on risk assessment for medtech startups, tips on clinical study design, and how to prioritize indications when working on platform technologies.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/amar-sawhney-instylla">here's a link to the full interview with Amar Sawhney.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 14 Aug 2024 15:39:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a8c209f3/8e97d5b9.mp3" length="82520445" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dHcQaM4La9S48YX1AF3uhXpk5d2qlnlYK_pBJJTf1Ws/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iZTk1/Y2U1MmFiNGIyYjBj/NjcyZjhmODAwYWM1/YTc5NS5qcGc.jpg"/>
      <itunes:duration>3437</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/amar-sawhney-a4b143/">Amarpreet Sawhney</a>, inventor, serial entrepreneur, and CEO of a few startups, including<a href="https://instylla.com/"> Instylla,</a> which is developing polymerizing liquid embolics that can be used to shut down blood supply to hypervascular tumors and control bleeding.</p><p>Amar is also the CEO of Rejoni, Sealonix, and Pramand. His FDA-approved inventions include ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Together, they have impacted over 8 million patients globally.</p><p>In this episode, Amar shares his frameworks on risk assessment for medtech startups, tips on clinical study design, and how to prioritize indications when working on platform technologies.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/amar-sawhney-instylla">here's a link to the full interview with Amar Sawhney.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Build for the User, Not the Spec Sheet: Interview with Phagenesis CEO Reinhard Krickl</title>
      <itunes:title>Build for the User, Not the Spec Sheet: Interview with Phagenesis CEO Reinhard Krickl</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9432ec14-2523-4a0c-90ac-c432021a7e11</guid>
      <link>https://medsider.com/interviews/reinhard-krickl-phagenesis</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging chat with <a href="https://www.linkedin.com/in/reinhard-krickl">Reinhard Krickl</a>, CEO of<a href="https://www.phagenesis.com/"> Phagenesis</a>, a startup commercializing a neurostimulation system designed to treat dysphagia, a condition that impairs a patient's ability to swallow.</p><p>An Austrian engineer with over 25 years of experience in medtech, Reinhard specializes in neurology-based medical devices. After beginning his career in academia, he got his industry start with Medtronic in 2000, where he would eventually lead the company’s efforts with deep brain stimulation (DBS) therapy across Europe. He is also an INSEAD-certified director and serves on several boards, chairing two of them. </p><p>In this interview, Reinhard shares insights on the importance of simplicity in design, what thorough market understanding truly means, and how he engages with stakeholders effectively. He also reveals the “market access checklist” he uses before entering the commercialization stage.<br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/reinhard-krickl-phagenesis">here's a link to the full interview with Reinhard Krickl.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging chat with <a href="https://www.linkedin.com/in/reinhard-krickl">Reinhard Krickl</a>, CEO of<a href="https://www.phagenesis.com/"> Phagenesis</a>, a startup commercializing a neurostimulation system designed to treat dysphagia, a condition that impairs a patient's ability to swallow.</p><p>An Austrian engineer with over 25 years of experience in medtech, Reinhard specializes in neurology-based medical devices. After beginning his career in academia, he got his industry start with Medtronic in 2000, where he would eventually lead the company’s efforts with deep brain stimulation (DBS) therapy across Europe. He is also an INSEAD-certified director and serves on several boards, chairing two of them. </p><p>In this interview, Reinhard shares insights on the importance of simplicity in design, what thorough market understanding truly means, and how he engages with stakeholders effectively. He also reveals the “market access checklist” he uses before entering the commercialization stage.<br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/reinhard-krickl-phagenesis">here's a link to the full interview with Reinhard Krickl.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 07 Aug 2024 16:47:18 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e555d4ab/ab649675.mp3" length="69346798" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/z7uyFK7Y6VcALGpMDypdLzMer8gmUyaz0HOGBlHf-D8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83YmU0/OGRjNjUxYmNmMDcz/OTc3NmY2ODY4NGZj/Mjg4Mi5qcGc.jpg"/>
      <itunes:duration>2889</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging chat with <a href="https://www.linkedin.com/in/reinhard-krickl">Reinhard Krickl</a>, CEO of<a href="https://www.phagenesis.com/"> Phagenesis</a>, a startup commercializing a neurostimulation system designed to treat dysphagia, a condition that impairs a patient's ability to swallow.</p><p>An Austrian engineer with over 25 years of experience in medtech, Reinhard specializes in neurology-based medical devices. After beginning his career in academia, he got his industry start with Medtronic in 2000, where he would eventually lead the company’s efforts with deep brain stimulation (DBS) therapy across Europe. He is also an INSEAD-certified director and serves on several boards, chairing two of them. </p><p>In this interview, Reinhard shares insights on the importance of simplicity in design, what thorough market understanding truly means, and how he engages with stakeholders effectively. He also reveals the “market access checklist” he uses before entering the commercialization stage.<br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/reinhard-krickl-phagenesis">here's a link to the full interview with Reinhard Krickl.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Stage-Appropriate Framework for Startups: Interview with Cherish CEO Sumit Nagpal</title>
      <itunes:title>A Stage-Appropriate Framework for Startups: Interview with Cherish CEO Sumit Nagpal</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">f6b607f0-e892-4f77-8a31-e92f18ce5ef0</guid>
      <link>https://medsider.com/interviews/sumit-nagpal-cherish-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an interesting chat with <a href="https://www.linkedin.com/in/sumitknagpal/">Sumit Nagpa</a>l, founder and CEO of <a href="https://www.cherishhealth.com/">Cherish Health</a>, a company developing radar-based health and safety monitoring devices. </p><p>Over the past three decades, serial entrepreneur and digital health veteran Sumit has co-founded and grown five companies that have tackled some of the boldest challenges faced by the healthcare economy. He also serves on the board of <a href="https://www.himss.org/">HIMSS</a> and chairs the Nominating Committee.</p><p><br>In this interview, Sumit shares his take on the importance of being stage-appropriate—both mentally and business-wise—and how to recognize patterns in the market by simply listening. Oh - and constantly learn from others because, as Steve Jobs paraphrasing Picasso put it, “great artists steal.”</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sumit-nagpal-cherish-health">here's a link to the full interview with Sumit Nagpal.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an interesting chat with <a href="https://www.linkedin.com/in/sumitknagpal/">Sumit Nagpa</a>l, founder and CEO of <a href="https://www.cherishhealth.com/">Cherish Health</a>, a company developing radar-based health and safety monitoring devices. </p><p>Over the past three decades, serial entrepreneur and digital health veteran Sumit has co-founded and grown five companies that have tackled some of the boldest challenges faced by the healthcare economy. He also serves on the board of <a href="https://www.himss.org/">HIMSS</a> and chairs the Nominating Committee.</p><p><br>In this interview, Sumit shares his take on the importance of being stage-appropriate—both mentally and business-wise—and how to recognize patterns in the market by simply listening. Oh - and constantly learn from others because, as Steve Jobs paraphrasing Picasso put it, “great artists steal.”</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sumit-nagpal-cherish-health">here's a link to the full interview with Sumit Nagpal.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 24 Jul 2024 15:33:48 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/61bb8712/7c09603a.mp3" length="72568248" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/OOGsiescweAiJiHSiQOS_tUUVGQIRf8TM9QXlfP0tKE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hNWI1/YTk0YzM4MjhmMTZk/YzFjYzBlODQ2ODlk/YzIyMy5qcGc.jpg"/>
      <itunes:duration>3023</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an interesting chat with <a href="https://www.linkedin.com/in/sumitknagpal/">Sumit Nagpa</a>l, founder and CEO of <a href="https://www.cherishhealth.com/">Cherish Health</a>, a company developing radar-based health and safety monitoring devices. </p><p>Over the past three decades, serial entrepreneur and digital health veteran Sumit has co-founded and grown five companies that have tackled some of the boldest challenges faced by the healthcare economy. He also serves on the board of <a href="https://www.himss.org/">HIMSS</a> and chairs the Nominating Committee.</p><p><br>In this interview, Sumit shares his take on the importance of being stage-appropriate—both mentally and business-wise—and how to recognize patterns in the market by simply listening. Oh - and constantly learn from others because, as Steve Jobs paraphrasing Picasso put it, “great artists steal.”</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sumit-nagpal-cherish-health">here's a link to the full interview with Sumit Nagpal.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Forging Win-Win Collaborations in Healthcare: Interview with Reimagine Care CEO Dan Nardi</title>
      <itunes:title>Forging Win-Win Collaborations in Healthcare: Interview with Reimagine Care CEO Dan Nardi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a6dfbdd4-d556-4c8f-b454-7d95de167291</guid>
      <link>https://medsider.com/interviews/dan-nardi-reimagine-care</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/danjnardi/">Dan Nardi</a>, CEO of<a href="https://reimaginecare.com/"> Reimagine Care</a>, a startup that integrates clinical oncology experts and robust capabilities to deliver individualized cancer treatment and recovery experience from home.</p><p>Dan has over two decades of experience in healthcare IT and digital health. Before Reimagine Care, he served as COO at Carrum Health, where he focused on value-based care and oversaw operations, including care delivery and growth. He also played a key role in scaling Livongo from 13 employees to its IPO as Vice President of Operations.</p><p> In this interview, Dan shares how he forms strategic partnerships that prioritize long-term value over short-term gains, how to leverage early adopters, and how he’s positioned his company in the emerging fee-for-value healthcare model.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-nardi-reimagine-care">here's a link to the full interview with Dan Nardi.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/danjnardi/">Dan Nardi</a>, CEO of<a href="https://reimaginecare.com/"> Reimagine Care</a>, a startup that integrates clinical oncology experts and robust capabilities to deliver individualized cancer treatment and recovery experience from home.</p><p>Dan has over two decades of experience in healthcare IT and digital health. Before Reimagine Care, he served as COO at Carrum Health, where he focused on value-based care and oversaw operations, including care delivery and growth. He also played a key role in scaling Livongo from 13 employees to its IPO as Vice President of Operations.</p><p> In this interview, Dan shares how he forms strategic partnerships that prioritize long-term value over short-term gains, how to leverage early adopters, and how he’s positioned his company in the emerging fee-for-value healthcare model.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-nardi-reimagine-care">here's a link to the full interview with Dan Nardi.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 17 Jul 2024 15:44:53 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c251aa69/9bfe1f16.mp3" length="71431862" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/PUN7CMPf8n1EROxxyIaYzC20ADjVpJNLOrItFotMSmU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mOWYz/ZmY2NzQ0YTYzMDA4/MGM3NTNiMTRhMmNl/YzA2Zi5qcGc.jpg"/>
      <itunes:duration>2975</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <a href="https://www.linkedin.com/in/danjnardi/">Dan Nardi</a>, CEO of<a href="https://reimaginecare.com/"> Reimagine Care</a>, a startup that integrates clinical oncology experts and robust capabilities to deliver individualized cancer treatment and recovery experience from home.</p><p>Dan has over two decades of experience in healthcare IT and digital health. Before Reimagine Care, he served as COO at Carrum Health, where he focused on value-based care and oversaw operations, including care delivery and growth. He also played a key role in scaling Livongo from 13 employees to its IPO as Vice President of Operations.</p><p> In this interview, Dan shares how he forms strategic partnerships that prioritize long-term value over short-term gains, how to leverage early adopters, and how he’s positioned his company in the emerging fee-for-value healthcare model.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-nardi-reimagine-care">here's a link to the full interview with Dan Nardi.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Build a Community of Investors: Interview with Pirouette Medical CEO Conor Cullinane</title>
      <itunes:title>How to Build a Community of Investors: Interview with Pirouette Medical CEO Conor Cullinane</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d4a599e5-51f3-4a3c-bd65-770d639cff74</guid>
      <link>https://medsider.com/interviews/conor-cullinane-pirouette-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/conorrcullinane/">Conor Cullinane</a>, co-founder and CEO of <a href="https://pirouettemedical.com/">Pirouette Medical</a>. The company, founded by three rocket scientists, is developing a low-profile, disc-shaped injector designed to deliver medicines as easily as pushing a button. <strong> </strong></p><p>Conor studied Aeronautical Engineering at Clarkson University and graduated with minors in Biomedical Engineering and Mathematics, followed by his PhD in Medical Engineering &amp; Medical Physics at MIT and Harvard Medical School. He is also a mentor for Field X at Harvard Business School and a NASA Space Technology Research Fellow.</p><p>In this interview, Conor shares learnings from launching a community fundraising round, insights on selective innovation, identifying different value propositions for diverse stakeholders, and building strong investor relationships.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/conor-cullinane-pirouette-medical">here's a link to the full interview with Conor Cullinane.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/conorrcullinane/">Conor Cullinane</a>, co-founder and CEO of <a href="https://pirouettemedical.com/">Pirouette Medical</a>. The company, founded by three rocket scientists, is developing a low-profile, disc-shaped injector designed to deliver medicines as easily as pushing a button. <strong> </strong></p><p>Conor studied Aeronautical Engineering at Clarkson University and graduated with minors in Biomedical Engineering and Mathematics, followed by his PhD in Medical Engineering &amp; Medical Physics at MIT and Harvard Medical School. He is also a mentor for Field X at Harvard Business School and a NASA Space Technology Research Fellow.</p><p>In this interview, Conor shares learnings from launching a community fundraising round, insights on selective innovation, identifying different value propositions for diverse stakeholders, and building strong investor relationships.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/conor-cullinane-pirouette-medical">here's a link to the full interview with Conor Cullinane.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 10 Jul 2024 17:26:01 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7ed5f93d/185d0d9b.mp3" length="72159388" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/2QI7i_UkQMnWYeAy30otCFbNqLnvQUMgLZWTyqWc6OM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jZmJl/MTcwOWU2ZTVkZWU1/MGRlZGI5MGM2MzIx/ZTIzYS5qcGc.jpg"/>
      <itunes:duration>3006</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/conorrcullinane/">Conor Cullinane</a>, co-founder and CEO of <a href="https://pirouettemedical.com/">Pirouette Medical</a>. The company, founded by three rocket scientists, is developing a low-profile, disc-shaped injector designed to deliver medicines as easily as pushing a button. <strong> </strong></p><p>Conor studied Aeronautical Engineering at Clarkson University and graduated with minors in Biomedical Engineering and Mathematics, followed by his PhD in Medical Engineering &amp; Medical Physics at MIT and Harvard Medical School. He is also a mentor for Field X at Harvard Business School and a NASA Space Technology Research Fellow.</p><p>In this interview, Conor shares learnings from launching a community fundraising round, insights on selective innovation, identifying different value propositions for diverse stakeholders, and building strong investor relationships.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/conor-cullinane-pirouette-medical">here's a link to the full interview with Conor Cullinane.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Physician's Guide to Turning Ideas into Reality: Interview With Canary Medical CEO Dr. Bill Hunter</title>
      <itunes:title>A Physician's Guide to Turning Ideas into Reality: Interview With Canary Medical CEO Dr. Bill Hunter</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e2ebd84a-ef47-4e4d-96c7-76661f2342c4</guid>
      <link>https://medsider.com/interviews/bill-hunter-canary-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <strong> </strong><a href="https://www.linkedin.com/in/bill-hunter-447107106/">Dr. Bill Hunter</a>, CEO of<a href="https://canarymedical.com/"> Canary Medical</a>. The company is developing smart, implantable medical devices that report on function, patient activity, and more.  </p><p>Bill is a former practicing physician with 30+ years of healthcare entrepreneurial experience and over 200 patents and patent applications to his name. He’s been intimately involved in the development of renowned devices like the TAXUS DES and paclitaxel-eluting balloons and spearheaded the success of companies like Angiotech and Correvio. As the CEO of Canary Medical, he’s now leading a new, smart, digital approach to patient monitoring and post-surgical care.</p><p>In this interview, Bill talks about his perspective on innovation in medtech, discusses what it takes for a device to be commercially viable, how Canary is alleviating the workload of healthcare professionals, and offers advice to physicians contemplating the transition to industry. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-hunter-canary-medical">here's a link to the full interview with Dr. Bill Hunter.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <strong> </strong><a href="https://www.linkedin.com/in/bill-hunter-447107106/">Dr. Bill Hunter</a>, CEO of<a href="https://canarymedical.com/"> Canary Medical</a>. The company is developing smart, implantable medical devices that report on function, patient activity, and more.  </p><p>Bill is a former practicing physician with 30+ years of healthcare entrepreneurial experience and over 200 patents and patent applications to his name. He’s been intimately involved in the development of renowned devices like the TAXUS DES and paclitaxel-eluting balloons and spearheaded the success of companies like Angiotech and Correvio. As the CEO of Canary Medical, he’s now leading a new, smart, digital approach to patient monitoring and post-surgical care.</p><p>In this interview, Bill talks about his perspective on innovation in medtech, discusses what it takes for a device to be commercially viable, how Canary is alleviating the workload of healthcare professionals, and offers advice to physicians contemplating the transition to industry. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-hunter-canary-medical">here's a link to the full interview with Dr. Bill Hunter.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Jun 2024 16:45:37 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7ab03e4d/6da13570.mp3" length="88776673" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dJCwuvYR5TbEFnBI9ErXrel0J-gLBzf3_UIbr0trSLo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xZDk1/ODM3NzE5ZDBlZDJl/NzU0NjgyMjEyY2Iz/YTc4OS5qcGc.jpg"/>
      <itunes:duration>3698</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful chat with <strong> </strong><a href="https://www.linkedin.com/in/bill-hunter-447107106/">Dr. Bill Hunter</a>, CEO of<a href="https://canarymedical.com/"> Canary Medical</a>. The company is developing smart, implantable medical devices that report on function, patient activity, and more.  </p><p>Bill is a former practicing physician with 30+ years of healthcare entrepreneurial experience and over 200 patents and patent applications to his name. He’s been intimately involved in the development of renowned devices like the TAXUS DES and paclitaxel-eluting balloons and spearheaded the success of companies like Angiotech and Correvio. As the CEO of Canary Medical, he’s now leading a new, smart, digital approach to patient monitoring and post-surgical care.</p><p>In this interview, Bill talks about his perspective on innovation in medtech, discusses what it takes for a device to be commercially viable, how Canary is alleviating the workload of healthcare professionals, and offers advice to physicians contemplating the transition to industry. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-hunter-canary-medical">here's a link to the full interview with Dr. Bill Hunter.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Silicon Valley Approach to Medtech: Interview with Oncoustics CEO Beth Rogozinski</title>
      <itunes:title>Silicon Valley Approach to Medtech: Interview with Oncoustics CEO Beth Rogozinski</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">112ba394-2dff-4a00-8b29-04c5588004e8</guid>
      <link>https://medsider.com/interviews/beth-rogozinski-oncoustics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a compelling chat with <a href="https://www.linkedin.com/in/bethrogozinski">Beth Rogozinski</a>, CEO of <a href="https://www.oncoustics.com/">Oncoustics</a>. The company uses advanced AI to analyze ultrasound data to offer a cost-effective alternative to traditional diagnostic methods. </p><p>Beth has held a variety of leadership roles in the field of digital health, including the development of the first FDA-cleared prescription digital therapeutic. She advises numerous startups and accelerators and has consulted with organizations like Stanford, UnitedHealth, and the National Mental Health Innovation Center. She is a guest lecturer at UCSF Health Hub and Columbia’s HIT Lab and serves on BIO’s Digital Health committee. </p><p><br>In this interview, Beth shares her insights on the importance of persistence and resilience in fundraising, the value of engaging with a diverse range of investors, and the need for a strong narrative about your technology, particularly when it involves AI capabilities.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/beth-rogozinski-oncoustics">here's a link to the full interview with Beth Rogozinski.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a compelling chat with <a href="https://www.linkedin.com/in/bethrogozinski">Beth Rogozinski</a>, CEO of <a href="https://www.oncoustics.com/">Oncoustics</a>. The company uses advanced AI to analyze ultrasound data to offer a cost-effective alternative to traditional diagnostic methods. </p><p>Beth has held a variety of leadership roles in the field of digital health, including the development of the first FDA-cleared prescription digital therapeutic. She advises numerous startups and accelerators and has consulted with organizations like Stanford, UnitedHealth, and the National Mental Health Innovation Center. She is a guest lecturer at UCSF Health Hub and Columbia’s HIT Lab and serves on BIO’s Digital Health committee. </p><p><br>In this interview, Beth shares her insights on the importance of persistence and resilience in fundraising, the value of engaging with a diverse range of investors, and the need for a strong narrative about your technology, particularly when it involves AI capabilities.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/beth-rogozinski-oncoustics">here's a link to the full interview with Beth Rogozinski.</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 21 Jun 2024 03:53:28 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f29a4adf/a71109a0.mp3" length="72951364" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/qdrF7qB1AWyuIW7iafcvocetAfUjcYUUcRZRSh1jmjg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85MGU4/YTk3NmViYWFjYzgx/YzkyNWEwMjZhYTI3/ZGZjNS5qcGc.jpg"/>
      <itunes:duration>3039</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a compelling chat with <a href="https://www.linkedin.com/in/bethrogozinski">Beth Rogozinski</a>, CEO of <a href="https://www.oncoustics.com/">Oncoustics</a>. The company uses advanced AI to analyze ultrasound data to offer a cost-effective alternative to traditional diagnostic methods. </p><p>Beth has held a variety of leadership roles in the field of digital health, including the development of the first FDA-cleared prescription digital therapeutic. She advises numerous startups and accelerators and has consulted with organizations like Stanford, UnitedHealth, and the National Mental Health Innovation Center. She is a guest lecturer at UCSF Health Hub and Columbia’s HIT Lab and serves on BIO’s Digital Health committee. </p><p><br>In this interview, Beth shares her insights on the importance of persistence and resilience in fundraising, the value of engaging with a diverse range of investors, and the need for a strong narrative about your technology, particularly when it involves AI capabilities.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/beth-rogozinski-oncoustics">here's a link to the full interview with Beth Rogozinski.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Proof Before Funding: Interview with VenoStent CEO and COO, Tim Boire and Geoffrey Lucks</title>
      <itunes:title>Proof Before Funding: Interview with VenoStent CEO and COO, Tim Boire and Geoffrey Lucks</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">0d72fc47-5518-4296-8f87-429e7ee5afcc</guid>
      <link>https://medsider.com/interviews/timothy-boire-geoffrey-lucks-venostent</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/timothy-boire-283bab10/">Timothy Boire</a> and <a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/">Geoffrey Lucks</a>, co-founders of<a href="https://www.venostent.com/"> VenoStent</a>. The company is developing SelfWrap, a bioabsorbable wrap to improve the success rate of vascular surgeries, starting with dialysis access creation for chronic kidney disease (CKD) patients.    </p><p>Tim holds a Ph.D. in Biomedical Engineering from Vanderbilt University. He has experience as a Research Associate at Genzyme and was an Entrepreneurial Lead at NSF I-Corps.<a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/"> </a>Geoffrey is a venture partner at Pioneer Fund and has a BA in Economics, Biology, and Zoology from the University of Wisconsin, a Master's in Bioethics from the University of Pennsylvania, and an MBA in Finance from Vanderbilt University.<br> <br>In this interview, they talk about understanding your end user, working collaboratively with FDA, structuring and executing large clinical trials, and staying resourceful to attract funding while developing your concept.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/timothy-boire-geoffrey-lucks-venostent">here's a link to the full interview with Tim Boire and Geoffrey Lucks.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/timothy-boire-283bab10/">Timothy Boire</a> and <a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/">Geoffrey Lucks</a>, co-founders of<a href="https://www.venostent.com/"> VenoStent</a>. The company is developing SelfWrap, a bioabsorbable wrap to improve the success rate of vascular surgeries, starting with dialysis access creation for chronic kidney disease (CKD) patients.    </p><p>Tim holds a Ph.D. in Biomedical Engineering from Vanderbilt University. He has experience as a Research Associate at Genzyme and was an Entrepreneurial Lead at NSF I-Corps.<a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/"> </a>Geoffrey is a venture partner at Pioneer Fund and has a BA in Economics, Biology, and Zoology from the University of Wisconsin, a Master's in Bioethics from the University of Pennsylvania, and an MBA in Finance from Vanderbilt University.<br> <br>In this interview, they talk about understanding your end user, working collaboratively with FDA, structuring and executing large clinical trials, and staying resourceful to attract funding while developing your concept.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/timothy-boire-geoffrey-lucks-venostent">here's a link to the full interview with Tim Boire and Geoffrey Lucks.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 12 Jun 2024 15:10:34 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b18d02ee/1949f8bf.mp3" length="81117743" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/OtrbUPLb1a5PDBpD1JT3D9pPi1hiZE_t1Pgdx3GQUYE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82N2Vh/M2NmMDJhZjEzMWYw/ODMwZTdlOWZmOTQ4/YTNjNy5qcGc.jpg"/>
      <itunes:duration>3379</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/timothy-boire-283bab10/">Timothy Boire</a> and <a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/">Geoffrey Lucks</a>, co-founders of<a href="https://www.venostent.com/"> VenoStent</a>. The company is developing SelfWrap, a bioabsorbable wrap to improve the success rate of vascular surgeries, starting with dialysis access creation for chronic kidney disease (CKD) patients.    </p><p>Tim holds a Ph.D. in Biomedical Engineering from Vanderbilt University. He has experience as a Research Associate at Genzyme and was an Entrepreneurial Lead at NSF I-Corps.<a href="https://www.linkedin.com/in/geoffrey-lucks-0495a239/"> </a>Geoffrey is a venture partner at Pioneer Fund and has a BA in Economics, Biology, and Zoology from the University of Wisconsin, a Master's in Bioethics from the University of Pennsylvania, and an MBA in Finance from Vanderbilt University.<br> <br>In this interview, they talk about understanding your end user, working collaboratively with FDA, structuring and executing large clinical trials, and staying resourceful to attract funding while developing your concept.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/timothy-boire-geoffrey-lucks-venostent">here's a link to the full interview with Tim Boire and Geoffrey Lucks.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Roadmap for Proving Clinical Efficacy and Economic Value: Interview with Mainstay Medical CEO Jason Hannon</title>
      <itunes:title>A Roadmap for Proving Clinical Efficacy and Economic Value: Interview with Mainstay Medical CEO Jason Hannon</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">384409a6-2a9d-4d99-be41-8da6fa549128</guid>
      <link>https://medsider.com/interviews/jason-hannon-mainstay-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jason-hannon-a4072891/">Jason Hannon</a>, President and CEO of<a href="https://mainstaymedical.com/"> Mainstay Medical,</a> where he and his team are commercializing ReActiv8, an implantable neurostimulation system for intractable mechanical chronic low back pain. </p><p>Jason holds a J.D. from Stanford University Law School and a B.A. from the University of California, Berkeley. After 12 years at NuVasive, where as COO, he led the company to incredible revenue milestones, he transitioned to his current role at Mainstay.<br> <br>In this interview, Jason shares his experiences on iterative product development, considerations for clinical trial design, the importance of patient education, and why reimbursement is paramount.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jason-hannon-mainstay-medical">here's a link to the full interview with Jason Hannon.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jason-hannon-a4072891/">Jason Hannon</a>, President and CEO of<a href="https://mainstaymedical.com/"> Mainstay Medical,</a> where he and his team are commercializing ReActiv8, an implantable neurostimulation system for intractable mechanical chronic low back pain. </p><p>Jason holds a J.D. from Stanford University Law School and a B.A. from the University of California, Berkeley. After 12 years at NuVasive, where as COO, he led the company to incredible revenue milestones, he transitioned to his current role at Mainstay.<br> <br>In this interview, Jason shares his experiences on iterative product development, considerations for clinical trial design, the importance of patient education, and why reimbursement is paramount.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jason-hannon-mainstay-medical">here's a link to the full interview with Jason Hannon.</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 31 May 2024 01:10:14 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9212a8b4/a7c73920.mp3" length="71338493" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/eAEdyYGkZw7umduNlXj9c0sS1ykfcUb14bhMlo-E2HU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kZjI3/MWI2Yjc1ZDQ3MDUw/ODFkMTg0YWRkYjU2/MTBkYS5qcGc.jpg"/>
      <itunes:duration>2971</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jason-hannon-a4072891/">Jason Hannon</a>, President and CEO of<a href="https://mainstaymedical.com/"> Mainstay Medical,</a> where he and his team are commercializing ReActiv8, an implantable neurostimulation system for intractable mechanical chronic low back pain. </p><p>Jason holds a J.D. from Stanford University Law School and a B.A. from the University of California, Berkeley. After 12 years at NuVasive, where as COO, he led the company to incredible revenue milestones, he transitioned to his current role at Mainstay.<br> <br>In this interview, Jason shares his experiences on iterative product development, considerations for clinical trial design, the importance of patient education, and why reimbursement is paramount.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/jason-hannon-mainstay-medical">here's a link to the full interview with Jason Hannon.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Overcoming Skepticism When Commercializing Novel Therapies: Interview with Taopatch USA CEO Dmitri Leonov</title>
      <itunes:title>Overcoming Skepticism When Commercializing Novel Therapies: Interview with Taopatch USA CEO Dmitri Leonov</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">897de71f-6245-40a1-9617-003b5d033acb</guid>
      <link>https://medsider.com/interviews/dmitri-leonov-taopatch-usa</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/dmitrileonov/">Dmitri Leonov</a>, co-founder and CEO of <a href="https://taopatch.co/">Taopatch USA</a>. The company is commercializing a range of wearable nanotechnology light therapy devices aimed at managing neurological conditions including pain management and sports performance. <br> <br>Dmitri is also an advisor in a number of transformative technology projects. After seven fruitful years at Overture and later at Yahoo, he dove into the startup world. He went on to found several companies, including Sanebox.com, but was intrigued by frequency medicine and started his current venture by bringing Taopatch to the United States from Italy, where it was first invented.</p><p><br>In this interview, Dmitri shares how the company was able to garner unique publicity and how strategic partnerships with holistic practitioners, authentic user testimonials, and a creative money-back guarantee strategy were instrumental in Taopatch USA's market success.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dmitri-leonov-taopatch-usa">here's a link to the full interview with Dmitri Leonov.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/dmitrileonov/">Dmitri Leonov</a>, co-founder and CEO of <a href="https://taopatch.co/">Taopatch USA</a>. The company is commercializing a range of wearable nanotechnology light therapy devices aimed at managing neurological conditions including pain management and sports performance. <br> <br>Dmitri is also an advisor in a number of transformative technology projects. After seven fruitful years at Overture and later at Yahoo, he dove into the startup world. He went on to found several companies, including Sanebox.com, but was intrigued by frequency medicine and started his current venture by bringing Taopatch to the United States from Italy, where it was first invented.</p><p><br>In this interview, Dmitri shares how the company was able to garner unique publicity and how strategic partnerships with holistic practitioners, authentic user testimonials, and a creative money-back guarantee strategy were instrumental in Taopatch USA's market success.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dmitri-leonov-taopatch-usa">here's a link to the full interview with Dmitri Leonov.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 23 May 2024 21:50:21 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ba3015dd/839dfdce.mp3" length="75189505" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/7mzbbrVJslTZ51KTuJtFiyvVajX9UypDVJL9G02g57U/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80MDhl/Yzk0ZTkyOTFiOGJk/YmYzOTkzMGY1ODVh/MDc3Mi5qcGc.jpg"/>
      <itunes:duration>3132</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating chat with <a href="https://www.linkedin.com/in/dmitrileonov/">Dmitri Leonov</a>, co-founder and CEO of <a href="https://taopatch.co/">Taopatch USA</a>. The company is commercializing a range of wearable nanotechnology light therapy devices aimed at managing neurological conditions including pain management and sports performance. <br> <br>Dmitri is also an advisor in a number of transformative technology projects. After seven fruitful years at Overture and later at Yahoo, he dove into the startup world. He went on to found several companies, including Sanebox.com, but was intrigued by frequency medicine and started his current venture by bringing Taopatch to the United States from Italy, where it was first invented.</p><p><br>In this interview, Dmitri shares how the company was able to garner unique publicity and how strategic partnerships with holistic practitioners, authentic user testimonials, and a creative money-back guarantee strategy were instrumental in Taopatch USA's market success.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dmitri-leonov-taopatch-usa">here's a link to the full interview with Dmitri Leonov.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Compete with Industry Goliaths: Interview with Butterfly Network CEO Joe DeVivo</title>
      <itunes:title>How to Compete with Industry Goliaths: Interview with Butterfly Network CEO Joe DeVivo</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">33e37af5-5064-4a0b-9731-d7c770ce9db4</guid>
      <link>https://medsider.com/interviews/joe-devivo-butterfly-network</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran <a href="https://www.linkedin.com/in/joe-devivo/">Joe DeVivo</a>, President and CEO of<a href="https://www.butterflynetwork.com/"> Butterfly Network</a>. Butterfly iQ3 is the startup's latest chip-powered, hand-held ultrasound device with superior image quality and ultrafast scan times. <br> <br>Joe is a proven executive with 35 years of business leadership experience, including 22 years in the medical device industry spanning small start-up companies to multi-billion-dollar organizations. He has acquired and fully integrated eight companies, engineered four business turnarounds, and delivered five company exits. </p><p><br>In this interview, Joe shares insights on why a lean start in commercialization is better than a high-burn, high-risk approach, the difference between your company being sold and being purchased, and best practices for managing M&amp;A transactions. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/joe-devivo-butterfly-network">here's a link to the full interview with Joe DeVivo.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran <a href="https://www.linkedin.com/in/joe-devivo/">Joe DeVivo</a>, President and CEO of<a href="https://www.butterflynetwork.com/"> Butterfly Network</a>. Butterfly iQ3 is the startup's latest chip-powered, hand-held ultrasound device with superior image quality and ultrafast scan times. <br> <br>Joe is a proven executive with 35 years of business leadership experience, including 22 years in the medical device industry spanning small start-up companies to multi-billion-dollar organizations. He has acquired and fully integrated eight companies, engineered four business turnarounds, and delivered five company exits. </p><p><br>In this interview, Joe shares insights on why a lean start in commercialization is better than a high-burn, high-risk approach, the difference between your company being sold and being purchased, and best practices for managing M&amp;A transactions. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/joe-devivo-butterfly-network">here's a link to the full interview with Joe DeVivo.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 15 May 2024 15:18:06 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3bf05d79/d4b28620.mp3" length="86034982" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/w8JKIInq_umSQZoxWMmJXHN1FZEVHaAG2WFILAZnw9s/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jNTY1/OWZhZDYzMDhhZDJj/MWZmMWJhYmIxZmRl/M2Q4OC5qcGc.jpg"/>
      <itunes:duration>3584</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with medtech veteran <a href="https://www.linkedin.com/in/joe-devivo/">Joe DeVivo</a>, President and CEO of<a href="https://www.butterflynetwork.com/"> Butterfly Network</a>. Butterfly iQ3 is the startup's latest chip-powered, hand-held ultrasound device with superior image quality and ultrafast scan times. <br> <br>Joe is a proven executive with 35 years of business leadership experience, including 22 years in the medical device industry spanning small start-up companies to multi-billion-dollar organizations. He has acquired and fully integrated eight companies, engineered four business turnarounds, and delivered five company exits. </p><p><br>In this interview, Joe shares insights on why a lean start in commercialization is better than a high-burn, high-risk approach, the difference between your company being sold and being purchased, and best practices for managing M&amp;A transactions. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/joe-devivo-butterfly-network">here's a link to the full interview with Joe DeVivo.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Outpace Your Competition: Interview with Contraline CEO Kevin Eisenfrats</title>
      <itunes:title>How to Outpace Your Competition: Interview with Contraline CEO Kevin Eisenfrats</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">3a126942-4810-472a-a160-f6924e6fd656</guid>
      <link>https://medsider.com/interviews/kevin-eisenfrats-contraline</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun conversation with <a href="https://www.linkedin.com/in/kevineisenfrats/">Kevin Eisenfrats</a>, CEO of <a href="https://www.contraline.com/">Contraline</a>. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.</p><p>Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.</p><p><br>In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kevin-eisenfrats-contraline">here's a link to the full interview with Kevin Eisenfrats.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun conversation with <a href="https://www.linkedin.com/in/kevineisenfrats/">Kevin Eisenfrats</a>, CEO of <a href="https://www.contraline.com/">Contraline</a>. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.</p><p>Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.</p><p><br>In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kevin-eisenfrats-contraline">here's a link to the full interview with Kevin Eisenfrats.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 01 May 2024 11:14:10 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c44f7590/be678ff5.mp3" length="79692160" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/pLM4NGm5WJTxjcu8PwGVLViI4RqX52YJZj_XKkvzbQ8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xZGMz/NzBmODk1OGY1Mzdm/ZmUyNjMxYTUzNGIz/NDg4Yy5qcGc.jpg"/>
      <itunes:duration>3319</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun conversation with <a href="https://www.linkedin.com/in/kevineisenfrats/">Kevin Eisenfrats</a>, CEO of <a href="https://www.contraline.com/">Contraline</a>. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.</p><p>Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.</p><p><br>In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kevin-eisenfrats-contraline">here's a link to the full interview with Kevin Eisenfrats.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Two Important Customers — FDA and CMS: Interview with Procyrion CEO Dr. Eric Fain</title>
      <itunes:title>Two Important Customers — FDA and CMS: Interview with Procyrion CEO Dr. Eric Fain</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">99e8c4c7-8e6a-4c24-aae2-44f45fb4ab21</guid>
      <link>https://medsider.com/interviews/eric-fain-procyrion</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/eric-fain-149408b/">Dr. Eric Fain</a>, CEO and President of<a href="https://www.procyrion.com/"> Procyrion</a> — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.  </p><p>Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&amp;D, and clinical, eventually becoming the Group President via St. Jude’s exit to Abbott. </p><p>In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-fain-procyrion">here's a link to the full interview with Dr. Eric Fain.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/eric-fain-149408b/">Dr. Eric Fain</a>, CEO and President of<a href="https://www.procyrion.com/"> Procyrion</a> — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.  </p><p>Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&amp;D, and clinical, eventually becoming the Group President via St. Jude’s exit to Abbott. </p><p>In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-fain-procyrion">here's a link to the full interview with Dr. Eric Fain.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 24 Apr 2024 13:57:38 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3e0e3e55/8a68ebe1.mp3" length="62962741" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3N9wQH5Bx4jH2oDUkAlLdJRP2dGWmZREE831LghluwI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZDM4/OTIxNmYyMmI3YjQ1/YzJiOGRiODE2ODg5/ZjI2NC5qcGc.jpg"/>
      <itunes:duration>2621</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with <a href="https://www.linkedin.com/in/eric-fain-149408b/">Dr. Eric Fain</a>, CEO and President of<a href="https://www.procyrion.com/"> Procyrion</a> — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.  </p><p>Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&amp;D, and clinical, eventually becoming the Group President via St. Jude’s exit to Abbott. </p><p>In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/eric-fain-procyrion">here's a link to the full interview with Dr. Eric Fain.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Balancing the Clinical-Commercial Tightrope: Interview with Mercator MedSystems CEO Trent Reutiman</title>
      <itunes:title>Balancing the Clinical-Commercial Tightrope: Interview with Mercator MedSystems CEO Trent Reutiman</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">3436c4e2-65dc-4afe-9744-bafe3f0ef515</guid>
      <link>https://medsider.com/interviews/trent-reutiman-mercator</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/trent-reutiman-5193093/">Trent Reutiman</a>, CEO of <a href="https://mercatormed.com/">Mercator MedSystems</a>. Trent and his team have developed microinfusion devices with the unique ability to locally and directly deliver targeted therapeutics during catheter-based interventions where mechanical therapy isn’t sufficient.<br>  <br>Trent has 25 years of leadership experience in medtech including roles in sales, marketing, and business management with a focus on minimally invasive interventional products for companies like IDEV, ROX Medical, RITA Medical Systems, Guidant, and Cordis.</p><p>In this interview, Trent talks about the importance of generating data, how to balance commercial efforts with clinical initiatives, and why meticulous management is critical for successful commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/trent-reutiman-mercator">here's a link to the full interview with Trent Reutiman.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/trent-reutiman-5193093/">Trent Reutiman</a>, CEO of <a href="https://mercatormed.com/">Mercator MedSystems</a>. Trent and his team have developed microinfusion devices with the unique ability to locally and directly deliver targeted therapeutics during catheter-based interventions where mechanical therapy isn’t sufficient.<br>  <br>Trent has 25 years of leadership experience in medtech including roles in sales, marketing, and business management with a focus on minimally invasive interventional products for companies like IDEV, ROX Medical, RITA Medical Systems, Guidant, and Cordis.</p><p>In this interview, Trent talks about the importance of generating data, how to balance commercial efforts with clinical initiatives, and why meticulous management is critical for successful commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/trent-reutiman-mercator">here's a link to the full interview with Trent Reutiman.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 17 Apr 2024 18:12:12 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b89d5ea4/40eb1740.mp3" length="86933227" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-uDCZGhSmZ5-IqGG1DGlTmLHndi2rYzQrIcHJ-dnJEo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jZmNj/YjY0ZTU0ZWM0NDkx/NGI1NjI3MmE5NWE4/ZjA5NS5qcGc.jpg"/>
      <itunes:duration>3615</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun chat with <a href="https://www.linkedin.com/in/trent-reutiman-5193093/">Trent Reutiman</a>, CEO of <a href="https://mercatormed.com/">Mercator MedSystems</a>. Trent and his team have developed microinfusion devices with the unique ability to locally and directly deliver targeted therapeutics during catheter-based interventions where mechanical therapy isn’t sufficient.<br>  <br>Trent has 25 years of leadership experience in medtech including roles in sales, marketing, and business management with a focus on minimally invasive interventional products for companies like IDEV, ROX Medical, RITA Medical Systems, Guidant, and Cordis.</p><p>In this interview, Trent talks about the importance of generating data, how to balance commercial efforts with clinical initiatives, and why meticulous management is critical for successful commercialization. </p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/trent-reutiman-mercator">here's a link to the full interview with Trent Reutiman.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Don’t Build A Unicorn, Build A Useful Zebra: Interview with DeepLook CEO Marissa Fayer</title>
      <itunes:title>Don’t Build A Unicorn, Build A Useful Zebra: Interview with DeepLook CEO Marissa Fayer</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">4bb17b3e-2c77-423f-b584-3fe42cf26311</guid>
      <link>https://medsider.com/interviews/marissa-fayer-deeplook-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/marissa-fayer/">Marissa Fayer</a>, CEO of <a href="https://www.deeplookmedical.com/">DeepLook Medical</a>. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.<br>  <br> Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She’s the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She’s a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award.<br> <br>In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/marissa-fayer-deeplook-medical">here's a link to the full interview with Marissa Fayer.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/marissa-fayer/">Marissa Fayer</a>, CEO of <a href="https://www.deeplookmedical.com/">DeepLook Medical</a>. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.<br>  <br> Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She’s the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She’s a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award.<br> <br>In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/marissa-fayer-deeplook-medical">here's a link to the full interview with Marissa Fayer.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 10 Apr 2024 16:48:44 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a2d1dca7/d440a855.mp3" length="77913030" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/I4q4i-n0rNgSxLWGatv4LmRFMRQKZPpJCLedfh9OEVs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85NjE1/M2VhNzAwZmVlNzFh/NGQ4NTgzMGVjMThj/NGRmOS5qcGc.jpg"/>
      <itunes:duration>3245</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/marissa-fayer/">Marissa Fayer</a>, CEO of <a href="https://www.deeplookmedical.com/">DeepLook Medical</a>. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.<br>  <br> Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She’s the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She’s a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award.<br> <br>In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/marissa-fayer-deeplook-medical">here's a link to the full interview with Marissa Fayer.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Managing to a Successful Acquisition: Interview with LimFlow CEO Dan Rose</title>
      <itunes:title>Managing to a Successful Acquisition: Interview with LimFlow CEO Dan Rose</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8b0cdc53-a319-4053-b7b9-36303ae4c871</guid>
      <link>https://medsider.com/interviews/dan-rose-limflow-inari</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening discussion with <a href="https://www.linkedin.com/in/dan-rose-b6b509/">Dan Rose</a>, former CEO of <a href="https://limflow.com/">LimFlow</a>, which recently sold to <a href="https://www.inarimedical.com/">Inari Medical</a>. The minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain, and promoting wound healing.</p><p>A leader with 25 years of experience in the medical device space, Dan has worked in both multinational corporations and startup ventures throughout his career. He holds a BA and an MA from the University of Virginia, and an MBA from the Darden Business School. Most recently, he led LimFlow’s exit to Inari as the company’s CEO and has held pivotal positions at Direct Flow Medical, Sequana Medical, Medtronic, and other medtech companies. </p><p>In this interview, Dan shares his extensive wisdom on M&amp;A transactions, engaging with investors while maintaining business autonomy, the importance of developing with the ‘average user’ in mind, and the significance of early dialogue with regulatory bodies.</p><p> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-rose-limflow-inari">here's a link to the full interview with Dan Rose.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening discussion with <a href="https://www.linkedin.com/in/dan-rose-b6b509/">Dan Rose</a>, former CEO of <a href="https://limflow.com/">LimFlow</a>, which recently sold to <a href="https://www.inarimedical.com/">Inari Medical</a>. The minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain, and promoting wound healing.</p><p>A leader with 25 years of experience in the medical device space, Dan has worked in both multinational corporations and startup ventures throughout his career. He holds a BA and an MA from the University of Virginia, and an MBA from the Darden Business School. Most recently, he led LimFlow’s exit to Inari as the company’s CEO and has held pivotal positions at Direct Flow Medical, Sequana Medical, Medtronic, and other medtech companies. </p><p>In this interview, Dan shares his extensive wisdom on M&amp;A transactions, engaging with investors while maintaining business autonomy, the importance of developing with the ‘average user’ in mind, and the significance of early dialogue with regulatory bodies.</p><p> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-rose-limflow-inari">here's a link to the full interview with Dan Rose.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 03 Apr 2024 18:27:56 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3953f521/b285c55c.mp3" length="86523594" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/nwltIssgwcqz9A0cBv7E0xuml4L1NciojeMJdJDO3O0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE4MjUzNTQv/MTcxMTk1MTg2My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3602</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening discussion with <a href="https://www.linkedin.com/in/dan-rose-b6b509/">Dan Rose</a>, former CEO of <a href="https://limflow.com/">LimFlow</a>, which recently sold to <a href="https://www.inarimedical.com/">Inari Medical</a>. The minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain, and promoting wound healing.</p><p>A leader with 25 years of experience in the medical device space, Dan has worked in both multinational corporations and startup ventures throughout his career. He holds a BA and an MA from the University of Virginia, and an MBA from the Darden Business School. Most recently, he led LimFlow’s exit to Inari as the company’s CEO and has held pivotal positions at Direct Flow Medical, Sequana Medical, Medtronic, and other medtech companies. </p><p>In this interview, Dan shares his extensive wisdom on M&amp;A transactions, engaging with investors while maintaining business autonomy, the importance of developing with the ‘average user’ in mind, and the significance of early dialogue with regulatory bodies.</p><p> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/dan-rose-limflow-inari">here's a link to the full interview with Dan Rose.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Run Your Medtech Startup on a Budget: Interview with Syntr Health CEO Ahmed Zobi</title>
      <itunes:title>How to Run Your Medtech Startup on a Budget: Interview with Syntr Health CEO Ahmed Zobi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">f77a9e75-e334-486f-9eb8-fb45c97d2e3f</guid>
      <link>https://medsider.com/interviews/ahmed-zobi-syntr-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down for an engaging chat with <a href="https://www.linkedin.com/in/ahmed-zobi-emba-4b210855/">Ahmed Zobi</a>, founder and CEO of <a href="http://www.syntrhealth.com/">Syntr Health Technologies,</a> which has developed an automated microfat processing system for use in aesthetics and plastic surgery. The FDA-cleared SyntrFuge device allows clinicians to harvest patients’ adipose tissue and then reinject it as processed microfat within minutes into the desired area, eliminating the use of fillers.<br> <br>Ahmed has a decade of experience in the medical device industry. He advises and mentors many startups, has been recognized as a Forbes Next 1000 Honoree, and is a guest lecturer at the USC Keck School of Medicine. Ahmed also serves as a board member at various organizations, including the Wound Healing Society and the UCI Center for Innovation and Entrepreneurship.</p><p>In this interview, Ahmed shares his ideas on the risks and rewards of entrepreneurship, how to operate in a lean fashion, why he puts regulatory clearance above all, and how he managed to be the youngest candidate to receive a phase 1 SBIR grant.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ahmed-zobi-syntr-health">here's a link to the full interview with Ahmed Zobi.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down for an engaging chat with <a href="https://www.linkedin.com/in/ahmed-zobi-emba-4b210855/">Ahmed Zobi</a>, founder and CEO of <a href="http://www.syntrhealth.com/">Syntr Health Technologies,</a> which has developed an automated microfat processing system for use in aesthetics and plastic surgery. The FDA-cleared SyntrFuge device allows clinicians to harvest patients’ adipose tissue and then reinject it as processed microfat within minutes into the desired area, eliminating the use of fillers.<br> <br>Ahmed has a decade of experience in the medical device industry. He advises and mentors many startups, has been recognized as a Forbes Next 1000 Honoree, and is a guest lecturer at the USC Keck School of Medicine. Ahmed also serves as a board member at various organizations, including the Wound Healing Society and the UCI Center for Innovation and Entrepreneurship.</p><p>In this interview, Ahmed shares his ideas on the risks and rewards of entrepreneurship, how to operate in a lean fashion, why he puts regulatory clearance above all, and how he managed to be the youngest candidate to receive a phase 1 SBIR grant.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ahmed-zobi-syntr-health">here's a link to the full interview with Ahmed Zobi.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 27 Mar 2024 14:48:35 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3c835574/4b57a2bc.mp3" length="99361487" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/wTlIB42aogI_LcVaRNuXYUFa9Lejn1fFRbxeHAtQkvg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE4MDkxMjQv/MTcxMTM2Njk0NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>4136</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down for an engaging chat with <a href="https://www.linkedin.com/in/ahmed-zobi-emba-4b210855/">Ahmed Zobi</a>, founder and CEO of <a href="http://www.syntrhealth.com/">Syntr Health Technologies,</a> which has developed an automated microfat processing system for use in aesthetics and plastic surgery. The FDA-cleared SyntrFuge device allows clinicians to harvest patients’ adipose tissue and then reinject it as processed microfat within minutes into the desired area, eliminating the use of fillers.<br> <br>Ahmed has a decade of experience in the medical device industry. He advises and mentors many startups, has been recognized as a Forbes Next 1000 Honoree, and is a guest lecturer at the USC Keck School of Medicine. Ahmed also serves as a board member at various organizations, including the Wound Healing Society and the UCI Center for Innovation and Entrepreneurship.</p><p>In this interview, Ahmed shares his ideas on the risks and rewards of entrepreneurship, how to operate in a lean fashion, why he puts regulatory clearance above all, and how he managed to be the youngest candidate to receive a phase 1 SBIR grant.</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ahmed-zobi-syntr-health">here's a link to the full interview with Ahmed Zobi.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Finding Your Place in the Healthcare Ecosystem: Interview with Vivante Health CEO Bill Snyder</title>
      <itunes:title>Finding Your Place in the Healthcare Ecosystem: Interview with Vivante Health CEO Bill Snyder</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">86132404-7311-45eb-9770-b3edeffde854</guid>
      <link>https://medsider.com/interviews/bill-snyder-vivante-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/snyderwilliamreed/">Bill Snyder</a>, CEO of <a href="https://vivantehealth.com/">Vivante Health</a>, a startup commercializing an all-in-one digital platform for digestive health conditions. GIThrive is a platform that combines data-driven technology with a team of physicians, registered dietitians, and health coaches to deliver personalized care.<br> <br>With over 15 years of experience in healthcare technology, Bill's background includes building and leading national sales efforts at Virta Health and overseeing their health plan practice. Previously, he spent 11 years at Humana in various leadership roles, including Vice President of the company's greater Chicago region.</p><p>In this interview, Bill talks about the importance of finding where your company stands in the overall healthcare ecosystem, why clinical outcomes and sorting out reimbursement are critical to survival, and his experiences raising capital for Vivante.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-snyder-vivante-health">here's a link to the full interview with Bill Snyder.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/snyderwilliamreed/">Bill Snyder</a>, CEO of <a href="https://vivantehealth.com/">Vivante Health</a>, a startup commercializing an all-in-one digital platform for digestive health conditions. GIThrive is a platform that combines data-driven technology with a team of physicians, registered dietitians, and health coaches to deliver personalized care.<br> <br>With over 15 years of experience in healthcare technology, Bill's background includes building and leading national sales efforts at Virta Health and overseeing their health plan practice. Previously, he spent 11 years at Humana in various leadership roles, including Vice President of the company's greater Chicago region.</p><p>In this interview, Bill talks about the importance of finding where your company stands in the overall healthcare ecosystem, why clinical outcomes and sorting out reimbursement are critical to survival, and his experiences raising capital for Vivante.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-snyder-vivante-health">here's a link to the full interview with Bill Snyder.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 20 Mar 2024 16:15:49 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3a95f662/85f8015a.mp3" length="72998827" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/teqS7xjh70lkM5SPY-LJ8ouWgHUsEkdRL5voKqm68V4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3OTUzODIv/MTcxMDc3OTg5Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3037</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/snyderwilliamreed/">Bill Snyder</a>, CEO of <a href="https://vivantehealth.com/">Vivante Health</a>, a startup commercializing an all-in-one digital platform for digestive health conditions. GIThrive is a platform that combines data-driven technology with a team of physicians, registered dietitians, and health coaches to deliver personalized care.<br> <br>With over 15 years of experience in healthcare technology, Bill's background includes building and leading national sales efforts at Virta Health and overseeing their health plan practice. Previously, he spent 11 years at Humana in various leadership roles, including Vice President of the company's greater Chicago region.</p><p>In this interview, Bill talks about the importance of finding where your company stands in the overall healthcare ecosystem, why clinical outcomes and sorting out reimbursement are critical to survival, and his experiences raising capital for Vivante.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/bill-snyder-vivante-health">here's a link to the full interview with Bill Snyder.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Crowdfunding and IPOs for Medtech Startups: Interview with Monogram Orthopedics CEO Benjamin Sexson</title>
      <itunes:title>Crowdfunding and IPOs for Medtech Startups: Interview with Monogram Orthopedics CEO Benjamin Sexson</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8ea7008e-8f20-4378-829b-9f85796d7338</guid>
      <link>https://medsider.com/interviews/benjamin-sexson-monogram-orthopedics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun and insightful conversation with <a href="https://www.linkedin.com/in/benjaminsexson/">Benjamin Sexson</a>, co-founder and CEO of <a href="https://www.monogramorthopedics.com/">Monogram Orthopedics</a>. At Monogram, Ben and his team are developing a fully autonomous robotic system for knee replacement surgery.<br>  <br>Benjamin's tenure at Pro-Dex, one of the world's top manufacturers of orthopedic robotic components, eventually brought him to lead the development and launch of Monogram’s flagship product mBôs. Ben has authored multiple patents and previously founded Brides &amp; Hairpins, a successful B2B retail brand. He holds a bachelor’s degree in mechanical engineering with honors from Caltech and is a CFA charterholder.</p><p>In this interview, Ben talks about the importance of a good team and a liberating company culture as well as the importance of believing in what you’re doing and openly reassessing its validity regularly. He also elaborates on Monogram’s daring strategies for validating its technology and walks us through the pros and cons of crowdfunding and going public.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/benjamin-sexson-monogram-orthopedics">here's a link to the full interview with Benjamin Sexson.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun and insightful conversation with <a href="https://www.linkedin.com/in/benjaminsexson/">Benjamin Sexson</a>, co-founder and CEO of <a href="https://www.monogramorthopedics.com/">Monogram Orthopedics</a>. At Monogram, Ben and his team are developing a fully autonomous robotic system for knee replacement surgery.<br>  <br>Benjamin's tenure at Pro-Dex, one of the world's top manufacturers of orthopedic robotic components, eventually brought him to lead the development and launch of Monogram’s flagship product mBôs. Ben has authored multiple patents and previously founded Brides &amp; Hairpins, a successful B2B retail brand. He holds a bachelor’s degree in mechanical engineering with honors from Caltech and is a CFA charterholder.</p><p>In this interview, Ben talks about the importance of a good team and a liberating company culture as well as the importance of believing in what you’re doing and openly reassessing its validity regularly. He also elaborates on Monogram’s daring strategies for validating its technology and walks us through the pros and cons of crowdfunding and going public.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/benjamin-sexson-monogram-orthopedics">here's a link to the full interview with Benjamin Sexson.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 13 Mar 2024 15:33:10 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b9405e6f/26c9fd1c.mp3" length="90440891" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/P_eAUGEs_OTB2Wk0lJxl3et1PiLVT-w7eCAY8A4MyxI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3ODQwNjYv/MTcxMDEzMjQyMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3764</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun and insightful conversation with <a href="https://www.linkedin.com/in/benjaminsexson/">Benjamin Sexson</a>, co-founder and CEO of <a href="https://www.monogramorthopedics.com/">Monogram Orthopedics</a>. At Monogram, Ben and his team are developing a fully autonomous robotic system for knee replacement surgery.<br>  <br>Benjamin's tenure at Pro-Dex, one of the world's top manufacturers of orthopedic robotic components, eventually brought him to lead the development and launch of Monogram’s flagship product mBôs. Ben has authored multiple patents and previously founded Brides &amp; Hairpins, a successful B2B retail brand. He holds a bachelor’s degree in mechanical engineering with honors from Caltech and is a CFA charterholder.</p><p>In this interview, Ben talks about the importance of a good team and a liberating company culture as well as the importance of believing in what you’re doing and openly reassessing its validity regularly. He also elaborates on Monogram’s daring strategies for validating its technology and walks us through the pros and cons of crowdfunding and going public.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/benjamin-sexson-monogram-orthopedics">here's a link to the full interview with Benjamin Sexson.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Innovate in Medtech with Limited Means: Interview with Field Medical CEO Dr. Steven Mickelsen</title>
      <itunes:title>How to Innovate in Medtech with Limited Means: Interview with Field Medical CEO Dr. Steven Mickelsen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d02fecc7-0994-49c7-8a1e-3203cd4b66bf</guid>
      <link>https://medsider.com/interviews/steven-mickelsen-field-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an inspiring discussion with <a href="https://www.linkedin.com/in/steven-mickelsen-0828145b/"> Dr. Steven Mickelsen</a>, CEO of <a href="https://www.fieldmedicalinc.com/">Field Medical</a>, which is developing the next generation of pulse field ablation (PFA) technology to address ventricular arrhythmias.</p><p>Starting out his career as a professional musician, Steven made a pivotal shift in his late twenties and ventured into the world of medicine. As a practicing electrophysiology (EP) physician, he has combined his medical expertise with an entrepreneurial spirit to revolutionize cardiac care. Steven made significant strides in the development of pulse field ablation (PFA) treatment with one of his previous companies, Farapulse, which sold to Boston Scientific.</p><p>In this episode, Dr. Mickelsen shares his hard-earned wisdom on how limited means can breed resourcefulness, how to build a modest yet effective prototype, why having real expertise in clinical and regulatory spheres is a necessity, and how to raise funds with a win-win mindset.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steven-mickelsen-field-medical">here's a link to the full interview with Dr. Mickelsen.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an inspiring discussion with <a href="https://www.linkedin.com/in/steven-mickelsen-0828145b/"> Dr. Steven Mickelsen</a>, CEO of <a href="https://www.fieldmedicalinc.com/">Field Medical</a>, which is developing the next generation of pulse field ablation (PFA) technology to address ventricular arrhythmias.</p><p>Starting out his career as a professional musician, Steven made a pivotal shift in his late twenties and ventured into the world of medicine. As a practicing electrophysiology (EP) physician, he has combined his medical expertise with an entrepreneurial spirit to revolutionize cardiac care. Steven made significant strides in the development of pulse field ablation (PFA) treatment with one of his previous companies, Farapulse, which sold to Boston Scientific.</p><p>In this episode, Dr. Mickelsen shares his hard-earned wisdom on how limited means can breed resourcefulness, how to build a modest yet effective prototype, why having real expertise in clinical and regulatory spheres is a necessity, and how to raise funds with a win-win mindset.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steven-mickelsen-field-medical">here's a link to the full interview with Dr. Mickelsen.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 07 Mar 2024 18:18:33 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/69cabed1/12b4e708.mp3" length="90269312" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ZjzaO82Y2lUMMqqCyfigAK-oFMum_EAktZNlYLMesDo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3NzEzNTAv/MTcwOTUzNTk0MS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3759</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an inspiring discussion with <a href="https://www.linkedin.com/in/steven-mickelsen-0828145b/"> Dr. Steven Mickelsen</a>, CEO of <a href="https://www.fieldmedicalinc.com/">Field Medical</a>, which is developing the next generation of pulse field ablation (PFA) technology to address ventricular arrhythmias.</p><p>Starting out his career as a professional musician, Steven made a pivotal shift in his late twenties and ventured into the world of medicine. As a practicing electrophysiology (EP) physician, he has combined his medical expertise with an entrepreneurial spirit to revolutionize cardiac care. Steven made significant strides in the development of pulse field ablation (PFA) treatment with one of his previous companies, Farapulse, which sold to Boston Scientific.</p><p>In this episode, Dr. Mickelsen shares his hard-earned wisdom on how limited means can breed resourcefulness, how to build a modest yet effective prototype, why having real expertise in clinical and regulatory spheres is a necessity, and how to raise funds with a win-win mindset.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/steven-mickelsen-field-medical">here's a link to the full interview with Dr. Mickelsen.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Grit and the Power of Showing Up: Interview with Venture Capitalist Anish Kaushal</title>
      <itunes:title>Grit and the Power of Showing Up: Interview with Venture Capitalist Anish Kaushal</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d2d60252-efc5-40ef-8dd7-7142c0bda216</guid>
      <link>https://medsider.com/interviews/anish-kaushal-amplitude-ventures</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with <a href="https://www.linkedin.com/in/anish-kaushal-md/">Anish Kaushal</a>, an ex-physician turned healthcare investor at <a href="https://www.amplitudevc.com/en">Amplitude Ventures</a>, one of Canada's leading healthcare VC firms. </p><p>Anish's engagement with venture capital began at M Ventures in Amsterdam, a corporate VC fund of Merck KGaA, where he quickly developed a passion for the field. Outside of his professional pursuits, Anish is an <a href="https://www.anichexperience.com/">avid reader and writer who has published over 900 articles and summarized 250 books across 50 categories</a>. He has also authored two books, the latest of which is <a href="https://www.amazon.ca/Here-There-Navigating-Career-Transitions/dp/1989849458/ref=sr_1_2?dib=eyJ2IjoiMSJ9.jQxiPYNUkImrWy1i1TJ9VMDCbjNOCRNfSmyITCo9IAA.6vR9uHWjSVhUQPRr8lE4VXhxHmOtFRliiBrryvBZgx0&amp;dib_tag=se&amp;qid=1708340202&amp;refinements=p_27%3ADr.+Anish+Kaushal&amp;s=books&amp;sr=1-2&amp;text=Dr.+Anish+Kaushal"><em>From Here To There: A Niche Guide to Navigating Career Transitions</em>.</a> </p><p>In this interview, Anish reveals vital fundraising strategies from a VC’s perspective, offers practical tips for crafting pitch decks that capture attention, discusses why always being in the mode of seeking funds is so important, expands on the value of building extensive networks, and talks about the cumulative effect of small improvements. He also provides guidance on staying open and ready for career shifts in today’s fast-paced professional environment as outlined in his latest book</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/anish-kaushal-amplitude-ventures">here's a link to the full interview with Anish Kaushal.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with <a href="https://www.linkedin.com/in/anish-kaushal-md/">Anish Kaushal</a>, an ex-physician turned healthcare investor at <a href="https://www.amplitudevc.com/en">Amplitude Ventures</a>, one of Canada's leading healthcare VC firms. </p><p>Anish's engagement with venture capital began at M Ventures in Amsterdam, a corporate VC fund of Merck KGaA, where he quickly developed a passion for the field. Outside of his professional pursuits, Anish is an <a href="https://www.anichexperience.com/">avid reader and writer who has published over 900 articles and summarized 250 books across 50 categories</a>. He has also authored two books, the latest of which is <a href="https://www.amazon.ca/Here-There-Navigating-Career-Transitions/dp/1989849458/ref=sr_1_2?dib=eyJ2IjoiMSJ9.jQxiPYNUkImrWy1i1TJ9VMDCbjNOCRNfSmyITCo9IAA.6vR9uHWjSVhUQPRr8lE4VXhxHmOtFRliiBrryvBZgx0&amp;dib_tag=se&amp;qid=1708340202&amp;refinements=p_27%3ADr.+Anish+Kaushal&amp;s=books&amp;sr=1-2&amp;text=Dr.+Anish+Kaushal"><em>From Here To There: A Niche Guide to Navigating Career Transitions</em>.</a> </p><p>In this interview, Anish reveals vital fundraising strategies from a VC’s perspective, offers practical tips for crafting pitch decks that capture attention, discusses why always being in the mode of seeking funds is so important, expands on the value of building extensive networks, and talks about the cumulative effect of small improvements. He also provides guidance on staying open and ready for career shifts in today’s fast-paced professional environment as outlined in his latest book</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/anish-kaushal-amplitude-ventures">here's a link to the full interview with Anish Kaushal.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 28 Feb 2024 17:43:51 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9201c6d7/d7ab6a83.mp3" length="122250909" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/as79tcmvSb1OYDR2Y83_QEGw5Nm1nozLBthe9bxLm-s/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3NTIzMzcv/MTcwODkyOTAyNy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>5087</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with <a href="https://www.linkedin.com/in/anish-kaushal-md/">Anish Kaushal</a>, an ex-physician turned healthcare investor at <a href="https://www.amplitudevc.com/en">Amplitude Ventures</a>, one of Canada's leading healthcare VC firms. </p><p>Anish's engagement with venture capital began at M Ventures in Amsterdam, a corporate VC fund of Merck KGaA, where he quickly developed a passion for the field. Outside of his professional pursuits, Anish is an <a href="https://www.anichexperience.com/">avid reader and writer who has published over 900 articles and summarized 250 books across 50 categories</a>. He has also authored two books, the latest of which is <a href="https://www.amazon.ca/Here-There-Navigating-Career-Transitions/dp/1989849458/ref=sr_1_2?dib=eyJ2IjoiMSJ9.jQxiPYNUkImrWy1i1TJ9VMDCbjNOCRNfSmyITCo9IAA.6vR9uHWjSVhUQPRr8lE4VXhxHmOtFRliiBrryvBZgx0&amp;dib_tag=se&amp;qid=1708340202&amp;refinements=p_27%3ADr.+Anish+Kaushal&amp;s=books&amp;sr=1-2&amp;text=Dr.+Anish+Kaushal"><em>From Here To There: A Niche Guide to Navigating Career Transitions</em>.</a> </p><p>In this interview, Anish reveals vital fundraising strategies from a VC’s perspective, offers practical tips for crafting pitch decks that capture attention, discusses why always being in the mode of seeking funds is so important, expands on the value of building extensive networks, and talks about the cumulative effect of small improvements. He also provides guidance on staying open and ready for career shifts in today’s fast-paced professional environment as outlined in his latest book</p><p><br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/anish-kaushal-amplitude-ventures">here's a link to the full interview with Anish Kaushal.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Essentials of Building the Right Foundation: Interview with Neuro42 Co-founder Abhita Batra</title>
      <itunes:title>The Essentials of Building the Right Foundation: Interview with Neuro42 Co-founder Abhita Batra</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ebcb3b84-c6b6-429c-9f23-12549a8e5f4e</guid>
      <link>https://medsider.com/interviews/abhita-batra-neuro42</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/abhitavohra/">Abhita Batra</a>, co-founder and Chief Strategy Officer at <a href="https://www.neuro42.ai/">Neuro42</a>. The company recently received 510(k) clearance for its portable head and brain MRI system, which integrates MRI, AI, and robotics in one platform.</p><p>Abhita holds a B.E. in Biotechnology from Panjab University, an M.S. in Pharmaceutical Biotechnology from the University of Pennsylvania, and Executive MBAs from UCLA Anderson and the National University of Singapore. Before Neuro42, she started several companies and held a variety of roles in business development and strategic consulting with organizations such as Otomagnetics and Admac Oncology. Her expertise spans across oncology, biotech, and medical devices. </p><p>In this interview, Abhita talks about her approach to building strategy at early-stage companies, the importance of a good team and thorough market analysis, and how to take a nuanced approach with regulatory bodies. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/abhita-batra-neuro42">here's a link to the full interview with Abhita Batra.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/abhitavohra/">Abhita Batra</a>, co-founder and Chief Strategy Officer at <a href="https://www.neuro42.ai/">Neuro42</a>. The company recently received 510(k) clearance for its portable head and brain MRI system, which integrates MRI, AI, and robotics in one platform.</p><p>Abhita holds a B.E. in Biotechnology from Panjab University, an M.S. in Pharmaceutical Biotechnology from the University of Pennsylvania, and Executive MBAs from UCLA Anderson and the National University of Singapore. Before Neuro42, she started several companies and held a variety of roles in business development and strategic consulting with organizations such as Otomagnetics and Admac Oncology. Her expertise spans across oncology, biotech, and medical devices. </p><p>In this interview, Abhita talks about her approach to building strategy at early-stage companies, the importance of a good team and thorough market analysis, and how to take a nuanced approach with regulatory bodies. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/abhita-batra-neuro42">here's a link to the full interview with Abhita Batra.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 22 Feb 2024 18:19:32 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/03bc57dc/750e5b0e.mp3" length="55754816" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/2RQNo6HqAm15LDNFOcpEb431A-DncSP01S9gBnGz5HI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3NDI0MDIv/MTcwODMyMzM1OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2318</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/abhitavohra/">Abhita Batra</a>, co-founder and Chief Strategy Officer at <a href="https://www.neuro42.ai/">Neuro42</a>. The company recently received 510(k) clearance for its portable head and brain MRI system, which integrates MRI, AI, and robotics in one platform.</p><p>Abhita holds a B.E. in Biotechnology from Panjab University, an M.S. in Pharmaceutical Biotechnology from the University of Pennsylvania, and Executive MBAs from UCLA Anderson and the National University of Singapore. Before Neuro42, she started several companies and held a variety of roles in business development and strategic consulting with organizations such as Otomagnetics and Admac Oncology. Her expertise spans across oncology, biotech, and medical devices. </p><p>In this interview, Abhita talks about her approach to building strategy at early-stage companies, the importance of a good team and thorough market analysis, and how to take a nuanced approach with regulatory bodies. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/abhita-batra-neuro42">here's a link to the full interview with Abhita Batra.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Empathy-Driven Innovation: Interview with MOLLI Surgical CEO Ananth Ravi</title>
      <itunes:title>Empathy-Driven Innovation: Interview with MOLLI Surgical CEO Ananth Ravi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a4f8a8a7-7ac4-49ca-a4ab-9f3c46b682e6</guid>
      <link>https://medsider.com/interviews/ananth-ravi-molli-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/ananth-ravi/">Ananth Ravi</a>, CEO of <a href="http://mollisurgical.com/">MOLLI Surgical</a>, a medtech startup that has developed an award-winning, wire-free soft tissue localization technology for breast cancer surgery.</p><p>Growing up in Zambia, Ananth lost his best friend to treatable brain cancer, which ignited his passion for creating equitable and innovative cancer care solutions. Before founding MOLLI Surgical, he served as a medical physicist at Sunnybrook Odette Cancer Center and as clinical operations lead in brachytherapy. He held faculty appointments at Sunnybrook Research Institute, the University of Toronto, and Toronto Metropolitan University. He is also a co-inventor on numerous patents and holds several grants for medical devices. </p><p>In this interview, Ananth unpacks his story, touching upon the benefits of being in close contact with a medical ecosystem, the importance of intuitive design, the ideal role of regulatory consultants, and the funding strategies he employs for MOLLI. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ananth-ravi-molli-surgical">here's a link to the full interview with Ananth Ravi.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/ananth-ravi/">Ananth Ravi</a>, CEO of <a href="http://mollisurgical.com/">MOLLI Surgical</a>, a medtech startup that has developed an award-winning, wire-free soft tissue localization technology for breast cancer surgery.</p><p>Growing up in Zambia, Ananth lost his best friend to treatable brain cancer, which ignited his passion for creating equitable and innovative cancer care solutions. Before founding MOLLI Surgical, he served as a medical physicist at Sunnybrook Odette Cancer Center and as clinical operations lead in brachytherapy. He held faculty appointments at Sunnybrook Research Institute, the University of Toronto, and Toronto Metropolitan University. He is also a co-inventor on numerous patents and holds several grants for medical devices. </p><p>In this interview, Ananth unpacks his story, touching upon the benefits of being in close contact with a medical ecosystem, the importance of intuitive design, the ideal role of regulatory consultants, and the funding strategies he employs for MOLLI. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ananth-ravi-molli-surgical">here's a link to the full interview with Ananth Ravi.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 14 Feb 2024 15:59:14 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b97f1853/5aebeda5.mp3" length="75430764" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-HkNsK8vP3s5RupH7lenr473pPTF6tIC91rqTnY47nk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3Mjc4ODMv/MTcwNzcxODg1OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3138</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an engaging conversation with <a href="https://www.linkedin.com/in/ananth-ravi/">Ananth Ravi</a>, CEO of <a href="http://mollisurgical.com/">MOLLI Surgical</a>, a medtech startup that has developed an award-winning, wire-free soft tissue localization technology for breast cancer surgery.</p><p>Growing up in Zambia, Ananth lost his best friend to treatable brain cancer, which ignited his passion for creating equitable and innovative cancer care solutions. Before founding MOLLI Surgical, he served as a medical physicist at Sunnybrook Odette Cancer Center and as clinical operations lead in brachytherapy. He held faculty appointments at Sunnybrook Research Institute, the University of Toronto, and Toronto Metropolitan University. He is also a co-inventor on numerous patents and holds several grants for medical devices. </p><p>In this interview, Ananth unpacks his story, touching upon the benefits of being in close contact with a medical ecosystem, the importance of intuitive design, the ideal role of regulatory consultants, and the funding strategies he employs for MOLLI. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ananth-ravi-molli-surgical">here's a link to the full interview with Ananth Ravi.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Think Big, Start Small, and Prioritize Ruthlessly: Interview with InterShunt CEO Harlee Sorkin</title>
      <itunes:title>Think Big, Start Small, and Prioritize Ruthlessly: Interview with InterShunt CEO Harlee Sorkin</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">3c5b7436-c2e9-490a-a339-993c2d709b61</guid>
      <link>https://medsider.com/interviews/harlee-sorkin-intershunt</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/harleesorkin/">Harlee Sorkin</a>, CEO of <a href="https://intershunt.com/">InterShunt Technologies</a>, a startup developing a minimally invasive catheter designed to treat heart failure. By improving blood flow and lessening the heart's workload via a shunt, the company's technology holds promise for easing heart failure symptoms.</p><p>Harlee is a co-founder of Common Place Holdings, a venture studio that has spun out eight medtech startups, including InterShunt. Before Common Place, Harlee led Traco Labs, a health and nutrition ingredient manufacturer, to a successful exit. He also served as the Clinical Assistant Professor at the University of Illinois at Urbana-Champaign, where he focused on translating research ideas into commercially viable applications. </p><p>In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/harlee-sorkin-intershunt">here's a link to the full interview with Harlee Sorkin.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/harleesorkin/">Harlee Sorkin</a>, CEO of <a href="https://intershunt.com/">InterShunt Technologies</a>, a startup developing a minimally invasive catheter designed to treat heart failure. By improving blood flow and lessening the heart's workload via a shunt, the company's technology holds promise for easing heart failure symptoms.</p><p>Harlee is a co-founder of Common Place Holdings, a venture studio that has spun out eight medtech startups, including InterShunt. Before Common Place, Harlee led Traco Labs, a health and nutrition ingredient manufacturer, to a successful exit. He also served as the Clinical Assistant Professor at the University of Illinois at Urbana-Champaign, where he focused on translating research ideas into commercially viable applications. </p><p>In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/harlee-sorkin-intershunt">here's a link to the full interview with Harlee Sorkin.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 07 Feb 2024 23:10:49 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/eaf07a10/b248cb2e.mp3" length="87019760" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/EuCyR_vPNoqdFmtDWaYBRSmZbyI52_dvnngyMkA_qP0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3MTczMDkv/MTcwNzEwODMxNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3623</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/harleesorkin/">Harlee Sorkin</a>, CEO of <a href="https://intershunt.com/">InterShunt Technologies</a>, a startup developing a minimally invasive catheter designed to treat heart failure. By improving blood flow and lessening the heart's workload via a shunt, the company's technology holds promise for easing heart failure symptoms.</p><p>Harlee is a co-founder of Common Place Holdings, a venture studio that has spun out eight medtech startups, including InterShunt. Before Common Place, Harlee led Traco Labs, a health and nutrition ingredient manufacturer, to a successful exit. He also served as the Clinical Assistant Professor at the University of Illinois at Urbana-Champaign, where he focused on translating research ideas into commercially viable applications. </p><p>In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/harlee-sorkin-intershunt">here's a link to the full interview with Harlee Sorkin.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Learning Fast Beats Failing Fast: Interview with Portal Instruments CEO Patrick Anquetil</title>
      <itunes:title>Why Learning Fast Beats Failing Fast: Interview with Portal Instruments CEO Patrick Anquetil</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e0bb9503-917b-481e-8c70-e1411b00e432</guid>
      <link>https://medsider.com/interviews/patrick-anquetil-portal-instruments</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with<strong> </strong><a href="https://www.linkedin.com/in/patrick-anquetil-780787/">Patrick Anquetil</a>, CEO of <a href="https://www.portalinstruments.com/">Portal Instruments</a>, a company developing a novel needle-free drug delivery system. This cutting-edge technology promises to revolutionize how medications are administered, making the process less invasive, more precise, and more comfortable for patients. </p><p>Patrick brings over 20 years of experience leading bioengineering companies from concept to commercial success. Before Portal, he co-founded two medtech startups, SynapDx and Aretais. Patrick holds a doctorate in Mechanical Engineering from MIT, and advanced degrees from Harvard Business School, ETH Zurich, and the University of Tokyo. His scientific achievements have been featured in top journals and media outlets such as MIT Technology Review, Wired Magazine, PBS, and CNBC.</p><p><br>In this interview, Patrick talks about how he landed on Portal’s business model, how their team condenses timelines across key company functions, and why their diverse set of partners is a golden asset to the company. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/patrick-anquetil-portal-instruments">here's a link to the full interview with Patrick Anquetil.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with<strong> </strong><a href="https://www.linkedin.com/in/patrick-anquetil-780787/">Patrick Anquetil</a>, CEO of <a href="https://www.portalinstruments.com/">Portal Instruments</a>, a company developing a novel needle-free drug delivery system. This cutting-edge technology promises to revolutionize how medications are administered, making the process less invasive, more precise, and more comfortable for patients. </p><p>Patrick brings over 20 years of experience leading bioengineering companies from concept to commercial success. Before Portal, he co-founded two medtech startups, SynapDx and Aretais. Patrick holds a doctorate in Mechanical Engineering from MIT, and advanced degrees from Harvard Business School, ETH Zurich, and the University of Tokyo. His scientific achievements have been featured in top journals and media outlets such as MIT Technology Review, Wired Magazine, PBS, and CNBC.</p><p><br>In this interview, Patrick talks about how he landed on Portal’s business model, how their team condenses timelines across key company functions, and why their diverse set of partners is a golden asset to the company. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/patrick-anquetil-portal-instruments">here's a link to the full interview with Patrick Anquetil.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 31 Jan 2024 19:18:07 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/bbed1754/639df89f.mp3" length="81737518" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/JSlLu9ybyim5ArFm4--xMzVXvmjlqhWJpsu-eHLmOiU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE3MDc0Mzkv/MTcwNjUwMzc1MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3398</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful discussion with<strong> </strong><a href="https://www.linkedin.com/in/patrick-anquetil-780787/">Patrick Anquetil</a>, CEO of <a href="https://www.portalinstruments.com/">Portal Instruments</a>, a company developing a novel needle-free drug delivery system. This cutting-edge technology promises to revolutionize how medications are administered, making the process less invasive, more precise, and more comfortable for patients. </p><p>Patrick brings over 20 years of experience leading bioengineering companies from concept to commercial success. Before Portal, he co-founded two medtech startups, SynapDx and Aretais. Patrick holds a doctorate in Mechanical Engineering from MIT, and advanced degrees from Harvard Business School, ETH Zurich, and the University of Tokyo. His scientific achievements have been featured in top journals and media outlets such as MIT Technology Review, Wired Magazine, PBS, and CNBC.</p><p><br>In this interview, Patrick talks about how he landed on Portal’s business model, how their team condenses timelines across key company functions, and why their diverse set of partners is a golden asset to the company. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/patrick-anquetil-portal-instruments">here's a link to the full interview with Patrick Anquetil.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Taking the Stress Out of Conception: Interview with Béa Fertility CEO Tess Cosad</title>
      <itunes:title>Taking the Stress Out of Conception: Interview with Béa Fertility CEO Tess Cosad</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7989e3ca-f9e4-4f61-bd41-343edbdacf07</guid>
      <link>https://medsider.com/interviews/tess-cosad-bea-fertility</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/tess-isabelle-cosad/">Tess Cosad</a>, a femtech enthusiast and CEO of <a href="https://beafertility.com/">Béa Fertility</a>. Béa offers effective, hormone-free, affordable, at-home fertility treatments and ovulation tracking as an alternative to traditional clinic-based offerings. </p><p>Before Béa, Tess founded Emberson Ventures, a B2B marketing agency, and Hers By Design, a femtech company. She was also the first woman to lead a digital marketing-focused accelerator program in Saudi Arabia.</p><p><br>In this interview, Tess delves into the challenges and triumphs of launching a consumer-facing product, the importance of a solid design team, how to be comfortable making decisions with imperfect information, and the lessons she learned about being a CEO while raising funds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tess-cosad-bea-fertility">here's a link to the full interview with Tess Cosad.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/tess-isabelle-cosad/">Tess Cosad</a>, a femtech enthusiast and CEO of <a href="https://beafertility.com/">Béa Fertility</a>. Béa offers effective, hormone-free, affordable, at-home fertility treatments and ovulation tracking as an alternative to traditional clinic-based offerings. </p><p>Before Béa, Tess founded Emberson Ventures, a B2B marketing agency, and Hers By Design, a femtech company. She was also the first woman to lead a digital marketing-focused accelerator program in Saudi Arabia.</p><p><br>In this interview, Tess delves into the challenges and triumphs of launching a consumer-facing product, the importance of a solid design team, how to be comfortable making decisions with imperfect information, and the lessons she learned about being a CEO while raising funds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tess-cosad-bea-fertility">here's a link to the full interview with Tess Cosad.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 24 Jan 2024 16:10:38 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/166b95d0/be697f87.mp3" length="80021553" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/asRPO9BO0vzxUb-GI03lvqanco2rMGEC2hTT3AWw-g4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2OTg2NzMv/MTcwNTkwMzkzMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3331</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/tess-isabelle-cosad/">Tess Cosad</a>, a femtech enthusiast and CEO of <a href="https://beafertility.com/">Béa Fertility</a>. Béa offers effective, hormone-free, affordable, at-home fertility treatments and ovulation tracking as an alternative to traditional clinic-based offerings. </p><p>Before Béa, Tess founded Emberson Ventures, a B2B marketing agency, and Hers By Design, a femtech company. She was also the first woman to lead a digital marketing-focused accelerator program in Saudi Arabia.</p><p><br>In this interview, Tess delves into the challenges and triumphs of launching a consumer-facing product, the importance of a solid design team, how to be comfortable making decisions with imperfect information, and the lessons she learned about being a CEO while raising funds.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tess-cosad-bea-fertility">here's a link to the full interview with Tess Cosad.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building a Startup in a Collaborative Ecosystem: Interview with Noa Therapeutics CEO Carla Spina</title>
      <itunes:title>Building a Startup in a Collaborative Ecosystem: Interview with Noa Therapeutics CEO Carla Spina</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e90332ad-18e1-4cd2-a668-82b2bd251a3e</guid>
      <link>https://medsider.com/interviews/carla-spina-noa-therapeutics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an awesome chat with  <a href="https://www.linkedin.com/in/carla-spina-22676827/">Carla Spina</a>, the pioneering force behind <a href="https://noatherapeutics.com/">Noa Therapeutics</a>. Carla and her team are developing treatments for inflammatory skin diseases with their innovative multimodal small-molecule therapies.</p><p>Carla began her academic journey at the University of Calgary in the fields of inorganic and analytical chemistry, and continued with a Ph.D. in Bioinorganic Chemistry at McGill University. After going to BASF in Germany to develop pharmaceutical formulations, Carla returned to Canada and led the development and global commercialization of antimicrobial wound care devices. Later, she also pioneered first-in-class pharmaceuticals for inflammatory and infectious skin diseases. Currently, she spearheads Noa Therapeutics, a Canadian biotech firm that is transforming how immune diseases are treated.</p><p>In this episode, Carla shares her invaluable experiences on the importance of engaging actively with the startup ecosystem and staying connected with those who are shaping the field. We talk about how building a company is a collaborative venture that requires a strong network of entrepreneurs, investors, and industry experts, and the significance of authentic interaction when reaching out to a variety of potential stakeholders.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We have also introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/carla-spina-noa-therapeutics">here's a link to the full interview with Carla Spina.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an awesome chat with  <a href="https://www.linkedin.com/in/carla-spina-22676827/">Carla Spina</a>, the pioneering force behind <a href="https://noatherapeutics.com/">Noa Therapeutics</a>. Carla and her team are developing treatments for inflammatory skin diseases with their innovative multimodal small-molecule therapies.</p><p>Carla began her academic journey at the University of Calgary in the fields of inorganic and analytical chemistry, and continued with a Ph.D. in Bioinorganic Chemistry at McGill University. After going to BASF in Germany to develop pharmaceutical formulations, Carla returned to Canada and led the development and global commercialization of antimicrobial wound care devices. Later, she also pioneered first-in-class pharmaceuticals for inflammatory and infectious skin diseases. Currently, she spearheads Noa Therapeutics, a Canadian biotech firm that is transforming how immune diseases are treated.</p><p>In this episode, Carla shares her invaluable experiences on the importance of engaging actively with the startup ecosystem and staying connected with those who are shaping the field. We talk about how building a company is a collaborative venture that requires a strong network of entrepreneurs, investors, and industry experts, and the significance of authentic interaction when reaching out to a variety of potential stakeholders.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We have also introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/carla-spina-noa-therapeutics">here's a link to the full interview with Carla Spina.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 16 Jan 2024 16:07:08 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/847c45c8/88690e79.mp3" length="80268664" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/HAEJZpBB1XyIvmEiARK-U8L7hPiT5E2x7OpNRpCa0YU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2OTAwNzcv/MTcwNTI5ODQ4Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3339</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an awesome chat with  <a href="https://www.linkedin.com/in/carla-spina-22676827/">Carla Spina</a>, the pioneering force behind <a href="https://noatherapeutics.com/">Noa Therapeutics</a>. Carla and her team are developing treatments for inflammatory skin diseases with their innovative multimodal small-molecule therapies.</p><p>Carla began her academic journey at the University of Calgary in the fields of inorganic and analytical chemistry, and continued with a Ph.D. in Bioinorganic Chemistry at McGill University. After going to BASF in Germany to develop pharmaceutical formulations, Carla returned to Canada and led the development and global commercialization of antimicrobial wound care devices. Later, she also pioneered first-in-class pharmaceuticals for inflammatory and infectious skin diseases. Currently, she spearheads Noa Therapeutics, a Canadian biotech firm that is transforming how immune diseases are treated.</p><p>In this episode, Carla shares her invaluable experiences on the importance of engaging actively with the startup ecosystem and staying connected with those who are shaping the field. We talk about how building a company is a collaborative venture that requires a strong network of entrepreneurs, investors, and industry experts, and the significance of authentic interaction when reaching out to a variety of potential stakeholders.<br> <br>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We have also introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/carla-spina-noa-therapeutics">here's a link to the full interview with Carla Spina.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Balancing Innovation with Practical Outsourcing: Interview with Spark Biomedical CEO Daniel Powell</title>
      <itunes:title>Balancing Innovation with Practical Outsourcing: Interview with Spark Biomedical CEO Daniel Powell</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7070e722-7049-48b2-bd72-2fae73736ca8</guid>
      <link>https://medsider.com/interviews/daniel-powell-spark-biomedical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating discussion with <a href="https://www.linkedin.com/in/daniel-powell-a377055/">Daniel Powel</a>, CEO of <a href="https://www.sparkbiomedical.com/">Spark Biomedical</a>, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. </p><p>Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.</p><p>In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/daniel-powell-spark-biomedical">here's a link to the full interview with Daniel Powell.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating discussion with <a href="https://www.linkedin.com/in/daniel-powell-a377055/">Daniel Powel</a>, CEO of <a href="https://www.sparkbiomedical.com/">Spark Biomedical</a>, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. </p><p>Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.</p><p>In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/daniel-powell-spark-biomedical">here's a link to the full interview with Daniel Powell.</a></p>]]>
      </content:encoded>
      <pubDate>Mon, 08 Jan 2024 22:07:57 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3c5e5d33/04275f10.mp3" length="80643003" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/BSwXC_0OEFvttTosr6x3O8giu9Eihb0-PoO0p3X36rU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2NzgyNjQv/MTcwNDcwNjgyMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3354</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fascinating discussion with <a href="https://www.linkedin.com/in/daniel-powell-a377055/">Daniel Powel</a>, CEO of <a href="https://www.sparkbiomedical.com/">Spark Biomedical</a>, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. </p><p>Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.</p><p>In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/daniel-powell-spark-biomedical">here's a link to the full interview with Daniel Powell.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash</title>
      <itunes:title>Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">2a70e906-67d8-42f5-bdb8-9859eef3424f</guid>
      <link>https://medsider.com/interviews/ken-mariash-sinaptica</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening conversation with <a href="https://www.linkedin.com/in/kenmariash/">Ken Mariash</a>, a leading figure in the neuromodulation space and the CEO of <a href="https://sinapticatx.com/">Sinaptica Therapeutics</a>, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease. </p><p>Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division. </p><p>In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&amp;A transactions, to mastering commercialization and best practices for engaging with investors.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ken-mariash-sinaptica">here's a link to the full interview with Ken Mariash.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening conversation with <a href="https://www.linkedin.com/in/kenmariash/">Ken Mariash</a>, a leading figure in the neuromodulation space and the CEO of <a href="https://sinapticatx.com/">Sinaptica Therapeutics</a>, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease. </p><p>Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division. </p><p>In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&amp;A transactions, to mastering commercialization and best practices for engaging with investors.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ken-mariash-sinaptica">here's a link to the full interview with Ken Mariash.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 03 Jan 2024 16:45:06 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/1ff732d6/4573c118.mp3" length="80920232" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/qn2Kky-syiaCXQ2QxyXD0zhG98bDOMYv9R6hS4ENJkQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2NjkyMDIv/MTcwNDE3MDE0Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3367</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an enlightening conversation with <a href="https://www.linkedin.com/in/kenmariash/">Ken Mariash</a>, a leading figure in the neuromodulation space and the CEO of <a href="https://sinapticatx.com/">Sinaptica Therapeutics</a>, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease. </p><p>Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division. </p><p>In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&amp;A transactions, to mastering commercialization and best practices for engaging with investors.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/ken-mariash-sinaptica">here's a link to the full interview with Ken Mariash.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Your Network is Your Net Worth: Interview with NeuroOne CEO Dave Rosa</title>
      <itunes:title>Your Network is Your Net Worth: Interview with NeuroOne CEO Dave Rosa</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ebb540a1-438e-4e6a-ba34-d57b422d3d01</guid>
      <link>https://medsider.com/interviews/dave-rosa-neuroone</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful conversation with <a href="https://www.linkedin.com/in/daverosa/">Dave Rosa</a>, President and CEO of <a href="https://nmtc1.com/">NeuroOne</a>, a company developing high-definition, minimally invasive neurology devices utilizing unique thin-film electrode technology. </p><p>Dave brings over three decades of experience in the medical device industry. His career spans several key roles at major firms like C.R. Bard, Boston Scientific, and St. Jude Medical, focusing on marketing, product development, strategy, and commercialization. Dave has several medical device patents to his name, has served on numerous corporate boards, and raised over $200 million in the capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.</p><p><br>In this interview, Dave discusses critical strategies to secure initial capital even before early development and regulatory milestones are achieved, how to leverage networks to connect with potential investors; and the importance of assembling a supportive and experienced team, including board members. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's <a href="https://medsider.com/interviews/dave-rosa-neuroone">a link to the full interview with Dave Rosa.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful conversation with <a href="https://www.linkedin.com/in/daverosa/">Dave Rosa</a>, President and CEO of <a href="https://nmtc1.com/">NeuroOne</a>, a company developing high-definition, minimally invasive neurology devices utilizing unique thin-film electrode technology. </p><p>Dave brings over three decades of experience in the medical device industry. His career spans several key roles at major firms like C.R. Bard, Boston Scientific, and St. Jude Medical, focusing on marketing, product development, strategy, and commercialization. Dave has several medical device patents to his name, has served on numerous corporate boards, and raised over $200 million in the capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.</p><p><br>In this interview, Dave discusses critical strategies to secure initial capital even before early development and regulatory milestones are achieved, how to leverage networks to connect with potential investors; and the importance of assembling a supportive and experienced team, including board members. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's <a href="https://medsider.com/interviews/dave-rosa-neuroone">a link to the full interview with Dave Rosa.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 27 Dec 2023 18:14:25 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/687d07c2/d275a4c3.mp3" length="69372493" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/tEe1lruc4a97BgQZABW_2ZyQAR95lY0XkOTFUHoy3dI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2NTk2ODgv/MTcwMzQ4NTgwMC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2882</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had an insightful conversation with <a href="https://www.linkedin.com/in/daverosa/">Dave Rosa</a>, President and CEO of <a href="https://nmtc1.com/">NeuroOne</a>, a company developing high-definition, minimally invasive neurology devices utilizing unique thin-film electrode technology. </p><p>Dave brings over three decades of experience in the medical device industry. His career spans several key roles at major firms like C.R. Bard, Boston Scientific, and St. Jude Medical, focusing on marketing, product development, strategy, and commercialization. Dave has several medical device patents to his name, has served on numerous corporate boards, and raised over $200 million in the capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.</p><p><br>In this interview, Dave discusses critical strategies to secure initial capital even before early development and regulatory milestones are achieved, how to leverage networks to connect with potential investors; and the importance of assembling a supportive and experienced team, including board members. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's <a href="https://medsider.com/interviews/dave-rosa-neuroone">a link to the full interview with Dave Rosa.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Pioneering AI in Patient Diagnosis: Interview with Digital Diagnostics CEO John Bertrand</title>
      <itunes:title>Pioneering AI in Patient Diagnosis: Interview with Digital Diagnostics CEO John Bertrand</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7ef8a512-efdd-440f-855f-2748b263bf4d</guid>
      <link>https://medsider.com/interviews/john-bertrand-digital-diagnostics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/-johnbertrand/">John Bertrand</a>, the CEO of <a href="https://www.digitaldiagnostics.com/">Digital Diagnostics</a>, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. </p><p>John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.</p><p><br>In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/john-bertrand-digital-diagnostics">link to the full interview with John Bertrand</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/-johnbertrand/">John Bertrand</a>, the CEO of <a href="https://www.digitaldiagnostics.com/">Digital Diagnostics</a>, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. </p><p>John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.</p><p><br>In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/john-bertrand-digital-diagnostics">link to the full interview with John Bertrand</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 20 Dec 2023 17:42:15 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/86c877c6/c3b77087.mp3" length="75569470" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/qO8EjbfQmB9785bDV3WMeXObQrnU__OiIyr-uLa-lns/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2NDkwOTQv/MTcwMjg4MzcwNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3139</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/-johnbertrand/">John Bertrand</a>, the CEO of <a href="https://www.digitaldiagnostics.com/">Digital Diagnostics</a>, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. </p><p>John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.</p><p><br>In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. </p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/john-bertrand-digital-diagnostics">link to the full interview with John Bertrand</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Collaborating for Clinical Credibility: Interview with Strados Labs CEO Nick Delmonico</title>
      <itunes:title>Collaborating for Clinical Credibility: Interview with Strados Labs CEO Nick Delmonico</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7ca7fcfa-7048-4c54-8855-dc31dc2f26e0</guid>
      <link>https://medsider.com/interviews/nick-delmonico-strados-labs</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun discussion with <a href="https://www.linkedin.com/in/nicksdelmonico/">Nick Delmonico</a>, CEO of <a href="https://stradoslabs.com/">Strados Labs</a>, the company developing a wearable stethoscope to remotely capture lung sounds. <strong> </strong></p><p>Nick boasts a dynamic background with an MBA from the Fox School of Business at Temple University and a Bachelor's in Accounting from the University of Delaware. His career includes roles at ECG Management Consultants, PwC, and J.P. Morgan, where he honed his skills in healthcare strategy, commercialization and operations, business planning, and project management.</p><p><br>In this interview, Nick talks about how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. He also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/nick-delmonico-strados-labs">link to the full interview with Nick Delmonico.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun discussion with <a href="https://www.linkedin.com/in/nicksdelmonico/">Nick Delmonico</a>, CEO of <a href="https://stradoslabs.com/">Strados Labs</a>, the company developing a wearable stethoscope to remotely capture lung sounds. <strong> </strong></p><p>Nick boasts a dynamic background with an MBA from the Fox School of Business at Temple University and a Bachelor's in Accounting from the University of Delaware. His career includes roles at ECG Management Consultants, PwC, and J.P. Morgan, where he honed his skills in healthcare strategy, commercialization and operations, business planning, and project management.</p><p><br>In this interview, Nick talks about how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. He also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/nick-delmonico-strados-labs">link to the full interview with Nick Delmonico.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 14 Dec 2023 16:53:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ce79e6aa/cc465eea.mp3" length="73746230" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/P-Ii6tzTTZiwxrL3yO_5ZDSN2OmaVwNblqriWkx_5l4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2NDEzNTkv/MTcwMjM2NTc4MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3066</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a fun discussion with <a href="https://www.linkedin.com/in/nicksdelmonico/">Nick Delmonico</a>, CEO of <a href="https://stradoslabs.com/">Strados Labs</a>, the company developing a wearable stethoscope to remotely capture lung sounds. <strong> </strong></p><p>Nick boasts a dynamic background with an MBA from the Fox School of Business at Temple University and a Bachelor's in Accounting from the University of Delaware. His career includes roles at ECG Management Consultants, PwC, and J.P. Morgan, where he honed his skills in healthcare strategy, commercialization and operations, business planning, and project management.</p><p><br>In this interview, Nick talks about how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. He also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/nick-delmonico-strados-labs">link to the full interview with Nick Delmonico.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Secure Widespread Adoption of Novel Technology: Interview with Magnolia Medical CEO Greg Bullington</title>
      <itunes:title>How to Secure Widespread Adoption of Novel Technology: Interview with Magnolia Medical CEO Greg Bullington</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e14ed042-e31d-4057-86ee-a13fb859f4b8</guid>
      <link>https://medsider.com/interviews/greg-bullington-magnolia-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with<strong> </strong><a href="https://www.linkedin.com/in/gbullington/">Greg Bullington</a>, co-founder and CEO of <a href="https://magnolia-medical.com/">Magnolia Medical</a>, who is leading a team in the development of Steripath, a revolutionary device that dramatically improves the accuracy of sepsis tests.</p><p>Greg’s previous expertise includes leadership positions across biotech, healthcare access, and enterprise software. Over the last decade, Greg has shaped every facet of Magnolia's success, from creating their own category and navigating the regulatory landscape with FDA to collaborating with the U.S. Senate for the widespread adoption of Steripath.</p><p><br>In this interview, Greg talks about the pivotal role of robust clinical data, why Magnolia is still running studies even after proving their device’s efficacy, and how to use the results to successfully convince different entities of its benefits, such as FDA and other government bodies in public health.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/greg-bullington-magnolia-medical">here's a link to the full interview with Greg Bullington</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with<strong> </strong><a href="https://www.linkedin.com/in/gbullington/">Greg Bullington</a>, co-founder and CEO of <a href="https://magnolia-medical.com/">Magnolia Medical</a>, who is leading a team in the development of Steripath, a revolutionary device that dramatically improves the accuracy of sepsis tests.</p><p>Greg’s previous expertise includes leadership positions across biotech, healthcare access, and enterprise software. Over the last decade, Greg has shaped every facet of Magnolia's success, from creating their own category and navigating the regulatory landscape with FDA to collaborating with the U.S. Senate for the widespread adoption of Steripath.</p><p><br>In this interview, Greg talks about the pivotal role of robust clinical data, why Magnolia is still running studies even after proving their device’s efficacy, and how to use the results to successfully convince different entities of its benefits, such as FDA and other government bodies in public health.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/greg-bullington-magnolia-medical">here's a link to the full interview with Greg Bullington</a>.</p>]]>
      </content:encoded>
      <pubDate>Mon, 11 Dec 2023 17:49:28 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a03d734d/0d1a404e.mp3" length="87187940" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ZWO4Pz1E4aLLPNnt5eqlramSavHXeP2mXCLDGDA1IMQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MzY1NzEv/MTcwMjAyOTkwMC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3630</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting conversation with<strong> </strong><a href="https://www.linkedin.com/in/gbullington/">Greg Bullington</a>, co-founder and CEO of <a href="https://magnolia-medical.com/">Magnolia Medical</a>, who is leading a team in the development of Steripath, a revolutionary device that dramatically improves the accuracy of sepsis tests.</p><p>Greg’s previous expertise includes leadership positions across biotech, healthcare access, and enterprise software. Over the last decade, Greg has shaped every facet of Magnolia's success, from creating their own category and navigating the regulatory landscape with FDA to collaborating with the U.S. Senate for the widespread adoption of Steripath.</p><p><br>In this interview, Greg talks about the pivotal role of robust clinical data, why Magnolia is still running studies even after proving their device’s efficacy, and how to use the results to successfully convince different entities of its benefits, such as FDA and other government bodies in public health.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/greg-bullington-magnolia-medical">here's a link to the full interview with Greg Bullington</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Get Users to Fall in Love with Your Product: Interview with SafKan Health CEO Sahil Diwan</title>
      <itunes:title>How to Get Users to Fall in Love with Your Product: Interview with SafKan Health CEO Sahil Diwan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c86f490c-aeca-4337-9411-f696871b0c43</guid>
      <link>https://medsider.com/interviews/sahil-diwan-safkan-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a spirited conversation with <a href="https://www.linkedin.com/in/sahildiwan/">Sahil Diwan</a>, CEO of <a href="https://otoset.com/">SafKan Health</a>. Sahil's company is developing the OtoSet, the first automated and FDA-cleared ear-cleaning device. </p><p>With a background in computer science from the University of Oregon, Sahil's entrepreneurial journey began early. He was already coding at the age of 16 and building startups during his college years. Sahil’s venture into medical technology was inspired by his brother Aadil's struggle with impacted earwax.</p><p>In this interview, we talk about consumer-driven medtech, the power of design, garnering experience from real-world data, focusing on building the business before fundraising, and how OtoSet went viral on social media.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sahil-diwan-safkan-health">here's a link to the full interview with Sahil Diwan</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a spirited conversation with <a href="https://www.linkedin.com/in/sahildiwan/">Sahil Diwan</a>, CEO of <a href="https://otoset.com/">SafKan Health</a>. Sahil's company is developing the OtoSet, the first automated and FDA-cleared ear-cleaning device. </p><p>With a background in computer science from the University of Oregon, Sahil's entrepreneurial journey began early. He was already coding at the age of 16 and building startups during his college years. Sahil’s venture into medical technology was inspired by his brother Aadil's struggle with impacted earwax.</p><p>In this interview, we talk about consumer-driven medtech, the power of design, garnering experience from real-world data, focusing on building the business before fundraising, and how OtoSet went viral on social media.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sahil-diwan-safkan-health">here's a link to the full interview with Sahil Diwan</a>.</p>]]>
      </content:encoded>
      <pubDate>Thu, 07 Dec 2023 16:54:24 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/773f758a/6e4a8f79.mp3" length="83218872" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/8sLifdV3ZebrEMUkeCLZgYlYfh4RVMcEgRhd82M0yP8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MjgwNjUv/MTcwMTY5MTQ4OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3466</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a spirited conversation with <a href="https://www.linkedin.com/in/sahildiwan/">Sahil Diwan</a>, CEO of <a href="https://otoset.com/">SafKan Health</a>. Sahil's company is developing the OtoSet, the first automated and FDA-cleared ear-cleaning device. </p><p>With a background in computer science from the University of Oregon, Sahil's entrepreneurial journey began early. He was already coding at the age of 16 and building startups during his college years. Sahil’s venture into medical technology was inspired by his brother Aadil's struggle with impacted earwax.</p><p>In this interview, we talk about consumer-driven medtech, the power of design, garnering experience from real-world data, focusing on building the business before fundraising, and how OtoSet went viral on social media.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/sahil-diwan-safkan-health">here's a link to the full interview with Sahil Diwan</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Winning Together in Medtech: Interview with Orchestra BioMed CEO David Hochman</title>
      <itunes:title>Winning Together in Medtech: Interview with Orchestra BioMed CEO David Hochman</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">189ff1ad-6220-420c-ad07-2395b2a9308b</guid>
      <link>https://medsider.com/interviews/david-hochman-orchestra-biomed</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting chat with <a href="https://www.linkedin.com/in/david-hochman-829b9832/">David Hochman</a>, founder and CEO of <a href="https://www.orchestrabiomed.com/">Orchestra BioMed</a>, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.</p><p>David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers &amp; acquisitions, and many fundraising successes.</p><p><br></p><p>In this interview he talks about driving successful partnerships, operational excellence in R&amp;D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-hochman-orchestra-biomed">here's a link to the full interview with David Hochman</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting chat with <a href="https://www.linkedin.com/in/david-hochman-829b9832/">David Hochman</a>, founder and CEO of <a href="https://www.orchestrabiomed.com/">Orchestra BioMed</a>, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.</p><p>David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers &amp; acquisitions, and many fundraising successes.</p><p><br></p><p>In this interview he talks about driving successful partnerships, operational excellence in R&amp;D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-hochman-orchestra-biomed">here's a link to the full interview with David Hochman</a>.</p>]]>
      </content:encoded>
      <pubDate>Mon, 04 Dec 2023 19:01:51 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f5b35791/79fc13b3.mp3" length="78417521" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/_BAEL_ZzN08SJiEI4nYEaAwXyw6kZscP6e-TzxQ5Wu8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MjExMDMv/MTcwMTQxNjIyMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3266</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a riveting chat with <a href="https://www.linkedin.com/in/david-hochman-829b9832/">David Hochman</a>, founder and CEO of <a href="https://www.orchestrabiomed.com/">Orchestra BioMed</a>, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.</p><p>David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers &amp; acquisitions, and many fundraising successes.</p><p><br></p><p>In this interview he talks about driving successful partnerships, operational excellence in R&amp;D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-hochman-orchestra-biomed">here's a link to the full interview with David Hochman</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From Nurse to Medical Device Entrepreneur: Interview with Swiftsure CEO Deanne McCarthy</title>
      <itunes:title>From Nurse to Medical Device Entrepreneur: Interview with Swiftsure CEO Deanne McCarthy</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">2297d943-e389-4f10-8c85-57ddf9f473a2</guid>
      <link>https://medsider.com/interviews/deanne-mccarthy-swiftsure</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/deanne-mccarthy-b418891aa">Deanne McCarthy</a>, founder and CEO of <a href="https://swiftsure.com/">Swiftsure Innovations</a>, a company developing a device capable of safely and effectively cleaning the oral cavity of patients on life support. </p><p>Deanne was a critical care nurse before she decided to make the switch to medtech entrepreneur. With Deanne's commitment to empowering nurses and enhancing patient outcomes, Swiftsure has assembled an adept team and a robust group of advisors that has enabled the company to move incredibly quickly across key functions like product development, regulatory affairs, and commercialization. </p><p>In this interview, we explore the invaluable role of mentors and connections in Deanne's journey, her insights on accelerator programs, and how her initial lack of startup experience gave her the tenacity to seek out and validate collaborative partners. </p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/deanne-mccarthy-swiftsure">here's a link to the full interview with Deanne McCarthy</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/deanne-mccarthy-b418891aa">Deanne McCarthy</a>, founder and CEO of <a href="https://swiftsure.com/">Swiftsure Innovations</a>, a company developing a device capable of safely and effectively cleaning the oral cavity of patients on life support. </p><p>Deanne was a critical care nurse before she decided to make the switch to medtech entrepreneur. With Deanne's commitment to empowering nurses and enhancing patient outcomes, Swiftsure has assembled an adept team and a robust group of advisors that has enabled the company to move incredibly quickly across key functions like product development, regulatory affairs, and commercialization. </p><p>In this interview, we explore the invaluable role of mentors and connections in Deanne's journey, her insights on accelerator programs, and how her initial lack of startup experience gave her the tenacity to seek out and validate collaborative partners. </p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/deanne-mccarthy-swiftsure">here's a link to the full interview with Deanne McCarthy</a>.</p>]]>
      </content:encoded>
      <pubDate>Fri, 01 Dec 2023 22:54:16 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/502bfd8e/c15bbbb6.mp3" length="82388431" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/OqInlWxnPwpqaeEtwK5SPebzQsMdnBHjESB0Nbfr8aI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MTM1MTMv/MTcwMTA4MjgyNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3432</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/deanne-mccarthy-b418891aa">Deanne McCarthy</a>, founder and CEO of <a href="https://swiftsure.com/">Swiftsure Innovations</a>, a company developing a device capable of safely and effectively cleaning the oral cavity of patients on life support. </p><p>Deanne was a critical care nurse before she decided to make the switch to medtech entrepreneur. With Deanne's commitment to empowering nurses and enhancing patient outcomes, Swiftsure has assembled an adept team and a robust group of advisors that has enabled the company to move incredibly quickly across key functions like product development, regulatory affairs, and commercialization. </p><p>In this interview, we explore the invaluable role of mentors and connections in Deanne's journey, her insights on accelerator programs, and how her initial lack of startup experience gave her the tenacity to seek out and validate collaborative partners. </p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/deanne-mccarthy-swiftsure">here's a link to the full interview with Deanne McCarthy</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Connecting the Dots Between Medtech and AI: Interview with Sonio CEO Cecile Brosset</title>
      <itunes:title>Connecting the Dots Between Medtech and AI: Interview with Sonio CEO Cecile Brosset</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">3783027c-6a7c-401d-80da-a2a465eeda10</guid>
      <link>https://medsider.com/interviews/cecile-brosset-sonio</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cecile-brosset-dubois-4b52b35/">Cecile Brosset Dubois</a>, CEO of <a href="https://sonio.ai/en/">Sonio</a>, a company dedicated to revolutionizing obstetric ultrasound through AI technology. </p><p> Cecile began her career in 2005 at Capgemini, later advancing to Bain &amp; Company. Her strategic insights as Head of Strategy at FSI - Fonds Stratégique d'Investissement - and her pivotal roles at Bpifrance set the stage for Cecile's entrepreneurial journey. At Kamet Ventures, she fully embraced the startup world before eventually co-founding Sonio. </p><p><br>In this interview, we touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cecile-brosset-sonio">here's a link to the full interview with Cecile Brosset</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cecile-brosset-dubois-4b52b35/">Cecile Brosset Dubois</a>, CEO of <a href="https://sonio.ai/en/">Sonio</a>, a company dedicated to revolutionizing obstetric ultrasound through AI technology. </p><p> Cecile began her career in 2005 at Capgemini, later advancing to Bain &amp; Company. Her strategic insights as Head of Strategy at FSI - Fonds Stratégique d'Investissement - and her pivotal roles at Bpifrance set the stage for Cecile's entrepreneurial journey. At Kamet Ventures, she fully embraced the startup world before eventually co-founding Sonio. </p><p><br>In this interview, we touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cecile-brosset-sonio">here's a link to the full interview with Cecile Brosset</a>.</p>]]>
      </content:encoded>
      <pubDate>Mon, 27 Nov 2023 17:20:13 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d4bac505/573dfd28.mp3" length="79817504" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/WjLSdhhFmV5SPbX_mKTxgF88168EkKBy0WPyD1IdQ60/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MTAxNTkv/MTcwMDcxNjA3MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3324</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/cecile-brosset-dubois-4b52b35/">Cecile Brosset Dubois</a>, CEO of <a href="https://sonio.ai/en/">Sonio</a>, a company dedicated to revolutionizing obstetric ultrasound through AI technology. </p><p> Cecile began her career in 2005 at Capgemini, later advancing to Bain &amp; Company. Her strategic insights as Head of Strategy at FSI - Fonds Stratégique d'Investissement - and her pivotal roles at Bpifrance set the stage for Cecile's entrepreneurial journey. At Kamet Ventures, she fully embraced the startup world before eventually co-founding Sonio. </p><p><br>In this interview, we touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/cecile-brosset-sonio">here's a link to the full interview with Cecile Brosset</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Rising to the PMA Challenge as a First-Time Founder: Interview with Corveus CEO Tyler Melton</title>
      <itunes:title>Rising to the PMA Challenge as a First-Time Founder: Interview with Corveus CEO Tyler Melton</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9bf0e72c-aaeb-4dc3-bce1-f038ed5f4df0</guid>
      <link>https://medsider.com/interviews/tyler-melton-corveus-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/tylermelton/">Tyler Melton</a>, the co-founder and CEO of <a href="https://www.corveusmedical.com/">Corveus Medical</a>, a Houston-based startup on a mission to redefine heart failure treatment. </p><p>Tyler previously worked at Accenture, consulting for top-tier pharmaceutical companies, and at the J&amp;J Center for Device Innovation, where he honed his skills in strategic planning and financial modeling. He then joined the Texas Medical Center Biodesign Program, where he uncovered his current mission: to treat heart failure with targeted nerve ablation. </p><p><br>In this interview, Tyler shares how using off-the-shelf products for early prototypes saved him both time and money and how accelerator programs provided the networking boost his startup needed to tackle the demanding PMA regulatory pathway.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tyler-melton-corveus-medical">here's a link to the full interview with Tyler Melton</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/tylermelton/">Tyler Melton</a>, the co-founder and CEO of <a href="https://www.corveusmedical.com/">Corveus Medical</a>, a Houston-based startup on a mission to redefine heart failure treatment. </p><p>Tyler previously worked at Accenture, consulting for top-tier pharmaceutical companies, and at the J&amp;J Center for Device Innovation, where he honed his skills in strategic planning and financial modeling. He then joined the Texas Medical Center Biodesign Program, where he uncovered his current mission: to treat heart failure with targeted nerve ablation. </p><p><br>In this interview, Tyler shares how using off-the-shelf products for early prototypes saved him both time and money and how accelerator programs provided the networking boost his startup needed to tackle the demanding PMA regulatory pathway.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tyler-melton-corveus-medical">here's a link to the full interview with Tyler Melton</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 22 Nov 2023 00:20:43 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4db51539/4986a81d.mp3" length="64618044" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/itkbGi4y_QGLEGE5mhV5tW62fI8i2_5b6XlXTMC555I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE2MDU2Njcv/MTcwMDQ2MTEwMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2691</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/tylermelton/">Tyler Melton</a>, the co-founder and CEO of <a href="https://www.corveusmedical.com/">Corveus Medical</a>, a Houston-based startup on a mission to redefine heart failure treatment. </p><p>Tyler previously worked at Accenture, consulting for top-tier pharmaceutical companies, and at the J&amp;J Center for Device Innovation, where he honed his skills in strategic planning and financial modeling. He then joined the Texas Medical Center Biodesign Program, where he uncovered his current mission: to treat heart failure with targeted nerve ablation. </p><p><br>In this interview, Tyler shares how using off-the-shelf products for early prototypes saved him both time and money and how accelerator programs provided the networking boost his startup needed to tackle the demanding PMA regulatory pathway.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/tyler-melton-corveus-medical">here's a link to the full interview with Tyler Melton</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Self-Starter’s Guide to Medtech: Interview with Liberate Medical CEO Angus McLachlan</title>
      <itunes:title>A Self-Starter’s Guide to Medtech: Interview with Liberate Medical CEO Angus McLachlan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">4c16f5a0-b927-4b8e-b197-50ce24537335</guid>
      <link>https://medsider.com/interviews/angus-mclachlan-liberate-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mclachlanangus/">Angus McLachlan</a>, CEO of <a href="https://liberatemedical.com/">Liberate Medical</a>, a company pioneering a non-invasive neuromuscular electrical stimulator to prevent muscle weakening in patients who rely on a ventilator to breathe.</p><p>Angus has a rich academic and professional history that intersects engineering and healthcare. Originating from Scotland, Angus began his academic journey in mechanical engineering at the University of Glasgow. This laid the foundation for his PhD research focused on electrical muscle stimulation for spinal cord injuries. His innovative work gained the attention of Apellis Pharma, leading to a collaboration that propelled the launch of his own company, Liberate Medical. </p><p> In this interview, we talk about Angus’s do-it-yourself philosophy, how a deep understanding of the technology you’re developing gives you leverage across multiple functions, and the nuances of pitching to investors.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/angus-mclachlan-liberate-medical">here's a link to the full interview with Angus McLachlan</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mclachlanangus/">Angus McLachlan</a>, CEO of <a href="https://liberatemedical.com/">Liberate Medical</a>, a company pioneering a non-invasive neuromuscular electrical stimulator to prevent muscle weakening in patients who rely on a ventilator to breathe.</p><p>Angus has a rich academic and professional history that intersects engineering and healthcare. Originating from Scotland, Angus began his academic journey in mechanical engineering at the University of Glasgow. This laid the foundation for his PhD research focused on electrical muscle stimulation for spinal cord injuries. His innovative work gained the attention of Apellis Pharma, leading to a collaboration that propelled the launch of his own company, Liberate Medical. </p><p> In this interview, we talk about Angus’s do-it-yourself philosophy, how a deep understanding of the technology you’re developing gives you leverage across multiple functions, and the nuances of pitching to investors.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/angus-mclachlan-liberate-medical">here's a link to the full interview with Angus McLachlan</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 15 Nov 2023 17:57:44 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/40efd7ca/a8ffb8d7.mp3" length="80520576" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/XoS3jWUr0jUmPbet_JWPfYZHqvvmaeUZDDQ9Odc1c80/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1OTcwMjMv/MTY5OTg1MjgzNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3354</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/mclachlanangus/">Angus McLachlan</a>, CEO of <a href="https://liberatemedical.com/">Liberate Medical</a>, a company pioneering a non-invasive neuromuscular electrical stimulator to prevent muscle weakening in patients who rely on a ventilator to breathe.</p><p>Angus has a rich academic and professional history that intersects engineering and healthcare. Originating from Scotland, Angus began his academic journey in mechanical engineering at the University of Glasgow. This laid the foundation for his PhD research focused on electrical muscle stimulation for spinal cord injuries. His innovative work gained the attention of Apellis Pharma, leading to a collaboration that propelled the launch of his own company, Liberate Medical. </p><p> In this interview, we talk about Angus’s do-it-yourself philosophy, how a deep understanding of the technology you’re developing gives you leverage across multiple functions, and the nuances of pitching to investors.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/angus-mclachlan-liberate-medical">here's a link to the full interview with Angus McLachlan</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Ancient Wisdom Meets Modern Medtech: Interview with Fisher Wallace CEO Kelly Roman</title>
      <itunes:title>Ancient Wisdom Meets Modern Medtech: Interview with Fisher Wallace CEO Kelly Roman</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">86c5b7e2-7b52-4f62-b9de-788b8bb7a094</guid>
      <link>https://medsider.com/interviews/kelly-roman-fisher-wallace</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kellyroman/">Kelly Roman</a>, co-founder and CEO of <a href="https://www.fisherwallace.com/">Fisher Wallace</a>, a company spearheading the development of wearable brain stimulation technology aimed at providing relief from depression, anxiety, and insomnia. </p><p><br>Kelly is a Harvard graduate with an English major who took an unconventional path to medtech inspired by his experience co-authoring the graphic novel adaptation of Sun Tzu's "The Art of War." He took a career leap from literature and marketing to pioneer a novel approach to the treatment of mental health. </p><p>In this interview, we delve into what Kelly's learned on his journey, touching on the value of unconventional thinking, the importance of making mental health treatments more accessible and less stigmatized, and the potential of decentralized clinical trials.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-roman-fisher-wallace">here's a link to the full interview with Kelly Roman</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kellyroman/">Kelly Roman</a>, co-founder and CEO of <a href="https://www.fisherwallace.com/">Fisher Wallace</a>, a company spearheading the development of wearable brain stimulation technology aimed at providing relief from depression, anxiety, and insomnia. </p><p><br>Kelly is a Harvard graduate with an English major who took an unconventional path to medtech inspired by his experience co-authoring the graphic novel adaptation of Sun Tzu's "The Art of War." He took a career leap from literature and marketing to pioneer a novel approach to the treatment of mental health. </p><p>In this interview, we delve into what Kelly's learned on his journey, touching on the value of unconventional thinking, the importance of making mental health treatments more accessible and less stigmatized, and the potential of decentralized clinical trials.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-roman-fisher-wallace">here's a link to the full interview with Kelly Roman</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 08 Nov 2023 15:58:18 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d54bd69a/7e0976f5.mp3" length="78550049" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DfMjP5caBdDSqpS6TOqpQIwCEO3rOOFHdoRfQbVEU-E/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1ODI4MTcv/MTY5OTI0Njk4NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3272</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kellyroman/">Kelly Roman</a>, co-founder and CEO of <a href="https://www.fisherwallace.com/">Fisher Wallace</a>, a company spearheading the development of wearable brain stimulation technology aimed at providing relief from depression, anxiety, and insomnia. </p><p><br>Kelly is a Harvard graduate with an English major who took an unconventional path to medtech inspired by his experience co-authoring the graphic novel adaptation of Sun Tzu's "The Art of War." He took a career leap from literature and marketing to pioneer a novel approach to the treatment of mental health. </p><p>In this interview, we delve into what Kelly's learned on his journey, touching on the value of unconventional thinking, the importance of making mental health treatments more accessible and less stigmatized, and the potential of decentralized clinical trials.</p><p> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/kelly-roman-fisher-wallace">here's a link to the full interview with Kelly Roman</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Childlike Curiosity and the Scientific Approach to Medtech Startups: Interview with Levita Magnetics CEO Dr. Alberto Rodriguez-Navarro</title>
      <itunes:title>Childlike Curiosity and the Scientific Approach to Medtech Startups: Interview with Levita Magnetics CEO Dr. Alberto Rodriguez-Navarro</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8cb6ded9-a210-48ff-9479-635f24a53e9d</guid>
      <link>https://medsider.com/interviews/alberto-rodriguez-navarro-levita-magnetics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/albertorodrigueznavarro/">Dr. Alberto Rodriguez-Navarro</a>, CEO of <a href="https://www.levita.com/">Levita Magnetics</a>, a startup aiming to make surgical procedures as minimally invasive as possible with its advanced magnetic technology. </p><p>Dr. Rodriguez-Navarro is not only a skilled surgeon but a medtech visionary with multiple patents to his name. Discover Alberto's journey spanning his childhood fascination with using magnets to clean the inside of his turtle tank to leveraging this concept into a cutting-edge magnetic surgery platform.  </p><p>In this interview,  Dr. Rodriguez-Navarro discusses what to consider when starting a new business, how to hone your framework when transitioning from the clinic, and early-stage strategies to ease the road to FDA approval.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/alberto-rodriguez-navarro-levita-magnetics">link to the full interview with Dr. Rodriguez-Navarro</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/albertorodrigueznavarro/">Dr. Alberto Rodriguez-Navarro</a>, CEO of <a href="https://www.levita.com/">Levita Magnetics</a>, a startup aiming to make surgical procedures as minimally invasive as possible with its advanced magnetic technology. </p><p>Dr. Rodriguez-Navarro is not only a skilled surgeon but a medtech visionary with multiple patents to his name. Discover Alberto's journey spanning his childhood fascination with using magnets to clean the inside of his turtle tank to leveraging this concept into a cutting-edge magnetic surgery platform.  </p><p>In this interview,  Dr. Rodriguez-Navarro discusses what to consider when starting a new business, how to hone your framework when transitioning from the clinic, and early-stage strategies to ease the road to FDA approval.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/alberto-rodriguez-navarro-levita-magnetics">link to the full interview with Dr. Rodriguez-Navarro</a>.</p>]]>
      </content:encoded>
      <pubDate>Fri, 03 Nov 2023 15:39:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/27b435ea/39116321.mp3" length="73606201" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/S_VXxCe17J2HEY6NXBWS2JDvB6JfGzXdLxcZLV_L1lU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1NzIwNjcv/MTY5ODY0MzY2Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3066</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we had a chat with <a href="https://www.linkedin.com/in/albertorodrigueznavarro/">Dr. Alberto Rodriguez-Navarro</a>, CEO of <a href="https://www.levita.com/">Levita Magnetics</a>, a startup aiming to make surgical procedures as minimally invasive as possible with its advanced magnetic technology. </p><p>Dr. Rodriguez-Navarro is not only a skilled surgeon but a medtech visionary with multiple patents to his name. Discover Alberto's journey spanning his childhood fascination with using magnets to clean the inside of his turtle tank to leveraging this concept into a cutting-edge magnetic surgery platform.  </p><p>In this interview,  Dr. Rodriguez-Navarro discusses what to consider when starting a new business, how to hone your framework when transitioning from the clinic, and early-stage strategies to ease the road to FDA approval.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/alberto-rodriguez-navarro-levita-magnetics">link to the full interview with Dr. Rodriguez-Navarro</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>A Roadmap to Serial Medtech Entrepreneurship: Interview with SinglePass CEO Bill Colone</title>
      <itunes:title>A Roadmap to Serial Medtech Entrepreneurship: Interview with SinglePass CEO Bill Colone</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">390f6c1d-1647-449a-ac93-d02f78734a8f</guid>
      <link>https://medsider.com/interviews/bill-colone-singlepass</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/bill-colone-2320613/">Bill Colone</a>, the CEO and Chairman of <a href="https://www.singlepass.co/">SinglePass</a>, a company developing an electrocautery device for deep tissue biopsies.</p><p>Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&amp;D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.</p><p>In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/bill-colone-singlepass">link to the full interview with Bill Colone</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/bill-colone-2320613/">Bill Colone</a>, the CEO and Chairman of <a href="https://www.singlepass.co/">SinglePass</a>, a company developing an electrocautery device for deep tissue biopsies.</p><p>Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&amp;D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.</p><p>In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/bill-colone-singlepass">link to the full interview with Bill Colone</a>.</p>]]>
      </content:encoded>
      <pubDate>Fri, 27 Oct 2023 20:35:06 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2b109122/7014c7c9.mp3" length="75780479" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/xOloK79H_4pH5DvEATLFjLeRGctsKkW1GclWN3AXXBE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1NTk2NDkv/MTY5ODAzNjYzMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3156</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/bill-colone-2320613/">Bill Colone</a>, the CEO and Chairman of <a href="https://www.singlepass.co/">SinglePass</a>, a company developing an electrocautery device for deep tissue biopsies.</p><p>Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&amp;D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.</p><p>In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/bill-colone-singlepass">link to the full interview with Bill Colone</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Data is Transforming Medtech: Interview with Avenda Health CEO Shyam Natarajan</title>
      <itunes:title>How Data is Transforming Medtech: Interview with Avenda Health CEO Shyam Natarajan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">bff59ccf-f61d-45b0-aecb-cd470222b0a2</guid>
      <link>https://medsider.com/interviews/shyam-natarajan-avenda-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shyam-natarajan-71014033/">Shyam Natarajan</a>, founder and CEO of <a href="https://avendahealth.com/">Avenda Health</a>, which utilizes artificial intelligence and cutting-edge imaging to improve the diagnosis and treatment of prostate cancer.</p><p>After getting his PhD in Biomedical Engineering from UCLA, Shyam worked as a postdoctoral scholar in UCLA's Department of Surgery, focusing on minimally invasive surgical interventions. He also managed the UCLA Business of Science Center, spearheading initiatives to guide students toward non-academic career paths. With experiences like founding UCLA Innovation Week and the Inventathon, he is committed to pushing the boundaries of medical technology. At Avenda Health, Shyam is now leading the charge in revolutionizing prostate cancer care. </p><p>In this interview, we talk about what it really takes to understand the market need for your product or service, how prototypes can be incredibly helpful in convincing relevant parties, how Shyam approaches fundraising, and what to expect from medtech in the future given current technological advancements in growing fields like AI.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/shyam-natarajan-avenda-health">link to the full interview with Shyam Natarajan</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shyam-natarajan-71014033/">Shyam Natarajan</a>, founder and CEO of <a href="https://avendahealth.com/">Avenda Health</a>, which utilizes artificial intelligence and cutting-edge imaging to improve the diagnosis and treatment of prostate cancer.</p><p>After getting his PhD in Biomedical Engineering from UCLA, Shyam worked as a postdoctoral scholar in UCLA's Department of Surgery, focusing on minimally invasive surgical interventions. He also managed the UCLA Business of Science Center, spearheading initiatives to guide students toward non-academic career paths. With experiences like founding UCLA Innovation Week and the Inventathon, he is committed to pushing the boundaries of medical technology. At Avenda Health, Shyam is now leading the charge in revolutionizing prostate cancer care. </p><p>In this interview, we talk about what it really takes to understand the market need for your product or service, how prototypes can be incredibly helpful in convincing relevant parties, how Shyam approaches fundraising, and what to expect from medtech in the future given current technological advancements in growing fields like AI.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/shyam-natarajan-avenda-health">link to the full interview with Shyam Natarajan</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 18 Oct 2023 16:37:03 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f2877e80/1063ffad.mp3" length="65927185" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/QizNckecNVM3cta3jx8f1XYwQxzaqMPSg8RAEmak9n0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1NDc2ODgv/MTY5NzQzNjM4Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2746</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shyam-natarajan-71014033/">Shyam Natarajan</a>, founder and CEO of <a href="https://avendahealth.com/">Avenda Health</a>, which utilizes artificial intelligence and cutting-edge imaging to improve the diagnosis and treatment of prostate cancer.</p><p>After getting his PhD in Biomedical Engineering from UCLA, Shyam worked as a postdoctoral scholar in UCLA's Department of Surgery, focusing on minimally invasive surgical interventions. He also managed the UCLA Business of Science Center, spearheading initiatives to guide students toward non-academic career paths. With experiences like founding UCLA Innovation Week and the Inventathon, he is committed to pushing the boundaries of medical technology. At Avenda Health, Shyam is now leading the charge in revolutionizing prostate cancer care. </p><p>In this interview, we talk about what it really takes to understand the market need for your product or service, how prototypes can be incredibly helpful in convincing relevant parties, how Shyam approaches fundraising, and what to expect from medtech in the future given current technological advancements in growing fields like AI.<br> </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/shyam-natarajan-avenda-health">link to the full interview with Shyam Natarajan</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Consumer-Facing Medtech: Interview with AliveCor Founder and Chief Medical Officer Dr. David Albert</title>
      <itunes:title>Consumer-Facing Medtech: Interview with AliveCor Founder and Chief Medical Officer Dr. David Albert</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b076d638-9540-4ece-84b0-f26a3ad242e4</guid>
      <link>https://medsider.com/interviews/david-albert-alivecor</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/drdavealbert/">Dr. David Albert</a>, founder of <a href="https://www.alivecor.com/">AliveCor</a>, which is pioneering the standard for personal ECG devices that extend beyond hardware and encompass services and partnerships to offer comprehensive personal cardiovascular solutions.</p><p>Dr. Albert is a multifaceted individual — a physician, scientist, inventor, serial entrepreneur, YouTube sensation, and even an adventurous surfer. His academic journey led him from Duke University, where he completed both engineering and medical graduate studies, back to his roots at the University of Oklahoma. He already had several licensed inventions when he decided to stake it all on a new cardiovascular device. The gamble led him to found AliveCor, now a frontrunner in personal electrocardiograms (ECGs) under the renowned<a href="https://kardia.com/"> Kardia brand</a>. </p><p><br>In this interview, we take a tour down the lanes of innovation, prototyping, fundraising, and why sometimes you have to ditch the white coat to take your ideas from the lab to the real world.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-albert-alivecor">here's a link to the full interview with Dr. Albert</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/drdavealbert/">Dr. David Albert</a>, founder of <a href="https://www.alivecor.com/">AliveCor</a>, which is pioneering the standard for personal ECG devices that extend beyond hardware and encompass services and partnerships to offer comprehensive personal cardiovascular solutions.</p><p>Dr. Albert is a multifaceted individual — a physician, scientist, inventor, serial entrepreneur, YouTube sensation, and even an adventurous surfer. His academic journey led him from Duke University, where he completed both engineering and medical graduate studies, back to his roots at the University of Oklahoma. He already had several licensed inventions when he decided to stake it all on a new cardiovascular device. The gamble led him to found AliveCor, now a frontrunner in personal electrocardiograms (ECGs) under the renowned<a href="https://kardia.com/"> Kardia brand</a>. </p><p><br>In this interview, we take a tour down the lanes of innovation, prototyping, fundraising, and why sometimes you have to ditch the white coat to take your ideas from the lab to the real world.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-albert-alivecor">here's a link to the full interview with Dr. Albert</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 11 Oct 2023 17:35:54 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/1135725e/5076b11c.mp3" length="76972158" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/uxaJ1QF2a7kizmFSO-cwC01gKrgujfFxoYoP7TgTGWk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1MzkyMzMv/MTY5Njg0OTA3Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3206</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/drdavealbert/">Dr. David Albert</a>, founder of <a href="https://www.alivecor.com/">AliveCor</a>, which is pioneering the standard for personal ECG devices that extend beyond hardware and encompass services and partnerships to offer comprehensive personal cardiovascular solutions.</p><p>Dr. Albert is a multifaceted individual — a physician, scientist, inventor, serial entrepreneur, YouTube sensation, and even an adventurous surfer. His academic journey led him from Duke University, where he completed both engineering and medical graduate studies, back to his roots at the University of Oklahoma. He already had several licensed inventions when he decided to stake it all on a new cardiovascular device. The gamble led him to found AliveCor, now a frontrunner in personal electrocardiograms (ECGs) under the renowned<a href="https://kardia.com/"> Kardia brand</a>. </p><p><br>In this interview, we take a tour down the lanes of innovation, prototyping, fundraising, and why sometimes you have to ditch the white coat to take your ideas from the lab to the real world.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/david-albert-alivecor">here's a link to the full interview with Dr. Albert</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From Academia to Medtech Entrepreneur: Interview with SpineX CEO Parag Gad</title>
      <itunes:title>From Academia to Medtech Entrepreneur: Interview with SpineX CEO Parag Gad</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">73bfd215-dfef-4797-a0ca-320bd7ffa3a0</guid>
      <link>https://medsider.com/interviews/parag-gad-spinex</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/parag-gad/">Parag Gad</a>, who founded <a href="http://www.spinex.co/">SpineX</a> to turn cutting-edge science into life-changing devices. The FDA has granted Breakthrough Device Designation for two of SpineX's non-invasive products aimed at improving the lives of adults with neurogenic bladder conditions and children with cerebral palsy.</p><p>Parag understands both sides of the coin — the research-intensive academic world and the rigorous standards of healthcare regulation. With SpineX, he's marrying the two, aiming for a transformation in spinal healthcare. The company has raised $3.6 million in equity financing and has also secured non-dilutive funding from government agencies. With ongoing multicenter clinical trials and plans for future enrollment, Parag is steering SpineX toward a new frontier in bioelectric medicine.</p><p><br>In this interview, Parag delves into the intricate journey of transitioning from academia to entrepreneurship, securing non-traditional funding, and the role of regulatory milestones in building a reputable healthcare brand.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/parag-gad-spinex">here's a link to the full interview with Parag Gad</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/parag-gad/">Parag Gad</a>, who founded <a href="http://www.spinex.co/">SpineX</a> to turn cutting-edge science into life-changing devices. The FDA has granted Breakthrough Device Designation for two of SpineX's non-invasive products aimed at improving the lives of adults with neurogenic bladder conditions and children with cerebral palsy.</p><p>Parag understands both sides of the coin — the research-intensive academic world and the rigorous standards of healthcare regulation. With SpineX, he's marrying the two, aiming for a transformation in spinal healthcare. The company has raised $3.6 million in equity financing and has also secured non-dilutive funding from government agencies. With ongoing multicenter clinical trials and plans for future enrollment, Parag is steering SpineX toward a new frontier in bioelectric medicine.</p><p><br>In this interview, Parag delves into the intricate journey of transitioning from academia to entrepreneurship, securing non-traditional funding, and the role of regulatory milestones in building a reputable healthcare brand.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/parag-gad-spinex">here's a link to the full interview with Parag Gad</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Oct 2023 17:04:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8a8111c9/cfbffefb.mp3" length="66287618" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/fnm7Gjjv6TUK4y4oOfBa0Xfltmps5bD4eBw-JZLY7_A/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1Mjk2Mjgv/MTY5NjIyMTg1Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2761</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/parag-gad/">Parag Gad</a>, who founded <a href="http://www.spinex.co/">SpineX</a> to turn cutting-edge science into life-changing devices. The FDA has granted Breakthrough Device Designation for two of SpineX's non-invasive products aimed at improving the lives of adults with neurogenic bladder conditions and children with cerebral palsy.</p><p>Parag understands both sides of the coin — the research-intensive academic world and the rigorous standards of healthcare regulation. With SpineX, he's marrying the two, aiming for a transformation in spinal healthcare. The company has raised $3.6 million in equity financing and has also secured non-dilutive funding from government agencies. With ongoing multicenter clinical trials and plans for future enrollment, Parag is steering SpineX toward a new frontier in bioelectric medicine.</p><p><br>In this interview, Parag delves into the intricate journey of transitioning from academia to entrepreneurship, securing non-traditional funding, and the role of regulatory milestones in building a reputable healthcare brand.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/parag-gad-spinex">here's a link to the full interview with Parag Gad</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Redefining Stroke Recovery: Interview with Kandu Health CEO Kirsten Carroll</title>
      <itunes:title>Redefining Stroke Recovery: Interview with Kandu Health CEO Kirsten Carroll</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">35eeeee5-1684-4b9b-b569-18babe90d644</guid>
      <link>https://medsider.com/interviews/kirsten-carroll-kandu</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirsten-carroll-43627b/">Kirsten Carroll</a>, CEO of <a href="https://kanduhealth.com/">Kandu Health</a>, and a medtech veteran specializing in neurovascular disorders with nearly 25 years of experience in the field. </p><p>Kirsten holds a degree in biomedical engineering and dual master's degrees in business and public health. She has held strategic roles at industry leaders like Boston Scientific and Stryker before joining Imperative Care and co-founding Kandu Health. Her startup focuses on revolutionizing post-stroke care and enhancing the quality of life for stroke survivors through tech-enabled healthcare services.</p><p><br></p><p>In this interview, Kirsten talks about redefining post-stroke care with a comprehensive set of services to improve the well-being of stroke survivors and, consequently, their care partners. From her unique perspective on innovation to her emphasis on a multi-stakeholder approach, Kirsten shares invaluable lessons on breaking down monumental challenges and fostering a culture of teamwork.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor! </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/kirsten-carroll-kandu">link to the full interview with Kirsten Carroll</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirsten-carroll-43627b/">Kirsten Carroll</a>, CEO of <a href="https://kanduhealth.com/">Kandu Health</a>, and a medtech veteran specializing in neurovascular disorders with nearly 25 years of experience in the field. </p><p>Kirsten holds a degree in biomedical engineering and dual master's degrees in business and public health. She has held strategic roles at industry leaders like Boston Scientific and Stryker before joining Imperative Care and co-founding Kandu Health. Her startup focuses on revolutionizing post-stroke care and enhancing the quality of life for stroke survivors through tech-enabled healthcare services.</p><p><br></p><p>In this interview, Kirsten talks about redefining post-stroke care with a comprehensive set of services to improve the well-being of stroke survivors and, consequently, their care partners. From her unique perspective on innovation to her emphasis on a multi-stakeholder approach, Kirsten shares invaluable lessons on breaking down monumental challenges and fostering a culture of teamwork.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor! </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/kirsten-carroll-kandu">link to the full interview with Kirsten Carroll</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 27 Sep 2023 15:49:45 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/5e78cc9c/6ba484c4.mp3" length="77471771" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dk4hY__YNCLiuVfWRHjrIGzSQ23YkGn7R4ga21RqEyg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1MTc5MTgv/MTY5NTYxNjcxNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3227</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/kirsten-carroll-43627b/">Kirsten Carroll</a>, CEO of <a href="https://kanduhealth.com/">Kandu Health</a>, and a medtech veteran specializing in neurovascular disorders with nearly 25 years of experience in the field. </p><p>Kirsten holds a degree in biomedical engineering and dual master's degrees in business and public health. She has held strategic roles at industry leaders like Boston Scientific and Stryker before joining Imperative Care and co-founding Kandu Health. Her startup focuses on revolutionizing post-stroke care and enhancing the quality of life for stroke survivors through tech-enabled healthcare services.</p><p><br></p><p>In this interview, Kirsten talks about redefining post-stroke care with a comprehensive set of services to improve the well-being of stroke survivors and, consequently, their care partners. From her unique perspective on innovation to her emphasis on a multi-stakeholder approach, Kirsten shares invaluable lessons on breaking down monumental challenges and fostering a culture of teamwork.</p><p><br></p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter.</p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!</p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor! </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a <a href="https://medsider.com/interviews/kirsten-carroll-kandu">link to the full interview with Kirsten Carroll</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Doing Well by Doing Good: Interview with Proprio CEO Gabriel Jones</title>
      <itunes:title>Doing Well by Doing Good: Interview with Proprio CEO Gabriel Jones</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5da74cd1-b521-47d4-a70f-5c2a7dcd6b11</guid>
      <link>https://medsider.com/interviews/gabriel-jones-proprio</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/agabrieljones/">Gabriel Jones</a>, co-founder and CEO of <a href="https://www.propriovision.com/">Proprio</a>, who has had a career spanning engineering, law, finance, and philanthropy across the world. </p><p><br></p><p>Gabriel studied engineering at the University of Washington before furthering his career at Tase Kensetsu, a major civil engineering and manufacturing firm in Japan. He then moved to Wall Street to work on large-scale mergers and acquisitions for high-profile clients like AT&amp;T and Google. After returning to Seattle, Gabriel collaborated with the Bill &amp; Melinda Gates Foundation on global healthcare initiatives. Today, he is the CEO of Proprio, a revolutionary medtech startup aiming to improve surgical precision with AI-powered technology.</p><p><br></p><p>In this interview, the eclectic Gabriel shares how his background has equipped him with a unique framework for creating a thriving startup ecosystem, tips on capital fundraising, and using public relations to his favor.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. </p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more! </p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!  </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-jones-proprio">here's a link to the full interview with Gabriel Jones.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/agabrieljones/">Gabriel Jones</a>, co-founder and CEO of <a href="https://www.propriovision.com/">Proprio</a>, who has had a career spanning engineering, law, finance, and philanthropy across the world. </p><p><br></p><p>Gabriel studied engineering at the University of Washington before furthering his career at Tase Kensetsu, a major civil engineering and manufacturing firm in Japan. He then moved to Wall Street to work on large-scale mergers and acquisitions for high-profile clients like AT&amp;T and Google. After returning to Seattle, Gabriel collaborated with the Bill &amp; Melinda Gates Foundation on global healthcare initiatives. Today, he is the CEO of Proprio, a revolutionary medtech startup aiming to improve surgical precision with AI-powered technology.</p><p><br></p><p>In this interview, the eclectic Gabriel shares how his background has equipped him with a unique framework for creating a thriving startup ecosystem, tips on capital fundraising, and using public relations to his favor.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. </p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more! </p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!  </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-jones-proprio">here's a link to the full interview with Gabriel Jones.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 20 Sep 2023 18:08:33 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/cf5497e1/d06defdd.mp3" length="85183223" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/_1T_uN2-Fnia3gTeznBpn2FN7FaP-ZFu48oWT0ul42I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE1MDc2NjIv/MTY5NTAxMzUxNC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3548</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/agabrieljones/">Gabriel Jones</a>, co-founder and CEO of <a href="https://www.propriovision.com/">Proprio</a>, who has had a career spanning engineering, law, finance, and philanthropy across the world. </p><p><br></p><p>Gabriel studied engineering at the University of Washington before furthering his career at Tase Kensetsu, a major civil engineering and manufacturing firm in Japan. He then moved to Wall Street to work on large-scale mergers and acquisitions for high-profile clients like AT&amp;T and Google. After returning to Seattle, Gabriel collaborated with the Bill &amp; Melinda Gates Foundation on global healthcare initiatives. Today, he is the CEO of Proprio, a revolutionary medtech startup aiming to improve surgical precision with AI-powered technology.</p><p><br></p><p>In this interview, the eclectic Gabriel shares how his background has equipped him with a unique framework for creating a thriving startup ecosystem, tips on capital fundraising, and using public relations to his favor.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. </p><p>Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more! </p><p>We recently introduced some fantastic additions exclusively for Medsider premium members, including <a href="https://medsider.com/playbooks">playbooks</a>, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and <a href="https://medsider.com/investors">a curated investor database</a> to help you discover your next medical device or health technology investor!  </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, <a href="https://medsider.com/interviews/gabriel-jones-proprio">here's a link to the full interview with Gabriel Jones.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Mission-Driven Entrepreneurship: Interview with NEXT Life Sciences’ Founder L.R. Fox</title>
      <itunes:title>Mission-Driven Entrepreneurship: Interview with NEXT Life Sciences’ Founder L.R. Fox</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">f7275abb-3134-4551-b6bc-a490070606fe</guid>
      <link>https://medsider.com/interviews/luke-fox-next-life-sciences</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we pull back the curtain on <a href="https://www.linkedin.com/in/lrfox/">L.R. Fox</a>, the visionary founder of <a href="https://nextlifesciences.org/">NEXT Life Sciences</a>. With an ambitious mission to democratize family planning, Fox and his team are on the brink of launching their flagship product, <a href="https://www.planaformen.com/">Plan A</a>— a groundbreaking male contraceptive.</p><p><br></p><p>Before founding NEXT Life Sciences, Fox was already a powerhouse entrepreneur in numerous highly regulated industries ranging from cybersecurity to aerospace, including WhiteFox Defense Technologies, a company that is shaping the future of drone airspace security. With a degree in engineering and as a member of the Forbes' 30 Under 30 list in 2019., Fox is currently leading NEXT’s efforts to introduce Plan A to the market. </p><p>In this interview, Fox shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, <a href="https://medsider.com/interviews/luke-fox-next-life-sciences">here's a link to the full interview with L.R. Fox.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we pull back the curtain on <a href="https://www.linkedin.com/in/lrfox/">L.R. Fox</a>, the visionary founder of <a href="https://nextlifesciences.org/">NEXT Life Sciences</a>. With an ambitious mission to democratize family planning, Fox and his team are on the brink of launching their flagship product, <a href="https://www.planaformen.com/">Plan A</a>— a groundbreaking male contraceptive.</p><p><br></p><p>Before founding NEXT Life Sciences, Fox was already a powerhouse entrepreneur in numerous highly regulated industries ranging from cybersecurity to aerospace, including WhiteFox Defense Technologies, a company that is shaping the future of drone airspace security. With a degree in engineering and as a member of the Forbes' 30 Under 30 list in 2019., Fox is currently leading NEXT’s efforts to introduce Plan A to the market. </p><p>In this interview, Fox shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, <a href="https://medsider.com/interviews/luke-fox-next-life-sciences">here's a link to the full interview with L.R. Fox.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 13 Sep 2023 18:02:38 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/de1e5147/2a7a2b60.mp3" length="80282010" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/VQU6ksdYia_DT0nuJptlEw_AUKhA3ZfDRktu0uJ5HrU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0OTk0ODcv/MTY5NDQwNTcwNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3344</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we pull back the curtain on <a href="https://www.linkedin.com/in/lrfox/">L.R. Fox</a>, the visionary founder of <a href="https://nextlifesciences.org/">NEXT Life Sciences</a>. With an ambitious mission to democratize family planning, Fox and his team are on the brink of launching their flagship product, <a href="https://www.planaformen.com/">Plan A</a>— a groundbreaking male contraceptive.</p><p><br></p><p>Before founding NEXT Life Sciences, Fox was already a powerhouse entrepreneur in numerous highly regulated industries ranging from cybersecurity to aerospace, including WhiteFox Defense Technologies, a company that is shaping the future of drone airspace security. With a degree in engineering and as a member of the Forbes' 30 Under 30 list in 2019., Fox is currently leading NEXT’s efforts to introduce Plan A to the market. </p><p>In this interview, Fox shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, <a href="https://medsider.com/interviews/luke-fox-next-life-sciences">here's a link to the full interview with L.R. Fox.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From Chaos to Order: The Journey of a Medtech CEO with Amplifi CEO Sean Morris</title>
      <itunes:title>From Chaos to Order: The Journey of a Medtech CEO with Amplifi CEO Sean Morris</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">03dae1e8-e6f8-41ca-97cd-ceeade5f53ca</guid>
      <link>https://medsider.com/interviews/sean-morris-amplifi</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/sean-morris-0b6a1a7/">Sean Morris</a>, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.</p><p><br></p><p>Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded <a href="https://euphratesvascular.com/">Euphrates Vascular</a>, an innovative startup in the field of microvascular obstructions.</p><p>In this interview,  Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, here's a <a href="https://medsider.com/interviews/sean-morris-amplifi">link to the full interview with Sean Morris</a>.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/sean-morris-0b6a1a7/">Sean Morris</a>, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.</p><p><br></p><p>Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded <a href="https://euphratesvascular.com/">Euphrates Vascular</a>, an innovative startup in the field of microvascular obstructions.</p><p>In this interview,  Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, here's a <a href="https://medsider.com/interviews/sean-morris-amplifi">link to the full interview with Sean Morris</a>.</p>]]>
      </content:encoded>
      <pubDate>Wed, 06 Sep 2023 21:13:07 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b20c2bcc/07c6190d.mp3" length="85746282" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/djo65cTbHL61hgPrJ5YSF4pFVgjvnsH6FW6eUZ25ZBE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0ODk5MDYv/MTY5Mzg4NzU3Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3571</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/sean-morris-0b6a1a7/">Sean Morris</a>, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.</p><p><br></p><p>Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded <a href="https://euphratesvascular.com/">Euphrates Vascular</a>, an innovative startup in the field of microvascular obstructions.</p><p>In this interview,  Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd much rather read, here's a <a href="https://medsider.com/interviews/sean-morris-amplifi">link to the full interview with Sean Morris</a>.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Bringing the ENT Clinic to the Community: Interview with Tympa Health CEO Dr. Krishan Ramdoo</title>
      <itunes:title>Bringing the ENT Clinic to the Community: Interview with Tympa Health CEO Dr. Krishan Ramdoo</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b192d6ef-055c-44e9-88d9-e3491921811a</guid>
      <link>https://medsider.com/interviews/krishan-ramdoo-tympa-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krishan-ramdoo-10086979/">Dr. Krishan Ramdoo</a>, the CEO and creative mind behind the <a href="https://tympahealth.com/">Tympa platform</a>, an all-in-one ear and hearing health assessment system that has gained global recognition.</p><p>Dr. Ramdoo is a celebrated international speaker, researcher, and educator with a keen focus on the intersection of medical science and technology. Some of the accolades Dr. Ramdoo and the Tympa team have received include the prestigious Royal Society of Medicine prize for innovation in ENT, the Rowena Ryan prize for research into ENT, and the Hartopp-Dixon ENT award.</p><p>In this interview, he talks about his journey toward becoming a technology innovator, starting as an ENT physician to eventually developing the Tympa platform. Dr. Ramdoo shares invaluable insights on the importance of patient-centric problem-solving, balancing external feedback with personal vision, and the power of tangible products in converting stakeholders to true believers in your solution.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/krishan-ramdoo-tympa-health">a link to the full interview with Dr. Ramdoo</a> if you prefer to read it.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krishan-ramdoo-10086979/">Dr. Krishan Ramdoo</a>, the CEO and creative mind behind the <a href="https://tympahealth.com/">Tympa platform</a>, an all-in-one ear and hearing health assessment system that has gained global recognition.</p><p>Dr. Ramdoo is a celebrated international speaker, researcher, and educator with a keen focus on the intersection of medical science and technology. Some of the accolades Dr. Ramdoo and the Tympa team have received include the prestigious Royal Society of Medicine prize for innovation in ENT, the Rowena Ryan prize for research into ENT, and the Hartopp-Dixon ENT award.</p><p>In this interview, he talks about his journey toward becoming a technology innovator, starting as an ENT physician to eventually developing the Tympa platform. Dr. Ramdoo shares invaluable insights on the importance of patient-centric problem-solving, balancing external feedback with personal vision, and the power of tangible products in converting stakeholders to true believers in your solution.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/krishan-ramdoo-tympa-health">a link to the full interview with Dr. Ramdoo</a> if you prefer to read it.</p>]]>
      </content:encoded>
      <pubDate>Wed, 30 Aug 2023 17:48:47 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/81527169/19e1254c.mp3" length="78303571" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/zchIgor6qZR2dqen3jcBLAijOPEkOCCh0FNJljTHXy4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0NzMxMTUv/MTY5Mjk0MDUyNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3261</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krishan-ramdoo-10086979/">Dr. Krishan Ramdoo</a>, the CEO and creative mind behind the <a href="https://tympahealth.com/">Tympa platform</a>, an all-in-one ear and hearing health assessment system that has gained global recognition.</p><p>Dr. Ramdoo is a celebrated international speaker, researcher, and educator with a keen focus on the intersection of medical science and technology. Some of the accolades Dr. Ramdoo and the Tympa team have received include the prestigious Royal Society of Medicine prize for innovation in ENT, the Rowena Ryan prize for research into ENT, and the Hartopp-Dixon ENT award.</p><p>In this interview, he talks about his journey toward becoming a technology innovator, starting as an ENT physician to eventually developing the Tympa platform. Dr. Ramdoo shares invaluable insights on the importance of patient-centric problem-solving, balancing external feedback with personal vision, and the power of tangible products in converting stakeholders to true believers in your solution.</p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/krishan-ramdoo-tympa-health">a link to the full interview with Dr. Ramdoo</a> if you prefer to read it.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Embracing Ambition Without Arrogance: Interview with Luminelle CEO Allison London Brown</title>
      <itunes:title>Embracing Ambition Without Arrogance: Interview with Luminelle CEO Allison London Brown</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">a33ee4cf-37dc-43ba-a4a6-ddfaeaaf26fe</guid>
      <link>https://medsider.com/interviews/allison-london-brown-luminelle</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/allisonlondonbrown/">Allison London Brown</a>, CEO of <a href="https://www.luminelle360.com/">Luminelle</a>, who has over 25 years of experience in the healthcare space and has been involved in nearly every aspect of product development for women's health.</p><p><br>From Fortune 50 companies like Johnson &amp; Johnson and GE Healthcare to founding startups, Allison has seen it all. Now, as the CEO and co-founder of Luminelle, she's channeling her decades of knowledge into a revolutionary new device aiming to transform gynecological procedures.</p><p>In this interview, Allison shares insights on how to best understand your strengths and weaknesses, the potential pitfalls of 'one size fits all' regulatory strategies, and innovative methods to secure capital in a risk-averse economy. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/allison-london-brown-luminelle">a link to the full interview with Allison</a> if you prefer reading.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/allisonlondonbrown/">Allison London Brown</a>, CEO of <a href="https://www.luminelle360.com/">Luminelle</a>, who has over 25 years of experience in the healthcare space and has been involved in nearly every aspect of product development for women's health.</p><p><br>From Fortune 50 companies like Johnson &amp; Johnson and GE Healthcare to founding startups, Allison has seen it all. Now, as the CEO and co-founder of Luminelle, she's channeling her decades of knowledge into a revolutionary new device aiming to transform gynecological procedures.</p><p>In this interview, Allison shares insights on how to best understand your strengths and weaknesses, the potential pitfalls of 'one size fits all' regulatory strategies, and innovative methods to secure capital in a risk-averse economy. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/allison-london-brown-luminelle">a link to the full interview with Allison</a> if you prefer reading.</p>]]>
      </content:encoded>
      <pubDate>Wed, 23 Aug 2023 18:33:03 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ae2f47ad/9ec35d89.mp3" length="69153541" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/TPjGbupxYaY_eguSRzMRwY3jmZuXVHCqwA9z4XEze04/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0NjQzNTgv/MTY5MjI5MDY4NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2880</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/allisonlondonbrown/">Allison London Brown</a>, CEO of <a href="https://www.luminelle360.com/">Luminelle</a>, who has over 25 years of experience in the healthcare space and has been involved in nearly every aspect of product development for women's health.</p><p><br>From Fortune 50 companies like Johnson &amp; Johnson and GE Healthcare to founding startups, Allison has seen it all. Now, as the CEO and co-founder of Luminelle, she's channeling her decades of knowledge into a revolutionary new device aiming to transform gynecological procedures.</p><p>In this interview, Allison shares insights on how to best understand your strengths and weaknesses, the potential pitfalls of 'one size fits all' regulatory strategies, and innovative methods to secure capital in a risk-averse economy. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's <a href="https://medsider.com/interviews/allison-london-brown-luminelle">a link to the full interview with Allison</a> if you prefer reading.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Iterating Towards Perfection in Medtech: Interview with Sonavex CEO David Narrow</title>
      <itunes:title>Iterating Towards Perfection in Medtech: Interview with Sonavex CEO David Narrow</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5161d677-e377-45a8-a9aa-2855c80cb5ab</guid>
      <link>https://medsider.com/interviews/david-narrow-sonavex</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/david-narrow-a4454023/">David Narrow</a>, CEO of <a href="https://www.sonavex.com/">Sonavex</a>, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances. </p><p><br>David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.</p><p>In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/david-narrow-sonavex">link to the full interview with David</a> if you prefer reading.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/david-narrow-a4454023/">David Narrow</a>, CEO of <a href="https://www.sonavex.com/">Sonavex</a>, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances. </p><p><br>David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.</p><p>In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/david-narrow-sonavex">link to the full interview with David</a> if you prefer reading.</p>]]>
      </content:encoded>
      <pubDate>Wed, 16 Aug 2023 18:33:44 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4e809109/087f05fe.mp3" length="74916990" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/r6XMAHI_o_ZifdfsqFG_1UyFaMzodW2tAFu696EJjw4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0NTYxNTcv/MTY5MTY3Nzc5Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3120</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/david-narrow-a4454023/">David Narrow</a>, CEO of <a href="https://www.sonavex.com/">Sonavex</a>, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances. </p><p><br>David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.</p><p>In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists. </p><p>Before we dive into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/david-narrow-sonavex">link to the full interview with David</a> if you prefer reading.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From Circuit Boards to Brainwaves: Interview with Noctrix Health CEO Shriram Raghunathan</title>
      <itunes:title>From Circuit Boards to Brainwaves: Interview with Noctrix Health CEO Shriram Raghunathan</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">098ad9c0-cb96-4bf1-8ca4-088cebe41cd0</guid>
      <link>https://medsider.com/interviews/shriram-raghunathan-noctrix-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shriram-raghunathan-ph-d-9b0a467/">Shriram Raghunathan</a>, a neuroengineering pioneer and CEO of <a href="https://noctrixhealth.com/">Noctrix Health</a>.</p><p><br>Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.</p><p>In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/shriram-raghunathan-noctrix-health">link to the full interview with Shriram</a> if you prefer reading.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shriram-raghunathan-ph-d-9b0a467/">Shriram Raghunathan</a>, a neuroengineering pioneer and CEO of <a href="https://noctrixhealth.com/">Noctrix Health</a>.</p><p><br>Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.</p><p>In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/shriram-raghunathan-noctrix-health">link to the full interview with Shriram</a> if you prefer reading.</p>]]>
      </content:encoded>
      <pubDate>Wed, 09 Aug 2023 15:04:48 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/cae9f74d/9cd5e098.mp3" length="67699358" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/0ce-fG_uq4NTI_ZP3c6wnOO7xWuc5MaBo88y-9jYFCI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0NDY5MDcv/MTY5MTA5MDMzOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2819</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/shriram-raghunathan-ph-d-9b0a467/">Shriram Raghunathan</a>, a neuroengineering pioneer and CEO of <a href="https://noctrixhealth.com/">Noctrix Health</a>.</p><p><br>Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.</p><p>In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/shriram-raghunathan-noctrix-health">link to the full interview with Shriram</a> if you prefer reading.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Seizing Unexpected Medtech Opportunities: Interview with Ablative Solutions CEO Kate Rumrill</title>
      <itunes:title>Seizing Unexpected Medtech Opportunities: Interview with Ablative Solutions CEO Kate Rumrill</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5ebb2bad-56ed-44e7-b7c6-4259526eee11</guid>
      <link>https://medsider.com/interviews/kate-rumrill-ablative-solutions</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krumrill/">Kate Rumrill</a>, CEO of <a href="https://ablativesolutions.com/">Ablative Solutions</a>, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.</p><p><br>Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.</p><p><br>Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.</p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/kate-rumrill-ablative-solutions">link to the full interview with Kate</a> if you prefer reading.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krumrill/">Kate Rumrill</a>, CEO of <a href="https://ablativesolutions.com/">Ablative Solutions</a>, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.</p><p><br>Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.</p><p><br>Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.</p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/kate-rumrill-ablative-solutions">link to the full interview with Kate</a> if you prefer reading.</p>]]>
      </content:encoded>
      <pubDate>Wed, 02 Aug 2023 20:37:40 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/66a35ba0/e53e61ca.mp3" length="70717674" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/zUbuosWqOhiX71dzg02o8oosyXtkOiHF6W52PhOGnE8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0MzU5NDQv/MTY5MDU3MjgxMC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2945</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/krumrill/">Kate Rumrill</a>, CEO of <a href="https://ablativesolutions.com/">Ablative Solutions</a>, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.</p><p><br>Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.</p><p><br>Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.</p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/kate-rumrill-ablative-solutions">link to the full interview with Kate</a> if you prefer reading.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Defying Boundaries in Medtech: Interview with Pixium Vision CEO Lloyd Diamond</title>
      <itunes:title>Defying Boundaries in Medtech: Interview with Pixium Vision CEO Lloyd Diamond</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">d58e4f9b-a77f-4b92-8d0b-fd82a3f54016</guid>
      <link>https://medsider.com/interviews/lloyd-diamond-pixium-vision</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-diamond-591abb5/">Lloyd Diamond,</a> CEO of <a href="https://www.pixium-vision.com/">Pixium Vision</a> a company that is developing a groundbreaking retinal implant system for patients suffering from advanced dry age-related macular degeneration (dry AMD).</p><p><br>Lloyd has a rich history of guiding medtech and biotech companies. His career spans decades, continents, and sectors, and he has been actively involved in both European and American markets. His experiences with large strategic firms and promising startups have equipped him with a unique entrepreneurial viewpoint. </p><p>In this interview, Lloyd shares practical lessons on building a lean and adaptable team, navigating the intricacies of regulatory processes, and succeeding at strategic fundraising. His insights, drawn from hands-on experience, provide actionable advice for startups making their way in the challenging medtech landscape.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-diamond-pixium-vision">link to the full interview with Lloyd</a> if you prefer reading.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-diamond-591abb5/">Lloyd Diamond,</a> CEO of <a href="https://www.pixium-vision.com/">Pixium Vision</a> a company that is developing a groundbreaking retinal implant system for patients suffering from advanced dry age-related macular degeneration (dry AMD).</p><p><br>Lloyd has a rich history of guiding medtech and biotech companies. His career spans decades, continents, and sectors, and he has been actively involved in both European and American markets. His experiences with large strategic firms and promising startups have equipped him with a unique entrepreneurial viewpoint. </p><p>In this interview, Lloyd shares practical lessons on building a lean and adaptable team, navigating the intricacies of regulatory processes, and succeeding at strategic fundraising. His insights, drawn from hands-on experience, provide actionable advice for startups making their way in the challenging medtech landscape.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-diamond-pixium-vision">link to the full interview with Lloyd</a> if you prefer reading.</p>]]>
      </content:encoded>
      <pubDate>Tue, 25 Jul 2023 18:44:58 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9cbe0dd9/14e4818b.mp3" length="67039771" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/CsqPGUQpUAD5TwJBJAlS_HDXQECbvqcVbezt_qGMcvU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0MzEyNjAv/MTY5MDI1MjMzMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2792</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-diamond-591abb5/">Lloyd Diamond,</a> CEO of <a href="https://www.pixium-vision.com/">Pixium Vision</a> a company that is developing a groundbreaking retinal implant system for patients suffering from advanced dry age-related macular degeneration (dry AMD).</p><p><br>Lloyd has a rich history of guiding medtech and biotech companies. His career spans decades, continents, and sectors, and he has been actively involved in both European and American markets. His experiences with large strategic firms and promising startups have equipped him with a unique entrepreneurial viewpoint. </p><p>In this interview, Lloyd shares practical lessons on building a lean and adaptable team, navigating the intricacies of regulatory processes, and succeeding at strategic fundraising. His insights, drawn from hands-on experience, provide actionable advice for startups making their way in the challenging medtech landscape.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-diamond-pixium-vision">link to the full interview with Lloyd</a> if you prefer reading.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Funding a Medtech Startup in Uncertain Times: Interview with NovaScan CEO Craig Davis</title>
      <itunes:title>Funding a Medtech Startup in Uncertain Times: Interview with NovaScan CEO Craig Davis</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b5a3d563-d384-4d35-a5ee-1ebf051cc713</guid>
      <link>https://medsider.com/interviews/craig-davis-novascan</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/craig-davis-4023a/">Craig Davis</a>, CEO of <a href="https://novascaninc.com/">NovaScan</a>, a company revolutionizing cancer diagnostics with a low-cost, single-use device capable of real-time cancer detection and stratification.</p><p><br>Craig is a strategist, entrepreneur, and leader with a resume boasting a unique blend of business acumen, investment insight, and technical expertise. </p><p><br></p><p>In this interview, Craig unveils his journey from being a partner at LaSalle Investments to leading the charge in revolutionizing cancer diagnostics. He delves into the myriad of challenges entrepreneurs face, like fostering efficient early-stage development, designing clinical trials for rapid data collection, and mastering the art of fundraising in an ever-evolving financial landscape. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/craig-davis-novascan">full interview with Craig Davis.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/craig-davis-4023a/">Craig Davis</a>, CEO of <a href="https://novascaninc.com/">NovaScan</a>, a company revolutionizing cancer diagnostics with a low-cost, single-use device capable of real-time cancer detection and stratification.</p><p><br>Craig is a strategist, entrepreneur, and leader with a resume boasting a unique blend of business acumen, investment insight, and technical expertise. </p><p><br></p><p>In this interview, Craig unveils his journey from being a partner at LaSalle Investments to leading the charge in revolutionizing cancer diagnostics. He delves into the myriad of challenges entrepreneurs face, like fostering efficient early-stage development, designing clinical trials for rapid data collection, and mastering the art of fundraising in an ever-evolving financial landscape. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/craig-davis-novascan">full interview with Craig Davis.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 20 Jul 2023 20:16:47 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0d064acd/5e84befa.mp3" length="63954734" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/VORk8hX7tDalMqdtNDelr0WSzqyWx4c_qz7N30bgbro/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0MjU5NDEv/MTY4OTgwODYwMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2663</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/craig-davis-4023a/">Craig Davis</a>, CEO of <a href="https://novascaninc.com/">NovaScan</a>, a company revolutionizing cancer diagnostics with a low-cost, single-use device capable of real-time cancer detection and stratification.</p><p><br>Craig is a strategist, entrepreneur, and leader with a resume boasting a unique blend of business acumen, investment insight, and technical expertise. </p><p><br></p><p>In this interview, Craig unveils his journey from being a partner at LaSalle Investments to leading the charge in revolutionizing cancer diagnostics. He delves into the myriad of challenges entrepreneurs face, like fostering efficient early-stage development, designing clinical trials for rapid data collection, and mastering the art of fundraising in an ever-evolving financial landscape. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/craig-davis-novascan">full interview with Craig Davis.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Shaping the Future of Mental Health: Interview with Magnus Medical Co-Founder Brett Wingeier</title>
      <itunes:title>Shaping the Future of Mental Health: Interview with Magnus Medical Co-Founder Brett Wingeier</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">1bb4e81f-f821-47b1-9679-ec3b4a29e2ac</guid>
      <link>https://medsider.com/interviews/brett-wingeier-magnus-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/wingeier/">Brett Wingeier</a>, co-founder and CTO of<a href="https://www.magnusmed.com/"> Magnus Medical</a>, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. </p><p><br>Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded<a href="https://www.haloneuro.com/"> Halo Neuroscience</a>. </p><p><br></p><p>In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/brett-wingeier-magnus-medical">full interview with Brett.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/wingeier/">Brett Wingeier</a>, co-founder and CTO of<a href="https://www.magnusmed.com/"> Magnus Medical</a>, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. </p><p><br>Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded<a href="https://www.haloneuro.com/"> Halo Neuroscience</a>. </p><p><br></p><p>In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/brett-wingeier-magnus-medical">full interview with Brett.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 13 Jul 2023 17:36:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7282dc7b/66ecef29.mp3" length="68532905" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/B9vAAY5nObPIzCFS6SW4HeJmEna2iz5E3mdhZJK551w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0MTc3MzUv/MTY4OTE5NTI1OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2854</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/wingeier/">Brett Wingeier</a>, co-founder and CTO of<a href="https://www.magnusmed.com/"> Magnus Medical</a>, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. </p><p><br>Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded<a href="https://www.haloneuro.com/"> Halo Neuroscience</a>. </p><p><br></p><p>In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/brett-wingeier-magnus-medical">full interview with Brett.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Failing Forward in Medtech: Interview with Mara McFadden, CEO of Endolumik</title>
      <itunes:title>Failing Forward in Medtech: Interview with Mara McFadden, CEO of Endolumik</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5b4a025e-af02-43cc-9e08-20032799f972</guid>
      <link>https://medsider.com/interviews/mara-mcfadden-endolumik</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/maramcfadden/">Mara McFadden</a> CEO of <a href="https://endolumik.com/">Endolumik</a><a href="https://shoulderinnovations.com/">,</a> developers of an innovative fluorescence-guided esophagogastric calibration system. </p><p><br>Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson &amp; Johnson and Philips Healthcare. </p><p>Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/mara-mcfadden-endolumik">full interview with Mara McFadden.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/maramcfadden/">Mara McFadden</a> CEO of <a href="https://endolumik.com/">Endolumik</a><a href="https://shoulderinnovations.com/">,</a> developers of an innovative fluorescence-guided esophagogastric calibration system. </p><p><br>Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson &amp; Johnson and Philips Healthcare. </p><p>Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/mara-mcfadden-endolumik">full interview with Mara McFadden.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 05 Jul 2023 17:35:25 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9ecb721c/3012f725.mp3" length="72823310" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/CdOkZNbx3tMJS_Yyk8dQJTngtkE9fZMY7bx489L332E/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE0MDI2NTYv/MTY4ODA2Njk0MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3032</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/maramcfadden/">Mara McFadden</a> CEO of <a href="https://endolumik.com/">Endolumik</a><a href="https://shoulderinnovations.com/">,</a> developers of an innovative fluorescence-guided esophagogastric calibration system. </p><p><br>Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson &amp; Johnson and Philips Healthcare. </p><p>Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/mara-mcfadden-endolumik">full interview with Mara McFadden.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Recruiting Top Players Sets the Stage for Medtech Success: Interview with Joe Rafferty, CEO of Vesteck</title>
      <itunes:title>How Recruiting Top Players Sets the Stage for Medtech Success: Interview with Joe Rafferty, CEO of Vesteck</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b89036f8-0cda-41d4-addd-c4b58f50a780</guid>
      <link>https://medsider.com/interviews/joe-rafferty-vesteck</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joseph-w-rafferty-a5579b4/">Joe Rafferty </a>CEO of <a href="https://www.vesteck.com/">Vesteck</a><a href="https://shoulderinnovations.com/">,</a> a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.</p><p><br>Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/joe-rafferty-vesteck">full interview with Joe Rafferty.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joseph-w-rafferty-a5579b4/">Joe Rafferty </a>CEO of <a href="https://www.vesteck.com/">Vesteck</a><a href="https://shoulderinnovations.com/">,</a> a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.</p><p><br>Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/joe-rafferty-vesteck">full interview with Joe Rafferty.</a></p>]]>
      </content:encoded>
      <pubDate>Mon, 26 Jun 2023 16:17:03 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7bd9735b/64ca4921.mp3" length="75327451" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/uD6HBl7kxN4zP28p_MylXt0ShQX2hoXChEl6LOeO_uc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzOTYxMzUv/MTY4NzU1MTU2OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3137</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/joseph-w-rafferty-a5579b4/">Joe Rafferty </a>CEO of <a href="https://www.vesteck.com/">Vesteck</a><a href="https://shoulderinnovations.com/">,</a> a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.</p><p><br>Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/joe-rafferty-vesteck">full interview with Joe Rafferty.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title> Bridging the Gap Between Clinical Trials and Commercial Success: Interview With Rob Ball, CEO of Shoulder Innovations</title>
      <itunes:title> Bridging the Gap Between Clinical Trials and Commercial Success: Interview With Rob Ball, CEO of Shoulder Innovations</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b7532809-98ef-4d39-b08c-edfa83cc244a</guid>
      <link>https://medsider.com/interviews/rob-ball-shoulder-innovations</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rob-ball-7281aaa/">Rob Ball </a>CEO of <a href="https://shoulderinnovations.com/">Shoulder Innovations,</a> a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.</p><p><br>Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years. </p><p>In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/rob-ball-shoulder-innovations"> full interview with Rob Ball.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rob-ball-7281aaa/">Rob Ball </a>CEO of <a href="https://shoulderinnovations.com/">Shoulder Innovations,</a> a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.</p><p><br>Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years. </p><p>In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/rob-ball-shoulder-innovations"> full interview with Rob Ball.</a></p>]]>
      </content:encoded>
      <pubDate>Mon, 19 Jun 2023 21:06:12 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0aa44cc7/f0a35483.mp3" length="64149554" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/BpTLn1gfgkVKPp53DeX9c8RqLQxcWa8rNkiNjA3qxA4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzODg4NjAv/MTY4NzIwMDM5Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2671</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/rob-ball-7281aaa/">Rob Ball </a>CEO of <a href="https://shoulderinnovations.com/">Shoulder Innovations,</a> a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.</p><p><br>Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years. </p><p>In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/rob-ball-shoulder-innovations"> full interview with Rob Ball.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>What it Takes to Bring a Medical Device to Market: Interview with Tim Blair, CEO of ICHOR</title>
      <itunes:title>What it Takes to Bring a Medical Device to Market: Interview with Tim Blair, CEO of ICHOR</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">5eb88be9-697c-49fa-b5ff-c2dde0f3d76b</guid>
      <link>https://medsider.com/interviews/tim-blair-ichor</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timothyscottblair/">Tim Blair,</a> CEO of <a href="https://ichorvascular.com/">ICHOR,</a> an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.</p><p><br>With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/tim-blair-ichor">full interview with Tim Blair.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timothyscottblair/">Tim Blair,</a> CEO of <a href="https://ichorvascular.com/">ICHOR,</a> an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.</p><p><br>With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/tim-blair-ichor">full interview with Tim Blair.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 13 Jun 2023 02:55:35 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d698baab/e072871a.mp3" length="153817185" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/45yColECp0rvTSsCORgNZLWMVa8T61__28yrKrX3M4E/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzNzY2Mzkv/MTY4NjI2NjE2OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3839</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/timothyscottblair/">Tim Blair,</a> CEO of <a href="https://ichorvascular.com/">ICHOR,</a> an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.</p><p><br>With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/tim-blair-ichor">full interview with Tim Blair.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Aligning Mutual Interests to Build Long-Term Partnerships: Interview with Alio CEO Dave Kuraguntla</title>
      <itunes:title>Aligning Mutual Interests to Build Long-Term Partnerships: Interview with Alio CEO Dave Kuraguntla</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">7d10c400-ee7e-4948-8d9b-9d2fc9c4f348</guid>
      <link>https://medsider.com/interviews/dave-kuraguntla-alio</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/davidkuraguntla/"> Dave Kuraguntla</a>, co-founder and CEO of <a href="https://alio.ai/">Alio</a>, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. </p><p><br>Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/dave-kuraguntla-alio">full interview with Dave Kuraguntla.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/davidkuraguntla/"> Dave Kuraguntla</a>, co-founder and CEO of <a href="https://alio.ai/">Alio</a>, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. </p><p><br>Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/dave-kuraguntla-alio">full interview with Dave Kuraguntla.</a></p>]]>
      </content:encoded>
      <pubDate>Sun, 04 Jun 2023 02:45:30 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e702ad70/6c25f67d.mp3" length="140033271" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/4Aj8b8xYz3Z1YID7Hz8QphgusyTACl5eBOEtGK5t1fk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzNTkyMjcv/MTY4NTQwMDQ2NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3494</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with<a href="https://www.linkedin.com/in/davidkuraguntla/"> Dave Kuraguntla</a>, co-founder and CEO of <a href="https://alio.ai/">Alio</a>, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. </p><p><br>Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/dave-kuraguntla-alio">full interview with Dave Kuraguntla.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>An Unorthodox Path to Medical Device Success: Interview with Cresilon CEO Joe Landolina</title>
      <itunes:title>An Unorthodox Path to Medical Device Success: Interview with Cresilon CEO Joe Landolina</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">205fb0d0-111c-4d52-8db9-62a4d85685b6</guid>
      <link>https://medsider.com/interviews/joe-landolina-cresilon</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jlandolina/">Joe Landolina</a>, co-founder and CEO of <a href="https://cresilon.com/">Cresilon</a>, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.</p><p><br>Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.</p><p><br></p><p>In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/joe-landolina-cresilon"> full interview with Joe Landolina.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jlandolina/">Joe Landolina</a>, co-founder and CEO of <a href="https://cresilon.com/">Cresilon</a>, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.</p><p><br>Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.</p><p><br></p><p>In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/joe-landolina-cresilon"> full interview with Joe Landolina.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 24 May 2023 22:33:33 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/027d3c3e/697114e0.mp3" length="137838761" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/bY4zySST14RxI0Wu1bIyLm207tovGdGvpDcj1pMY4HA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzNDk0NjAv/MTY4NDgwNzQ3NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3439</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jlandolina/">Joe Landolina</a>, co-founder and CEO of <a href="https://cresilon.com/">Cresilon</a>, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.</p><p><br>Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.</p><p><br></p><p>In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the<a href="https://medsider.com/interviews/joe-landolina-cresilon"> full interview with Joe Landolina.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Tried-and-True Recipes for Success: Interview with IRRAS CEO Will Martin</title>
      <itunes:title>Tried-and-True Recipes for Success: Interview with IRRAS CEO Will Martin</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">340de740-2d2b-40f0-95e2-cd575d968df7</guid>
      <link>https://medsider.com/interviews/will-martin-irras</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/will-martin-01b3105/">Will Martin</a>, CEO of <a href="https://irras.com/">IRRAS</a>, a company revolutionizing the treatment of intracranial bleeding.</p><p><br>Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.</p><p><br></p><p>In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/will-martin-irras">full interview with Will Martin.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/will-martin-01b3105/">Will Martin</a>, CEO of <a href="https://irras.com/">IRRAS</a>, a company revolutionizing the treatment of intracranial bleeding.</p><p><br>Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.</p><p><br></p><p>In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/will-martin-irras">full interview with Will Martin.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 17 May 2023 03:21:32 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/53301403/cdd48793.mp3" length="140949248" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/vSBJNBAC-ZCvS_vo1epB1Qd3LlfpeD4CnoTXtMT2IDY/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzMzg3MjIv/MTY4NDE5NTIxNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3523</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/will-martin-01b3105/">Will Martin</a>, CEO of <a href="https://irras.com/">IRRAS</a>, a company revolutionizing the treatment of intracranial bleeding.</p><p><br>Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.</p><p><br></p><p>In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/will-martin-irras">full interview with Will Martin.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Cultivating a Culture of Continuous Learning and Improvement: Interview with Biotricity CEO Waqaas Al-Siddiq</title>
      <itunes:title>Cultivating a Culture of Continuous Learning and Improvement: Interview with Biotricity CEO Waqaas Al-Siddiq</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">05e779df-184d-4c29-ab0a-c56fdd1888e7</guid>
      <link>https://medsider.com/interviews/waqaas-alsiddiq-biotricity</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dr-waqaas-al-siddiq-dba-5a0b682/">Waqaas Al-Siddiq</a>, CEO of <a href="https://www.biotricity.com">Biotrocity</a>, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. </p><p><br>Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.</p><p><br>In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/waqaas-alsiddiq-biotricity">full interview with Waqaas.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dr-waqaas-al-siddiq-dba-5a0b682/">Waqaas Al-Siddiq</a>, CEO of <a href="https://www.biotricity.com">Biotrocity</a>, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. </p><p><br>Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.</p><p><br>In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/waqaas-alsiddiq-biotricity">full interview with Waqaas.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 04 May 2023 12:36:39 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4e28c5bf/8d4b22d1.mp3" length="139469531" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/RgjrmvlpdSaS4Vj9hW0mySy2cpATXkyTkRSAmB6TG1I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzMTczNTcv/MTY4MzA0ODU0Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3480</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/dr-waqaas-al-siddiq-dba-5a0b682/">Waqaas Al-Siddiq</a>, CEO of <a href="https://www.biotricity.com">Biotrocity</a>, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. </p><p><br>Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.</p><p><br>In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/waqaas-alsiddiq-biotricity">full interview with Waqaas.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Bridging the Gaps as a Startup Medtech CEO: Interview with Cagent Vascular CEO Carol Burns</title>
      <itunes:title>Bridging the Gaps as a Startup Medtech CEO: Interview with Cagent Vascular CEO Carol Burns</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ee2ff40c-cd63-4bf1-bf03-efc1d7c27294</guid>
      <link>https://medsider.com/interviews/carol-burns-cagent-vascular</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/carol-burns-339428/">Carol Burns</a>, CEO of <a href="https://cagentvascular.com/">Cagent Vascular</a>, a medical device company focused on developing and commercializing an innovative angioplasty balloon called the Serenator.</p><p>Carol is a seasoned CEO and serial entrepreneur with a passion for cardiovascular devices. Her tireless energy and proven track record have enabled Carol to excel in all phases of medical device development, from early-stage proof of concept to eventual commercialization. Carol thrives in the fast-paced startup world, leveraging her industry relationships and clinical knowledge to identify technologies with the highest potential for success.</p><p><br></p><p>In this interview, Carol highlights the importance of establishing the right team to lay the proper foundation for your medtech startup. We further discuss how to prioritize essential product features and their clinical applications for future growth, as well as overcoming fundraising challenges through effective networking. She also highlights the importance of listening to study investigators and designing strategic clinical trials to generate valuable data and drive success.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to<a href="https://medsider.com/interviews/carol-burns-cagent-vascular"> the full interview with Carol Burns.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/carol-burns-339428/">Carol Burns</a>, CEO of <a href="https://cagentvascular.com/">Cagent Vascular</a>, a medical device company focused on developing and commercializing an innovative angioplasty balloon called the Serenator.</p><p>Carol is a seasoned CEO and serial entrepreneur with a passion for cardiovascular devices. Her tireless energy and proven track record have enabled Carol to excel in all phases of medical device development, from early-stage proof of concept to eventual commercialization. Carol thrives in the fast-paced startup world, leveraging her industry relationships and clinical knowledge to identify technologies with the highest potential for success.</p><p><br></p><p>In this interview, Carol highlights the importance of establishing the right team to lay the proper foundation for your medtech startup. We further discuss how to prioritize essential product features and their clinical applications for future growth, as well as overcoming fundraising challenges through effective networking. She also highlights the importance of listening to study investigators and designing strategic clinical trials to generate valuable data and drive success.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to<a href="https://medsider.com/interviews/carol-burns-cagent-vascular"> the full interview with Carol Burns.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Apr 2023 19:28:12 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/dcace45e/19180277.mp3" length="116332808" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/XGkL08cMlgXQAta1L1MUEmgZo1SR51wYqSD8QrVlC2M/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEzMDY4Njgv/MTY4MjQ1MzExMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2908</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/carol-burns-339428/">Carol Burns</a>, CEO of <a href="https://cagentvascular.com/">Cagent Vascular</a>, a medical device company focused on developing and commercializing an innovative angioplasty balloon called the Serenator.</p><p>Carol is a seasoned CEO and serial entrepreneur with a passion for cardiovascular devices. Her tireless energy and proven track record have enabled Carol to excel in all phases of medical device development, from early-stage proof of concept to eventual commercialization. Carol thrives in the fast-paced startup world, leveraging her industry relationships and clinical knowledge to identify technologies with the highest potential for success.</p><p><br></p><p>In this interview, Carol highlights the importance of establishing the right team to lay the proper foundation for your medtech startup. We further discuss how to prioritize essential product features and their clinical applications for future growth, as well as overcoming fundraising challenges through effective networking. She also highlights the importance of listening to study investigators and designing strategic clinical trials to generate valuable data and drive success.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to<a href="https://medsider.com/interviews/carol-burns-cagent-vascular"> the full interview with Carol Burns.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Listen to What the Market is Saying: Interview with CurvaFix CEO Steve Dimmer </title>
      <itunes:title>How to Listen to What the Market is Saying: Interview with CurvaFix CEO Steve Dimmer </itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c4238277-19b8-4a47-9470-ef31fe522e26</guid>
      <link>https://medsider.com/interviews/steve-dimmer-curvafix</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steve-dimmer/">Steve Dimmer</a>, CEO of <a href="https://curvafix.com/">CurvaFix</a>, a medical device company focused on developing innovative solutions for orthopedic procedures.</p><p> <br>Steve holds a Bachelor of Science in Electrical Engineering from San Diego State University and a Master’s in Business Administration from the University of Washington. He has over 30 years of experience building medtech companies, including multiple start-ups and stints at several large multinationals.</p><p><br>In this interview, Steve highlights the importance of mitigating risk and pitching to investors early in the development process. He also provides valuable advice on designing clinical trials that meet specific goals based on his own experiences at CurvaFix. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/steve-dimmer-curvafix">full interview with Steve Dimmer.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steve-dimmer/">Steve Dimmer</a>, CEO of <a href="https://curvafix.com/">CurvaFix</a>, a medical device company focused on developing innovative solutions for orthopedic procedures.</p><p> <br>Steve holds a Bachelor of Science in Electrical Engineering from San Diego State University and a Master’s in Business Administration from the University of Washington. He has over 30 years of experience building medtech companies, including multiple start-ups and stints at several large multinationals.</p><p><br>In this interview, Steve highlights the importance of mitigating risk and pitching to investors early in the development process. He also provides valuable advice on designing clinical trials that meet specific goals based on his own experiences at CurvaFix. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/steve-dimmer-curvafix">full interview with Steve Dimmer.</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 18 Apr 2023 17:23:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ac0ec3a8/68f22777.mp3" length="142469939" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dNoFVcJMIGitq0QmbZc5aTn8uAP8_8Cca97TKRl4myY/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyOTIyMDMv/MTY4MTc1MTcyNy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3555</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/steve-dimmer/">Steve Dimmer</a>, CEO of <a href="https://curvafix.com/">CurvaFix</a>, a medical device company focused on developing innovative solutions for orthopedic procedures.</p><p> <br>Steve holds a Bachelor of Science in Electrical Engineering from San Diego State University and a Master’s in Business Administration from the University of Washington. He has over 30 years of experience building medtech companies, including multiple start-ups and stints at several large multinationals.</p><p><br>In this interview, Steve highlights the importance of mitigating risk and pitching to investors early in the development process. He also provides valuable advice on designing clinical trials that meet specific goals based on his own experiences at CurvaFix. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, if you'd rather read than listen, here's a link to the <a href="https://medsider.com/interviews/steve-dimmer-curvafix">full interview with Steve Dimmer.</a></p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Be Resilient as a Startup Medtech CEO: Interview with Aqua Medical CEO Lloyd Mencinger</title>
      <itunes:title>How to Be Resilient as a Startup Medtech CEO: Interview with Aqua Medical CEO Lloyd Mencinger</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">88c718bc-6994-4dec-a8e2-0cd418ce3f87</guid>
      <link>https://medsider.com/interviews/lloyd-mencinger-aqua-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-mencinger-b588673/">Lloyd Mencinger</a>, CEO of<a href="https://reflexion.com/"> </a><a href="https://aquaendoscopy.com/">Aqua Medical</a>, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. </p><p> <br>Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. </p><p><br>In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-mencinger-aqua-medical">link to the full interview</a> with Lloyd if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-mencinger-b588673/">Lloyd Mencinger</a>, CEO of<a href="https://reflexion.com/"> </a><a href="https://aquaendoscopy.com/">Aqua Medical</a>, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. </p><p> <br>Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. </p><p><br>In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-mencinger-aqua-medical">link to the full interview</a> with Lloyd if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 12 Apr 2023 16:13:02 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c270c5b1/8ac79af1.mp3" length="144124697" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/cU5CiaHISSmVJrKOeI-pEXLJnVSkFOLdaC_1JJ1dG3U/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyODU0MzEv/MTY4MTI2MDM2NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3596</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/lloyd-mencinger-b588673/">Lloyd Mencinger</a>, CEO of<a href="https://reflexion.com/"> </a><a href="https://aquaendoscopy.com/">Aqua Medical</a>, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. </p><p> <br>Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. </p><p><br>In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/lloyd-mencinger-aqua-medical">link to the full interview</a> with Lloyd if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Early Risk Retirement is the Best Investment You Can Make: Interview with Dr. Sam Mazin, co-founder and CTO of RefleXion Medical</title>
      <itunes:title>Why Early Risk Retirement is the Best Investment You Can Make: Interview with Dr. Sam Mazin, co-founder and CTO of RefleXion Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">4b36812e-6d6a-4c6f-8238-a02c2a59641c</guid>
      <link>https://medsider.com/interviews/sam-mazin-reflexion</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/samuelmazin/">Dr. Sam Mazin</a>, CEO of<a href="https://reflexion.com/"> RefleXion,</a> a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy.</p><p> <br>Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. </p><p><br></p><p>In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/sam-mazin-reflexion">link to the full interview</a> with Sam if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/samuelmazin/">Dr. Sam Mazin</a>, CEO of<a href="https://reflexion.com/"> RefleXion,</a> a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy.</p><p> <br>Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. </p><p><br></p><p>In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/sam-mazin-reflexion">link to the full interview</a> with Sam if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 05 Apr 2023 18:02:40 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/1620a102/449fbc73.mp3" length="120273551" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/LSbyLJxy4hEGKpVsNiuRrmFlpOluoE7tBmCHJLz2gY8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyNzUxMTgv/MTY4MDU3MDkxMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3000</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/samuelmazin/">Dr. Sam Mazin</a>, CEO of<a href="https://reflexion.com/"> RefleXion,</a> a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy.</p><p> <br>Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. </p><p><br></p><p>In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/sam-mazin-reflexion">link to the full interview</a> with Sam if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The 3 Pillars of a Successful Medical Device Startup: Interview With Clarius CEO Ohad Arazi</title>
      <itunes:title>The 3 Pillars of a Successful Medical Device Startup: Interview With Clarius CEO Ohad Arazi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">254019e7-7599-4b63-88f3-7baad8f598ee</guid>
      <link>https://medsider.com/interviews/ohad-arazi-clarius</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ohad-arazi-44492293/">Dr. Ohad Arazi</a>, CEO of <a href="https://www.clarius.com/">Clarius</a>, a leading provider of high-definition wireless ultrasound systems. </p><p>With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.</p><p>In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/ohad-arazi-clarius">link to the full interview</a> with Ohad if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ohad-arazi-44492293/">Dr. Ohad Arazi</a>, CEO of <a href="https://www.clarius.com/">Clarius</a>, a leading provider of high-definition wireless ultrasound systems. </p><p>With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.</p><p>In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/ohad-arazi-clarius">link to the full interview</a> with Ohad if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 22 Mar 2023 20:00:07 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d7b836d5/e23b1397.mp3" length="116013949" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/QfK02YjZJjKBHn3ggmJjvdzArFXORPeV2cX18ajXhHM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyNTc1NzIv/MTY3OTQyMzg1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2894</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/ohad-arazi-44492293/">Dr. Ohad Arazi</a>, CEO of <a href="https://www.clarius.com/">Clarius</a>, a leading provider of high-definition wireless ultrasound systems. </p><p>With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.</p><p>In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/ohad-arazi-clarius">link to the full interview</a> with Ohad if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Align Goals in an Interconnected Healthcare Ecosystem: Interview with Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics</title>
      <itunes:title>How to Align Goals in an Interconnected Healthcare Ecosystem: Interview with Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">dfbc5a29-67f4-4329-9827-8553c6bf730f</guid>
      <link>https://medsider.com/interviews/meesha-dogan-cardio-diagnostics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/meeshadogan/">Dr. Meesha Dogan</a>, co-founder and CEO of <a href="https://cardiodiagnosticsinc.com/">Cardio Diagnostics</a>.</p><p>Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. </p><p><br></p><p>In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/meesha-dogan-cardio-diagnostics">link to the full interview</a> with Meesha if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/meeshadogan/">Dr. Meesha Dogan</a>, co-founder and CEO of <a href="https://cardiodiagnosticsinc.com/">Cardio Diagnostics</a>.</p><p>Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. </p><p><br></p><p>In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/meesha-dogan-cardio-diagnostics">link to the full interview</a> with Meesha if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 15 Mar 2023 20:14:31 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c832a223/2e14af2b.mp3" length="117922467" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/_y3d1Qrd4xn0XLfxMehJwDUrWnC9r4RKln64gPiS_iM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyNDQ5Mjgv/MTY3ODc1MDM1NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2941</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/meeshadogan/">Dr. Meesha Dogan</a>, co-founder and CEO of <a href="https://cardiodiagnosticsinc.com/">Cardio Diagnostics</a>.</p><p>Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. </p><p><br></p><p>In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. </p><p><br>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/meesha-dogan-cardio-diagnostics">link to the full interview</a> with Meesha if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Early-Stage Technical Risk Reduction is Crucial for Medical Device Startups: Interview with Diality CEO Osman Khawar</title>
      <itunes:title>Why Early-Stage Technical Risk Reduction is Crucial for Medical Device Startups: Interview with Diality CEO Osman Khawar</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">e86fd4fc-79c8-4998-9abf-5635d42227e8</guid>
      <link>https://medsider.com/interviews/osman-khawar-diality</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/osman-khawar-73b687b2/">Osman Khawar</a> CEO of <a href="https://www.diality.com/">Diality</a>.</p><p>After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. </p><p><br>In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/osman-khawar-diality">link to the full interview</a> with Osman if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/osman-khawar-73b687b2/">Osman Khawar</a> CEO of <a href="https://www.diality.com/">Diality</a>.</p><p>After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. </p><p><br>In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/osman-khawar-diality">link to the full interview</a> with Osman if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 08 Mar 2023 17:27:16 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a7f54863/41a130d1.mp3" length="104683475" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ljb0DNBqAz-SVlnDu0XN8vTZ8P9SnMGn9YRGr2ROXh4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyMzc0NDAv/MTY3ODIzODEzNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2610</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/osman-khawar-73b687b2/">Osman Khawar</a> CEO of <a href="https://www.diality.com/">Diality</a>.</p><p>After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. </p><p><br>In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/osman-khawar-diality">link to the full interview</a> with Osman if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Build a Successful DTC Healthtech Company: Interview with Nutrisense Co-Founder Dan Zavorotny</title>
      <itunes:title>How to Build a Successful DTC Healthtech Company: Interview with Nutrisense Co-Founder Dan Zavorotny</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">00b9f4bf-094b-4536-bdee-92fb90f828e3</guid>
      <link>https://medsider.com/interviews/dan-zavorotny-nutrisense</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/danzav/">Dan Zavorotny</a>, co-founder of <a href="https://www.nutrisense.io/">Nutrisense</a></p><p>Before co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. </p><p><br></p><p>In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/dan-zavorotny-nutrisense">link to the full interview</a> with Dan if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/danzav/">Dan Zavorotny</a>, co-founder of <a href="https://www.nutrisense.io/">Nutrisense</a></p><p>Before co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. </p><p><br></p><p>In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/dan-zavorotny-nutrisense">link to the full interview</a> with Dan if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 27 Feb 2023 21:59:07 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8de2ea24/2cfde444.mp3" length="150822995" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/d7sowWYu8ZD0w-LOzPJLI_RE85GGNtXMyqJ9hbxCbjo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEyMTU2OTMv/MTY3Njk5NjI2My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3764</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/danzav/">Dan Zavorotny</a>, co-founder of <a href="https://www.nutrisense.io/">Nutrisense</a></p><p>Before co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. </p><p><br></p><p>In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/dan-zavorotny-nutrisense">link to the full interview</a> with Dan if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Prevent Your Device From Getting Knocked Off: Interview with PN Medical CEO Mark Carbone</title>
      <itunes:title>How to Prevent Your Device From Getting Knocked Off: Interview with PN Medical CEO Mark Carbone</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">538b19f5-e86c-475a-9e82-057688adf350</guid>
      <link>https://medsider.com/interviews/mark-carbone-pn-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/markacarbone/">Mark Carbone</a>, CEO of <a href="https://www.pnmedical.com/">PN Medical</a>.</p><p>Mark is the CEO of PN Medical, makers of medical devices that help improve pulmonary performance of patients, vocal artists, and professional athletes. Mark used his technology background and entrepreneurial experience to turn PN Medical into a frontrunner in the pulmonary space.</p><p>In this interview, Mark shares crucial lessons on how business leaders should build teams, bring a device to market, and protect the company’s brand.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/mark-carbone-pn-medical">link to the full interview</a> with Mark if you'd rather read the summary instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/markacarbone/">Mark Carbone</a>, CEO of <a href="https://www.pnmedical.com/">PN Medical</a>.</p><p>Mark is the CEO of PN Medical, makers of medical devices that help improve pulmonary performance of patients, vocal artists, and professional athletes. Mark used his technology background and entrepreneurial experience to turn PN Medical into a frontrunner in the pulmonary space.</p><p>In this interview, Mark shares crucial lessons on how business leaders should build teams, bring a device to market, and protect the company’s brand.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/mark-carbone-pn-medical">link to the full interview</a> with Mark if you'd rather read the summary instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 09 Feb 2023 12:51:22 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c68d3224/c770a56f.mp3" length="133304144" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DYr1hXKtvYtcYFeuKdEEVIhMEQwUnrVsVElB7BPuK8c/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExOTYwNTYv/MTY3NTc0MTIyMC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3326</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/markacarbone/">Mark Carbone</a>, CEO of <a href="https://www.pnmedical.com/">PN Medical</a>.</p><p>Mark is the CEO of PN Medical, makers of medical devices that help improve pulmonary performance of patients, vocal artists, and professional athletes. Mark used his technology background and entrepreneurial experience to turn PN Medical into a frontrunner in the pulmonary space.</p><p>In this interview, Mark shares crucial lessons on how business leaders should build teams, bring a device to market, and protect the company’s brand.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's a <a href="https://medsider.com/interviews/mark-carbone-pn-medical">link to the full interview</a> with Mark if you'd rather read the summary instead.</p>]]>
      </itunes:summary>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Innovate or Get Left Behind: Interview With Bright Uro CEO Derek Herrera</title>
      <itunes:title>Innovate or Get Left Behind: Interview With Bright Uro CEO Derek Herrera</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">81acd23b-a34f-4799-aea3-cff9f85a9059</guid>
      <link>https://medsider.com/interviews/derek-herrera-bright-uro</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/derekherrera">Derek Herrera</a>, founder and CEO of <a href="https://brighturo.com">Bright Uro</a>.</p><p>Derek served as an elite Marine officer in the U.S. military before suffering debilitating injuries while in the line of duty. Using his personal experience, he founded UroDev Medical, Habit Camera, and Bright Uro. His latest venture aims to launch an innovative urology device that’s meant to replace an invasive bladder diagnostic test that hasn’t changed in decades. </p><p>In this interview, Derek shares important lessons in driving device innovation, running a medtech startup, and developing products efficiently.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/derek-herrera-bright-uro">link to the full interview</a> with Derek if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/derekherrera">Derek Herrera</a>, founder and CEO of <a href="https://brighturo.com">Bright Uro</a>.</p><p>Derek served as an elite Marine officer in the U.S. military before suffering debilitating injuries while in the line of duty. Using his personal experience, he founded UroDev Medical, Habit Camera, and Bright Uro. His latest venture aims to launch an innovative urology device that’s meant to replace an invasive bladder diagnostic test that hasn’t changed in decades. </p><p>In this interview, Derek shares important lessons in driving device innovation, running a medtech startup, and developing products efficiently.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/derek-herrera-bright-uro">link to the full interview</a> with Derek if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 31 Jan 2023 22:59:07 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/cc640249/0cf3c14c.mp3" length="123330876" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Npx7SSLYPY21poDZ6uYnLj74ohdvu_gvAC9B6i_XT9U/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExODgxMTUv/MTY3NTE5MDQwMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3077</itunes:duration>
      <itunes:summary>Bright Uro Founder and CEO Derek Herrera shares how his personal experience pushed him to champion innovation in the urology space and the ways he’s optimizing his latest medtech venture for efficiency and success.</itunes:summary>
      <itunes:subtitle>Bright Uro Founder and CEO Derek Herrera shares how his personal experience pushed him to champion innovation in the urology space and the ways he’s optimizing his latest medtech venture for efficiency and success.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Power of Storytelling in a Medical Device Startup: Interview with Endiatx CEO Torrey Smith</title>
      <itunes:title>The Power of Storytelling in a Medical Device Startup: Interview with Endiatx CEO Torrey Smith</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">24f2fce3-8c22-4e35-882e-417df0ee7a72</guid>
      <link>https://medsider.com/interviews/torrey-smith-endiatx</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/torreypsmith/">Torrey Smith</a>, co-founder and CEO of <a href="https://endiatx.com/">Endiatx</a>.</p><p>Torrey founded Endiatx alongside fellow Silicon Valley technology experts Dan Moyer, James Erd, and Alex Luebke. After leaving a different medical device company to scratch his entrepreneurial itch, Torrey and his co-founders are developing a new technology that aims to lower the barrier for patients to get diagnosed and treated for gastrointestinal diseases. </p><p>In this interview, Torrey discusses the importance of both in-person and online networking, and best practices for sharing your product development progress with the investment community, stakeholders, and target patients. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/torrey-smith-endiatx">link to the full interview</a> with Torrey if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/torreypsmith/">Torrey Smith</a>, co-founder and CEO of <a href="https://endiatx.com/">Endiatx</a>.</p><p>Torrey founded Endiatx alongside fellow Silicon Valley technology experts Dan Moyer, James Erd, and Alex Luebke. After leaving a different medical device company to scratch his entrepreneurial itch, Torrey and his co-founders are developing a new technology that aims to lower the barrier for patients to get diagnosed and treated for gastrointestinal diseases. </p><p>In this interview, Torrey discusses the importance of both in-person and online networking, and best practices for sharing your product development progress with the investment community, stakeholders, and target patients. </p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/torrey-smith-endiatx">link to the full interview</a> with Torrey if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 26 Jan 2023 17:14:04 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8b655768/3d1d28ca.mp3" length="134290956" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/nMEZAHyy_AuI1qwPKQzKEKpORs-i6DEDXkKTCxIqVP0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExODA5MDMv/MTY3NDc1MjYyNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3351</itunes:duration>
      <itunes:summary>Torrey Smith, CEO of Endiatx, breaks down the unique online networking strategies that helped him connect with venture capitalist investors and influential physicians, plus his company's plans to achieve FDA clearance for the PillBot through a fast-tracked regulatory process.</itunes:summary>
      <itunes:subtitle>Torrey Smith, CEO of Endiatx, breaks down the unique online networking strategies that helped him connect with venture capitalist investors and influential physicians, plus his company's plans to achieve FDA clearance for the PillBot through a fast-tracke</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>First Impressions are Crucial in Medtech: Interview with Retia Medical CEO Marc Zemel</title>
      <itunes:title>First Impressions are Crucial in Medtech: Interview with Retia Medical CEO Marc Zemel</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">13ccbb4e-0917-424b-ad6c-28cbb9a1a995</guid>
      <link>https://medsider.com/interviews/marc-zemel-retia-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marc-zemel-digitalhealth">Marc Zemel</a>, CEO of Retia Medial.</p><p>Marc has extensive experience in fundraising for successful startups and is an experienced leader of Fortune 500 companies. Prior to founding <a href="https://retiamedical.com">Retia Medical</a>, Marc earned an MS in Mechanical Engineering from MIT and an MBA in Sales and Marketing from Yale. He’s also held key leadership roles at Becton Dickinson as well as a capital equipment start-up.</p><p>In this interview, Marc talks about managing a medtech start-up that’s developing groundbreaking technology while pursuing fundraising that drives sustainable growth.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/marc-zemel-retia-medical">link to the full interview</a> with Marc if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/marc-zemel-digitalhealth">Marc Zemel</a>, CEO of Retia Medial.</p><p>Marc has extensive experience in fundraising for successful startups and is an experienced leader of Fortune 500 companies. Prior to founding <a href="https://retiamedical.com">Retia Medical</a>, Marc earned an MS in Mechanical Engineering from MIT and an MBA in Sales and Marketing from Yale. He’s also held key leadership roles at Becton Dickinson as well as a capital equipment start-up.</p><p>In this interview, Marc talks about managing a medtech start-up that’s developing groundbreaking technology while pursuing fundraising that drives sustainable growth.</p><p><br></p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/marc-zemel-retia-medical">link to the full interview</a> with Marc if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 18 Jan 2023 22:27:42 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a24b25a7/cfe6f8d3.mp3" length="120589414" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/UwKqiX-kB2F_QCxcz9SDvcirLRe-MpIOyTEBxEGi5Mc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExNzIwMDAv/MTY3NDA3OTQxOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3008</itunes:duration>
      <itunes:summary>Retia Medical CEO Marc Zemel talks about his experience bringing game-changing software to the medtech industry, why first impressions are critical, and how to ensure you have built-in safety mechanisms during third-party diligence processes.</itunes:summary>
      <itunes:subtitle>Retia Medical CEO Marc Zemel talks about his experience bringing game-changing software to the medtech industry, why first impressions are critical, and how to ensure you have built-in safety mechanisms during third-party diligence processes.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Creative Ways to Market Your Technology While Navigating the Regulatory Landscape: Interview with X-trodes CEO Ziv Peremen</title>
      <itunes:title>Creative Ways to Market Your Technology While Navigating the Regulatory Landscape: Interview with X-trodes CEO Ziv Peremen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ce4f3c86-32ec-4700-981b-a67544ef8904</guid>
      <link>https://medsider.com/interviews/ziv-peremen-xtrodes</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/zivperemen">Ziv Peremen</a>, CEO of X-trodes.</p><p>After completing his PhD in neurocognitive science<strong> </strong>with a specializaton in understanding consciousness,<strong> </strong>Ziv Peremen has spent the past 12 years focused on the intersection of data and physiology. Together with Professor Yael Hanein, an expert in the field of human-machine interface learning and inventor of innovative sensor technology, they founded <a href="https://xtrodes.com">X-trodes</a>.</p><p>In this interview, Ziv discusses his wireless wearable sleep diagnostic technology, commercializing a product before FDA clearance, and how to build the right company infrastructure from the start.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/ziv-peremen-xtrodes">link to the full interview</a> with Ziv if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/zivperemen">Ziv Peremen</a>, CEO of X-trodes.</p><p>After completing his PhD in neurocognitive science<strong> </strong>with a specializaton in understanding consciousness,<strong> </strong>Ziv Peremen has spent the past 12 years focused on the intersection of data and physiology. Together with Professor Yael Hanein, an expert in the field of human-machine interface learning and inventor of innovative sensor technology, they founded <a href="https://xtrodes.com">X-trodes</a>.</p><p>In this interview, Ziv discusses his wireless wearable sleep diagnostic technology, commercializing a product before FDA clearance, and how to build the right company infrastructure from the start.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/ziv-peremen-xtrodes">link to the full interview</a> with Ziv if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 12 Jan 2023 22:34:40 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2f16b2ef/4126d978.mp3" length="120370558" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dtgNJTfHMLPr8so3vReuYD5i3khaF6q0SLBPfQyyjPI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExNjU5ODUv/MTY3MzU2MTU4Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3009</itunes:duration>
      <itunes:summary>Ziv Peremen, CEO of X-trodes, discusses his wireless wearable sleep diagnostic technology, commercializing a product before FDA clearance, and how to build the right company infrastructure from the start.</itunes:summary>
      <itunes:subtitle>Ziv Peremen, CEO of X-trodes, discusses his wireless wearable sleep diagnostic technology, commercializing a product before FDA clearance, and how to build the right company infrastructure from the start.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Marrying Clinical Outcomes with Cost Savings: Interview with Hinge Health President Jim Pursley</title>
      <itunes:title>Marrying Clinical Outcomes with Cost Savings: Interview with Hinge Health President Jim Pursley</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b9cc8413-f722-4982-bb9f-bb582eecbc0b</guid>
      <link>https://medsider.com/interviews/jim-pursley-hinge-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jim-pursley-781b45">Jim Pursley</a>, President of Hinge Health.</p><p>Jim has spent the last decade tackling some of the biggest problems in healthcare. He was part of the founding executive team as the Chief Commercial Officer of Livongo Health, and took the company public, culminating in an $18.5B acquisition by Teladoc Health. Since March 2021,  Jim has been<a href="https://www.hingehealth.com/"> Hinge Health's</a> President. The company is ranked #2 on Crunchbase's Diversity Spotlight Report.</p><p>In this interview, Jim discusses finding the right market, being your own biggest critic, and marrying clinical improvements with cost savings.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/jim-pursley-hinge-health">link to the full interview</a> with Jim if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jim-pursley-781b45">Jim Pursley</a>, President of Hinge Health.</p><p>Jim has spent the last decade tackling some of the biggest problems in healthcare. He was part of the founding executive team as the Chief Commercial Officer of Livongo Health, and took the company public, culminating in an $18.5B acquisition by Teladoc Health. Since March 2021,  Jim has been<a href="https://www.hingehealth.com/"> Hinge Health's</a> President. The company is ranked #2 on Crunchbase's Diversity Spotlight Report.</p><p>In this interview, Jim discusses finding the right market, being your own biggest critic, and marrying clinical improvements with cost savings.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/interviews/jim-pursley-hinge-health">link to the full interview</a> with Jim if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 07 Dec 2022 17:25:50 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/205e833d/88d43144.mp3" length="149215916" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/EAqw_KnmQT5q8Gg95HAqXbl_QP0X88gxp4SF5UOzR_o/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExMjU2Nzcv/MTY3MDQzMjk3Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3724</itunes:duration>
      <itunes:summary>Jim Pursley is the President of Hinge Health and former Chief Commercial Officer for Livongo Health. In this interview, he discusses finding the right market, being your own biggest critic, and marrying clinical improvements with cost savings.</itunes:summary>
      <itunes:subtitle>Jim Pursley is the President of Hinge Health and former Chief Commercial Officer for Livongo Health. In this interview, he discusses finding the right market, being your own biggest critic, and marrying clinical improvements with cost savings.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Lessons Learned Bootstrapping a Startup from $0 to $20 Million: Interview with Medsider Founder Scott Nelson</title>
      <itunes:title>Lessons Learned Bootstrapping a Startup from $0 to $20 Million: Interview with Medsider Founder Scott Nelson</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">dce40efb-830a-4a59-8c39-9e9249cbee12</guid>
      <link>https://www.medsider.com/interviews/scott-nelson-medsider</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, I sat down with myself. Well, sort of. </p><p>This unique episode of Medsider flips the script, putting myself in the interviewee seat alongside my good friend, and temporary host, Brett Johnston. We discussed where founders should focus early on, guidance for taking the leap from your corporate position, and how to know which opportunities to pursue.</p><p>If you’re new to this show, here’s a little more about me: </p><p>I spent the last two decades in the medtech space, starting in medical device sales roles that ultimately led to startup leadership positions. During that time, I followed my curiosity through several career transitions while engaging in side projects along the way. I'm the founder of <a href="https://medsider.com/">Medsider</a>, <a href="https://joovv.com/">Joovv</a>, <a href="https://crossfiremedical.com/">Crossfire Medical</a>, and <a href="https://fastwavemedical.com/">FastWave Medical</a>. The latter two are spinouts from <a href="https://bigskybiomedical.com/">Big Sky Biomedical</a>, a medtech accelerator that I also started with several other serial entrepreneurs.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/scott-nelson-medsider">link to the full interview</a> with if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/interviews">Medsider Radio</a>, I sat down with myself. Well, sort of. </p><p>This unique episode of Medsider flips the script, putting myself in the interviewee seat alongside my good friend, and temporary host, Brett Johnston. We discussed where founders should focus early on, guidance for taking the leap from your corporate position, and how to know which opportunities to pursue.</p><p>If you’re new to this show, here’s a little more about me: </p><p>I spent the last two decades in the medtech space, starting in medical device sales roles that ultimately led to startup leadership positions. During that time, I followed my curiosity through several career transitions while engaging in side projects along the way. I'm the founder of <a href="https://medsider.com/">Medsider</a>, <a href="https://joovv.com/">Joovv</a>, <a href="https://crossfiremedical.com/">Crossfire Medical</a>, and <a href="https://fastwavemedical.com/">FastWave Medical</a>. The latter two are spinouts from <a href="https://bigskybiomedical.com/">Big Sky Biomedical</a>, a medtech accelerator that I also started with several other serial entrepreneurs.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/scott-nelson-medsider">link to the full interview</a> with if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 30 Nov 2022 21:11:05 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b4343d06/b0c0abd9.mp3" length="180093493" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/4XdCt7ixF0v4SkSlSd4ms0vJ71Xnuuu59Ij-CB8F8Js/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzExMTQyMzQv/MTY2OTg0MjY2NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>4502</itunes:duration>
      <itunes:summary>Scott Nelson, founder of Medsider and numerous medtech startups, tells how each of his career transitions brought invaluable lessons, the risk and reward of leaving corporate life, the essential values for any medical device founder, and how to find opportunities that are rooted in your experiences. </itunes:summary>
      <itunes:subtitle>Scott Nelson, founder of Medsider and numerous medtech startups, tells how each of his career transitions brought invaluable lessons, the risk and reward of leaving corporate life, the essential values for any medical device founder, and how to find oppor</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building a Consumer-Focused Medtech Business: Interview with Tivic Health Co-founder and CEO Jennifer Ernst</title>
      <itunes:title>Building a Consumer-Focused Medtech Business: Interview with Tivic Health Co-founder and CEO Jennifer Ernst</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11613875</guid>
      <link>https://www.medsider.com/interviews/jennifer-ernst-tivic-health</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jenniferernst/">Jennifer Ernst</a>, CEO of Tivic Health.</p><p>Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Electronics. In 2016, Jennifer founded direct-to-consumer medtech company Tivic Health and helped lead the development and commercialization of the company’s flagship device ClearUP.</p><p>In this interview, Jennifer shares how consumers can play a key role in boosting support and evidence for over-the-counter medical devices, and why she thinks direct-to-consumer business models will transform the medtech space.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jennifer-ernst-tivic-health">link to the full interview</a> with Jennifer if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/jenniferernst/">Jennifer Ernst</a>, CEO of Tivic Health.</p><p>Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Electronics. In 2016, Jennifer founded direct-to-consumer medtech company Tivic Health and helped lead the development and commercialization of the company’s flagship device ClearUP.</p><p>In this interview, Jennifer shares how consumers can play a key role in boosting support and evidence for over-the-counter medical devices, and why she thinks direct-to-consumer business models will transform the medtech space.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jennifer-ernst-tivic-health">link to the full interview</a> with Jennifer if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 09 Nov 2022 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/486b2010/9ab2baad.mp3" length="41355875" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/yGS-fCdMYyt7S488AvgK31k71XNFXlTgBwc7gQNb3tM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzYv/MTY2ODEwMjIzOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3443</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Jennifer Ernst, CEO of Tivic Health.Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Electronics. In 2016, Jennifer founded direct-to-consumer medtech company Tivic Health and helped lead the development and commercialization of the company’s flagship device ClearUP.In this interview, Jennifer shares how consumers can play a key role in boosting support and evidence for over-the-counter medical devices, and why she thinks direct-to-consumer business models will transform the medtech space.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jennifer if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Jennifer Ernst, CEO of Tivic Health.Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Elec</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Pull the Right Regulatory Levers: Interview with Linear Health Sciences Founder and President Daniel Clark</title>
      <itunes:title>How to Pull the Right Regulatory Levers: Interview with Linear Health Sciences Founder and President Daniel Clark</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11530976</guid>
      <link>https://www.medsider.com/interviews/dan-clark-linear-health-sciences</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Dan Clark, President of Linear Health Sciences.</p><p> <a href="https://www.linkedin.com/in/clarkdl/">Dan Clark</a> started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.</p><p>In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/dan-clark-linear-health-sciences">link to the full interview</a> with Dan if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Dan Clark, President of Linear Health Sciences.</p><p> <a href="https://www.linkedin.com/in/clarkdl/">Dan Clark</a> started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.</p><p>In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/dan-clark-linear-health-sciences">link to the full interview</a> with Dan if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Oct 2022 18:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/6c36af95/4960c820.mp3" length="41511826" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/65KDuVzKu6o8UOAk-ywnHTXCmHSqubn54j0U3xpBeiA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzUv/MTY2ODEwMjIzOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3456</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Dan Clark, President of Linear Health Sciences. Dan Clark started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Dan if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Dan Clark, President of Linear Health Sciences. Dan Clark started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Flexibility and Curiosity Can Influence a Successful Medtech Startup: Interview with EvoEndo CEO Heather Underwood</title>
      <itunes:title>How Flexibility and Curiosity Can Influence a Successful Medtech Startup: Interview with EvoEndo CEO Heather Underwood</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11351512</guid>
      <link>https://www.medsider.com/interviews/heather-underwood-evoendo</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Heather Underwood, CEO of <a href="https://evoendo.com">EvoEndo</a>.</p><p><a href="https://www.linkedin.com/in/hmunderwood">Heather</a> is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-centered design, education, and international development. </p><p>In this interview, Heather elaborates on her unique approach to innovation in the medtech arena, how fundraising isn’t one-size-fits-all, and why regulatory clearance isn’t the end of the road. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/heather-underwood-evoendo">link to the full interview</a> with Heather if you'd instead read it.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Heather Underwood, CEO of <a href="https://evoendo.com">EvoEndo</a>.</p><p><a href="https://www.linkedin.com/in/hmunderwood">Heather</a> is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-centered design, education, and international development. </p><p>In this interview, Heather elaborates on her unique approach to innovation in the medtech arena, how fundraising isn’t one-size-fits-all, and why regulatory clearance isn’t the end of the road. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/heather-underwood-evoendo">link to the full interview</a> with Heather if you'd instead read it.</p>]]>
      </content:encoded>
      <pubDate>Wed, 12 Oct 2022 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/66d75bc8/6781654f.mp3" length="35372799" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/GhNUhqnrY9ptbtzLBo0S6KQvV0kdCe4liJyrgnowdQs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzQv/MTY2ODEwMjIzOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2944</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Heather Underwood, CEO of EvoEndo.Heather is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-centered design, education, and international development. In this interview, Heather elaborates on her unique approach to innovation in the medtech arena, how fundraising isn’t one-size-fits-all, and why regulatory clearance isn’t the end of the road.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Heather if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Heather Underwood, CEO of EvoEndo.Heather is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-c</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Lessons in Leadership — Building a Successful Team and Checking Your Ego at the Door: Interview with Check-Cap Founder and CTO Yoav Kimchy</title>
      <itunes:title>Lessons in Leadership — Building a Successful Team and Checking Your Ego at the Door: Interview with Check-Cap Founder and CTO Yoav Kimchy</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11430726</guid>
      <link>https://www.medsider.com/interviews/yoav-kimchy-check-cap</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.</p><p><a href="https://www.linkedin.com/in/yoav-kimchy-9b8a7060/">Yoav </a>has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded <a href="https://check-cap.com/">Check-Cap</a>, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system.<strong> </strong></p><p>In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/yoav-kimchy-check-cap">link to the full interview</a> with Yoav if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.</p><p><a href="https://www.linkedin.com/in/yoav-kimchy-9b8a7060/">Yoav </a>has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded <a href="https://check-cap.com/">Check-Cap</a>, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system.<strong> </strong></p><p>In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/yoav-kimchy-check-cap">link to the full interview</a> with Yoav if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 06 Oct 2022 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f2e04965/2a31db1a.mp3" length="29852643" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/8VQpH25SMNii4EpbyKPMXR7dft7fOnDnSNqcL7ykGpE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzMv/MTY2ODEwMjIzNy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2484</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.Yoav has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded Check-Cap, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system. In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Yoav if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.Yoav has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded Check-Cap, a clinical-sta</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Find Product-Market Fit by Going Deep Versus Wide: Interview with New View Surgical CEO Bryce Klontz</title>
      <itunes:title>How to Find Product-Market Fit by Going Deep Versus Wide: Interview with New View Surgical CEO Bryce Klontz</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11316951</guid>
      <link>https://www.medsider.com/interviews/bryce-klontz-new-view-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Bryce Klontz, President and CEO of New View Surgical.</p><p>With over 20 years of experience working in the surgical device space from Canada to Singapore, <a href="https://www.linkedin.com/in/bryceklontz">Bryce </a>brings a tactical advantage to his role as the CEO of <a href="http://newviewsurg.com">New View Surgical</a>. </p><p>Under his leadership, New View Surgical has closed a successful Series B with a cumulative total of $14.5 million in investments and secured 510(k) clearance along the way. He previously worked as the VP of Commercial Strategy for Emerging Markets at Covidien in addition to leadership roles at several other startups.</p><p>In this discussion, Bryce shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bryce-klontz-new-view-surgical">link to the full interview</a> with Bryce if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Bryce Klontz, President and CEO of New View Surgical.</p><p>With over 20 years of experience working in the surgical device space from Canada to Singapore, <a href="https://www.linkedin.com/in/bryceklontz">Bryce </a>brings a tactical advantage to his role as the CEO of <a href="http://newviewsurg.com">New View Surgical</a>. </p><p>Under his leadership, New View Surgical has closed a successful Series B with a cumulative total of $14.5 million in investments and secured 510(k) clearance along the way. He previously worked as the VP of Commercial Strategy for Emerging Markets at Covidien in addition to leadership roles at several other startups.</p><p>In this discussion, Bryce shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bryce-klontz-new-view-surgical">link to the full interview</a> with Bryce if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 14 Sep 2022 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/51348545/a341ed9d.mp3" length="45927360" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/h37xeeBlt3dlaANwNtJQ7HPgQH-xbgPdGbqdlZyhCfM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzIv/MTY2ODEwMjIzMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3824</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Bryce Klontz, President and CEO of New View Surgical.With over 20 years of experience working in the surgical device space from Canada to Singapore, Bryce brings a tactical advantage to his role as the CEO of New View Surgical. Under his leadership, New View Surgical has closed a successful Series B with a cumulative total of $14.5 million in investments and secured 510(k) clearance along the way. He previously worked as the VP of Commercial Strategy for Emerging Markets at Covidien in addition to leadership roles at several other startups.In this discussion, Bryce shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Bryce if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Bryce Klontz, President and CEO of New View Surgical.With over 20 years of experience working in the surgical device space from Canada to Singapore, Bryce brings a tactical advantage to his role as the C</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Turning Your End Users Into Key Investors: Interview with Lazurite CEO and Co-founder Eugene Malinskiy</title>
      <itunes:title>Turning Your End Users Into Key Investors: Interview with Lazurite CEO and Co-founder Eugene Malinskiy</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11220680</guid>
      <link>https://www.medsider.com/interviews/eugene-malinskiy-lazurite</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.</p><p><a href="https://www.linkedin.com/in/emalinskiy/">Eugene </a>is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded <a href="https://lazurite.co">Lazurite</a>, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.</p><p>In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/eugene-malinskiy-lazurite">link to the full interview</a> with Eugene if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.</p><p><a href="https://www.linkedin.com/in/emalinskiy/">Eugene </a>is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded <a href="https://lazurite.co">Lazurite</a>, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.</p><p>In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/eugene-malinskiy-lazurite">link to the full interview</a> with Eugene if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 07 Sep 2022 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9fd3acad/b5d17164.mp3" length="39033547" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Lioye_GhgMTTZBWDQ7doZRMFgy_Pxz0fn2c_UTkceMU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzEv/MTY2ODEwMjIzMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3249</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.Eugene is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded Lazurite, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Eugene if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.Eugene is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Build a Strong Network of Investors and Partners for Your Medtech Startup: Interview with DermaSensor CEO Cody Simmons</title>
      <itunes:title>How to Build a Strong Network of Investors and Partners for Your Medtech Startup: Interview with DermaSensor CEO Cody Simmons</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11146873</guid>
      <link>https://www.medsider.com/interviews/cody-simmons-dermasensor</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Cody Simmons, CEO of DermaSensor.</p><p><a href="https://www.linkedin.com/in/codyvsimmons/">Cody </a>spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.</p><p>In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/cody-simmons-dermasensor">link to the full interview</a> with Cody if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Cody Simmons, CEO of DermaSensor.</p><p><a href="https://www.linkedin.com/in/codyvsimmons/">Cody </a>spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.</p><p>In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/cody-simmons-dermasensor">link to the full interview</a> with Cody if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 22 Aug 2022 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/33c06f19/cb3f6ec2.mp3" length="39197146" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-NFOCmGuuvl38sjn9gx6VLpJa_ZMbPciuAYOqzNLjY4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NzAv/MTY2ODEwMjIzMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3263</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Cody Simmons, CEO of DermaSensor.Cody spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Cody if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Cody Simmons, CEO of DermaSensor.Cody spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads developme</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Your Medical Device Should Generate Revenue for End Users: Interview with Cognetivity CEO Sina Habibi</title>
      <itunes:title>Why Your Medical Device Should Generate Revenue for End Users: Interview with Cognetivity CEO Sina Habibi</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11072649</guid>
      <link>https://www.medsider.com/interviews/sina-habibi-cognetivity</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Sina Habibi, CEO of Cognetivity.</p><p><a href="https://www.linkedin.com/in/sina-habibi-b208633b/">Sina </a>has a Ph.D. in engineering from the University of Cambridge, where he met his business partner <a href="https://www.linkedin.com/in/seyed-mahdi-khaligh-razavi-5a343a42/">Seyed-Mahdi Khaligh-Razavi</a>. The two co-founded <a href="https://cognetivity.com/">Cognetivity Neurosciences</a>, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. </p><p>In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/sina-habibi-cognetivity">link to the full interview</a> with Sina if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Sina Habibi, CEO of Cognetivity.</p><p><a href="https://www.linkedin.com/in/sina-habibi-b208633b/">Sina </a>has a Ph.D. in engineering from the University of Cambridge, where he met his business partner <a href="https://www.linkedin.com/in/seyed-mahdi-khaligh-razavi-5a343a42/">Seyed-Mahdi Khaligh-Razavi</a>. The two co-founded <a href="https://cognetivity.com/">Cognetivity Neurosciences</a>, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. </p><p>In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/sina-habibi-cognetivity">link to the full interview</a> with Sina if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 08 Aug 2022 15:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d2ec7308/cd30abb5.mp3" length="37197972" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/E84iJsspy1vebW4wadMKz2KtwBkOJaKJo4T9f-ukpew/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Njkv/MTY2ODEwMjIzMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3096</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Sina Habibi, CEO of Cognetivity.Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neurosciences, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Sina if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Sina Habibi, CEO of Cognetivity.Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neuroscience</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte</title>
      <itunes:title>Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-11035442</guid>
      <link>https://www.medsider.com/interviews/olivier-delporte-miracor-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Olivier Delporte, CEO of Miracor Medical.</p><p><a href="https://www.linkedin.com/in/olivier-delporte-3229a3/">Olivier </a>has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of <a href="https://miracormedical.com/">Miracor Medical</a>, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  </p><p>In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/olivier-delporte-miracor-medical">link to the full interview</a> with Olivier if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Olivier Delporte, CEO of Miracor Medical.</p><p><a href="https://www.linkedin.com/in/olivier-delporte-3229a3/">Olivier </a>has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of <a href="https://miracormedical.com/">Miracor Medical</a>, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  </p><p>In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/olivier-delporte-miracor-medical">link to the full interview</a> with Olivier if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 01 Aug 2022 15:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/255e5d88/a0b4531d.mp3" length="35251161" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/1PJfnGnwLVtV9fDLF5KfM3sETBX-0hOL5fjT3tTPlpc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Njgv/MTY2ODEwMjIyMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2934</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Olivier if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miraco</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies</title>
      <itunes:title>How to Convince Investors, Payers, and Patients Your Device is Worth the Cost: Interview with Bone Health Technologies CEO Laura Yecies</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10944385</guid>
      <link>https://www.medsider.com/interviews/laura-yecies-bone-health-technologies</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Laura Yecies, CEO of Bone Health Technologies.</p><p><a href="https://www.linkedin.com/in/laurayecies/">Laura</a> is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup <a href="https://www.bonehealthtech.com/">Bone Health Technologies</a>, which is developing a vibration belt intended to prevent osteoporosis. </p><p>In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/laura-yecies-bone-health-technologies">link to the full interview</a> with Laura if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Laura Yecies, CEO of Bone Health Technologies.</p><p><a href="https://www.linkedin.com/in/laurayecies/">Laura</a> is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup <a href="https://www.bonehealthtech.com/">Bone Health Technologies</a>, which is developing a vibration belt intended to prevent osteoporosis. </p><p>In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/laura-yecies-bone-health-technologies">link to the full interview</a> with Laura if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 19 Jul 2022 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0fb46e7d/964a103a.mp3" length="39400316" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/quyKf9h-5xwlDVw2UFtL8jrJETHICtdmy1gBHegR9jI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Njcv/MTY2ODEwMjIyMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3280</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Bone Health Technologies.Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup Bone Health Technologies, which is developing a vibration belt intended to prevent osteoporosis. In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Laura if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Bone Health Technologies.Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar</title>
      <itunes:title>The Importance of Going All In On Your Medtech Business: Interview with SynerFuse Co-Founders Justin Zenanko and Greg Molnar</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10899691</guid>
      <link>https://medsider.com/synerfuse</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse. </p><p><a href="https://www.linkedin.com/in/justin-zenanko-83641864/">Justin</a> is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and <a href="https://www.linkedin.com/in/gregmolnar2/">Greg</a> is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build <a href="https://www.synerfuse.com">SynerFuse</a>, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.</p><p>In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.<br> <br>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/synerfuse">link to the full interview</a> with Justin and Greg if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse. </p><p><a href="https://www.linkedin.com/in/justin-zenanko-83641864/">Justin</a> is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and <a href="https://www.linkedin.com/in/gregmolnar2/">Greg</a> is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build <a href="https://www.synerfuse.com">SynerFuse</a>, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.</p><p>In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.<br> <br>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://medsider.com/synerfuse">link to the full interview</a> with Justin and Greg if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 06 Jul 2022 21:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/37d7d6a7/baee2986.mp3" length="42799037" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/jA9hBJGBD_5cfaj_Ra-tSMjBxr1huKFSyGchBRmqFBM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjYv/MTY2ODEwMjIyMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3563</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse. Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build SynerFuse, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture. Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Justin and Greg if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse. Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulatio</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why You Should Weigh the Global and Economic Impact of Your Technology: Interview with Argá Medtech CEO David Neale</title>
      <itunes:title>Why You Should Weigh the Global and Economic Impact of Your Technology: Interview with Argá Medtech CEO David Neale</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10855159</guid>
      <link>https://www.medsider.com/interviews/david-neale-arga-medtech</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with David Neale, CEO and co-founder of Argá Medtech.<br><strong><br></strong>David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched <a href="https://argamedtech.com/">Argá Medtech</a>, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.<strong> </strong></p><p>In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies. <strong> </strong></p><p>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/david-neale-arga-medtech">link to the full interview</a> with David if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with David Neale, CEO and co-founder of Argá Medtech.<br><strong><br></strong>David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched <a href="https://argamedtech.com/">Argá Medtech</a>, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.<strong> </strong></p><p>In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies. <strong> </strong></p><p>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/david-neale-arga-medtech">link to the full interview</a> with David if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 28 Jun 2022 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/97d3a922/31f724a7.mp3" length="40501851" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/LQaFQ96JvlgseQkxJn-Bj-pWIqK6KJ9MLdQ0oiuHOZU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjUv/MTY2ODEwMjIyNC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3371</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation. In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.  Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with David if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, h</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How To Make Health Technology Fun and Accessible: Interview with Osso VR Co-Founder and CEO Justin Barad</title>
      <itunes:title>How To Make Health Technology Fun and Accessible: Interview with Osso VR Co-Founder and CEO Justin Barad</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10758670</guid>
      <link>https://www.medsider.com/interviews/justin-barad-osso-vr</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/justinbaradmd/">Justin Barad</a>, Co-Founder and CEO of <a href="https://www.ossovr.com/">Osso VR</a>.</p><p>Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed. </p><p>In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can <em>and</em> should be fun — even in healthcare.</p><p>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/justin-barad-osso-vr">link to the full interview</a> with Justin if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/justinbaradmd/">Justin Barad</a>, Co-Founder and CEO of <a href="https://www.ossovr.com/">Osso VR</a>.</p><p>Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed. </p><p>In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can <em>and</em> should be fun — even in healthcare.</p><p>Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/justin-barad-osso-vr">link to the full interview</a> with Justin if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 09 Jun 2022 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d250b3ae/ea97180e.mp3" length="38691661" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3SCyrWSsvZehXDvxVxViIUJVDNPraSmijAbnCCKoa1I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjQv/MTY2ODEwMjIyMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3221</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed. In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can and should be fun — even in healthcare.Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Justin if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he devel</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Medtech Companies Should Approach the Consumer Health Market: Interview with Movano CEO John Mastrototaro</title>
      <itunes:title>How Medtech Companies Should Approach the Consumer Health Market: Interview with Movano CEO John Mastrototaro</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10666998</guid>
      <link>https://www.medsider.com/interviews/john-mastrototaro-movano</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with John Mastrototaro, CEO of <a href="https://movano.com/">Movano</a>.</p><p>John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. </p><p>In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.  Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/john-mastrototaro-movano">link to the full interview</a> with John if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with John Mastrototaro, CEO of <a href="https://movano.com/">Movano</a>.</p><p>John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. </p><p>In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.  Before we jump into the discussion, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.</p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/john-mastrototaro-movano">link to the full interview</a> with John if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 25 May 2022 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0a06f0b6/f80cc30b.mp3" length="44202221" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ynV22w0PzrDWxAC5X8g_ghPJ_Icf9d8NZWGJDX7RDnk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjMv/MTY2ODEwMjIyMC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3680</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.  Before we jump into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with John if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuo</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Apply an Engineering Mindset to Your Medical Device Startup: Interview with Access Vascular CEO Jim Biggins</title>
      <itunes:title>How to Apply an Engineering Mindset to Your Medical Device Startup: Interview with Access Vascular CEO Jim Biggins</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10609055</guid>
      <link>https://www.medsider.com/interviews/jim-biggins-access-vascular</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Jim Biggins, Founder and CEO of <a href="https://www.accessvascularinc.com">Access Vascular</a>.</p><p>Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.</p><p>In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. </p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jim-biggins-access-vascular">link to the full interview</a> with Jim if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Jim Biggins, Founder and CEO of <a href="https://www.accessvascularinc.com">Access Vascular</a>.</p><p>Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.</p><p>In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. </p><p>This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jim-biggins-access-vascular">link to the full interview</a> with Jim if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 18 May 2022 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b5f808a9/d5c4fff4.mp3" length="36651686" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/KyDGomhtXe-eOWTf0TW6Sc2X6noBaNaiHuyGugp5lYo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjIv/MTY2ODEwMjIxMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3051</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jim if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 mo</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>4 Key Considerations to Win Over Investors: Interview with Glympse Bio CEO Caroline Loew</title>
      <itunes:title>4 Key Considerations to Win Over Investors: Interview with Glympse Bio CEO Caroline Loew</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10549437</guid>
      <link>https://www.medsider.com/interviews/caroline-loew-glympsebio</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/carolineloew/">Caroline Loew</a>, President and CEO of Glympse Bio.</p><p>Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&amp;D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. </p><p>In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/caroline-loew-glympsebio">link to the full interview</a> with Caroline if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/carolineloew/">Caroline Loew</a>, President and CEO of Glympse Bio.</p><p>Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&amp;D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. </p><p>In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/caroline-loew-glympsebio">link to the full interview</a> with Caroline if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 05 May 2022 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0372b7ef/13f1662e.mp3" length="36921828" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DWZ8HA0gygOkMwGgfzF3yyUcyjUoaL9dsyQ52HOP9A4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjEv/MTY2ODEwMjIxMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3073</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Caroline Loew, President and CEO of Glympse Bio.Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&amp;amp;D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Caroline if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Caroline Loew, President and CEO of Glympse Bio.Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&amp;amp;D. Caroli</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Building Relationships, Raising Capital, and Establishing Reimbursement Codes: Interview with Oculogica CEO Rosina Samadani</title>
      <itunes:title>Building Relationships, Raising Capital, and Establishing Reimbursement Codes: Interview with Oculogica CEO Rosina Samadani</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10500429</guid>
      <link>https://www.medsider.com/interviews/rosina-samadani-oculogica</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Rosina Samadani, CEO of Oculogica.</p><p><a href="https://www.linkedin.com/in/rsamadani/">Rosina Samadani</a> initially joined <a href="https://oculogica.com/">Oculogica</a> in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. </p><p>In this discussion,  Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/rosina-samadani-oculogica">link to the full interview</a> with Rosina if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Rosina Samadani, CEO of Oculogica.</p><p><a href="https://www.linkedin.com/in/rsamadani/">Rosina Samadani</a> initially joined <a href="https://oculogica.com/">Oculogica</a> in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. </p><p>In this discussion,  Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors">Medsider Mentors</a> sent to their door at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/rosina-samadani-oculogica">link to the full interview</a> with Rosina if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 25 Apr 2022 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c656df61/368f1195.mp3" length="41837431" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/H7VKKO2iwGpkC9orMM7hrOYYEwaAJyxYCqBtuwFizP0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NjAv/MTY2ODEwMjIxMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3483</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Rosina Samadani, CEO of Oculogica.Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. In this discussion,  Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Rosina if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Rosina Samadani, CEO of Oculogica.Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Planning Your Regulatory Pathway Around Your Product Roadmap: Interview with Virtual Incision CEO John Murphy</title>
      <itunes:title>Planning Your Regulatory Pathway Around Your Product Roadmap: Interview with Virtual Incision CEO John Murphy</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10405787</guid>
      <link>https://www.medsider.com/interviews/john-murphy-virtual-incision</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with John Murphy, President and CEO of Virtual Incision.</p><p>With a background in life sciences, aerospace, private equity, and venture capital, John co-founded <a href="https://virtualincision.com/">Virtual Incision</a> in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.</p><p>In this discussion,  John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/john-murphy-virtual-incision">link to the full interview</a> with John if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with John Murphy, President and CEO of Virtual Incision.</p><p>With a background in life sciences, aerospace, private equity, and venture capital, John co-founded <a href="https://virtualincision.com/">Virtual Incision</a> in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.</p><p>In this discussion,  John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/john-murphy-virtual-incision">link to the full interview</a> with John if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 11 Apr 2022 22:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/027d173d/8bafd603.mp3" length="36109027" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-ptnT7jHRXvsulbQDgaUq-qyyNMz9ZyRglWqYHG2e_0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTkv/MTY2ODEwMjIwNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3005</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.In this discussion,  John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with John if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniatur</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Maintain Velocity Without Sacrificing Quality: Interview with Qualio Founder and CEO Robert Fenton</title>
      <itunes:title>How to Maintain Velocity Without Sacrificing Quality: Interview with Qualio Founder and CEO Robert Fenton</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10332505</guid>
      <link>https://www.medsider.com/interviews/robert-fenton-qualio</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. </p><p>Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&amp;D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. </p><p>In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can <em>support </em>(and not <em>hinder</em>)<em> </em>medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/robert-fenton-qualio">link to the full interview</a> with Robert if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. </p><p>Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&amp;D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. </p><p>In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can <em>support </em>(and not <em>hinder</em>)<em> </em>medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/robert-fenton-qualio">link to the full interview</a> with Robert if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 30 Mar 2022 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/dd3f7a25/521b067e.mp3" length="29198527" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/h87BSZ5EdC1VPUYWq5S1nPd3jyclfFYNDP1Jr_tbwDU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTgv/MTY2ODEwMjIwNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2429</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&amp;amp;D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. Prior to founding Qualio in 2012, Robert studied pharmacy for five year</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Design Thinking is Crucial for Medical Device Innovation: Interview with Madorra CEO Holly Rockweiler</title>
      <itunes:title>Why Design Thinking is Crucial for Medical Device Innovation: Interview with Madorra CEO Holly Rockweiler</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10248096</guid>
      <link>https://www.medsider.com/interviews/holly-rockweiler-madorra</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.</p><p>Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health. </p><p>In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program.  </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/holly-rockweiler-madorra">link to the full interview</a> with Holly if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.</p><p>Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health. </p><p>In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program.  </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/holly-rockweiler-madorra">link to the full interview</a> with Holly if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 15 Mar 2022 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/150cba6d/0d92f53f.mp3" length="32691749" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/vnSCfx3fojLNO_ICQYLbGa4Sezdb6To48Q3AyEqSgRE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTcv/MTY2ODEwMjIwNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2721</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health. In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program.  Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Holly if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford Universit</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Lessons Learned From Selling 3 Medtech Companies: Interview with ThermoTek Chairman Robert Kline</title>
      <itunes:title>Lessons Learned From Selling 3 Medtech Companies: Interview with ThermoTek Chairman Robert Kline</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10157331</guid>
      <link>https://www.medsider.com/interviews/robert-kline-thermotek</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with Robert Kline, the Chairman of ThermoTek.</p><p>Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.</p><p>In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/robert-kline-thermotek">link to the full interview</a> with Robert if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with Robert Kline, the Chairman of ThermoTek.</p><p>Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.</p><p>In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/robert-kline-thermotek">link to the full interview</a> with Robert if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 28 Feb 2022 22:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f2231095/b45788fc.mp3" length="40364288" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/XNV2ENIzDv9rpxHLOngJSbR1DSWbtFuK4DTqxTPhxCg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTYv/MTY2ODEwMjIwNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3360</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re sitting down with Robert Kline, the Chairman of ThermoTek.Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re sitting down with Robert Kline, the Chairman of ThermoTek.Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University o</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Finding Investors Who Understand Your Product is Critical: Interview with EchoNous CEO Kevin Goodwin</title>
      <itunes:title>Why Finding Investors Who Understand Your Product is Critical: Interview with EchoNous CEO Kevin Goodwin</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-10078742</guid>
      <link>https://www.medsider.com/interviews/kevin-goodwin-echonous</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/kevin-m-goodwin-2bb82a86/">Kevin Goodwin</a>, the CEO and founder of <a href="https://echonous.com/en_us/">EchoNous</a>. </p><p>Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue. </p><p>Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014. </p><p>In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was <a href="https://www.prnewswire.com/news-releases/echonous-inc-announces-fda-approval-for-its-new-kosmos-platform-301030795.html">approved by the FDA</a> in 2020. </p><p>In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/kevin-goodwin-echonous">link to the full interview</a> with Kevin if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/kevin-m-goodwin-2bb82a86/">Kevin Goodwin</a>, the CEO and founder of <a href="https://echonous.com/en_us/">EchoNous</a>. </p><p>Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue. </p><p>Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014. </p><p>In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was <a href="https://www.prnewswire.com/news-releases/echonous-inc-announces-fda-approval-for-its-new-kosmos-platform-301030795.html">approved by the FDA</a> in 2020. </p><p>In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/kevin-goodwin-echonous">link to the full interview</a> with Kevin if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 22 Feb 2022 18:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e3667d7f/4cbb3a56.mp3" length="39175728" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/5bAHWifYf8MJQtBE8peEnzqxH3N65gKGoNZPW6bf0zA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTUv/MTY2ODEwMjE5Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3261</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re sitting down with Kevin Goodwin, the CEO and founder of EchoNous. Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue. Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014. In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was approved by the FDA in 2020. In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Kevin if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re sitting down with Kevin Goodwin, the CEO and founder of EchoNous. Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the f</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Building a Community is Crucial for Medical Device Startups: Interview with Blackrock Neurotech’s Co-Founder and CEO Marcus Gerhardt</title>
      <itunes:title>Why Building a Community is Crucial for Medical Device Startups: Interview with Blackrock Neurotech’s Co-Founder and CEO Marcus Gerhardt</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9903183</guid>
      <link>https://www.medsider.com/interviews/marcus-gerhardt-blackrock-neurotech</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/marcus-gerhardt-1583524/">Marcus Gerhardt</a>, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded <a href="https://blackrockneurotech.com/">Blackrock Neurotech</a>, a pioneer in brain-computer interface (BCI) technology, and the world’s leading collaborative partner for developing approved medical devices at scale for neurological therapies. He currently serves as CEO and is on the company’s board.</p><p>In this episode of Medsider, Marcus explains why Blackrock’s business model works for medtech companies, how the approach gave the company an “in” with the neuroscience research community, and why medical device companies need to work with — and not against — regulatory bodies like the Food and Drug Administration (FDA). </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/marcus-gerhardt-blackrock-neurotech">link to the full interview</a> with Marcus if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/marcus-gerhardt-1583524/">Marcus Gerhardt</a>, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded <a href="https://blackrockneurotech.com/">Blackrock Neurotech</a>, a pioneer in brain-computer interface (BCI) technology, and the world’s leading collaborative partner for developing approved medical devices at scale for neurological therapies. He currently serves as CEO and is on the company’s board.</p><p>In this episode of Medsider, Marcus explains why Blackrock’s business model works for medtech companies, how the approach gave the company an “in” with the neuroscience research community, and why medical device companies need to work with — and not against — regulatory bodies like the Food and Drug Administration (FDA). </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.</p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/marcus-gerhardt-blackrock-neurotech">link to the full interview</a> with Marcus if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Jan 2022 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/87230ef3/a1c08e95.mp3" length="37003689" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/-7Tm6sYFSTf-haTpce8jQcvFu--BSTElG6QadvqGCq8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTQv/MTY3OTY3NTE4Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3080</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re sitting down with Marcus Gerhardt, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded Blackrock Neurotech, a pioneer in brain-computer interface (BCI) technology, and the world’s leading collaborative partner for developing approved medical devices at scale for neurological therapies. He currently serves as CEO and is on the company’s board.In this episode of Medsider, Marcus explains why Blackrock’s business model works for medtech companies, how the approach gave the company an “in” with the neuroscience research community, and why medical device companies need to work with — and not against — regulatory bodies like the Food and Drug Administration (FDA). Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Marcus if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re sitting down with Marcus Gerhardt, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded Blackrock Neurotech, a pioneer in brain-computer inte</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Navigate Clinical Trials and Fundraising Challenges: Interview with Eyevensys CEO Patricia Zilliox</title>
      <itunes:title>How to Navigate Clinical Trials and Fundraising Challenges: Interview with Eyevensys CEO Patricia Zilliox</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9842126</guid>
      <link>https://www.medsider.com/interviews/patricia-zilliox-eyevensys</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/patricia-zilliox-b433671/">Patricia Zilliox</a>, who has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company <a href="https://www.alcon.com/">Alcon</a>. In 2017, Patricia became CEO of <a href="https://www.eyevensys.com/">Eyevensys</a>, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. </p><p>In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/patricia-zilliox-eyevensys">link to the full interview</a> with Patricia if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re sitting down with <a href="https://www.linkedin.com/in/patricia-zilliox-b433671/">Patricia Zilliox</a>, who has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company <a href="https://www.alcon.com/">Alcon</a>. In 2017, Patricia became CEO of <a href="https://www.eyevensys.com/">Eyevensys</a>, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. </p><p>In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/patricia-zilliox-eyevensys">link to the full interview</a> with Patricia if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 19 Jan 2022 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/731d70e1/c6b1c433.mp3" length="34002564" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/cyzrF4xQlxlPcJr-leJMcogMENm4JLNp69IUiKFdiuQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTMv/MTY3OTYzODI5Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2830</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, wo has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Patricia if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, wo has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From Investor Pitch to Eventual Partnership: Interview With HealthQuest Capital Founder Garheng Kong</title>
      <itunes:title>From Investor Pitch to Eventual Partnership: Interview With HealthQuest Capital Founder Garheng Kong</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9674164</guid>
      <link>https://www.medsider.com/interviews/garheng-kong-healthquest-capital</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with the  <a href="https://www.healthquestcapital.com/">HealthQuest Capital</a> Founder,  <a href="https://www.linkedin.com/in/garhengkong/">Garheng Kong</a>, who worked at GlaxoSmithKline, McKinsey, and TherOx before transitioning into healthcare investing with Intersouth Partners and Sofinnova. </p><p>Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career. </p><p>Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go of. </p><p>In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/garheng-kong-healthquest-capital">link to the full interview</a> with Garheng if you'd instead read it.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with the  <a href="https://www.healthquestcapital.com/">HealthQuest Capital</a> Founder,  <a href="https://www.linkedin.com/in/garhengkong/">Garheng Kong</a>, who worked at GlaxoSmithKline, McKinsey, and TherOx before transitioning into healthcare investing with Intersouth Partners and Sofinnova. </p><p>Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career. </p><p>Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go of. </p><p>In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/garheng-kong-healthquest-capital">link to the full interview</a> with Garheng if you'd instead read it.</p>]]>
      </content:encoded>
      <pubDate>Tue, 11 Jan 2022 18:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/52c10366/8dd5eb1a.mp3" length="40062870" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ckNrXYJ03-MaVQbBNcynTG3jqnBrZAzQyK4lkYummCs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTIv/MTY3OTYzNTMyMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3335</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with the  HealthQuest Capital Founder,  Garheng Kong, who worked at GlaxoSmithKline, McKinsey and TherOx before transitioning into the world of healthcare investing with Intersouth Partners and Sofinnova. Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career. Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go. In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Garheng if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with the  HealthQuest Capital Founder,  Garheng Kong, who worked at GlaxoSmithKline, McKinsey and TherOx before transitioning into the world of healthcare investing with Intersouth Partners and Sofinnova. Ga</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How To Launch Your Medical Device With a Global Perspective: Interview With Lightpoint Medical CEO Graeme Smith</title>
      <itunes:title>How To Launch Your Medical Device With a Global Perspective: Interview With Lightpoint Medical CEO Graeme Smith</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9672872</guid>
      <link>https://www.medsider.com/interviews/graeme-smith-lightpoint-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>,   we’re talking with <a href="https://lightpointmedical.com/">Lightpoint Medical</a> CEO <a href="https://www.linkedin.com/in/graemelsmith/">Graeme Smith</a>, a medtech veteran with over 32 years of experience in the industry. </p><p>After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-in gamma probe, <a href="https://senseisurgical.com/">SENSEI</a>, a revolutionary tool used in surgeries to non-invasively identify the presence of cancer. </p><p>In this Medsider interview, Graeme shares his tried and true strategies for successful commercial launches and how to introduce products using a global distribution model. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/graeme-smith-lightpoint-medical">link to the full interview</a> with Graeme if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>,   we’re talking with <a href="https://lightpointmedical.com/">Lightpoint Medical</a> CEO <a href="https://www.linkedin.com/in/graemelsmith/">Graeme Smith</a>, a medtech veteran with over 32 years of experience in the industry. </p><p>After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-in gamma probe, <a href="https://senseisurgical.com/">SENSEI</a>, a revolutionary tool used in surgeries to non-invasively identify the presence of cancer. </p><p>In this Medsider interview, Graeme shares his tried and true strategies for successful commercial launches and how to introduce products using a global distribution model. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/graeme-smith-lightpoint-medical">link to the full interview</a> with Graeme if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 27 Dec 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/39a9b5a1/2e506280.mp3" length="37553539" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3gWYnUPcAqgdBrCPguMHmdrI8nE3G0zhsI8kATMgSZw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTEv/MTY3OTQ0MzU5OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3126</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio,   we’re talking with Lightpoint Medical CEO Graeme Smith, a medtech veteran with over 32 years of experience in the industry. After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-in gamma probe, SENSEI, a revolutionary tool used in surgeries to non-invasively identify the presence of cancer. In this Medsider interview, Graeme shares his tried and true strategies for successful commercial launches and how to introduce products using a global distribution model. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Graeme if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio,   we’re talking with Lightpoint Medical CEO Graeme Smith, a medtech veteran with over 32 years of experience in the industry. After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-i</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Your Medical Device Company Needs Different Value Props For Different Stakeholders: Interview With Steve Anderson, Co-Founder and CEO of Preceptis Medical</title>
      <itunes:title>Why Your Medical Device Company Needs Different Value Props For Different Stakeholders: Interview With Steve Anderson, Co-Founder and CEO of Preceptis Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9392939</guid>
      <link>https://www.medsider.com/interviews/steve-anderson-preceptis-medical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://www.linkedin.com/in/steve-anderson-19744231/">Steve Anderson</a>, CEO of <a href="https://www.hummingbirdeartubes.com/">Preceptis Medical,</a> and a serial medical device entrepreneur. </p><p>While serving as CEO of <a href="https://www.bloomberg.com/profile/company/861420Z:US">Acorn Cardiovascular</a>, he and a neighbor came up with the idea of creating a device that could help doctors insert a tube in children’s ears in the doctor’s office instead of the operating room. They ended up starting <a href="https://www.hummingbirdeartubes.com/">Preceptis Medical</a> in 2011, and in 2020, their Hummingbird device received clearance from the FDA.</p><p>In this discussion, Steve explains why your value proposition needs to be front of mind from the start, why having someone who’s been there and done it before can help you navigate the process of getting to market and writing a study protocol that shows regulators exactly what they need to see. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/steve-anderson-preceptis-medical">link to the full interview</a> with Steve if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://www.linkedin.com/in/steve-anderson-19744231/">Steve Anderson</a>, CEO of <a href="https://www.hummingbirdeartubes.com/">Preceptis Medical,</a> and a serial medical device entrepreneur. </p><p>While serving as CEO of <a href="https://www.bloomberg.com/profile/company/861420Z:US">Acorn Cardiovascular</a>, he and a neighbor came up with the idea of creating a device that could help doctors insert a tube in children’s ears in the doctor’s office instead of the operating room. They ended up starting <a href="https://www.hummingbirdeartubes.com/">Preceptis Medical</a> in 2011, and in 2020, their Hummingbird device received clearance from the FDA.</p><p>In this discussion, Steve explains why your value proposition needs to be front of mind from the start, why having someone who’s been there and done it before can help you navigate the process of getting to market and writing a study protocol that shows regulators exactly what they need to see. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/steve-anderson-preceptis-medical">link to the full interview</a> with Steve if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 06 Dec 2021 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a214ed2a/718bbb83.mp3" length="41832215" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/6L0Yh9Dnb1Dgu99A5bP5EMkB_r7QLUO2QTqRHYdRvfM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NTAv/MTY3OTU5MjAwMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3482</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with Steve Anderson, CEO of Preceptis Medical, and a serial medical device entrepreneur. While serving as CEO of Acorn Cardiovascular, he and a neighbor came up with the idea of creating a device that could help doctors insert a tube in children’s ears in the doctor’s office instead of the operating room. They ended up starting Preceptis Medical in 2011, and in 2020, their Hummingbird device received clearance from the FDA.In this discussion, Steve explains why your value proposition needs to be front of mind from the start, why having someone who’s been there and done it before can help you navigate the process of getting to market, and writing a study protocol that shows regulators exactly what they need to see.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Steve if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with Steve Anderson, CEO of Preceptis Medical, and a serial medical device entrepreneur. While serving as CEO of Acorn Cardiovascular, he and a neighbor came up with the idea of creating a device that could </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why You Can’t Build a Medtech Start-Up Without Publicity: Interview with Peter Vranes, CEO of Nutromics</title>
      <itunes:title>Why You Can’t Build a Medtech Start-Up Without Publicity: Interview with Peter Vranes, CEO of Nutromics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9281761</guid>
      <link>https://www.medsider.com/interviews/peter-vranes-nutromics</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with chemical engineer and serial entrepreneur <a href="https://www.linkedin.com/in/peter-vranes-085bb810/">Peter Vranes</a>, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.</p><p>Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.</p><p>In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies and the reason he never stops raising money. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/peter-vranes-nutromics">link to the full interview</a> with Peter if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with chemical engineer and serial entrepreneur <a href="https://www.linkedin.com/in/peter-vranes-085bb810/">Peter Vranes</a>, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.</p><p>Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.</p><p>In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies and the reason he never stops raising money. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/peter-vranes-nutromics">link to the full interview</a> with Peter if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 16 Nov 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/da741710/fcc7e326.mp3" length="41374010" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/gDK-Y1X-JIuPzCvYmBnJJTPfxYgq0Cba3SpRu7G6a3Q/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDkv/MTY3OTU5MTYyNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3444</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with chemical engineer and serial entrepreneur Peter Vranes, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies, and the reason he never stops raising money. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Peter if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with chemical engineer and serial entrepreneur Peter Vranes, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targ</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Doubling Down on Your Mission by Diversifying Your Medtech Portfolio: Interview With ReShape Lifesciences CEO Bart Bandy</title>
      <itunes:title>Doubling Down on Your Mission by Diversifying Your Medtech Portfolio: Interview With ReShape Lifesciences CEO Bart Bandy</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9362258</guid>
      <link>https://www.medsider.com/interviews/bart-bandy-reshape-lifesciences</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re talking with <a href="https://www.reshapelifesciences.com/">ReShape Lifesciences</a> CEO <a href="https://www.linkedin.com/in/bart-bandy-6569577/">Bart Bandy</a>, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and managed the San Francisco division, before becoming the Group Marketing Manager of Karl Storz Endoscopy.</p><p>In 1999, Bart was recruited to become COO of laparoscopic weight loss startup Inamed. He helped manage the company’s $3.5 billion acquisition by Allergan in 2006. Then in 2019, he became CEO and President of ReShape, which had just acquired the Lap-Band, previously owned by Inamed.</p><p>In this discussion, Bart explains how he writes and tests his presentations for maximum impact, the challenges and solutions of moving manufacturing from Costa Rica to the U.S., and why he wanted to add telemedicine to ReShape Lifesciences without moving away from the brand’s core mission.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bart-bandy-reshape-lifesciences">link to the full interview</a> with Bart if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re talking with <a href="https://www.reshapelifesciences.com/">ReShape Lifesciences</a> CEO <a href="https://www.linkedin.com/in/bart-bandy-6569577/">Bart Bandy</a>, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and managed the San Francisco division, before becoming the Group Marketing Manager of Karl Storz Endoscopy.</p><p>In 1999, Bart was recruited to become COO of laparoscopic weight loss startup Inamed. He helped manage the company’s $3.5 billion acquisition by Allergan in 2006. Then in 2019, he became CEO and President of ReShape, which had just acquired the Lap-Band, previously owned by Inamed.</p><p>In this discussion, Bart explains how he writes and tests his presentations for maximum impact, the challenges and solutions of moving manufacturing from Costa Rica to the U.S., and why he wanted to add telemedicine to ReShape Lifesciences without moving away from the brand’s core mission.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bart-bandy-reshape-lifesciences">link to the full interview</a> with Bart if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 03 Nov 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/1c5d6b5e/dedadcff.mp3" length="37753440" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/jVSinzqBFFXLmEsoOxLBAwHkPohYWFlJ8Et9w_MsLXI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDgv/MTY3OTQ0MTc2OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3142</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re talking with ReShape Lifesciences CEO Bart Bandy, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and managed the San Francisco division, before becoming Group Marketing Manager of Karl Storz Endoscopy.In 1999, Bart was recruited to become COO of laparoscopic weight loss startup Inamed. He helped manage the company’s $3.5 billion acquisition by Allergan in 2006. Then in 2019, he became CEO and President of ReShape, which had just acquired the Lap-Band, previously owned by Inamed.In this discussion, Bart explains how he writes and tests his presentations for maximum impact, the challenges and solutions of moving manufacturing from Costa Rica to the U.S., and why he wanted to add telemedicine to ReShape Lifesciences without moving away from the brand’s core mission.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Bart if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re talking with ReShape Lifesciences CEO Bart Bandy, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>When You Should Give a Struggling Medtech Company a Second Chance: Interview With IONIQ CEO Jared Bauer</title>
      <itunes:title>When You Should Give a Struggling Medtech Company a Second Chance: Interview With IONIQ CEO Jared Bauer</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9319693</guid>
      <link>https://www.medsider.com/interviews/jared-bauer-ioniq-sciences</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://ioniqsciences.com/">IONIQ Sciences</a> CEO <a href="https://www.linkedin.com/in/jaredbbauer">Jared Bauer</a>, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of the mobile diagnostics system ApolloDx. Shortly after, he became CEO of the spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases. </p><p>In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jared-bauer-ioniq-sciences">link to the full interview</a> with Jared if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://ioniqsciences.com/">IONIQ Sciences</a> CEO <a href="https://www.linkedin.com/in/jaredbbauer">Jared Bauer</a>, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of the mobile diagnostics system ApolloDx. Shortly after, he became CEO of the spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases. </p><p>In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/jared-bauer-ioniq-sciences">link to the full interview</a> with Jared if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 19 Oct 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/06dca13f/05e9f819.mp3" length="38879820" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/myG9dFlKjMJ1o9Y6BoK-bZYp1FfTsB3EUo1tkQE9g9g/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDcv/MTY3OTU5MDM3NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3236</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with IONIQ Sciences CEO Jared Bauer, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of mobile diagnostics system ApolloDx. Shortly after, he became CEO of spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases. In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jared if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with IONIQ Sciences CEO Jared Bauer, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of mobile</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Your Medtech Strategy Should Start with Healthcare Payers: Interview with Health Economist Nic Anderson</title>
      <itunes:title>Why Your Medtech Strategy Should Start with Healthcare Payers: Interview with Health Economist Nic Anderson</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9269823</guid>
      <link>https://www.medsider.com/interviews/nic-anderson</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or healthcare technology. </p><p>After co-founding a biotech company, Nic turned his experience as a payer into an in-demand consultancy. He’s also served on payer advisory boards and was an expert in residence at a digital health accelerator in Dubai. He now works as a health economist for Boston Scientific.</p><p>In <a href="https://medsider.com/nic-anderson">this conversation</a>, Nic explains why medtech companies, in particular, need to win over insurance payers, how investing early in a health economics and market access (HEMA) team will help you do that, and how to write a dossier a payer won’t want to throw out the window.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/nic-anderson">link to the full interview</a> with Nic if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or healthcare technology. </p><p>After co-founding a biotech company, Nic turned his experience as a payer into an in-demand consultancy. He’s also served on payer advisory boards and was an expert in residence at a digital health accelerator in Dubai. He now works as a health economist for Boston Scientific.</p><p>In <a href="https://medsider.com/nic-anderson">this conversation</a>, Nic explains why medtech companies, in particular, need to win over insurance payers, how investing early in a health economics and market access (HEMA) team will help you do that, and how to write a dossier a payer won’t want to throw out the window.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/nic-anderson">link to the full interview</a> with Nic if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 06 Oct 2021 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f49dbe18/16c23ede.mp3" length="40880114" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/sDXbks65IVIDt0l-n5zybFrCGHdkVDFakaMtfYzR-G0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDYv/MTY3OTU5MTIxNy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3403</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or healthcare technology. After co-founding a biotech company, Nic turned his experience as a payer into an in-demand consultancy. He’s also served on payer advisory boards, and was an expert in residence at a digital health accelerator in Dubai. He now works as a health economist for Boston Scientific.In this conversation, Nic explains why medtech companies, in particular, need to win over insurance payers, how investing early in a health economics and market access (HEMA) team will help you do that, and how to write a dossier a payer won’t want to throw out the window.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Nic if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or h</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Raise Capital for Your Medical Device Start-Up: Interview with Giovanni Lauricella and Aaron Green</title>
      <itunes:title>How to Raise Capital for Your Medical Device Start-Up: Interview with Giovanni Lauricella and Aaron Green</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-9038539</guid>
      <link>https://www.medsider.com/interviews/medtech-money-giovanni-lauricella-aaron-green</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://www.linkedin.com/in/giovannilauricella/">Giovanni Lauricella</a> and <a href="https://www.linkedin.com/in/aarongabrielgreen/">Aaron Green</a> to discuss all things related to fundraising for early-stage medical device start-ups. </p><p>In this interview, we learn about the ins and outs of raising medtech capital, what investors want to see in a medical device start-up, and best practices for pitching potential partners. But first, here’s a bit more about their backgrounds:</p><p>Giovanni Lauricella holds a Bachelor’s in Finance, a Master’s in Regulatory Affairs in Medical Devices, Biologics, and Pharmaceuticals, a Harvard University Certificate for Advanced Negotiation Strategy, and a Università Bocconi Certificate for Private Equity and Venture Capital. He has more than a decade of experience partnering with startups, SMEs, boards of directors, and investors on structuring technical and commercial teams from the C-level to individual contributors. Giovanni and his team have hired more than 7,000 employees for over 500 startups in more than 40 countries and assisted in facilitating capital raises for startups that amount to more than $150 million.</p><p>Aaron Green has a Ph.D. in computational chemistry from UCLA. In 2014, he became the first hire at Neural Analytics (now NovaSignal) where he held leadership roles spanning clinical, finance, sales, and marketing. Aaron currently runs U.S. operations for Labgnostic, a global interoperability platform for clinical laboratories. He co-founded MedTech Money with Giovanni Lauricella in 2020 and founded ExtractEx, a botanical extraction startup, in 2021. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/medtech-money-giovanni-lauricella-aaron-green">link to the full interview</a> with Giovanni and Aaron if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we caught up with <a href="https://www.linkedin.com/in/giovannilauricella/">Giovanni Lauricella</a> and <a href="https://www.linkedin.com/in/aarongabrielgreen/">Aaron Green</a> to discuss all things related to fundraising for early-stage medical device start-ups. </p><p>In this interview, we learn about the ins and outs of raising medtech capital, what investors want to see in a medical device start-up, and best practices for pitching potential partners. But first, here’s a bit more about their backgrounds:</p><p>Giovanni Lauricella holds a Bachelor’s in Finance, a Master’s in Regulatory Affairs in Medical Devices, Biologics, and Pharmaceuticals, a Harvard University Certificate for Advanced Negotiation Strategy, and a Università Bocconi Certificate for Private Equity and Venture Capital. He has more than a decade of experience partnering with startups, SMEs, boards of directors, and investors on structuring technical and commercial teams from the C-level to individual contributors. Giovanni and his team have hired more than 7,000 employees for over 500 startups in more than 40 countries and assisted in facilitating capital raises for startups that amount to more than $150 million.</p><p>Aaron Green has a Ph.D. in computational chemistry from UCLA. In 2014, he became the first hire at Neural Analytics (now NovaSignal) where he held leadership roles spanning clinical, finance, sales, and marketing. Aaron currently runs U.S. operations for Labgnostic, a global interoperability platform for clinical laboratories. He co-founded MedTech Money with Giovanni Lauricella in 2020 and founded ExtractEx, a botanical extraction startup, in 2021. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/medtech-money-giovanni-lauricella-aaron-green">link to the full interview</a> with Giovanni and Aaron if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 16 Aug 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/07d1f261/59459281.mp3" length="62796160" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/n3kec4pz8Kp4yjK8pp0-XqjdTxsylKObZ7aQm1t2pcQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDUv/MTY3OTU5MTAwNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>5229</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with Giovanni Lauricella and Aaron Green to discuss all things related to fundraising for early-stage medical device start-ups. In this interview, we learn about the ins and outs of raising medtech capital, what investors want to see in a medical device start-up, and best practices for pitching potential partners.But first, here’s a bit more about their backgrounds:Giovanni Lauricella holds a Bachelor’s in Finance, a Master’s in Regulatory Affairs in Medical Devices, Biologics, and Pharmaceuticals, a Harvard University Certificate for Advanced Negotiation Strategy, and a Università Bocconi Certificate for Private Equity and Venture Capital. He has more than a decade of experience partnering with startups, SMEs, boards of directors, and investors on structuring technical and commercial teams from the C-level to individual contributors. Giovanni and his team have hired more than 7,000 employees for over 500 startups in more than 40 countries, and assisted in facilitating capital raises for startups that amount to more than $150 million.Aaron Green has a PhD in computational chemistry from UCLA. In 2014, he became the first hire at Neural Analytics (now NovaSignal) where he held leadership roles spanning clinical, finance, sales, and marketing. Aaron currently runs U.S. operations for Labgnostic, a global interoperability platform for clinical laboratories. He co-founded MedTech Money with Giovanni Lauricella in 2020 and founded ExtractEx, a botanical extraction startup, in 2021.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Giovanni and Aaron if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with Giovanni Lauricella and Aaron Green to discuss all things related to fundraising for early-stage medical device start-ups. In this interview, we learn about the ins and outs of raising medtech capital, </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Get a Medical Device Startup Off the Ground: Interview with Asha Parekh, CEO of FrontLine Medical Technologies</title>
      <itunes:title>How to Get a Medical Device Startup Off the Ground: Interview with Asha Parekh, CEO of FrontLine Medical Technologies</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8739580</guid>
      <link>https://www.medsider.com/interviews/asha-parekh-frontline</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re talking with <a href="https://www.linkedin.com/in/ashaparekh">Dr. Asha Parekh</a>, a biomedical engineer and the co-founder &amp; CEO of <a href="https://frontlinemedtech.com">FrontLine Medical Technologies</a>, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma patients survive in emergency situations. If you're not familiar, REBOA stands for Resuscitative Endovascular Balloon Occlusion of the Aorta.</p><p>In this discussion with Asha, we learn about her medtech journey from early-stage device prototypes to raising venture capital to navigate the global regulatory landscape. But first, here’s a bit more on Asha’s background:</p><p>Asha has a Ph.D. in biomedical engineering from Western University in Ontario. In 2015, she partnered with Dr. Adam Power, a practicing vascular surgeon, to co-found FrontLine, which makes the COBRA-OS device for trauma patients. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/asha-parekh-frontline">link to the full interview</a> with Asha if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we’re talking with <a href="https://www.linkedin.com/in/ashaparekh">Dr. Asha Parekh</a>, a biomedical engineer and the co-founder &amp; CEO of <a href="https://frontlinemedtech.com">FrontLine Medical Technologies</a>, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma patients survive in emergency situations. If you're not familiar, REBOA stands for Resuscitative Endovascular Balloon Occlusion of the Aorta.</p><p>In this discussion with Asha, we learn about her medtech journey from early-stage device prototypes to raising venture capital to navigate the global regulatory landscape. But first, here’s a bit more on Asha’s background:</p><p>Asha has a Ph.D. in biomedical engineering from Western University in Ontario. In 2015, she partnered with Dr. Adam Power, a practicing vascular surgeon, to co-found FrontLine, which makes the COBRA-OS device for trauma patients. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/asha-parekh-frontline">link to the full interview</a> with Asha if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 21 Jun 2021 18:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/92d3e17d/bb7ed05a.mp3" length="39846474" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/MgvuYETFlNTIGRhz4mdbMc-6JnSmgf-CWusD1qUU0Sk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDQv/MTY3OTQ0MTUwMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3317</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re talking with Dr. Asha Parekh, a biomedical engineer and the co-founder &amp;amp; CEO of FrontLine Medical Technologies, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma patients survive in emergency situations. If you're not familiar, REBOA stands for Resuscitative Endovascular Balloon Occlusion of the Aorta.In this discussion with Asha, we learn about her medtech journey from early-stage device prototypes to raising venture capital to navigating the global regulatory landscape.But first, here’s a bit more on Asha’s background:Asha has a PhD in biomedical engineering from Western University in Ontario. In 2015, she partnered with Dr. Adam Power, a practicing vascular surgeon, to co-found FrontLine, which makes the COBRA-OS device for trauma patients. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Asha if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re talking with Dr. Asha Parekh, a biomedical engineer and the co-founder &amp;amp; CEO of FrontLine Medical Technologies, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Successfully Launch a New Medical Device: Interview with Mark Toland, CEO of Medical Micro Instruments</title>
      <itunes:title>How to Successfully Launch a New Medical Device: Interview with Mark Toland, CEO of Medical Micro Instruments</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8631503</guid>
      <link>https://www.medsider.com/interviews/mark-toland-mmi</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we're chatting with <a href="https://www.linkedin.com/in/mark-toland-76970780/">Mark Toland</a>, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space. </p><p>MMI stands for <a href="https://www.mmimicro.com/">Medical Micro Instruments</a>, and it’s an Italian company that’s developing a surgical robotic system capable of performing microsurgery on capillaries, small vessels, and other parts of the body existing robotic technology can’t reach. We’re going to dig into the robotics arena and chat about things like growing medtech startups, raising venture capital, positioning for an acquisition, and keys to successful commercial launches. First, here’s a bit more on Mark's background: </p><p>Before MMI, Mark was the CEO of Corindus, transforming the company into a leader in vascular robotics before it was acquired by Siemens for $1.1 billion in 2019. Prior to Corindus, Mark was at Boston Scientific for over 15 years, serving as Senior Vice President, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, representing approximately $4 billion in revenue. </p><p>He also serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an intravascular lithotripsy company. He also serves as a partner and EIR at <a href="https://www.biostar.capital">Biostar Capital</a>, a healthcare-focused venture capital firm. Mark got his bachelor’s in business from the University of Louisville. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mark-toland-mmi">link to the full interview</a> with Mark if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we're chatting with <a href="https://www.linkedin.com/in/mark-toland-76970780/">Mark Toland</a>, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space. </p><p>MMI stands for <a href="https://www.mmimicro.com/">Medical Micro Instruments</a>, and it’s an Italian company that’s developing a surgical robotic system capable of performing microsurgery on capillaries, small vessels, and other parts of the body existing robotic technology can’t reach. We’re going to dig into the robotics arena and chat about things like growing medtech startups, raising venture capital, positioning for an acquisition, and keys to successful commercial launches. First, here’s a bit more on Mark's background: </p><p>Before MMI, Mark was the CEO of Corindus, transforming the company into a leader in vascular robotics before it was acquired by Siemens for $1.1 billion in 2019. Prior to Corindus, Mark was at Boston Scientific for over 15 years, serving as Senior Vice President, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, representing approximately $4 billion in revenue. </p><p>He also serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an intravascular lithotripsy company. He also serves as a partner and EIR at <a href="https://www.biostar.capital">Biostar Capital</a>, a healthcare-focused venture capital firm. Mark got his bachelor’s in business from the University of Louisville. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mark-toland-mmi">link to the full interview</a> with Mark if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 02 Jun 2021 15:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/03f72825/445c0518.mp3" length="41703193" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Ta6agNih8_yox6feX1s_4hf0xwYVqAHOkisLAN9dpOI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDMv/MTY3OTU5MDU5MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3472</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we're chatting with Mark Toland, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space. MMI stands for Medical Micro Instruments, and it’s an Italian company that’s developing a surgical robotic system capable of performing microsurgery on capillaries, small vessels, and other parts of the body existing robotic technology can’t reach.We’re going to dig into the robotics arena and chat about things like growing medtech startups, raising venture capital, positioning for an acquisition, and keys to successful commercial launches.First, here’s a bit more on Mark's background: Before MMI, Mark was the CEO of Corindus, transforming the company into a leader in vascular robotics before it was acquired by Siemens for $1.1 billion in 2019. Prior to Corindus, Mark was at Boston Scientific for over 15 years, serving as Senior Vice President, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, representing approximately $4 billion in revenue. He also serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an intravascular lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare-focused venture capital firm. Mark got his bachelor’s in business from the University of Louisville.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Mark if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we're chatting with Mark Toland, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space. MMI stands for Medical Micro Instruments, and it’s an Italian company that’s dev</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Getting Past Rejection as a First-Time Medical Device Entrepreneur: Interview with Derek Herrera, Founder of UroDev and Habit Camera</title>
      <itunes:title>Getting Past Rejection as a First-Time Medical Device Entrepreneur: Interview with Derek Herrera, Founder of UroDev and Habit Camera</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8514281</guid>
      <link>https://www.medsider.com/interviews/derek-herrera-urodev-habit-camera</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we're catching up with <a href="http://www.derekherrera.com">Derek Herrera</a>, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the founder of <a href="https://www.urodevmedical.com">UroDev</a>, originally Spinal Singularity, as well as <a href="https://habit.camera">Habit Camera</a>, the first low-cost, wireless camera purpose-built for skin inspection and telehealth.</p><p>UroDev is on the cusp of bringing its Intelliflow device to market, a product uniquely designed for spinal injury patients who have urology conditions like a neurogenic bladder that require extensive catheter use. </p><p>Today, Derek and I are going to chat about his journey from the military to the medical device space and get into what he’s learned about becoming a first-time entrepreneur with a big idea but not a lot of funding or experience.  First, here’s a bit more on Derek’s background: </p><p>He graduated from the United States Naval Academy and served as a Marine Infantry and Special Operations Officer for over eight years. In 2014, he was medically retired due to combat injuries and left paralyzed from the waist down. Since this injury, Derek has earned an MBA from the UCLA Anderson School of Management and founded both UroDev and Habit Camera. He also serves as President of the Board for the <a href="https://marineraiderfoundation.org">Marine Raider Foundation</a>.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/derek-herrera-urodev-habit-camera">link to the full interview</a> with Derek if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com/news">Medsider Radio</a>, we're catching up with <a href="http://www.derekherrera.com">Derek Herrera</a>, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the founder of <a href="https://www.urodevmedical.com">UroDev</a>, originally Spinal Singularity, as well as <a href="https://habit.camera">Habit Camera</a>, the first low-cost, wireless camera purpose-built for skin inspection and telehealth.</p><p>UroDev is on the cusp of bringing its Intelliflow device to market, a product uniquely designed for spinal injury patients who have urology conditions like a neurogenic bladder that require extensive catheter use. </p><p>Today, Derek and I are going to chat about his journey from the military to the medical device space and get into what he’s learned about becoming a first-time entrepreneur with a big idea but not a lot of funding or experience.  First, here’s a bit more on Derek’s background: </p><p>He graduated from the United States Naval Academy and served as a Marine Infantry and Special Operations Officer for over eight years. In 2014, he was medically retired due to combat injuries and left paralyzed from the waist down. Since this injury, Derek has earned an MBA from the UCLA Anderson School of Management and founded both UroDev and Habit Camera. He also serves as President of the Board for the <a href="https://marineraiderfoundation.org">Marine Raider Foundation</a>.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/derek-herrera-urodev-habit-camera">link to the full interview</a> with Derek if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 13 May 2021 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3049b2b1/9b47181d.mp3" length="52007485" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/fxsVENoRI3Ylqq2nzfXEK9mVQSz355eVXGYfJpDqasQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDIv/MTY3OTQ0MjI1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>4330</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we're catching up with Derek Herrera, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the founder of UroDev, originally Spinal Singularity, as well as Habit Camera, the first low-cost, wireless camera purpose-built for skin inspection and telehealth.UroDev is on the cusp of bringing its Intelliflow device to market, a product uniquely designed for spinal injury patients who have urology conditions like neurogenic bladder that require extensive catheter use. Today, Derek and I are going to chat about his journey from the military to the medical device space, and get into what he’s learned about becoming a first-time entrepreneur with a big idea but not a lot of funding or experience. First, here’s a bit more on Derek’s background: He graduated from the United States Naval Academy and served as a Marine Infantry and Special Operations Officer for over eight years. In 2014, he was medically retired due to combat injuries, and left paralyzed from the waist down. Since this injury, Derek has earned an MBA from the UCLA Anderson School of Management and founded both UroDev and Habit Camera. He also serves as President of the Board for the Marine Raider Foundation. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Derek if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we're catching up with Derek Herrera, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the foun</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Key Mistakes to Avoid in Early-Stage Medical Device Development: Interview with Bob Paulson, CEO of VentureMed</title>
      <itunes:title>Key Mistakes to Avoid in Early-Stage Medical Device Development: Interview with Bob Paulson, CEO of VentureMed</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8406784</guid>
      <link>https://www.medsider.com/interviews/bob-paulson-venturemed</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re catching up with <a href="https://www.linkedin.com/in/bob-paulson-a9278b1">Bob Paulson</a>, the CEO of <a href="https://www.venturemedgroup.com">VentureMed</a>, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leadership roles at Endocardial Solutions, Advanced Bionics, and Medtronic. Bob’s excited multiple medtech startups, and today, he’s going to share his vast expertise, including capital fundraising tips, keys to early-stage medical device product development, and best practices when it comes to clinical evidence and insurance reimbursement. But first, here’s a bit more on Bob’s background:</p><p>In addition to being CEO of VentureMed, he serves as a Director for Veran Medical Technologies and Spineology. Before he got started in medtech, he worked for General Mills, got an MBA from St. Thomas, and went to law school at Vanderbilt. Bob got involved with medical devices at Medtronic in the early 90s and later was CEO of NxThera, which commercialized benign prostate hyperplasia therapies before it was acquired by Boston Scientific. Bob is one of the most knowledgeable executives in the field, and I’m excited to get his take on the business landscape in today’s rapidly-changing healthcare environment.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bob-paulson-venturemed">link to the full interview</a> with Bob Paulson if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re catching up with <a href="https://www.linkedin.com/in/bob-paulson-a9278b1">Bob Paulson</a>, the CEO of <a href="https://www.venturemedgroup.com">VentureMed</a>, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leadership roles at Endocardial Solutions, Advanced Bionics, and Medtronic. Bob’s excited multiple medtech startups, and today, he’s going to share his vast expertise, including capital fundraising tips, keys to early-stage medical device product development, and best practices when it comes to clinical evidence and insurance reimbursement. But first, here’s a bit more on Bob’s background:</p><p>In addition to being CEO of VentureMed, he serves as a Director for Veran Medical Technologies and Spineology. Before he got started in medtech, he worked for General Mills, got an MBA from St. Thomas, and went to law school at Vanderbilt. Bob got involved with medical devices at Medtronic in the early 90s and later was CEO of NxThera, which commercialized benign prostate hyperplasia therapies before it was acquired by Boston Scientific. Bob is one of the most knowledgeable executives in the field, and I’m excited to get his take on the business landscape in today’s rapidly-changing healthcare environment.  Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bob-paulson-venturemed">link to the full interview</a> with Bob Paulson if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Mon, 26 Apr 2021 15:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/17bda60d/98db26ad.mp3" length="43098844" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/miP4hBdG0LhOiRmNWHHMAH4D66u1xSjGJQ2W1IQrYJ8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDEv/MTY3OTQ0MTk0OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3588</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re catching up with Bob Paulson, the CEO of VentureMed, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leadership roles at Endocardial Solutions, Advanced Bionics, and Medtronic. Bob’s excited multiple medtech startups, and today, he’s going to share his vast expertise, including capital fundraising tips, keys to early-stage medical device product development, and best practices when it comes to clinical evidence and insurance reimbursement.But first, here’s a bit more on Bob’s background:In addition to being CEO of VentureMed, he serves as a Director for Veran Medical Technologies and Spineology. Before he got started in medtech, he worked for General Mills, got an MBA from St. Thomas, and went to law school at Vanderbilt. Bob got involved with medical devices at Medtronic in the early 90s and later was CEO of NxThera, which commercialized benign prostate hyperplasia therapies before it was acquired by Boston Scientific. Bob is one of the most knowledgeable executives in the field, and I’m excited to get his take on the business landscape in today’s rapidly-changing healthcare environment. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Bob Paulson if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re catching up with Bob Paulson, the CEO of VentureMed, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leaders</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Take Your Medtech Idea from Zero to One: Interview with Dr. Scott Wolf, Founder of Aerin Medical</title>
      <itunes:title>How to Take Your Medtech Idea from Zero to One: Interview with Dr. Scott Wolf, Founder of Aerin Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8289912</guid>
      <link>https://www.medsider.com/interviews/scott-wolf-aerin-medical</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re chatting with <a href="https://www.linkedin.com/in/sjwolf">Dr. Scott Wolf</a>, a prolific medical device entrepreneur and investor who founded <a href="https://aerinmedical.com">Aerin Medical</a> to bring non-surgical therapies to patients with common nasal airway problems. </p><p>Prior to founding Aerin Medical, Scott started Zeltiq Aesthetics, the maker of CoolSculpting. His other startups include Endogastric Solutions and Cardiac Dimensions, and he was a partner at Prospect Venture Partners as well as VP at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.</p><p>You won’t find many people with more hands-on medtech experience than Dr. Scott Wolf, and today he’s going to share his expertise with the Medsider community. In this interview, we’ll discuss Aerin’s technology, break down the advantages of cash-pay versus insurance reimbursement, and get Scott’s advice for would-be founders hoping to turn a great idea into a real prototype.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/scott-wolf-aerin-medical">link to the full interview</a> with Dr. Scott Wolf if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re chatting with <a href="https://www.linkedin.com/in/sjwolf">Dr. Scott Wolf</a>, a prolific medical device entrepreneur and investor who founded <a href="https://aerinmedical.com">Aerin Medical</a> to bring non-surgical therapies to patients with common nasal airway problems. </p><p>Prior to founding Aerin Medical, Scott started Zeltiq Aesthetics, the maker of CoolSculpting. His other startups include Endogastric Solutions and Cardiac Dimensions, and he was a partner at Prospect Venture Partners as well as VP at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.</p><p>You won’t find many people with more hands-on medtech experience than Dr. Scott Wolf, and today he’s going to share his expertise with the Medsider community. In this interview, we’ll discuss Aerin’s technology, break down the advantages of cash-pay versus insurance reimbursement, and get Scott’s advice for would-be founders hoping to turn a great idea into a real prototype.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/scott-wolf-aerin-medical">link to the full interview</a> with Dr. Scott Wolf if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 07 Apr 2021 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/53e6ee03/563de7e6.mp3" length="34320409" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/qT1UlgVIOwEum-y65rppgUAYp7gNnvI_M3-MkIdoUFw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0NDAv/MTY2ODEwMjE3MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2857</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re chatting with Dr. Scott Wolf, a prolific medical device entrepreneur and investor who founded Aerin Medical to bring non-surgical therapies to patients with common nasal airway problems. Prior to founding Aerin Medical, Scott started Zeltiq Aesthetics, the maker of CoolSculpting. His other startups include Endogastric Solutions and Cardiac Dimensions, and he was a partner at Prospect Venture Partners as well as VP at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.You won’t find many people with more hands-on medtech experience than Dr. Scott Wolf, and today he’s going to share his expertise with the Medsider community. In this interview, we’ll discuss Aerin’s technology, break down the advantages of cash-pay versus insurance reimbursement, and get Scott’s advice for would-be founders hoping to turn a great idea into a real prototype.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Dr. Scott Wolf if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re chatting with Dr. Scott Wolf, a prolific medical device entrepreneur and investor who founded Aerin Medical to bring non-surgical therapies to patients with common nasal airway problems. Prior to founding Aerin Med</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Transition from a Consumer Product to a Medical Device: Interview with Rohan Dixit, CEO of Lief Therapeutics</title>
      <itunes:title>How to Transition from a Consumer Product to a Medical Device: Interview with Rohan Dixit, CEO of Lief Therapeutics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8199175</guid>
      <link>https://www.medsider.com/interviews/rohan-dixit-lief-therapeutics</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of <a href="https://getlief.com">Lief Therapeutics</a>, which makes consumer- and clinical-grade wearable devices for mental health. </p><p>Rohan is a neuroscientist who started his career as a researcher with Stanford and Harvard. Rohan founded BrainBot, his first company, at age 23. He’s been the CEO of Lief since 2015.</p><p>Today, Rohan’s going to break down how Lief started, and we’ll get into product development, how he approaches clinical research, why they initially launched their device as an over-the-counter consumer product, and many other topics related to medtech startups. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/rohan-dixit-lief-therapeutics">link to the full interview</a> with Rohan Dixit if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of <a href="https://getlief.com">Lief Therapeutics</a>, which makes consumer- and clinical-grade wearable devices for mental health. </p><p>Rohan is a neuroscientist who started his career as a researcher with Stanford and Harvard. Rohan founded BrainBot, his first company, at age 23. He’s been the CEO of Lief since 2015.</p><p>Today, Rohan’s going to break down how Lief started, and we’ll get into product development, how he approaches clinical research, why they initially launched their device as an over-the-counter consumer product, and many other topics related to medtech startups. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/rohan-dixit-lief-therapeutics">link to the full interview</a> with Rohan Dixit if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 24 Mar 2021 00:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/427a7ba5/676fed3d.mp3" length="38494324" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/yDXzUAFWi8d8vBEGCHuOXpBmKxwoimZxfL18-NL-qmE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mzkv/MTY2ODEwMjE2OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3205</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of Lief Therapeutics, which makes consumer- and clinical-grade wearable devices for mental health. Rohan is a neuroscientist who started his career as a researcher with Stanford and Harvard. Rohan founded BrainBot, his first company, at age 23. He’s been the CEO of Lief since 2015.Today, Rohan’s going to break down how Lief started, and we’ll get into product development, how he approaches clinical research, why they initially launched their device as an over-the-counter consumer product, and many other topics related to medtech startups. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Rohan Dixit if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of Lief Therapeutics, which makes consumer- and clinical-grade wearable devices for mental health. Rohan is a neuroscientist who started his career as a researcher with</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx</title>
      <itunes:title>The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-8076430</guid>
      <link>https://www.medsider.com/interviews/nadim-yared-cvrx</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with <a href="https://www.linkedin.com/in/nadim-yared">Nadim Yared</a>, the CEO of <a href="https://www.cvrx.com">CVRx</a>, a pioneer in neuromodulation for cardiovascular diseases. </p><p>Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA &amp; CMS. </p><p>But first, here’s a bit more about Nadim Yared and his background: </p><p>Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/nadim-yared-cvrx">link to the full interview</a> with Nadim Yared if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with <a href="https://www.linkedin.com/in/nadim-yared">Nadim Yared</a>, the CEO of <a href="https://www.cvrx.com">CVRx</a>, a pioneer in neuromodulation for cardiovascular diseases. </p><p>Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA &amp; CMS. </p><p>But first, here’s a bit more about Nadim Yared and his background: </p><p>Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.</p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/nadim-yared-cvrx">link to the full interview</a> with Nadim Yared if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 04 Mar 2021 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8a51f1fb/a1e32a04.mp3" length="40491807" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ddotIXHB_Usu7J9tj5jn1Avsnjirpr5tOq2bR3XFrAM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mzgv/MTY2ODEwMjE2My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3372</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re talking with Nadim Yared, the CEO of CVRx, a pioneer in neuromodulation for cardiovascular diseases. Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA &amp;amp; CMS. But first, here’s a bit more about Nadim Yared and his background: Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Nadim Yared if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re talking with Nadim Yared, the CEO of CVRx, a pioneer in neuromodulation for cardiovascular diseases. Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re goi</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>3 Critical Goals Every New Medical Device Should Aim For: Interview with Doug Evans, CEO of Lungpacer Medical</title>
      <itunes:title>3 Critical Goals Every New Medical Device Should Aim For: Interview with Doug Evans, CEO of Lungpacer Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7947916</guid>
      <link>https://www.medsider.com/interviews/doug-evans-lungpacer-medical</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with the CEO of <a href="http://lungpacer.com">Lungpacer Medical</a>, <a href="https://www.linkedin.com/in/doug-evans-7a38126/">Doug Evans</a>. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation. </p><p>Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers &amp; regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics and hear more about Lungpacer’s impressive technology. But first, here’s a bit more about Doug Evans and his background: </p><p>Doug started his career at GE in business development and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.</p><p>Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from medtech experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit. </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/doug-evans-lungpacer-medical">link to the full interview</a> with Doug Evans if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re talking with the CEO of <a href="http://lungpacer.com">Lungpacer Medical</a>, <a href="https://www.linkedin.com/in/doug-evans-7a38126/">Doug Evans</a>. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation. </p><p>Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers &amp; regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics and hear more about Lungpacer’s impressive technology. But first, here’s a bit more about Doug Evans and his background: </p><p>Doug started his career at GE in business development and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.</p><p>Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community. Before we jump into the conversation, I wanted to mention a few things:</p><p>If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. </p><p>Second, if you want even more inside info from medtech experts, think about a <a href="https://medsider.com/subscribe">Medsider premium membership</a>. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit. </p><p>In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to <a href="https://medsider.com/subscribe">medsider.com/subscribe</a> to learn more.</p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/doug-evans-lungpacer-medical">link to the full interview</a> with Doug Evans if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 18 Feb 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c098e1ee/553ed7d0.mp3" length="44382879" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/YYzw2YSyd0bDEGHLfAAKY_bdxVREdYXozvuLw-5oNsk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mzcv/MTY3OTQ0MjcyMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3695</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re talking with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation.Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers &amp;amp; regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics, and hear more about Lungpacer’s impressive technology. But first, here’s a bit more about Doug Evans and his background: Doug started his career at GE in business development, and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from medtech experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit. In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Doug Evans if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re talking with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation.</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health</title>
      <itunes:title>Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7577032</guid>
      <link>https://www.medsider.com/interviews/renee-ryan-cala-health</link>
      <description>
        <![CDATA[<p>We recently caught up with <a href="https://www.linkedin.com/in/renee-ryan-251b161/">Renee Ryan</a>, the CEO of <a href="https://calahealth.com">Cala Health</a>, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community. </p><p>Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage &amp; reimbursement. Renee also gives us some key learnings from her time at Johnson &amp; Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation. </p><p>But first, here’s a bit more on Renee’s background:</p><p>She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson &amp; Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&amp;J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&amp;J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/renee-ryan-cala-health">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>We recently caught up with <a href="https://www.linkedin.com/in/renee-ryan-251b161/">Renee Ryan</a>, the CEO of <a href="https://calahealth.com">Cala Health</a>, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community. </p><p>Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage &amp; reimbursement. Renee also gives us some key learnings from her time at Johnson &amp; Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation. </p><p>But first, here’s a bit more on Renee’s background:</p><p>She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson &amp; Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&amp;J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&amp;J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/renee-ryan-cala-health">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 04 Feb 2021 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/6d55adca/37435df6.mp3" length="9242571" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/q4FNLAoCab2TjU0yDobrBGSWcrHKPt-xVNmIopDqKd4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzYv/MTY2ODEwMjE2MS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>768</itunes:duration>
      <itunes:summary>We recently caught up with Renee Ryan, the CEO of Cala Health, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community. Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage &amp;amp; reimbursement. Renee also gives us some key learnings from her time at Johnson &amp;amp; Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation. But first, here’s a bit more on Renee’s background:She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson &amp;amp; Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&amp;amp;J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&amp;amp;J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today. Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>We recently caught up with Renee Ryan, the CEO of Cala Health, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare a</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Biggest Mistakes to Avoid When Designing Medical Device Prototypes: Interview with Mike Wallace, CEO of DeVoro Medical</title>
      <itunes:title>The Biggest Mistakes to Avoid When Designing Medical Device Prototypes: Interview with Mike Wallace, CEO of DeVoro Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7538767</guid>
      <link>https://www.medsider.com/interviews/mike-wallace-devoro-medical</link>
      <description>
        <![CDATA[<p>We recently caught up with medtech start-up extraordinaire, <a href="https://www.linkedin.com/in/michael-p-wallace-6748013/">Mike Wallace</a>, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of <a href="https://www.devoromedical.com">DeVoro Medical</a>, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.</p><p>Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!</p><p>In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.</p><p>But first, a bit more on Mike’s medtech background:</p><p>Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips). </p><p>Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mike-wallace-devoro-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>We recently caught up with medtech start-up extraordinaire, <a href="https://www.linkedin.com/in/michael-p-wallace-6748013/">Mike Wallace</a>, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of <a href="https://www.devoromedical.com">DeVoro Medical</a>, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.</p><p>Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!</p><p>In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.</p><p>But first, a bit more on Mike’s medtech background:</p><p>Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips). </p><p>Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mike-wallace-devoro-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 28 Jan 2021 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/82ec863b/98cb7a65.mp3" length="12759038" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/tg3KplrJshIho3bt5XeX2czLbcQPr6OMNJJsmxSftwk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzUv/MTY2ODEwMjE1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>1060</itunes:duration>
      <itunes:summary>We recently caught up with medtech start-up extraordinaire, Mike Wallace, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of DeVoro Medical, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.But first, a bit more on Mike’s medtech background:Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips). Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>We recently caught up with medtech start-up extraordinaire, Mike Wallace, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of DeVoro Medical, an early-stage medical device company focused on developing in</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Position Your Medtech Start-Up for an Exit: Interview with Bruce Shook, CEO of Vesper Medical</title>
      <itunes:title>How to Position Your Medtech Start-Up for an Exit: Interview with Bruce Shook, CEO of Vesper Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7297603</guid>
      <link>https://www.medsider.com/interviews/bruce-shook-vesper-medical</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President &amp; CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!</p><p>In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. </p><p>But first, here’s a bit about Bruce Shook’s background:</p><p>Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.</p><p>Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.</p><p>Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bruce-shook-vesper-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President &amp; CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!</p><p>In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. </p><p>But first, here’s a bit about Bruce Shook’s background:</p><p>Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.</p><p>Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.</p><p>Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. </p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/bruce-shook-vesper-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Thu, 14 Jan 2021 23:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4888e8e5/d2c3f97b.mp3" length="11274356" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/LP9JoVFqDNXf5stEmIzT9uoAA0uRiYUk16QJfCuB6DM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzQv/MTY2ODEwMjE1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>937</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President &amp;amp; CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. But first, here’s a bit about Bruce Shook’s background:Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President &amp;amp; CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!I</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Key Lessons for Developing an Insurance Coverage and Reimbursement Strategy: Interview with Mike Kujak, CEO of Francis Medical</title>
      <itunes:title>Key Lessons for Developing an Insurance Coverage and Reimbursement Strategy: Interview with Mike Kujak, CEO of Francis Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7281826</guid>
      <link>https://medsider.com/interviews/mike-kujak-francis-medical</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio,  we’re talking with Mike Kujak, the President &amp; CEO of Francis Medical.</p><p>Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha &amp; beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan &amp; execute a clinical research strategy.</p><p>Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program. </p><p>But first, a bit more on Mike's background...</p><p>Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.</p><p>Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mike-kujak-francis-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio,  we’re talking with Mike Kujak, the President &amp; CEO of Francis Medical.</p><p>Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha &amp; beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan &amp; execute a clinical research strategy.</p><p>Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program. </p><p>But first, a bit more on Mike's background...</p><p>Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.</p><p>Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.</p><p>Before we jump into the conversation, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com/">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/mike-kujak-francis-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Wed, 13 Jan 2021 23:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d8bf9414/9a29d042.mp3" length="8573380" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/zN_nLL45slfWPAfIAmZpGUDI3GbEe23hZ6M-M9FXQVE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzMv/MTY2ODEwMjE1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>711</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio,  we’re talking with Mike Kujak, the President &amp;amp; CEO of Francis Medical.Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha &amp;amp; beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan &amp;amp; execute a clinical research strategy.Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program. But first, a bit more on Mike's background...Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.Before we jump into the conversation, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio,  we’re talking with Mike Kujak, the President &amp;amp; CEO of Francis Medical.Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha &amp;amp; beta versions of a m</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Most Important Piece of Advice for Raising Medtech Venture Capital: Interview with Sean Saint, Founder of Companion Medical</title>
      <itunes:title>The Most Important Piece of Advice for Raising Medtech Venture Capital: Interview with Sean Saint, Founder of Companion Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-7146592</guid>
      <link>https://www.medsider.com/interviews/sean-saint-companion-medical</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:</p><ul><li>How Sean and his team at Companion Medical came up with the idea for the InPen.</li><li>Sean's advice for raising money from medtech investors.</li><li>Companion Medical's insurance and reimbursement strategy for the InPen.</li></ul><p><br>There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/sean-saint-companion-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:</p><ul><li>How Sean and his team at Companion Medical came up with the idea for the InPen.</li><li>Sean's advice for raising money from medtech investors.</li><li>Companion Medical's insurance and reimbursement strategy for the InPen.</li></ul><p><br>There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:</p><p>First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. </p><p>So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.</p><p>I’ve never tried this before, so let me know what you think!</p><p>Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to <a href="https://medsider.com">Medsider.com</a>. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. </p><p>Lastly, here's the <a href="https://www.medsider.com/interviews/sean-saint-companion-medical">link to the full interview</a> if you'd rather read it instead.</p>]]>
      </content:encoded>
      <pubDate>Tue, 05 Jan 2021 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/9c6439b1/e64c4810.mp3" length="10141376" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/AB5juiTlbM8GbovAwPAHckytrPJJR8fjFuNpecnzT10/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzIv/MTY2ODEwMjE1My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>842</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:How Sean and his team at Companion Medical came up with the idea for the InPen.Sean's advice for raising money from medtech investors.Companion Medical's insurance and reimbursement strategy for the InPen.There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.I’ve never tried this before, so let me know what you think!Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we cover</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>	 How to Fund Your Medical Device Startup: Interview with Rich Ferrari, Managing Director of De Novo Ventures</title>
      <itunes:title>	 How to Fund Your Medical Device Startup: Interview with Rich Ferrari, Managing Director of De Novo Ventures</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6735505</guid>
      <link>https://www.medsider.com/interviews/fund-medtech-startups-capital-efficient-manner-interview-rich-ferrari-denovo-ventures</link>
      <description>
        <![CDATA[<p>This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.</p><p>On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VCs in the Medtech space. Here are some of the points we covered:</p><ul><li>Novel ways to fund early-stage medical device companies.</li><li>The metrics that are most important when it comes to early-stage versus late-stage medtech investing.</li><li>Why does the FDA “runway” seem to get longer and longer over time?</li><li>How Rich identifies and validates whether an idea is truly disruptive.</li></ul><p><a href="https://medsider.com/interviews/fund-medtech-startups-capital-efficient-manner-interview-rich-ferrari-denovo-ventures/">Download the transcript here.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.</p><p>On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VCs in the Medtech space. Here are some of the points we covered:</p><ul><li>Novel ways to fund early-stage medical device companies.</li><li>The metrics that are most important when it comes to early-stage versus late-stage medtech investing.</li><li>Why does the FDA “runway” seem to get longer and longer over time?</li><li>How Rich identifies and validates whether an idea is truly disruptive.</li></ul><p><a href="https://medsider.com/interviews/fund-medtech-startups-capital-efficient-manner-interview-rich-ferrari-denovo-ventures/">Download the transcript here.</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 09 Dec 2020 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/252fd836/9079f397.mp3" length="26770958" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/f78HpZ9UirtQixTdkm8acrbiim_RxAecIzKnY_i22Y0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzEv/MTY3OTAxOTA2OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2228</itunes:duration>
      <itunes:summary>This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VC’s in the medtech space. Here are some of the points we covered:Novel ways to fund early-stage medical device companies.The metrics that are most important when it comes to early-stage versus late-stage medtech investing.Why does the FDA “runway” seem to get longer and longer over time?How Rich identifies and validates whether an idea is truly disruptive.Download the transcript here.</itunes:summary>
      <itunes:subtitle>This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ven</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Enhance your Medical Device Approval Process: Interview with Sheila Heyer, President of Heyer Regulatory Solutions</title>
      <itunes:title>How to Enhance your Medical Device Approval Process: Interview with Sheila Heyer, President of Heyer Regulatory Solutions</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6693311</guid>
      <link>https://medsider.com/interviews/how-to-enhance-your-medical-device-approval-process-interview-sheila-hemeon-heyer-president-heyer-regulatory-solutions/</link>
      <description>
        <![CDATA[<p>We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.</p><p>In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:</p><ul><li>The three most important steps you can take right now to get your medical device approved faster.</li><li>Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.</li><li>The key characteristics that great medtech regulatory professionals all have in common.</li></ul><p><a href="https://medsider.com/interviews/how-to-enhance-your-medical-device-approval-process-interview-sheila-hemeon-heyer-president-heyer-regulatory-solutions/">Check out the full interview here.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.</p><p>In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:</p><ul><li>The three most important steps you can take right now to get your medical device approved faster.</li><li>Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.</li><li>The key characteristics that great medtech regulatory professionals all have in common.</li></ul><p><a href="https://medsider.com/interviews/how-to-enhance-your-medical-device-approval-process-interview-sheila-hemeon-heyer-president-heyer-regulatory-solutions/">Check out the full interview here.</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 04 Dec 2020 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2a4d33b5/e5694081.mp3" length="26148107" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/svKDV9RXYm-R4G6fzOO6i6sqyqvxFCxpgn_fggxuD80/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MzAv/MTY3OTAxOTMxOC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2176</itunes:duration>
      <itunes:summary>We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:The three most important steps you can take right now to get your medical device approved faster.Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.The key characteristics that great medtech regulatory professionals all have in common.Check out the full interview here.</itunes:summary>
      <itunes:subtitle>We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Glob</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>What it Takes to Get a Medtech VC to Say Yes: Interview with Lisa Suennen</title>
      <itunes:title>What it Takes to Get a Medtech VC to Say Yes: Interview with Lisa Suennen</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6520549</guid>
      <link>https://medsider.com/interviews/what-takes-get-medtech-vc-say-yes-interview-lisa-suennen-psilos-group/</link>
      <description>
        <![CDATA[<p>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.</p><p>One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the things we covered:</p><ul><li>What does Lisa think when the goal of physicians is to “dagger historical price lists."</li><li>Why Lisa and her partners at the Psilos Group favor late-stage deals.</li><li>Corporate venture capital arms: friend or foe? </li><li>And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?</li></ul><p><a href="https://medsider.com/interviews/what-takes-get-medtech-vc-say-yes-interview-lisa-suennen-psilos-group/">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.</p><p>One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the things we covered:</p><ul><li>What does Lisa think when the goal of physicians is to “dagger historical price lists."</li><li>Why Lisa and her partners at the Psilos Group favor late-stage deals.</li><li>Corporate venture capital arms: friend or foe? </li><li>And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?</li></ul><p><a href="https://medsider.com/interviews/what-takes-get-medtech-vc-say-yes-interview-lisa-suennen-psilos-group/">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Mon, 23 Nov 2020 23:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4c0ae43d/3e7dac87.mp3" length="30324681" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/wqX-Z026XvFZPJWIq6Gxbbgezq_72xSri8vSlebSPpw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mjkv/MTY3OTAxODUwMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2524</itunes:duration>
      <itunes:summary>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the thing we covered:What does Lisa think when the goal of physicians is to “dagger historical price lists."Why Lisa and her partners at the Psilos Group favor late-stage deals.Corporate venture capital arms: friend or foe? And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?See more...</itunes:summary>
      <itunes:subtitle>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-fo</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Art of Medical Device Reimbursement: Interview with Randel Richner, Founder of Neocure Group</title>
      <itunes:title>The Art of Medical Device Reimbursement: Interview with Randel Richner, Founder of Neocure Group</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6424873</guid>
      <link>https://www.medsider.com/interviews/art-of-medical-device-reimbursement-interview-with-randel-richner-founder-president-neocure</link>
      <description>
        <![CDATA[<p>This interview is a continuation of a throwback mini-series I’ve been releasing over the past few weeks with some of my favorite Medsider guests.</p><p>On this particular episode, I chatted with Randel Richner, a true expert in healthcare economics and reimbursement.  At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign. Although this discussion is several years old and the audio quality isn’t ideal, Randel's insights are timeless. Here are some of the things we covered:</p><ul><li>A case study of how Randel helped save a medical device company from severe reimbursement implications.</li><li>Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.</li><li>The importance of defining the difference between how hospitals get paid and how physicians get paid.</li><li>And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.</li></ul><p><a href="https://www.medsider.com/interviews/art-of-medical-device-reimbursement-interview-with-randel-richner-founder-president-neocure">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview is a continuation of a throwback mini-series I’ve been releasing over the past few weeks with some of my favorite Medsider guests.</p><p>On this particular episode, I chatted with Randel Richner, a true expert in healthcare economics and reimbursement.  At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign. Although this discussion is several years old and the audio quality isn’t ideal, Randel's insights are timeless. Here are some of the things we covered:</p><ul><li>A case study of how Randel helped save a medical device company from severe reimbursement implications.</li><li>Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.</li><li>The importance of defining the difference between how hospitals get paid and how physicians get paid.</li><li>And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.</li></ul><p><a href="https://www.medsider.com/interviews/art-of-medical-device-reimbursement-interview-with-randel-richner-founder-president-neocure">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 17 Nov 2020 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e8b7cf91/077a5dd0.mp3" length="23951282" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/E4d3UJFWxU6hcKFHL0wrxfqFuTU54u-TLitEdKT5Jkc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mjgv/MTY3OTAxODY2Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>1993</itunes:duration>
      <itunes:summary>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.On this particular episode, I chatted with Randel Richner, a true expert when it comes to healthcare economics and reimbursement.  At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign.Although this discussion is several years old and the audio quality isn’t ideal, the insights Randel provides are timeless. Here are some of the thing we covered:A case study of how Randel helped save a medical device company from severe reimbursement implications.Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.The importance of defining the difference between how hospitals get paid and how physicians get paid.And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.See more...</itunes:summary>
      <itunes:subtitle>This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.On this particular episode, I chatted with Randel Richner, a true expert when it comes to hea</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>What Medtech Venture Capitalists Want to See in Your Startup</title>
      <itunes:title>What Medtech Venture Capitalists Want to See in Your Startup</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6310975</guid>
      <link>https://medsider.com/interviews/medtech-venture-capital-dead-in-water/</link>
      <description>
        <![CDATA[<p>This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:</p><ul><li>What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success. </li><li>What requirements would make for an attractive IPO opportunity?</li><li>What questions should medtech startups have already answered before approaching a potential buyer?</li><li>And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?</li></ul><p><a href="https://medsider.com/interviews/medtech-venture-capital-dead-in-water/">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:</p><ul><li>What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success. </li><li>What requirements would make for an attractive IPO opportunity?</li><li>What questions should medtech startups have already answered before approaching a potential buyer?</li><li>And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?</li></ul><p><a href="https://medsider.com/interviews/medtech-venture-capital-dead-in-water/">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Tue, 10 Nov 2020 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ba4dcbf7/fc089dad.mp3" length="23126752" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/7z4P-SMJHu1zAt4RTbqpwJo3P3-6C3YDRxlOPWQjE-I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0Mjcv/MTY3OTAxODMzNS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>1924</itunes:duration>
      <itunes:summary>This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success. What requirements would make for an attractive IPO opportunity?What questions should medtech startups have already answered before approaching a potential buyer?And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?See more...</itunes:summary>
      <itunes:subtitle>This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>4 Ideas Your Medical Device Company is Missing from its Marketing Strategy: Interview with Joe Hage, Chairman of the Medical Devices Group</title>
      <itunes:title>4 Ideas Your Medical Device Company is Missing from its Marketing Strategy: Interview with Joe Hage, Chairman of the Medical Devices Group</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6222151</guid>
      <link>https://medsider.com/interviews/4-ideas-medical-device-company-missing-from-marketing-strategy-interview-joe-hage-medical-marcom/</link>
      <description>
        <![CDATA[<p>This interview is part of a throwback mini-series from several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:</p><ul><li>How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.</li><li>Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.</li><li>How you can use editorials to demonstrate medical device industry leadership.</li><li>And why sending prospects to your website homepage may not be the best idea.</li></ul><p><a href="https://medsider.com/interviews/4-ideas-medical-device-company-missing-from-marketing-strategy-interview-joe-hage-medical-marcom/">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview is part of a throwback mini-series from several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:</p><ul><li>How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.</li><li>Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.</li><li>How you can use editorials to demonstrate medical device industry leadership.</li><li>And why sending prospects to your website homepage may not be the best idea.</li></ul><p><a href="https://medsider.com/interviews/4-ideas-medical-device-company-missing-from-marketing-strategy-interview-joe-hage-medical-marcom/">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Nov 2020 18:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/3e125add/65b0988b.mp3" length="33721684" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/dqKJIUILMXK1BuknXVto8JjFAd0VztWb__ObLe7P2Uo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjYv/MTY3OTAxNzgxOS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2807</itunes:duration>
      <itunes:summary>This interview is part of a throwback mini-series to several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.How you can use editorials to demonstrate medical device industry leadership.And why sending prospects to your website homepage may not be the best idea.See more...</itunes:summary>
      <itunes:subtitle>This interview is part of a throwback mini-series to several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this ente</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Incredible Story of How Dr. David Albert Brought the AliveCor ECG iPhone App to Market</title>
      <itunes:title>The Incredible Story of How Dr. David Albert Brought the AliveCor ECG iPhone App to Market</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-6015607</guid>
      <link>https://medsider.com/interviews/having-heart-attack-app-for-that-the-incredible-story-of-how-dr-david-albert-brought-the-ecg-iphone-app-to-marke/</link>
      <description>
        <![CDATA[<p>This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:</p><ul><li>The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!</li><li>The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.</li><li>Five key lessons you can learn from Dr. Albert’s experiences. </li><li>And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.</li></ul><p><a href="https://medsider.com/interviews/having-heart-attack-app-for-that-the-incredible-story-of-how-dr-david-albert-brought-the-ecg-iphone-app-to-marke/">Click here to learn more.</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:</p><ul><li>The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!</li><li>The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.</li><li>Five key lessons you can learn from Dr. Albert’s experiences. </li><li>And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.</li></ul><p><a href="https://medsider.com/interviews/having-heart-attack-app-for-that-the-incredible-story-of-how-dr-david-albert-brought-the-ecg-iphone-app-to-marke/">Click here to learn more.</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 22 Oct 2020 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4cd20962/4baffff3.mp3" length="35449222" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/4UMo56_YcGJPWfLjw3MPXFGWAvDMeLeKbU1uDw9JveU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjUv/MTY3ODgzODA2Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2951</itunes:duration>
      <itunes:summary>This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.Five key lessons you can learn from Dr. Albert’s experiences. And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.Click here to learn more.</itunes:summary>
      <itunes:subtitle>This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:The amazing story of how AliveCor’s iPhone app helped save a </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Win with Contract Manufacturers: Interview with Travis Sessions, CEO of Biomerics</title>
      <itunes:title>How to Win with Contract Manufacturers: Interview with Travis Sessions, CEO of Biomerics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-5079755</guid>
      <link>https://share.transistor.fm/s/e0c4c280</link>
      <description>
        <![CDATA[<p>On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of <a href="https://biomerics.com/">Biomerics</a>, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of <a href="http://medventureholdings.com/">Med Venture Holdings</a>, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan. </p><p><strong>Interview Highlights with Travis Sessions:</strong></p><ul><li>Macro trends within the medtech market, including Travis’ thoughts on the future.</li><li>Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).</li><li>Critical things that OEMs should look for when identifying and working with CMs.</li><li>The origin story of Med Venture Holdings.</li><li>What Travis looks for when vetting early-stage medtech ideas.</li><li>Critical functions that need to be in place for a medical device startup to be acquired.</li><li>Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/travis-sessions-biomerics-med-venture-holdings">Learn more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of <a href="https://biomerics.com/">Biomerics</a>, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of <a href="http://medventureholdings.com/">Med Venture Holdings</a>, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan. </p><p><strong>Interview Highlights with Travis Sessions:</strong></p><ul><li>Macro trends within the medtech market, including Travis’ thoughts on the future.</li><li>Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).</li><li>Critical things that OEMs should look for when identifying and working with CMs.</li><li>The origin story of Med Venture Holdings.</li><li>What Travis looks for when vetting early-stage medtech ideas.</li><li>Critical functions that need to be in place for a medical device startup to be acquired.</li><li>Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/travis-sessions-biomerics-med-venture-holdings">Learn more...</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 20 Aug 2020 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/e0c4c280/2189874e.mp3" length="33987925" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ltcaKX12tFhgfz_C0hlolNJTdvDugDgF7pDkkY4IU-Q/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjQv/MTY3ODgzNzg0NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2828</itunes:duration>
      <itunes:summary>On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of Biomerics, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of Med Venture Holdings, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan. Interview Highlights with Travis Sessions:Macro trends within the medtech market, including Travis’ thoughts on the future.Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).Critical things that OEMs should look for when identifying and working with CMs.The origin story of Med Venture Holdings.What Travis looks for when vetting early-stage medtech ideas.Critical functions that need to be in place for a medical device startup to be acquired.Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.Learn more...</itunes:summary>
      <itunes:subtitle>On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of Biomerics, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of Med Venture Holdings, a unique medtech</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Clinical Trials as Revenue Drivers: Interview with Matthew Amsden, CEO of ProofPilot</title>
      <itunes:title>Clinical Trials as Revenue Drivers: Interview with Matthew Amsden, CEO of ProofPilot</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-4675493</guid>
      <link>https://medsider.com/interviews/matthew-amsden-proofpilot</link>
      <description>
        <![CDATA[<p>In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder, and CEO of <a href="https://proofpilot.com/">ProofPilot</a>, a platform designed to help people design, launch and participate in clinical trials.</p><p>ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun.      </p><p>In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.</p><p><strong>Interview Highlights with Matthew Amsden</strong></p><ul><li>Who is Matthew Amsden and where did the idea for ProofPilot begin?    </li><li>The importance of letting early customers try product iterations.</li><li>How clinical studies can become a revenue driver. </li><li>Various types of clinical trials and how they’re conducted on the ProofPilot platform.</li><li>Risky and costly approaches to traditional clinical studies.     </li><li>The synergy between data, compliance, and incentives.</li><li>How a virtual, hybrid model can solve problems when it comes to traditional clinical trials. </li><li>Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/matthew-amsden-proofpilot">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder, and CEO of <a href="https://proofpilot.com/">ProofPilot</a>, a platform designed to help people design, launch and participate in clinical trials.</p><p>ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun.      </p><p>In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.</p><p><strong>Interview Highlights with Matthew Amsden</strong></p><ul><li>Who is Matthew Amsden and where did the idea for ProofPilot begin?    </li><li>The importance of letting early customers try product iterations.</li><li>How clinical studies can become a revenue driver. </li><li>Various types of clinical trials and how they’re conducted on the ProofPilot platform.</li><li>Risky and costly approaches to traditional clinical studies.     </li><li>The synergy between data, compliance, and incentives.</li><li>How a virtual, hybrid model can solve problems when it comes to traditional clinical trials. </li><li>Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/matthew-amsden-proofpilot">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 22 Jul 2020 21:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d6df43ed/cc847b8c.mp3" length="57285656" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/33JXG9hKt7BywcW-qPhjLf3fMdFwB2rMvbzvDKcsh54/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjMv/MTY3ODgzNjgwMS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3578</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder and CEO of ProofPilot, a platform designed to help people design, launch and participate in clinical trials.ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun.      In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.Interview Highlights with Matthew AmsdenWho is Matthew Amsden and where did the idea for ProofPilot begin?    The importance of letting early customers try product iterations.How clinical studies can become a revenue driver. Various types of clinical trials and how they’re conducted on the ProofPilot platform.Risky and costly approaches to traditional clinical studies.     The synergy between data, compliance, and incentives.How a virtual, hybrid model can solve problems when it comes to traditional clinical trials. Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old-self.See more...</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder and CEO of ProofPilot, a platform designed to help people design, launch and participate in clinical trials.ProofPilot’s mission statement revolves around making it incredibly eas</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Practicing Strategic Patience is Critical for Medtech Entrepreneurs: Interview with Dr. Tej Singh, Founder of Fist Assist Devices</title>
      <itunes:title>Why Practicing Strategic Patience is Critical for Medtech Entrepreneurs: Interview with Dr. Tej Singh, Founder of Fist Assist Devices</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-4583072</guid>
      <link>https://medsider.com/interviews/dr-tej-sing-fist-assist-devices/</link>
      <description>
        <![CDATA[<p>Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures and is acutely focused on his first company, <a href="http://fistassistdevices.com">Fist Assist Devices</a>. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement. </p><p>In this episode, Dr. Singh and I talk about the primary challenge that<em> </em>First Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more.      </p><p><strong>Interview Highlights with Dr. Tej Singh</strong></p><ul><li>Who is Dr. Tej Singh and what is his background?</li><li>What are Fist Assist Devices and what challenges are they trying to solve?</li><li>The origin story for their first product and the critical inflection points for the company.    </li><li>How Dr. Singh evaluated the IP landscape for his first device. </li><li>Dr. Singh’s approach to mapping out clinical trial strategies.</li><li>How he navigated the insurance coverage and reimbursement landscape.</li><li>His unique approach to strategic patience and why it’s crucial for medtech startups.</li><li>Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/dr-tej-sing-fist-assist-devices/">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures and is acutely focused on his first company, <a href="http://fistassistdevices.com">Fist Assist Devices</a>. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement. </p><p>In this episode, Dr. Singh and I talk about the primary challenge that<em> </em>First Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more.      </p><p><strong>Interview Highlights with Dr. Tej Singh</strong></p><ul><li>Who is Dr. Tej Singh and what is his background?</li><li>What are Fist Assist Devices and what challenges are they trying to solve?</li><li>The origin story for their first product and the critical inflection points for the company.    </li><li>How Dr. Singh evaluated the IP landscape for his first device. </li><li>Dr. Singh’s approach to mapping out clinical trial strategies.</li><li>How he navigated the insurance coverage and reimbursement landscape.</li><li>His unique approach to strategic patience and why it’s crucial for medtech startups.</li><li>Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/dr-tej-sing-fist-assist-devices/">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 15 Jul 2020 19:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0441ed07/f38f1ec6.mp3" length="48931955" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/jIAGVo3CJKkfOfJ1uiKzVe4g4VKe6IIkCHVV0KClq34/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjIv/MTY3ODgzNzY1NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3056</itunes:duration>
      <itunes:summary>Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures, and is acutely focused on his first company, Fist Assist Devices. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement. In this episode, Dr. Singh and I talk about the primary challenge that Fist Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more.      Interview Highlights with Dr. Tej SinghWho is Dr. Tej Singh and what is his background?What is Fist Assist Devices and what challenges are they trying to solve?The origin story for their first product and the critical inflection points for the company.    How Dr. Singh evaluated the IP landscape for his first device. Dr. Singh’s approach to mapping out clinical trial strategies.How he navigated the insurance coverage and reimbursement landscape.His unique approach to strategic patience and why it’s crucial for medtech startups.Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.See more...</itunes:summary>
      <itunes:subtitle>Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures, and is acutely </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Remote Testing Can Change the Game for Patients and Clinicians: Interview with Katherine Ward of Healthy.io</title>
      <itunes:title>How Remote Testing Can Change the Game for Patients and Clinicians: Interview with Katherine Ward of Healthy.io</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-4501763</guid>
      <link>https://medsider.com/interviews/katherine-ward-healthy-io</link>
      <description>
        <![CDATA[<p>I recently <a href="https://medsider.com/interviews/katherine-ward-healthy-io">sat down with Katherine Ward</a>, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was the Chief Executive with United Health UK and Chief Growth Officer with Optimum International. </p><p>In this conversation, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, clinical-grade population health technology, decentralized remote diagnostic screening, and how their technology works with existing health systems. </p><p><strong>Interview Highlights with Katherine Ward</strong></p><ul><li>Who is Katherine and what is her background?</li><li>What is Healthy.io and what challenges or problems do they solve for patients and clinicians?</li><li>Why the time finally come for decentralized remote diagnostic screening, using urine testing as an example.</li><li>Lessons on the importance of virtual testing from the COVID-19 crisis.</li><li>How Healthy.io has approached the regulatory and reimbursement landscapes, including their clinical trial strategy.</li><li>How their population health technology works together (with and within) existing healthcare systems.</li><li>Katherine’s favorite genre of books, the leader she most admires, and the advice she’d give to her younger self.</li></ul><p><a href="https://medsider.com/interviews/katherine-ward-healthy-io">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>I recently <a href="https://medsider.com/interviews/katherine-ward-healthy-io">sat down with Katherine Ward</a>, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was the Chief Executive with United Health UK and Chief Growth Officer with Optimum International. </p><p>In this conversation, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, clinical-grade population health technology, decentralized remote diagnostic screening, and how their technology works with existing health systems. </p><p><strong>Interview Highlights with Katherine Ward</strong></p><ul><li>Who is Katherine and what is her background?</li><li>What is Healthy.io and what challenges or problems do they solve for patients and clinicians?</li><li>Why the time finally come for decentralized remote diagnostic screening, using urine testing as an example.</li><li>Lessons on the importance of virtual testing from the COVID-19 crisis.</li><li>How Healthy.io has approached the regulatory and reimbursement landscapes, including their clinical trial strategy.</li><li>How their population health technology works together (with and within) existing healthcare systems.</li><li>Katherine’s favorite genre of books, the leader she most admires, and the advice she’d give to her younger self.</li></ul><p><a href="https://medsider.com/interviews/katherine-ward-healthy-io">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 09 Jul 2020 11:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0b437671/bfbe5bdc.mp3" length="44643671" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Sac2QeeQPWiRNmxFvdOCJzULYJt9nJa6PAowHODCoE4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjEv/MTY3ODgzNTg4NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2788</itunes:duration>
      <itunes:summary>I recently sat down with Katherine Ward, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was the Chief Executive with United Health UK and Chief Growth Officer with Optimum International. In this conversation, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, clinical-grade population health technology, decentralized remote diagnostic screening, and how their technology works with existing health systems. Interview Highlights with Katherine WardWho is Katherine and what is her background?What is Healthy.io and what challenges or problems do they solve for patients and clinicians?Why the time finally come for decentralized remote diagnostic screening, using urine testing as an example.Lessons on the importance of virtual testing from the COVID-19 crisis.How Healthy.io has approached the regulatory and reimbursement landscapes, including their clinical trial strategy.How their population health technology works together (with and within) existing healthcare systems.Katherine’s favorite genre of books, the leader she most admires, and the advice she’d give to her younger self.See more...</itunes:summary>
      <itunes:subtitle>I recently sat down with Katherine Ward, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Medtech Companies Can Enhance Procedural Workflow and Capture Intra-Operative Data: Interview with Jennifer Fried, CEO of ExplORer Surgical</title>
      <itunes:title>How Medtech Companies Can Enhance Procedural Workflow and Capture Intra-Operative Data: Interview with Jennifer Fried, CEO of ExplORer Surgical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-3872522</guid>
      <link>https://medsider.com/interviews/jennifer-fried-explorer-surgical</link>
      <description>
        <![CDATA[<p>In this episode of <a href="https://medsider.com">Medsider Radio</a>, we downloaded with Jennifer Fried, the CEO and Co-Founder of <a href="https://explorersurgical.com/">ExplORer Surgical</a>. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in finance and entrepreneurship.</p><p>Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain &amp; Company in Chicago after graduating from Northwestern University.</p><p>With me on this episode is special guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, who runs Sales Performance Resources, where he specializes in recruiting for medical device marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Jennifer Fried</strong></p><p>● How most medical device companies capture procedural data &amp; workflow processes -- and why it’s completely outdated. </p><p>● The challenges medtech companies are facing when it comes to educational training &amp; product development and why they’re considering platforms like ExplORer Surgical.</p><p>● Jennifer’s favorite business book, the business leader she most admires, and the advice she’d give to herself 5-10 years ago.</p><p><a href="https://medsider.com/interviews/jennifer-fried-explorer-surgical">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this episode of <a href="https://medsider.com">Medsider Radio</a>, we downloaded with Jennifer Fried, the CEO and Co-Founder of <a href="https://explorersurgical.com/">ExplORer Surgical</a>. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in finance and entrepreneurship.</p><p>Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain &amp; Company in Chicago after graduating from Northwestern University.</p><p>With me on this episode is special guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, who runs Sales Performance Resources, where he specializes in recruiting for medical device marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Jennifer Fried</strong></p><p>● How most medical device companies capture procedural data &amp; workflow processes -- and why it’s completely outdated. </p><p>● The challenges medtech companies are facing when it comes to educational training &amp; product development and why they’re considering platforms like ExplORer Surgical.</p><p>● Jennifer’s favorite business book, the business leader she most admires, and the advice she’d give to herself 5-10 years ago.</p><p><a href="https://medsider.com/interviews/jennifer-fried-explorer-surgical">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 22 May 2020 14:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/439c1bd3/04410048.mp3" length="38489672" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/xtgsXKLf4lLF1dtxjJRIFEXMD5SHs87H765iXicW-cU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MjAv/MTY3ODgzNTYyMy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2404</itunes:duration>
      <itunes:summary>In this episode of Medsider Radio, we downloaded with Jennifer Fried, the CEO and Co-Founder of ExplORer Surgical. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in finance and entrepreneurship.Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain &amp;amp; Company in Chicago after graduating from Northwestern University.With me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, where he specializes in recruiting for medical device marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. Interview Highlights with Jennifer Fried● How most medical device companies capture procedural data &amp;amp; workflow processes -- and why it’s completely outdated. ● The challenges medtech companies are facing when it comes to educational training &amp;amp; product development and why they’re considering platforms like ExplORer Surgical.● Jennifer’s favorite business book, the business leader she most admires, and the advice she’d give to herself 5-10 years ago.See more...</itunes:summary>
      <itunes:subtitle>In this episode of Medsider Radio, we downloaded with Jennifer Fried, the CEO and Co-Founder of ExplORer Surgical. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she rece</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Use Checks and Balances in Your Medtech Start-Up: Interview with Michael Tozzi, President and CEO of TAS Medical</title>
      <itunes:title>How to Use Checks and Balances in Your Medtech Start-Up: Interview with Michael Tozzi, President and CEO of TAS Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-3588820</guid>
      <link>https://medsider.com/interviews/mike-tozzi-tas-medical</link>
      <description>
        <![CDATA[<p>On <a href="https://medsider.com/interviews/mike-tozzi-tas-medical/">this episode of Medsider Radio</a>, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.</p><p>Mike has over 20 years of commercial medical device experience and specializes in investor relations, sales &amp; marketing readiness, and improving the execution of early-stage medical device companies. </p><p>Previous to TAS Medical, Mike served as Chief Commercial Officer at Carevoyance, where he and his team created groundbreaking analytics tools designed to help medical device companies better understand their markets and execute their commercial goals.</p><p>Prior to this, Mike helped to build Cardiovascular Systems, Inc. (or CSI) from the ground floor, taking the company from an early stage to over $1.3 billion in market capitalization in just seven years. At CSI, Mike held various executive roles in sales and marketing. </p><p>Joining me on this episode is special guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, who runs Sales Performance Resources, which specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Mike Tozzi</strong></p><ul><li>The origin story of TAS Medical and how Mike got involved.</li><li>The strategies that TAS Medical followed to go from initial product concept to eventual commercialization.</li><li>The regulatory and clinical paths that Mike and his team considered.</li><li>How much did the insurance coverage and reimbursement landscape factor into Mike’s early decision-making process?</li><li>Mike’s approach to raising capital for CSI and TAS Medical. </li><li>Common mistakes that early-stage medtech companies make and how to avoid them.</li><li>Mike’s favorite book, the business leader he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/mike-tozzi-tas-medical">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>On <a href="https://medsider.com/interviews/mike-tozzi-tas-medical/">this episode of Medsider Radio</a>, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.</p><p>Mike has over 20 years of commercial medical device experience and specializes in investor relations, sales &amp; marketing readiness, and improving the execution of early-stage medical device companies. </p><p>Previous to TAS Medical, Mike served as Chief Commercial Officer at Carevoyance, where he and his team created groundbreaking analytics tools designed to help medical device companies better understand their markets and execute their commercial goals.</p><p>Prior to this, Mike helped to build Cardiovascular Systems, Inc. (or CSI) from the ground floor, taking the company from an early stage to over $1.3 billion in market capitalization in just seven years. At CSI, Mike held various executive roles in sales and marketing. </p><p>Joining me on this episode is special guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, who runs Sales Performance Resources, which specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Mike Tozzi</strong></p><ul><li>The origin story of TAS Medical and how Mike got involved.</li><li>The strategies that TAS Medical followed to go from initial product concept to eventual commercialization.</li><li>The regulatory and clinical paths that Mike and his team considered.</li><li>How much did the insurance coverage and reimbursement landscape factor into Mike’s early decision-making process?</li><li>Mike’s approach to raising capital for CSI and TAS Medical. </li><li>Common mistakes that early-stage medtech companies make and how to avoid them.</li><li>Mike’s favorite book, the business leader he most admires, and the advice he’d give to his 30-year-old self.</li></ul><p><a href="https://medsider.com/interviews/mike-tozzi-tas-medical">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Sat, 02 May 2020 07:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7a5aabde/b5d5f15a.mp3" length="47174004" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/m4zUDDYqEu8Od1z5gTc8-dcMdeYlu-Z8bL2gv_787oc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTkv/MTY3ODgzNzE2Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2946</itunes:duration>
      <itunes:summary>On this episode of Medsider Radio, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.Mike has over 20 years of commercial medical device experience and specializes in investor relations, sales &amp;amp; marketing readiness, and improving the execution of early-stage medical device companies.. Previous to TAS Medical, Mike served as Chief Commercial Officer at Carevoyance, where he and his team created groundbreaking analytics tools designed to help medical device companies better understand their markets and execute their commercial goals.Prior to this, Mike helped to build Cardiovascular Systems, Inc. (or CSI) from the ground floor, taking the company from early stage to over $1.3 billion in market capitalization in just seven years. At CSI, Mike held various executive roles in sales and marketing. Joining me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, which specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. Interview Highlights with Mike TozziThe origin story of TAS Medical and how Mike got involved.The strategies that TAS Medical followed to go from initial product concept to eventual commercialization.The regulatory and clinical paths that Mike and his team considered.How much the insurance coverage and reimbursement landscape factored into Mike’s early decision-making process.Mike’s approach to raising capital for CSI and TAS Medical. Common mistakes that early-stage medtech companies make and how to avoid them.Mike’s favorite book, the business leader he most admires, and the advice he’d give to his 30-year old self.See more...</itunes:summary>
      <itunes:subtitle>On this episode of Medsider Radio, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.Mike has over 20 ye</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Resiliency and Relentlessness are Crucial for Raising Medtech Capital: Interview with Beverly Huss, President and CEO of Qool Therapeutics</title>
      <itunes:title>Resiliency and Relentlessness are Crucial for Raising Medtech Capital: Interview with Beverly Huss, President and CEO of Qool Therapeutics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-3490465</guid>
      <link>https://medsider.com/interviews/beverly-huss-qool-therapeutics</link>
      <description>
        <![CDATA[<p>Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.</p><p>Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.</p><p>She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.</p><p>With me on this episode is guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Beverly Huss</strong></p><ul><li>The origin story of Qool Therapeutics and how Beverly got involved with the company.</li><li>The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.</li><li>Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.</li><li>Key learnings from Beverly’s time at Vibrynt. </li><li>The “other R&amp;R”: the importance of resilience and relentlessness when you are raising money for a company.</li><li>How to get the attention of medical device venture capitalists.</li><li>Critical lessons Beverly throughout her career at ACS and Guidant.</li><li>Beverly’s favorite books and how they inspire resiliency.</li><li>The business leaders and mentors that Beverly most admires.</li><li>Advice Beverly would give to her 30-year old self.</li></ul><p><a href="https://medsider.com/interviews/beverly-huss-qool-therapeutics">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.</p><p>Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.</p><p>She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.</p><p>With me on this episode is guest host, <a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. </p><p><strong>Interview Highlights with Beverly Huss</strong></p><ul><li>The origin story of Qool Therapeutics and how Beverly got involved with the company.</li><li>The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.</li><li>Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.</li><li>Key learnings from Beverly’s time at Vibrynt. </li><li>The “other R&amp;R”: the importance of resilience and relentlessness when you are raising money for a company.</li><li>How to get the attention of medical device venture capitalists.</li><li>Critical lessons Beverly throughout her career at ACS and Guidant.</li><li>Beverly’s favorite books and how they inspire resiliency.</li><li>The business leaders and mentors that Beverly most admires.</li><li>Advice Beverly would give to her 30-year old self.</li></ul><p><a href="https://medsider.com/interviews/beverly-huss-qool-therapeutics">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 24 Apr 2020 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/5def1625/ead0724a.mp3" length="47343715" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/PWyUOgIYBTtHfxSkhJKBxC5YLVwuQZ7MO4tNPxARzAg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTgv/MTY3ODczNjM0NS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2957</itunes:duration>
      <itunes:summary>Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.With me on this episode is guest host, Norbert Juist, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. Interview Highlights with Beverly HussThe origin story of Qool Therapeutics and how Beverly got involved with the company.The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.Key learnings from Beverly’s time at Vibrynt. The “other R&amp;amp;R”: the importance of resilience and relentlessness when you are raising money for a company.How to get the attention of medical device venture capitalists.Critical lessons Beverly throughout her career at ACS and Guidant.Beverly’s favorite books and how they inspire resiliency.The business leaders and mentors that Beverly most admires.Advice Beverly would give to her 30-year old self.See more...</itunes:summary>
      <itunes:subtitle>Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Essential Tips for First-Time Medtech CEOs: Interview with Dan Rose, CEO of LimFlow</title>
      <itunes:title>Essential Tips for First-Time Medtech CEOs: Interview with Dan Rose, CEO of LimFlow</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-2992129</guid>
      <link>https://medsider.com/interviews/dan-rose-limflow</link>
      <description>
        <![CDATA[<p>I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company <a href="http://www.limflow.com/">LimFlow</a>. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing. </p><p>Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company. </p><p>Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.</p><p>Here are a few of the topics we discuss in this episode:</p><ul><li>How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.</li><li>How Med Start played an instrumental role in the launch and ultimate success of LimFlow.</li><li>Why it’s essential to find a physician champion willing to invest time and energy in your tech.</li><li>Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.</li><li>Key factors you can’t ignore if you want to succeed as a first-time CEO.</li><li>Why investing in independent market research is well worth the cost.</li><li>Why the FDA Breakthrough Devices Program has been a game changer in the US.</li></ul><p><a href="https://medsider.com/interviews/dan-rose-limflow">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company <a href="http://www.limflow.com/">LimFlow</a>. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing. </p><p>Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company. </p><p>Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.</p><p>Here are a few of the topics we discuss in this episode:</p><ul><li>How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.</li><li>How Med Start played an instrumental role in the launch and ultimate success of LimFlow.</li><li>Why it’s essential to find a physician champion willing to invest time and energy in your tech.</li><li>Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.</li><li>Key factors you can’t ignore if you want to succeed as a first-time CEO.</li><li>Why investing in independent market research is well worth the cost.</li><li>Why the FDA Breakthrough Devices Program has been a game changer in the US.</li></ul><p><a href="https://medsider.com/interviews/dan-rose-limflow">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Thu, 12 Mar 2020 17:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f8e30d76/1e9e402b.mp3" length="48064557" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/bBhVqEYaANmGvEuqHyaVv3mBJ-Lyb8cZMIhOHnqqyYs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTcv/MTY3ODgzNDk1Mi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3002</itunes:duration>
      <itunes:summary>I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company LimFlow. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing. Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company. Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.Here are a few of the topics we discuss in this episode:How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.How Med Start played an instrumental role in the launch and ultimate success of LimFlow.Why it’s essential to find a physician champion willing to invest time and energy in your tech.Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.Key factors you can’t ignore if you want to succeed as a first-time CEO.Why investing in independent market research is well worth the cost.Why the FDA Breakthrough Devices Program has been a game changer in the US.See more...</itunes:summary>
      <itunes:subtitle>I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company LimFlow. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:chapters url="https://share.transistor.fm/s/f8e30d76/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>How Failure and Flexibility Can Spell Success in Medtech: Interview With Kyle Frye, U.S. President of SyntheticMR</title>
      <itunes:title>How Failure and Flexibility Can Spell Success in Medtech: Interview With Kyle Frye, U.S. President of SyntheticMR</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-2918752</guid>
      <link>https://medsider.com/interviews/kyle-frye-leverage-medical-device-failures-success/</link>
      <description>
        <![CDATA[<p>After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of <a href="https://www.syntheticmr.com/">SyntheticMR</a>, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based company that is creating the future of quantitative MRI technology. Their innovative MRI software solutions support shorter exam times and deliver more information to clinicians, leading to improved diagnostic efficacies.</p><p>Prior to assuming this role in August 2019, Kyle was a Zone Vice President of Sales for Siemens and also was in leadership positions at both niche and large medtech companies including Blue Belt Technologies (now Smith &amp; Nephew), Verathon, and Brainlab. He also worked for BioMedix for three years, working his way up from a sales rep driving 4–5 hours a day to Western Area Sales Director, which required relocation from metro Cincinnati to the San Francisco Bay area. Kyle received a B.A. degree in political science and finance from Northern Kentucky University in 2004.</p><p><a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, an executive recruiter who specializes in medical device sales and marketing, joined me as a special guest for this interview with Kyle. He brings a unique perspective to this discussion, having worked as a sales rep and consultant in pharma and medtech for nearly 20 years prior to transitioning to recruiting.</p><p>Here are a few of the key topics we discussed in this podcast: </p><ul><li>Why a competitive spirit and winning are important, but not the “be-all and end-all” to medical device success.</li><li>Why communicating “the why” of career moves is key to landing new opportunities.</li><li>How being flexible and willing to relocate can help advance your career, especially in the medtech space.</li><li>The pros and cons of working for large vs. small companies.</li><li>Kyle’s favorite business books, the importance of having a mentor, and the advice he would tell his 25-year-old self.</li></ul><p><a href="https://medsider.com/interviews/kyle-frye-leverage-medical-device-failures-success/">Check out the rest of the show notes here...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of <a href="https://www.syntheticmr.com/">SyntheticMR</a>, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based company that is creating the future of quantitative MRI technology. Their innovative MRI software solutions support shorter exam times and deliver more information to clinicians, leading to improved diagnostic efficacies.</p><p>Prior to assuming this role in August 2019, Kyle was a Zone Vice President of Sales for Siemens and also was in leadership positions at both niche and large medtech companies including Blue Belt Technologies (now Smith &amp; Nephew), Verathon, and Brainlab. He also worked for BioMedix for three years, working his way up from a sales rep driving 4–5 hours a day to Western Area Sales Director, which required relocation from metro Cincinnati to the San Francisco Bay area. Kyle received a B.A. degree in political science and finance from Northern Kentucky University in 2004.</p><p><a href="https://www.linkedin.com/in/norbertjuist/">Norbert Juist</a>, an executive recruiter who specializes in medical device sales and marketing, joined me as a special guest for this interview with Kyle. He brings a unique perspective to this discussion, having worked as a sales rep and consultant in pharma and medtech for nearly 20 years prior to transitioning to recruiting.</p><p>Here are a few of the key topics we discussed in this podcast: </p><ul><li>Why a competitive spirit and winning are important, but not the “be-all and end-all” to medical device success.</li><li>Why communicating “the why” of career moves is key to landing new opportunities.</li><li>How being flexible and willing to relocate can help advance your career, especially in the medtech space.</li><li>The pros and cons of working for large vs. small companies.</li><li>Kyle’s favorite business books, the importance of having a mentor, and the advice he would tell his 25-year-old self.</li></ul><p><a href="https://medsider.com/interviews/kyle-frye-leverage-medical-device-failures-success/">Check out the rest of the show notes here...</a></p>]]>
      </content:encoded>
      <pubDate>Wed, 04 Mar 2020 21:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ed131138/7d896e59.mp3" length="50529592" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/lgvvPoY4HuecLMA7RLbgFuJY46rNL1xfQJ1wmY5SmTs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTYv/MTY3ODgzNjQ0MC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3156</itunes:duration>
      <itunes:summary>After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of SyntheticMR, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based company that is creating the future of quantitative MRI technology. Their innovative MRI software solutions support shorter exam times and deliver more information to clinicians, leading to improved diagnostic efficacies.Prior to assuming this role in August 2019, Kyle was a Zone Vice President of Sales for Siemens, and also was in leadership positions at both niche and large medtech companies including Blue Belt Technologies (now Smith &amp;amp; Nephew), Verathon, and Brainlab. He also worked for BioMedix for three years, working his way up from a sales rep driving 4–5 hours a day to Western Area Sales Director, which required relocation from metro Cincinnati to the San Francisco Bay area. Kyle received a B.A. degree in political science and finance from Northern Kentucky University in 2004.Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, joined me as a special guest for this interview with Kyle. He brings a unique perspective to this discussion, having worked as a sales rep and consultant in pharma and medtech for nearly 20 years prior to transitioning to recruiting.Here are a few of the key topics we discussed in this podcast: Why a competitive spirit and winning are important, but not the “be-all and end-all” to medical device success.Why communicating “the why” of career moves is key to landing new opportunities.How being flexible and willing to relocate can help advance your career, especially in the medtech space.The pros and cons of working for large vs. small companies.Kyle’s favorite business books, the importance of having a mentor, and the advice he would tell his 25-year-old self.Check out the rest of the show notes here...</itunes:summary>
      <itunes:subtitle>After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of SyntheticMR, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based compa</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Ruthless Prioritization and How it Can Help Every Medtech Startup: Interview With Paul Buckman Former CEO of Conventus, SentreHEART, and Pathway Medical Technologies</title>
      <itunes:title>Ruthless Prioritization and How it Can Help Every Medtech Startup: Interview With Paul Buckman Former CEO of Conventus, SentreHEART, and Pathway Medical Technologies</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-2685565</guid>
      <link>https://medsider.com/interviews/paul-buckman-interview-medtech-startup-priortiization/</link>
      <description>
        <![CDATA[<p>A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. </p><p>Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical. </p><p>Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.</p><p>Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University. </p><p>Here are a few of the things we’re going to learn in this interview with Paul:</p><p>- Of all the medtech startups that Paul’s been a part of, the two are closest to his heart.<br>- Two of the many key learnings that Paul recalls during his time helping to build Scimed.<br>- When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization?</p><p><a href="https://medsider.com/interviews/paul-buckman-interview-medtech-startup-priortiization/">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. </p><p>Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical. </p><p>Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.</p><p>Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University. </p><p>Here are a few of the things we’re going to learn in this interview with Paul:</p><p>- Of all the medtech startups that Paul’s been a part of, the two are closest to his heart.<br>- Two of the many key learnings that Paul recalls during his time helping to build Scimed.<br>- When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization?</p><p><a href="https://medsider.com/interviews/paul-buckman-interview-medtech-startup-priortiization/">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Sat, 08 Feb 2020 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/11f04606/ef4be386.mp3" length="55302432" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/A5rXd4J5kGYDNDcqWC350dt40jBBwtxvbL-naViPwWo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTQv/MTY3ODgzNzM3OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3454</itunes:duration>
      <itunes:summary>A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical. Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University. Here are a few of the things we’re going to learn in this interview with Paul:- Of all the medtech startups that Paul’s been a part of, the two that are closest to his heart.- Two of the many key learnings that Paul recalls during his time helping to build Scimed.- When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization.See more...</itunes:summary>
      <itunes:subtitle>A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which </itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Move Forward After a Thumbs Down from FDA: Interview with Kevin Sidow, Former CEO and President of Moximed</title>
      <itunes:title>How to Move Forward After a Thumbs Down from FDA: Interview with Kevin Sidow, Former CEO and President of Moximed</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-2689312</guid>
      <link>https://medsider.com/interviews/kevin-sidow-interview-ceo-president-moximed-depuy</link>
      <description>
        <![CDATA[<p>In late 2016, I was able to sit down with Kevin Sidow. At the time he was President &amp; Chief Executive Officer for Moximed and had been since 2008.</p><p>Prior to his time at Moximed, Kevin was President &amp; CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.</p><p>Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.</p><p>Here are a few of the things we learned from Kevin:</p><p>- How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.<br>- What makes the Atlas System different than other orthopedic knee implants?<br>- How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.</p><p><a href="https://medsider.com/interviews/kevin-sidow-interview-ceo-president-moximed-depuy">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In late 2016, I was able to sit down with Kevin Sidow. At the time he was President &amp; Chief Executive Officer for Moximed and had been since 2008.</p><p>Prior to his time at Moximed, Kevin was President &amp; CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.</p><p>Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.</p><p>Here are a few of the things we learned from Kevin:</p><p>- How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.<br>- What makes the Atlas System different than other orthopedic knee implants?<br>- How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.</p><p><a href="https://medsider.com/interviews/kevin-sidow-interview-ceo-president-moximed-depuy">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Sat, 08 Feb 2020 16:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/41f1ebeb/73bfec92.mp3" length="40067350" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/IgA6D_UOfOUojJ7F-7R6tUsb79vVo6RXLZjvlXO86xQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTUv/MTY3ODgzNjE4OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2502</itunes:duration>
      <itunes:summary>In late 2016, I was able to sit down with Kevin Sidow. At the time he was President &amp;amp; Chief Executive Officer for Moximed, and had been since 2008.Prior to his time at Moximed, Kevin was President &amp;amp; CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.Here are a few of the things we learned from Kevin:- How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.- What makes the Atlas System different than other orthopedic knee implants.- How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.See more...</itunes:summary>
      <itunes:subtitle>In late 2016, I was able to sit down with Kevin Sidow. At the time he was President &amp;amp; Chief Executive Officer for Moximed, and had been since 2008.Prior to his time at Moximed, Kevin was President &amp;amp; CEO for St. Francis Medical Technologies, a priv</itunes:subtitle>
      <itunes:keywords>medtech, medical device, healthcare, healthtech, regulatory, reimbursement, startup, entrepreneur, health care, med tech, med-tech, health tech, health-tech</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Keeping The End in Mind is Critical for Every Medtech Entrepreneur: Interview with Erica Rogers, CEO of Silk Road Medical</title>
      <itunes:title>Why Keeping The End in Mind is Critical for Every Medtech Entrepreneur: Interview with Erica Rogers, CEO of Silk Road Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">Buzzsprout-2516185</guid>
      <link>https://medsider.com/interviews/erica-rogers-interview-silk-road-medical</link>
      <description>
        <![CDATA[<p>In this <a href="https://medsider.com/interviews/erica-rogers-interview-silk-road-medical">two-part interview</a>, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.</p><p>During our catch up, we discussed how Erica led her team at Silk Road through PMA approval, successful insurance coverage and reimbursement strategy, which led to a very rewarding public offering for Silk Road, opening at $20 a share. This resulted in the opportunity to continue the company’s goal, which is to change the standard of care in carotid artery disease with their TCAR procedure.</p><p>Much of our first conversation was about Erica’s career trajectory and how she was able to successfully, and gracefully, exit multiple medtech companies. Her lengthy career and insight as a medtech thought leader is just as interesting today as it was when we recorded our conversation.</p><p>Before leading Silk Road, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009.</p><p>Prior to that, Erica spent over 12 years at Boston Scientific in a variety of sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in Zoology from San Diego State University. Erica holds five issued and 15 pending US patents for medical devices in nanotechnology. </p><p><a href="https://medsider.com/interviews/erica-rogers-interview-silk-road-medical">See more...</a></p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>In this <a href="https://medsider.com/interviews/erica-rogers-interview-silk-road-medical">two-part interview</a>, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.</p><p>During our catch up, we discussed how Erica led her team at Silk Road through PMA approval, successful insurance coverage and reimbursement strategy, which led to a very rewarding public offering for Silk Road, opening at $20 a share. This resulted in the opportunity to continue the company’s goal, which is to change the standard of care in carotid artery disease with their TCAR procedure.</p><p>Much of our first conversation was about Erica’s career trajectory and how she was able to successfully, and gracefully, exit multiple medtech companies. Her lengthy career and insight as a medtech thought leader is just as interesting today as it was when we recorded our conversation.</p><p>Before leading Silk Road, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009.</p><p>Prior to that, Erica spent over 12 years at Boston Scientific in a variety of sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in Zoology from San Diego State University. Erica holds five issued and 15 pending US patents for medical devices in nanotechnology. </p><p><a href="https://medsider.com/interviews/erica-rogers-interview-silk-road-medical">See more...</a></p>]]>
      </content:encoded>
      <pubDate>Fri, 17 Jan 2020 20:00:00 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/53745d48/54a15afe.mp3" length="69290232" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/taNPwbNPrtZzzSVa1wzeDwUJYzz4ZorP_HjZZyu4I_0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTMv/MTY3ODgzNTM4My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>4329</itunes:duration>
      <itunes:summary>In this two-part interview, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.During our catch up, we discussed how Erica led her team at Silk Road through PMA approval, successful insurance coverage and reimbursement strategy, which led to a very rewarding public offering for Silk Road, opening at $20 a share. This resulted in the opportunity to continue the company’s goal, which is to change the standard of care in carotid artery disease with their TCAR procedure.Much of our first conversation was about Erica’s career trajectory and how she was able to successfully, and gracefully, exit multiple medtech companies. Her lengthy career and insight as a medtech thought leader is just as interesting today as it was when we recorded our conversation.Before leading Silk Road, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009.Prior to that, Erica spent over 12 years at Boston Scientific in a variety of sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in Zoology from San Diego State University. Erica holds five issued and 15 pending US patents for medical devices in nanotechnology. See more...</itunes:summary>
      <itunes:subtitle>In this two-part interview, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.During our c</itunes:subtitle>
      <itunes:keywords>medsider, medtech, medical device, healthcare, shockwave</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Focusing on Pain Killers is Imperative for Medical Device Startups: Interview with Daniel Hawkins, CEO of Shockwave Medical</title>
      <itunes:title>Why Focusing on Pain Killers is Imperative for Medical Device Startups: Interview with Daniel Hawkins, CEO of Shockwave Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3772</guid>
      <link>https://share.transistor.fm/s/774aeadc</link>
      <description>
        <![CDATA[<p>Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public...[<a href="https://medsider.com/interviews/daniel-hawkins-interview-shockwave-medical-focus-pain-killers-medical-device-startups/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public...[<a href="https://medsider.com/interviews/daniel-hawkins-interview-shockwave-medical-focus-pain-killers-medical-device-startups/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 06 Apr 2017 01:58:14 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/774aeadc/4962523c.mp3" length="29241116" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/Wn9wE2TULjXcGj54P0D-RoDJOdudKHB4Ygv4XuzJ_k0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTIv/MTY2ODEwMjExMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2435</itunes:duration>
      <itunes:summary>Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior </itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Importance of Having Investors as Customers: Interview with Eric Stone, CEO of Velano Vascular</title>
      <itunes:title>The Importance of Having Investors as Customers: Interview with Eric Stone, CEO of Velano Vascular</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3767</guid>
      <link>https://share.transistor.fm/s/b11f21d5</link>
      <description>
        <![CDATA[<p>Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano’s first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investment firms, leading U.S. health systems, and dozens of health industry veterans. Before starting Velano Vascular, Stone most recently served...[<a href="https://medsider.com/interviews/eric-stone-velano-vascular-importance-investors-as-customers-medtech/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano’s first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investment firms, leading U.S. health systems, and dozens of health industry veterans. Before starting Velano Vascular, Stone most recently served...[<a href="https://medsider.com/interviews/eric-stone-velano-vascular-importance-investors-as-customers-medtech/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 16 Mar 2017 17:26:31 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/b11f21d5/fbe301c7.mp3" length="36149340" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/phyrtVKBmw2JzEtj4_XxP4ttZ7EPBoV6CbVEL1HnK7M/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTEv/MTY2ODEwMjExMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3011</itunes:duration>
      <itunes:summary>Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano’s first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investment firms, leading U.S. health systems, and dozens of health industry veterans. Before starting Velano Vascular, Stone most recently served...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano’s first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investm</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK</title>
      <itunes:title>The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3759</guid>
      <link>https://share.transistor.fm/s/f2366056</link>
      <description>
        <![CDATA[<p>Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the...[<a href="https://medsider.com/interviews/biggest-mistakes-medical-device-companies-make-commercializing-europe-interview-michael-branagan-harris-ceo-device-access-uk/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the...[<a href="https://medsider.com/interviews/biggest-mistakes-medical-device-companies-make-commercializing-europe-interview-michael-branagan-harris-ceo-device-access-uk/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 07 Mar 2017 23:07:03 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f2366056/61799ba5.mp3" length="29827152" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/11wwb0MJZDo1UTtFGIiLE7k5TtoMWFR7w6exN_1U-o8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MTAv/MTY2ODEwMjExMi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2481</itunes:duration>
      <itunes:summary>Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the...[read more]Related StoriesHow Will These 2 Major Healthcare Changes Affect Medical Device Companies?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical Devices </itunes:summary>
      <itunes:subtitle>Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction</itunes:subtitle>
      <itunes:keywords>Radio,Regulatory and Reimbursement,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular</title>
      <itunes:title>Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3754</guid>
      <link>https://share.transistor.fm/s/8ce3b9d4</link>
      <description>
        <![CDATA[<p>Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously...[<a href="https://medsider.com/interviews/bruce-shook-intact-vascular-conquering-coverage-reimbursement-landscape/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously...[<a href="https://medsider.com/interviews/bruce-shook-intact-vascular-conquering-coverage-reimbursement-landscape/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 21 Feb 2017 20:33:41 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/8ce3b9d4/3e08e5e6.mp3" length="30647048" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/CqTGO1qKqpjKa7bHuf5tyDwkXTQuvjKHpgGnn9gaqqI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDkv/MTY2ODEwMjEwOS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2550</itunes:duration>
      <itunes:summary>Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privat</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical</title>
      <itunes:title>How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3750</guid>
      <link>https://share.transistor.fm/s/d5e6ca61</link>
      <description>
        <![CDATA[<p>Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a...[<a href="https://medsider.com/interviews/dr-bob-smouse-brightwater-medical-physician-medtech-entrepreneur/">read more</a>]<br><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a...[<a href="https://medsider.com/interviews/dr-bob-smouse-brightwater-medical-physician-medtech-entrepreneur/">read more</a>]<br><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 09 Feb 2017 22:08:46 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/d5e6ca61/7feccc20.mp3" length="34103313" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DzKywuRJiSKiEpy2TkSZcudUKSNgFSX0-N0t6HMQN7E/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDgv/MTY2ODEwMjEwNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2838</itunes:duration>
      <itunes:summary>Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular</title>
      <itunes:title>Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3744</guid>
      <link>https://share.transistor.fm/s/aa4f4abd</link>
      <description>
        <![CDATA[<p>More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of...[<a href="https://medsider.com/interviews/marie-johnson-aum-cardiovascular-manage-clinical-trial-small-team-raising-money-medtech-startup/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of...[<a href="https://medsider.com/interviews/marie-johnson-aum-cardiovascular-manage-clinical-trial-small-team-raising-money-medtech-startup/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 01 Feb 2017 04:04:20 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/aa4f4abd/710b4cc1.mp3" length="29491029" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3VJRtKaCvkoTUt9uGgaBlPoLH5WuCSZX3vzo9xdOoiI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDcv/MTY2ODEwMjEwNy1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2453</itunes:duration>
      <itunes:summary>More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured pla</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx</title>
      <itunes:title>The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3727</guid>
      <link>https://share.transistor.fm/s/c1988183</link>
      <description>
        <![CDATA[<p>Shaun Bagai is the CEO of RenovoRx.  He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most<a href="https://medsider.com/interviews/shaun-bagai-renovorx-medtech-networking-renal-denervation-cross-functional-experience/">...[read more]<br></a><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Shaun Bagai is the CEO of RenovoRx.  He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most<a href="https://medsider.com/interviews/shaun-bagai-renovorx-medtech-networking-renal-denervation-cross-functional-experience/">...[read more]<br></a><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Sun, 22 Jan 2017 01:51:26 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/c1988183/99de4657.mp3" length="31037750" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/rcRHmCE9du1cpZyV4riXqb8O0Cn1Nms4u9cwY6E-uJk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDYv/MTY2ODEwMjEwNi1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2582</itunes:duration>
      <itunes:summary>Shaun Bagai is the CEO of RenovoRx.  He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Shaun Bagai is the CEO of RenovoRx.  He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation,</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens</title>
      <itunes:title>The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3720</guid>
      <link>https://share.transistor.fm/s/6a719b9a</link>
      <description>
        <![CDATA[<p>Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson &amp; Johnson from early 2010 through early 2012 as...[<a href="https://medsider.com/interviews/bill-facteau-earlens-medical-device-sales-acclarent-medtech-personal-growth/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson &amp; Johnson from early 2010 through early 2012 as...[<a href="https://medsider.com/interviews/bill-facteau-earlens-medical-device-sales-acclarent-medtech-personal-growth/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Mon, 09 Jan 2017 11:09:17 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/6a719b9a/e616278b.mp3" length="32381258" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/PV_AXdn6SyCwXP5uD_5-iP-3LNTpu32oUbfdDenUXWk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDUv/MTY2ODEwMjA5Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2694</itunes:duration>
      <itunes:summary>Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson &amp;amp; Johnson from early 2010 through early 2012 as...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Assoc</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger</title>
      <itunes:title>Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3714</guid>
      <link>https://share.transistor.fm/s/764cd5eb</link>
      <description>
        <![CDATA[<p><a href="https://www.linkedin.com/in/john-simpson-5a652287/">Dr. John Simpson</a>.  Even if you’re a medical device newbie, you’ve probably heard of him.  He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career...[<a href="https://medsider.com/interviews/curiosity-persistence-medtech-entrepreneurs-dr-john-simpson-avinger/">read more</a>]</p><p><strong>Related Stories</strong></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p><a href="https://www.linkedin.com/in/john-simpson-5a652287/">Dr. John Simpson</a>.  Even if you’re a medical device newbie, you’ve probably heard of him.  He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career...[<a href="https://medsider.com/interviews/curiosity-persistence-medtech-entrepreneurs-dr-john-simpson-avinger/">read more</a>]</p><p><strong>Related Stories</strong></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 06 Dec 2016 02:48:45 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/764cd5eb/6d4730c9.mp3" length="28643431" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/DhRCss_RDgl_m64ksKvtWpiYgwNVJ2kL_4E1hPI9vBM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDQv/MTY2ODEwMjA5Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2383</itunes:duration>
      <itunes:summary>Dr. John Simpson.  Even if you’re a medical device newbie, you’ve probably heard of him.  He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Dr. John Simpson.  Even if you’re a medical device newbie, you’ve probably heard of him.  He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This singl</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>4 Rounds of Financing, CE Mark, FDA Clearance, and a Category 1 CPT Code – How NeoTract has Grinded its Way to Success Over the Past Decade</title>
      <itunes:title>4 Rounds of Financing, CE Mark, FDA Clearance, and a Category 1 CPT Code – How NeoTract has Grinded its Way to Success Over the Past Decade</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3663</guid>
      <link>https://share.transistor.fm/s/375e6827</link>
      <description>
        <![CDATA[<p>Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.”   In the world of medtech startups, this is almost always the case.  And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[<a href="https://medsider.com/interviews/4-rounds-financing-ce-mark-fda-clearance-cpt-code-neotract-urolift-ted-lamson/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.”   In the world of medtech startups, this is almost always the case.  And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[<a href="https://medsider.com/interviews/4-rounds-financing-ce-mark-fda-clearance-cpt-code-neotract-urolift-ted-lamson/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 11 Oct 2016 01:58:37 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/375e6827/40bfb613.mp3" length="41093908" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/B4uD2ObmPMLVOOWbgQhPfTQ9vTDr5U1_wJG-16YMT-s/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDMv/MTY2ODEwMjA5Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3420</itunes:duration>
      <itunes:summary>Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.”   In the world of medtech startups, this is almost always the case.  And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?How Will These 2 Major Healthcare Changes Affect Medical Device Companies? </itunes:summary>
      <itunes:subtitle>Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.”   In the world of medtech startups, this is almost always the case.  And it’s certainly true</itunes:subtitle>
      <itunes:keywords>Radio,Regulatory and Reimbursement,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Patient Engagement for Medtech Companies is Hard – Here’s Some Advice on How to Do it Right</title>
      <itunes:title>Patient Engagement for Medtech Companies is Hard – Here’s Some Advice on How to Do it Right</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3645</guid>
      <link>https://share.transistor.fm/s/00da8a31</link>
      <description>
        <![CDATA[<p>Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new...[<a href="https://medsider.com/interviews/patient-engagement-advice-best-practices-medtech-medical-device/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new...[<a href="https://medsider.com/interviews/patient-engagement-advice-best-practices-medtech-medical-device/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 11 Aug 2016 16:57:22 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/00da8a31/986ed694.mp3" length="35764461" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/tJNzJzR97U5G2QihBJv4G7YCRoGQQsE6fwjDiSV8SOQ/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDIv/MTY2ODEwMjA5OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2976</itunes:duration>
      <itunes:summary>Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup? </itunes:summary>
      <itunes:subtitle>Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to </itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Demystifying Value-Based Healthcare – A Physician Expert Explains All (with Real-World Examples)</title>
      <itunes:title>Demystifying Value-Based Healthcare – A Physician Expert Explains All (with Real-World Examples)</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3651</guid>
      <link>https://share.transistor.fm/s/2a86e6dd</link>
      <description>
        <![CDATA[<p>CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018.  And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. But the topic of value-based healthcare can be pretty confusing , right?  Comprehensive Care for Joint Replacement.  Medicare Access...[<a href="https://medsider.com/interviews/demystifying-value-based-healthcare-physician-expert-explains-real-world-examples-dan-mazanec/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018.  And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. But the topic of value-based healthcare can be pretty confusing , right?  Comprehensive Care for Joint Replacement.  Medicare Access...[<a href="https://medsider.com/interviews/demystifying-value-based-healthcare-physician-expert-explains-real-world-examples-dan-mazanec/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Sun, 17 Jul 2016 15:10:48 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/2a86e6dd/59322074.mp3" length="29580710" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/mMvImbQVdgjy2Wbhq-bjo8dLnHJn2RP9FdQdNmrwD8I/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDEv/MTY2ODEwMjA5NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2461</itunes:duration>
      <itunes:summary>CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018.  And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. But the topic of value-based healthcare can be pretty confusing , right?  Comprehensive Care for Joint Replacement.  Medicare Access...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup? </itunes:summary>
      <itunes:subtitle>CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018.  And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. Bu</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Regulatory and Reimbursement,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Is Off-Label Promotion Now Legal?  What the Recent Criminal Case Against Vascular Solutions Means for Medtech</title>
      <itunes:title>Is Off-Label Promotion Now Legal?  What the Recent Criminal Case Against Vascular Solutions Means for Medtech</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3634</guid>
      <link>https://share.transistor.fm/s/57b62048</link>
      <description>
        <![CDATA[<p>For as long as I can remember, at every company meeting I’ve ever been to, the topic of off-label promotion is always covered.  Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-label information was always presented as not only a fireable offense, but something that could get you...[<a href="https://medsider.com/interviews/off-label-promotion-legal-vascular-solutions-criminal-case-medtech-implications/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>For as long as I can remember, at every company meeting I’ve ever been to, the topic of off-label promotion is always covered.  Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-label information was always presented as not only a fireable offense, but something that could get you...[<a href="https://medsider.com/interviews/off-label-promotion-legal-vascular-solutions-criminal-case-medtech-implications/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 08 Jun 2016 19:19:10 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/57b62048/98fe0025.mp3" length="29868653" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/XUbDHL4ABU-cTUXBL00_QqM_GsBEfR_SJcLluQKfVPU/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTM0MDAv/MTY2ODEwMjA4OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2485</itunes:duration>
      <itunes:summary>For as long as I can remember, at every company meeting I’ve ever been to, the topic of off-label promotion is always covered.  Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-label information was always presented as not only a fireable offense, but something that could get you...[read more]Related StoriesHow Will These 2 Major Healthcare Changes Affect Medical Device Companies?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical Devices </itunes:summary>
      <itunes:subtitle>For as long as I can remember, at every company meeting I’ve ever been to, the topic of off-label promotion is always covered.  Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-l</itunes:subtitle>
      <itunes:keywords>Radio,Regulatory and Reimbursement,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics</title>
      <itunes:title>After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3622</guid>
      <link>https://share.transistor.fm/s/7d2df1ce</link>
      <description>
        <![CDATA[<p>Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen.  Duke led FoxHollow Technologies...[<a href="https://medsider.com/interviews/selling-2-cardiovascular-companies-over-1-billion-duke-rohlen-now-hoping-spirox-advanced-catheter-therapeutics/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen.  Duke led FoxHollow Technologies...[<a href="https://medsider.com/interviews/selling-2-cardiovascular-companies-over-1-billion-duke-rohlen-now-hoping-spirox-advanced-catheter-therapeutics/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 31 May 2016 20:12:56 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/7d2df1ce/abd71cef.mp3" length="28999945" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/kO828Z9WoEUtAtazJX9UDMWFDcqTcTQ5ngV-9_LhvWg/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTkv/MTY2ODEwMjA4OS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2413</itunes:duration>
      <itunes:summary>Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen.  Duke led FoxHollow Technologies...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter.  Why?  Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version o</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>From an Idea on the Back of a Napkin to an Eventual $240 Million Exit – The Amazing Story of Sapheon</title>
      <itunes:title>From an Idea on the Back of a Napkin to an Eventual $240 Million Exit – The Amazing Story of Sapheon</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3602</guid>
      <link>https://share.transistor.fm/s/70b59f2e</link>
      <description>
        <![CDATA[<p>I’ll be candid. This is an interview I’ve wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflux. The more I learned about Sapheon through the diligence process (as well as...[<a href="https://medsider.com/interviews/napkin-idea-250-million-dollar-exit-sapheon-story-interview-don-crawford/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>I’ll be candid. This is an interview I’ve wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflux. The more I learned about Sapheon through the diligence process (as well as...[<a href="https://medsider.com/interviews/napkin-idea-250-million-dollar-exit-sapheon-story-interview-don-crawford/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 14 Apr 2016 19:59:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/70b59f2e/49b5b409.mp3" length="34299556" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/UxxpI28mpifPWThw9TXjdqX5C2OJT0lbO5_6WX2qbpM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTgv/MTY2ODEwMjA4OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2854</itunes:duration>
      <itunes:summary>I’ll be candid. This is an interview I’ve wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflux. The more I learned about Sapheon through the diligence process (as well as...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>I’ll be candid. This is an interview I’ve wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflu</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>After Selling Their First Spin-out (Corventis) to Medtronic, this Team is Aiming for an Even Bigger Splash in the Wearables Space</title>
      <itunes:title>After Selling Their First Spin-out (Corventis) to Medtronic, this Team is Aiming for an Even Bigger Splash in the Wearables Space</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3577</guid>
      <link>https://share.transistor.fm/s/0985a209</link>
      <description>
        <![CDATA[<p>When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare market. Medtronic launched the SEEQ device. Although implantable, St. Jude commercialized the...[<a href="https://medsider.com/interviews/sold-corventis-medtronic-aiming-bigger-splash-wearable-space-interview-darrel-drinan-bioribbon-health/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare market. Medtronic launched the SEEQ device. Although implantable, St. Jude commercialized the...[<a href="https://medsider.com/interviews/sold-corventis-medtronic-aiming-bigger-splash-wearable-space-interview-darrel-drinan-bioribbon-health/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 31 Mar 2016 02:26:05 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/0985a209/b09117cd.mp3" length="27745200" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ZoMoa9OBT_-2qpRTOD-vYyHEnB3JpMUm9QWQGeYFypM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTcv/MTY2ODEwMjA4Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2308</itunes:duration>
      <itunes:summary>When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare market. Medtronic launched the SEEQ device. Although implantable, St. Jude commercialized the...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare marke</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>They Sold Their Company to Boston Scientific and Then Reacquired the Technology Years Later – The Unique Story of NuCryo Vascular</title>
      <itunes:title>They Sold Their Company to Boston Scientific and Then Reacquired the Technology Years Later – The Unique Story of NuCryo Vascular</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3389</guid>
      <link>https://share.transistor.fm/s/84bb1174</link>
      <description>
        <![CDATA[<p>Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging. When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what...[<a href="https://medsider.com/interviews/they-sold-their-company-to-boston-scientific-and-then-reacquired-the-technology-years-later-the-unique-story-nucryo-vascular/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging. When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what...[<a href="https://medsider.com/interviews/they-sold-their-company-to-boston-scientific-and-then-reacquired-the-technology-years-later-the-unique-story-nucryo-vascular/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 26 Feb 2016 18:22:42 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/84bb1174/795628fd.mp3" length="31959341" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/EqafctNEGt0E5ArYl8VDcBen3bZSK47BSxrfWfZ98ks/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTYv/MTY2ODEwMjA4OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2659</itunes:duration>
      <itunes:summary>Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging. When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging. When the bag gets too big, a typical sales force wil</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>The Steady and Successful Climb of BAROnova</title>
      <itunes:title>The Steady and Successful Climb of BAROnova</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3382</guid>
      <link>https://share.transistor.fm/s/bf59d9dd</link>
      <description>
        <![CDATA[<p>Henry Ford is famous for stating, “If I had asked people what they wanted, I would have built a faster horse.” Although it’s arguable whether he ever uttered those words, the statement is still very powerful. And it’s one that Hugh Narciso has taken to heart. In fact, in the early days of BAROnova, when...[<a href="https://medsider.com/interviews/steady-successful-climb-baronova-interview-hugh-narciso-founder-ceo/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Henry Ford is famous for stating, “If I had asked people what they wanted, I would have built a faster horse.” Although it’s arguable whether he ever uttered those words, the statement is still very powerful. And it’s one that Hugh Narciso has taken to heart. In fact, in the early days of BAROnova, when...[<a href="https://medsider.com/interviews/steady-successful-climb-baronova-interview-hugh-narciso-founder-ceo/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 05 Feb 2016 19:36:20 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/bf59d9dd/2ec126cf.mp3" length="38989923" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/PeC-bB-zMcQwJmmnzCmaFJhtFKbULJLr4q0RZg8Y4yY/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTUv/MTY2ODEwMjA4OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3245</itunes:duration>
      <itunes:summary>Henry Ford is famous for stating, “If I had asked people what they wanted, I would have built a faster horse.” Although it’s arguable whether he ever uttered those words, the statement is still very powerful. And it’s one that Hugh Narciso has taken to heart. In fact, in the early days of BAROnova, when...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Henry Ford is famous for stating, “If I had asked people what they wanted, I would have built a faster horse.” Although it’s arguable whether he ever uttered those words, the statement is still very powerful. And it’s one that Hugh Narciso has taken to he</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Inside the Mind of a Medtech VP of Sales</title>
      <itunes:title>Inside the Mind of a Medtech VP of Sales</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3223</guid>
      <link>https://share.transistor.fm/s/f1429088</link>
      <description>
        <![CDATA[<p>Sean Moore went from medical device sales rep to VP of Sales for one of the largest medtech companies in less than 10 years. Pretty impressive, right? Just like me, you might be thinking, “How did he do it? Killer sales results year after year? Right place at the right time?” In this interview with...[<a href="https://medsider.com/interviews/inside-mind-medtech-vp-sales-marketing-sean-moore-conmed/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Sean Moore went from medical device sales rep to VP of Sales for one of the largest medtech companies in less than 10 years. Pretty impressive, right? Just like me, you might be thinking, “How did he do it? Killer sales results year after year? Right place at the right time?” In this interview with...[<a href="https://medsider.com/interviews/inside-mind-medtech-vp-sales-marketing-sean-moore-conmed/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 07 Oct 2014 00:40:23 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/f1429088/6847d3cb.mp3" length="29850264" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/66oZlaKhOFm1Gewl0K4dNWK1WQSajU6S8yjALYU8NUI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTQv/MTY2ODEwMjA3Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2483</itunes:duration>
      <itunes:summary>Sean Moore went from medical device sales rep to VP of Sales for one of the largest medtech companies in less than 10 years. Pretty impressive, right? Just like me, you might be thinking, “How did he do it? Killer sales results year after year? Right place at the right time?” In this interview with...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup? </itunes:summary>
      <itunes:subtitle>Sean Moore went from medical device sales rep to VP of Sales for one of the largest medtech companies in less than 10 years. Pretty impressive, right? Just like me, you might be thinking, “How did he do it? Killer sales results year after year? Right plac</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts,Career Advancement</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Medtech Companies Should Care More About Sales Operations</title>
      <itunes:title>Why Medtech Companies Should Care More About Sales Operations</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3215</guid>
      <link>https://share.transistor.fm/s/73257e0d</link>
      <description>
        <![CDATA[<p>It’s safe to say that IDNs are important customers for the overwhelming majority of medical device companies. Therefore, it’s probably rational to assume that medtech companies do a good job of tracking the changing IDN landscape, right? Wrong. Based on the 2014 ZS Associates Commercial Operations Benchmark Study, only 56% of medtech companies track IDN...[<a href="https://medsider.com/interviews/medtech-companies-should-care-more-about-sales-operations-andrea-traverso-zs-associates/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>It’s safe to say that IDNs are important customers for the overwhelming majority of medical device companies. Therefore, it’s probably rational to assume that medtech companies do a good job of tracking the changing IDN landscape, right? Wrong. Based on the 2014 ZS Associates Commercial Operations Benchmark Study, only 56% of medtech companies track IDN...[<a href="https://medsider.com/interviews/medtech-companies-should-care-more-about-sales-operations-andrea-traverso-zs-associates/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 18 Sep 2014 02:08:57 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/73257e0d/12eacb70.mp3" length="32262000" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/V3Plw0kUizwScclEqkkXbs7zuOoYIRswGxpjs6fK_L8/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTMv/MTY2ODEwMjA3Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2684</itunes:duration>
      <itunes:summary>It’s safe to say that IDNs are important customers for the overwhelming majority of medical device companies. Therefore, it’s probably rational to assume that medtech companies do a good job of tracking the changing IDN landscape, right? Wrong. Based on the 2014 ZS Associates Commercial Operations Benchmark Study, only 56% of medtech companies track IDN...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup? </itunes:summary>
      <itunes:subtitle>It’s safe to say that IDNs are important customers for the overwhelming majority of medical device companies. Therefore, it’s probably rational to assume that medtech companies do a good job of tracking the changing IDN landscape, right? Wrong. Based on t</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>4 Can’t Miss Opportunities That All Medtech Companies Need to Consider</title>
      <itunes:title>4 Can’t Miss Opportunities That All Medtech Companies Need to Consider</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3197</guid>
      <link>https://share.transistor.fm/s/36926625</link>
      <description>
        <![CDATA[<p>According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated, “We’re constantly trying to limit the sales reps…We want to see what they’re selling before they get a hold of...[<a href="https://medsider.com/interviews/4-cant-miss-medtech-opportunities-jonas-funk-lek/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated, “We’re constantly trying to limit the sales reps…We want to see what they’re selling before they get a hold of...[<a href="https://medsider.com/interviews/4-cant-miss-medtech-opportunities-jonas-funk-lek/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 27 Sep 2013 15:41:37 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/36926625/d843074d.mp3" length="40109656" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/3-rCtuTFU2PLS4PZY8UA0Ajgw8kq9Iz9N0y-vfYM_Yk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTIv/MTY2ODEwMjA3Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3338</itunes:duration>
      <itunes:summary>According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated, “We’re constantly trying to limit the sales reps…We want to see what they’re selling before they get a hold of...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup? </itunes:summary>
      <itunes:subtitle>According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated, “We’re constantly trying to limit the sale</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Can This Service Solve the Problem of Information Overload in Healthcare?</title>
      <itunes:title>Can This Service Solve the Problem of Information Overload in Healthcare?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3185</guid>
      <link>https://share.transistor.fm/s/617558f7</link>
      <description>
        <![CDATA[<p>Information overload is an issue that all of us face. Finding a decent signal in the midst of a very noisy world is a difficult challenge. Few are able to master it on a consistent basis. And that includes doctors. Check out some of these stats: 100,000 scientific journals are now in circulation. 30,000 new...[<a href="https://medsider.com/interviews/service-solve-problem-information-overload-healthcare-zvi-mowshowitz-metamed/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Information overload is an issue that all of us face. Finding a decent signal in the midst of a very noisy world is a difficult challenge. Few are able to master it on a consistent basis. And that includes doctors. Check out some of these stats: 100,000 scientific journals are now in circulation. 30,000 new...[<a href="https://medsider.com/interviews/service-solve-problem-information-overload-healthcare-zvi-mowshowitz-metamed/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Mon, 05 Aug 2013 17:36:21 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/617558f7/8dc4307c.mp3" length="38112822" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/WpfFuu6uPt29J2mrFzOyjL5flW5VNn-8f72hlpRJDic/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTEv/MTY2ODEwMjA3Ni1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3172</itunes:duration>
      <itunes:summary>Information overload is an issue that all of us face. Finding a decent signal in the midst of a very noisy world is a difficult challenge. Few are able to master it on a consistent basis. And that includes doctors. Check out some of these stats: 100,000 scientific journals are now in circulation. 30,000 new...[read more]Related StoriesSocial Media Best Practices for Marketing Medical DevicesCan Nurep Solve the Inefficiency Problem in Medical Device Sales?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Information overload is an issue that all of us face. Finding a decent signal in the midst of a very noisy world is a difficult challenge. Few are able to master it on a consistent basis. And that includes doctors. Check out some of these stats: 100,000 s</itunes:subtitle>
      <itunes:keywords>Digital Health,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</title>
      <itunes:title>Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3169</guid>
      <link>https://share.transistor.fm/s/a0668d41</link>
      <description>
        <![CDATA[<p>What do Stryker, Biomet, Medtronic, and Boston Scientific all have in common? Yes, they all manufacture medical devices. But more specifically, all four of these medtech companies have implantable device divisions. And from 2005 – 2011, the implantable device segment has been the most consistent top performer relative to other categories including: in vitro diagnostics...[<a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">read more</a>]<br><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>What do Stryker, Biomet, Medtronic, and Boston Scientific all have in common? Yes, they all manufacture medical devices. But more specifically, all four of these medtech companies have implantable device divisions. And from 2005 – 2011, the implantable device segment has been the most consistent top performer relative to other categories including: in vitro diagnostics...[<a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">read more</a>]<br><br><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Mon, 22 Jul 2013 16:26:06 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/a0668d41/2a2801fa.mp3" length="40883498" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/aUNXcfS4_hWnRwXsO_LTlslnzzoxutKGiBlj8ccndL4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzOTAv/MTY2ODEwMjA2Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3403</itunes:duration>
      <itunes:summary>What do Stryker, Biomet, Medtronic, and Boston Scientific all have in common? Yes, they all manufacture medical devices. But more specifically, all four of these medtech companies have implantable device divisions. And from 2005 – 2011, the implantable device segment has been the most consistent top performer relative to other categories including: in vitro diagnostics...[read more]Related StoriesSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup?Can Nurep Solve the Inefficiency Problem in Medical Device Sales? </itunes:summary>
      <itunes:subtitle>What do Stryker, Biomet, Medtronic, and Boston Scientific all have in common? Yes, they all manufacture medical devices. But more specifically, all four of these medtech companies have implantable device divisions. And from 2005 – 2011, the implantable de</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Digital Health,Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Early Stage Medical Device Deals Aren’t as Bad as You May Think</title>
      <itunes:title>Why Early Stage Medical Device Deals Aren’t as Bad as You May Think</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=3153</guid>
      <link>https://share.transistor.fm/s/ad4ba67d</link>
      <description>
        <![CDATA[<p>Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space? Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early stage medical device companies? In this interview with Mike Carusi...[<a href="https://www.medsider.com/interviews/why-early-stage-medical-device-deals-arent-as-bad-as-you-may-think-interview-with-mike-carusi-general-partner-at-lightstone-ventures">read more</a>]</p><p><strong>Related Stories</strong></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space? Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early stage medical device companies? In this interview with Mike Carusi...[<a href="https://www.medsider.com/interviews/why-early-stage-medical-device-deals-arent-as-bad-as-you-may-think-interview-with-mike-carusi-general-partner-at-lightstone-ventures">read more</a>]</p><p><strong>Related Stories</strong></p><ul><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Thu, 11 Jul 2013 22:45:58 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/ad4ba67d/99e9fe3b.mp3" length="37546418" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/41n3oO-tuguzXkf3tfctKLNoO4QOyG-bRvx304keWEo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODkv/MTY2ODEwMjA2Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3125</itunes:duration>
      <itunes:summary>Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space? Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early stage medical device companies? In this interview with Mike Carusi...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space? Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early stage </itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</title>
      <itunes:title>How Will These 2 Major Healthcare Changes Affect Medical Device Companies?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2979</guid>
      <link>https://share.transistor.fm/s/4b9565ea</link>
      <description>
        <![CDATA[<p>How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies? These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future. Unfortunately, there aren’t solid answers at this point. But there are some people that can help...[<a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies? These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future. Unfortunately, there aren’t solid answers at this point. But there are some people that can help...[<a href="https://medsider.com/interviews/how-will-these-2-major-healthcare-changes-affect-medical-device-companies-interview-brian-contos-advisory-board-company/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">Why Intersect ENT is an Example of Hope for the Medtech Industry</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 14 Jun 2013 19:10:29 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/4b9565ea/9b2c71a4.mp3" length="39697464" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/jK9M19nYrnjmTZ8HnUlANfSpnDSK89pgKG6D9yAcIks/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODgv/MTY2ODEwMjA2NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3304</itunes:duration>
      <itunes:summary>How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies? These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future. Unfortunately, there aren’t solid answers at this point. But there are some people that can help...[read more]Related StoriesSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical DevicesWhy Intersect ENT is an Example of Hope for the Medtech Industry </itunes:summary>
      <itunes:subtitle>How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies? These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future. Unfortunately,</itunes:subtitle>
      <itunes:keywords>Radio,Regulatory and Reimbursement,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</title>
      <itunes:title>Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2966</guid>
      <link>https://share.transistor.fm/s/39ff6c13</link>
      <description>
        <![CDATA[<p>Picture this. You’re a medical device sales rep covering a procedure in one part of your territory. But unexpectedly, you get a call from a physician needing case support on the other side of your geography. What do you do? There’s no way you can cover the case, right? The drive-time won’t allow you to...[<a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Picture this. You’re a medical device sales rep covering a procedure in one part of your territory. But unexpectedly, you get a call from a physician needing case support on the other side of your geography. What do you do? There’s no way you can cover the case, right? The drive-time won’t allow you to...[<a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">read more</a>]</p><p><b>Related Stories</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 04 Jun 2013 17:17:14 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/39ff6c13/73a1afdc.mp3" length="35233886" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/HFrULfU-VU958Jzssq-SBVtryhvdh_bJvp1Wft5SzpY/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODcv/MTY2ODEwMjA2My1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2932</itunes:duration>
      <itunes:summary>Picture this. You’re a medical device sales rep covering a procedure in one part of your territory. But unexpectedly, you get a call from a physician needing case support on the other side of your geography. What do you do? There’s no way you can cover the case, right? The drive-time won’t allow you to...[read more]Related StoriesSocial Media Best Practices for Marketing Medical DevicesCan Medical Device Companies Increase Sales and Reduce Costs at the Same Time?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Picture this. You’re a medical device sales rep covering a procedure in one part of your territory. But unexpectedly, you get a call from a physician needing case support on the other side of your geography. What do you do? There’s no way you can cover th</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Digital Health,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Are Medical Device Models the Key to Building a Lean Medtech Startup?</title>
      <itunes:title>Are Medical Device Models the Key to Building a Lean Medtech Startup?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2750</guid>
      <link>https://share.transistor.fm/s/06250147</link>
      <description>
        <![CDATA[<p>The lean startup movement has become increasingly popular within the tech community after the release of Eric Ries’ book in 2011. Although I personally believe the lean startup methodology is brilliant, some aspects are difficult to apply to the medtech space. For example, it costs significantly less money to iterate on a software idea in...[<a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>The lean startup movement has become increasingly popular within the tech community after the release of Eric Ries’ book in 2011. Although I personally believe the lean startup methodology is brilliant, some aspects are difficult to apply to the medtech space. For example, it costs significantly less money to iterate on a software idea in...[<a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a></li><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 08 May 2013 22:36:39 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/06250147/5668b799.mp3" length="37028951" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/sl6wvo8vQ2akglK8LuUZSzl_ZsT5IeDifQrZLP24fHk/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODYv/MTY2ODEwMjA2NC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>3082</itunes:duration>
      <itunes:summary>The lean startup movement has become increasingly popular within the tech community after the release of Eric Ries’ book in 2011. Although I personally believe the lean startup methodology is brilliant, some aspects are difficult to apply to the medtech space. For example, it costs significantly less money to iterate on a software idea in...[read more]Related ArticlesCan Medical Device Companies Increase Sales and Reduce Costs at the Same Time?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used ToSocial Media Best Practices for Marketing Medical Devices </itunes:summary>
      <itunes:subtitle>The lean startup movement has become increasingly popular within the tech community after the release of Eric Ries’ book in 2011. Although I personally believe the lean startup methodology is brilliant, some aspects are difficult to apply to the medtech s</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Why Intersect ENT is an Example of Hope for the Medtech Industry</title>
      <itunes:title>Why Intersect ENT is an Example of Hope for the Medtech Industry</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2740</guid>
      <link>https://share.transistor.fm/s/bff72a32</link>
      <description>
        <![CDATA[<p>The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[<a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/early-stage-medical-device-deals-not-bad-interview-mike-carusi/">Why Early Stage Medical Device Deals Aren’t as Bad as You May Think</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[<a href="https://medsider.com/interviews/intersect-ent-example-hope-medtech-industry-interview-lisa-earnhardt/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/early-stage-medical-device-deals-not-bad-interview-mike-carusi/">Why Early Stage Medical Device Deals Aren’t as Bad as You May Think</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 26 Apr 2013 21:46:58 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/bff72a32/87887388.mp3" length="27056831" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/u8E_QFVt7vH6OFMEZKQ42UkkwoOku1iAVmYrfbfcqKI/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODUv/MTY2ODEwMjA1Ny1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2251</itunes:duration>
      <itunes:summary>The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]Related ArticlesAre Medical Device Models the Key to Building a Lean Medtech Startup?Why Early Stage Medical Device Deals Aren’t as Bad as You May ThinkSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all down</itunes:subtitle>
      <itunes:keywords>Radio,Interviews with Medtech Experts,Start-Ups</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Social Media Best Practices for Marketing Medical Devices</title>
      <itunes:title>Social Media Best Practices for Marketing Medical Devices</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2720</guid>
      <link>https://share.transistor.fm/s/6a07f05b</link>
      <description>
        <![CDATA[<p>Did you know the FDA recently issued a multi-million dollar contract to a private company that will be charged with monitoring social media? Yes, multi-million. Needless to say, that’s a significant amount of money. Although many would argue the FDA has not been very clear regarding its guidance towards social media, you can’t deny that...[<a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a></li><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Did you know the FDA recently issued a multi-million dollar contract to a private company that will be charged with monitoring social media? Yes, multi-million. Needless to say, that’s a significant amount of money. Although many would argue the FDA has not been very clear regarding its guidance towards social media, you can’t deny that...[<a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a></li><li><a href="https://medsider.com/interviews/medical-device-companies-increase-sales-reduce-costs-same-time-interview-gavin-fabian-medpassage/">Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?</a></li><li><a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 10 Apr 2013 16:59:01 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/6a07f05b/4077f8af.mp3" length="32921181" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/ZSmOHItPlkwKNwbXose4gmni_lSaYeBsats24HkIL_A/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODQv/MTY2ODEwMjA1OC1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2739</itunes:duration>
      <itunes:summary>Did you know the FDA recently issued a multi-million dollar contract to a private company that will be charged with monitoring social media? Yes, multi-million. Needless to say, that’s a significant amount of money. Although many would argue the FDA has not been very clear regarding its guidance towards social media, you can’t deny that...[read more]Related ArticlesCan Nurep Solve the Inefficiency Problem in Medical Device Sales?Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To </itunes:summary>
      <itunes:subtitle>Did you know the FDA recently issued a multi-million dollar contract to a private company that will be charged with monitoring social media? Yes, multi-million. Needless to say, that’s a significant amount of money. Although many would argue the FDA has n</itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Digital Health,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
    <item>
      <title>Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</title>
      <itunes:title>Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">https://medsider.com/?p=2689</guid>
      <link>https://share.transistor.fm/s/da1683f4</link>
      <description>
        <![CDATA[<p>As the world of healthcare continues to change and evolve, hospitals and healthcare providers are facing a major dilemma. There will continue to be an increasing number of patients that need healthcare. But, the reimbursement for healthcare services will continue to decline. In other words, there will be more customers checking out, but less money...[<a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a> </li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>As the world of healthcare continues to change and evolve, hospitals and healthcare providers are facing a major dilemma. There will continue to be an increasing number of patients that need healthcare. But, the reimbursement for healthcare services will continue to decline. In other words, there will be more customers checking out, but less money...[<a href="https://medsider.com/interviews/substantial-sustainable-2-words-medtech-companies-should-get-used-to/">read more</a>]</p><p><b>Related Articles</b></p><ul><li><a href="https://medsider.com/interviews/social-media-best-practices-marketing-medical-devices-interview-mukesh-kumar/">Social Media Best Practices for Marketing Medical Devices</a></li><li><a href="https://medsider.com/interviews/medical-device-models-key-building-lean-medtech-startup-interview-allison-rae-pulse-research-development/">Are Medical Device Models the Key to Building a Lean Medtech Startup?</a></li><li><a href="https://medsider.com/interviews/nurep-solve-inefficiency-problem-medical-device-sales-interview-paul-schultz/">Can Nurep Solve the Inefficiency Problem in Medical Device Sales?</a> </li></ul>]]>
      </content:encoded>
      <pubDate>Tue, 05 Feb 2013 19:38:55 +0000</pubDate>
      <author>Scott Nelson</author>
      <enclosure url="https://media.transistor.fm/da1683f4/f9be45c2.mp3" length="32470118" type="audio/mpeg"/>
      <itunes:author>Scott Nelson</itunes:author>
      <itunes:image href="https://img.transistorcdn.com/RTyiQyCe-Om06Mrlpxnagt5pNQhIbvYMoI3Zxy7keHw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzEwOTMzODMv/MTY2ODEwMjA1MS1h/cnR3b3JrLmpwZw.jpg"/>
      <itunes:duration>2702</itunes:duration>
      <itunes:summary>As the world of healthcare continues to change and evolve, hospitals and healthcare providers are facing a major dilemma. There will continue to be an increasing number of patients that need healthcare. But, the reimbursement for healthcare services will continue to decline. In other words, there will be more customers checking out, but less money...[read more]Related ArticlesSocial Media Best Practices for Marketing Medical DevicesAre Medical Device Models the Key to Building a Lean Medtech Startup?Can Nurep Solve the Inefficiency Problem in Medical Device Sales? </itunes:summary>
      <itunes:subtitle>As the world of healthcare continues to change and evolve, hospitals and healthcare providers are facing a major dilemma. There will continue to be an increasing number of patients that need healthcare. But, the reimbursement for healthcare services will </itunes:subtitle>
      <itunes:keywords>Sales and Marketing,Radio,Interviews with Medtech Experts</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
  </channel>
</rss>
